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Cystic Fibrosis (CF) is the most common life-limiting single gene disorder in Caucasian 
populations. CF results from mutations in the gene encoding the CF transmembrane 
conductance regulator (CFTR) protein, which leads to accumulation of thick and sticky 
mucus in the airways of people with CF, ultimately dampening immune clearance of 
potential respiratory pathogens. In fact, chronic airway infection by the opportunistic 
bacterial pathogen Pseudomonas aeruginosa is the major cause of mortality and morbidity 
in individuals with CF. The ability of P. aeruginosa to chronically infect the airways of people 
with CF stems, in part at least, from its remarkable capacity to grow as complex multi-
cellular communities called biofilms, which offer protection from host immune responses 
and eradication by conventional antibiotics. Biofilm formation by P. aeruginosa is co-
ordinated by a cell density-dependent signalling system called quorum sensing (QS). While 
P. aeruginosa has multiple QS systems, the major system involves the diffusible signalling
molecule N-3-oxo-dodecanoyl-L-homoserine lactone (C12HSL). C12HSL not only acts an 
important biofilm signalling molecule but also regulates bacterial virulence factor 
production. In addition, C12HSL has gene modulatory and cytotoxic effects in host cells. 
Collectively, these properties have stimulated much research interest in developing novel 
antimicrobial therapies that specifically target QS. 
The present study investigated the potential of using the human enzyme, Paraoxonase-2 
(PON2), to target and inhibit biofilm formation by, and virulence of, P. aeruginosa. Human 
PON2 is usually produced intracellularly and has previously been demonstrated to have 
highly specific hydrolytic activity towards C12HSL, and thereby seems to represent an 
innate mechanism by which host cells might attempt to counter P. aeruginosa QS, and hence 
infection by this organism. Here, it was hypothesized that the virulence of, and biofilm-
formation by, P. aeruginosa could be diminished by manipulating human PON2 (hPON2) 
levels, either by augmenting native PON2 expression, or by supplementing lactonase 
activity using a recombinant form of human PON2 (rhPON2) exogenously. Thus, the aim of 
the first part of this thesis was to determine the gene modulatory and cytotoxic effects of 
C12HSL on airway epithelia, and investigate the regulation of PON2 expression in 
mammalian cells. The second part of this thesis was aimed at producing rhPON2 and 
investigating whether exogenously supplied rhPON2 could disrupt P. aeruginosa QS, and 
thereby increase its susceptibility to the clinically relevant antibiotic tobramycin.  
Abstract 
[iii] 
C12HSL was found to alter gene expression in cultured airway epithelial cells, even at low 
concentrations. This included the down-regulation of genes involved in immune signalling 
and the unfolded protein response. C12HSL also induced apoptosis and affected epithelial 
cell viability and metabolic activity in a concentration dependent manner. The results also 
show that while C12HSL itself did not significantly alter the expression of native PON2 in 
airway epithelial cells, PON2 gene expression and PON2 protein levels rapidly increased in 
response to agonism of the major mammalian C12HSL receptor PPARγ; in turn, these 
results would seem to link the regulation of human PON2 to a known major regulator of the 
inflammatory response.  
Recombinant hPON2 was able to hydrolyse almost all detectable C12HSL produced in P. 
aeruginosa cultures with no effect on bacterial growth. Treatment of P. aeruginosa cultures 
with rhPON2 tended to decrease expression of all three P. aeruginosa QS systems and 
associated virulence genes. Importantly, rhPON2-dependent hydrolysis of C12HSL during 
bacterial growth, significantly increased the susceptibility of P. aeruginosa cells to the 
bactericidal effects of the antibiotic tobramycin. In contrast, treatment of P. aeruginosa with 
rhPON2 combined with a high concentration of tobramycin, whilst hydrolysing the C12HSL 
and increasing bacterial killing by over an order of magnitude, significantly up-regulated the 
expression levels of a number of important QS and QS-dependent virulence genes of P. 
aeruginosa including, lasI, lasB and algD. One interpretation of this result is that bacterial 
cells treated with this combination up-regulate lasI, the gene that catalyses C12HSL 
synthesis, and other virulence encoding genes, presumably due to antibiotic-induced stress, 
via a C12HSL-independent mechanism.  
Taken together, the results of this thesis demonstrate that low-level C12HSL can influence 
gene expression in human airway cells, and reveal for the first time that native human PON2 
expression is regulated via a major mammalian C12HSL receptor. In addition, rhPON2-
treatment of P. aeruginosa leads to reduction of C12HSL levels and the reduction of bacterial 
virulence gene expression. The efficacy of rhPON2 in conjunction with antibiotics however, 
requires further investigation, using lower-concentrations (clinically achievable levels) of 
antibiotic and antibiotics with alternative mechanisms of action. The results of this thesis 
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COMMON ABBREVIATIONS  
Table i List of commonly used abbreviations 




AHL Acyl homoserine lactone 
C12HSL N-3-oxo-dodecanoyl-L-Homoresine Lactone 
C4HSl N-butyryl-L-Homoserine Lactone 
CCCM Complete cell culture medium 
cDNA Complimentary deoxyribonucleic acid 
CF Cystic fibrosis 
CFTR Cystic fibrosis transmembrane conductance regulator 
CFU Colony forming units 
CT Cycle threshold 
DMEM Dulbecco’s modified eagle medium 
DMSO Dimethylsulfoxide 
DNA Deoxyribonucleic acid 
DPBS Dulbecco’s phosphate buffered saline 
EDTA Ethylenediaminetetraacetic acid 
ENac Epithelial sodium channel 
EPS Exopolymeric substance 
ER Endoplasmic reticulum  
FBS Foetal bovine serum 
FEV1 Forced expiratory volume in one second 
FITC Fluorescein isothiocyanate 
GW GW9662 




LB Lysogeny broth 
Log Logarithmic 
LPS Lipopolysaccharide 
MAPK Mitogen-activated protein kinase 





mRNA Messenger ribonucleic acid 
NaOH Sodium hydroxide 
NFκB Nuclear factor -κB 
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Abbreviation Full form 
ng Nanogram 
NLR Nod-like receptor 
nM Nanomolar 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PFU Plaque forming units 
PI Propidium iodide 
Pio Pioglitazone 
PON Paraoxonase 
PPAR Peroxisome proliferator activated receptor 
PPRE PPAR response element 
PQS Pseudomonas quinolone signal 
qPCR Quantitative polymerase chain reaction 
QS Quorum sensing 
QSI  Quorum sensing inhibition 
RG Rosiglitazone 
rhPON2 Recombinant human paraoxonase 2 
RNA Ribonucleic acid 
ROS Reactive oxygen species 
RPM Revolutions per minute 
RT-qPCR Reverse transcription-quantitative polymerase chain reaction 
RXR Retinoid x receptor 
S.E.M Standard error of mean 
SDS Sodium dodecyl sulphate  
SDS-PAGE Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
TE Tris-EDTA buffer 
TLR Toll-like receptor 
T3SS  Type three secretion systems 
TZD Thiazolidinediones 
UPR Unfolded protein response 
wt Wild-type 
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1.1 CYSTIC FIBROSIS, A LIFE LIMITING DISEASE 
 
Cystic Fibrosis (CF) has been known as 
a distinct clinical entity since the 1930s 
and is now recognized as the most 
common life-limiting monogenic 
disorder in Caucasian individuals. An 
estimated 100,000 people globally are 
affected by CF. The incidence rate of CF 
varies between countries and people of 
different ethnicities (summarized in 
Table 1.1), but CF is most common 
among people of Northern European 
descent [1]. In Australia, the figure is 
approximately 1 in 2500 births. The 
disease is particularly relevant to 
Tasmania as Tasmania has the second 
highest incidence in the world, 1 in 
1600 births, second only to Ireland [2, 
3].  
CF is a multi-organ disease, primarily 
affecting the lungs, but also the liver, 
pancreas and intestine. While the 
disease severity varies from individual 
to individual, the average life 
expectancy of individuals with CF is considerably shorter than that of a healthy individual. 
Despite a remarkable improvement in life expectancy over the last two decades, a child born 
in the developed world after the year 2000 with CF is still only expected to live into his/her 
50s [6, 18]. The treatment burden is also high for CF patients. They experience frequent 
hospitalizations because of periodic worsening of lung function (exacerbations) as a result 
of persistent lung infections. They typically need to take combinations of multiple 
antibiotics to manage infections and must participate in daily physiotherapy to ease chest 
congestion. The use of antibiotics has heralded the emergence of antibiotic-resistant strains, 
and the use of ever higher doses of, and more toxic, antibiotics. This has led to a call for 
Table 1.1 Global CF incidence rates. Table 
shows the estimated incidence of CF in a 





Australia 1:2500 [4] 
Tasmania 1:1600 [4] 
People of North European 
descent 
1:3000 [1] 
USA 1:3500 [5] 
UK 1:2,381 [3, 6] 
Canada 1:3608 [7] 
Ireland 1:1,353 [2, 3] 
Japan 1:350,000 [8] 
Sweden 1:5,600 [9] 
Denmark 1:4,700 [10] 
Finland 1:25,000 [10] 
Spain 1:3,750 [11] 
Italy 1:4,238 [12] 
Greece 1:3,500 [11] 
Saudi Arabia  1:4,300 [13] 
Chile 1:3,500 [14] 
Brazil 1:6,902 [15] 
Mexico 1:8,500 [16] 
African populations 1:15,000 [17] 
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novel antimicrobial therapies. To this day, there is no cure for the disease, and though there 
are emerging therapies that small subsets of the CF population benefit from, these come at 
great financial cost to individuals and healthcare organizations. 
Pulmonary failure, a consequence of persistent bacterial lung infections particularly with 
the Gram-negative pathogen Pseudomonas aeruginosa, accounts for 80% of CF related 
deaths [5]. Infection with P. aeruginosa in CF increases the risk of early death by almost 
three-fold [19]. Despite intense research being focused on easing bacterial lung infections, 
there are to date no reports of sustained eradication from, or indeed prevention of, bacterial 
infections in the CF lung [20, 21]. 
 
1.1.2 Genetic basis of Cystic Fibrosis 
 
CF is an autosomal recessive genetic disorder, resulting from inherited mutations in the 
Cystic Fibrosis Transmembrane conductance Regulator (CFTR) gene. The protein product of 
CFTR is a cyclic adenosine monophosphate regulated (cAMP) transmembrane chloride ion 
channel located on the apical membrane of epithelial and blood cells (Figure 1.1). Although 
CFTR primarily functions as a chloride channel, it also has various regulatory roles including 
inhibition of the Epithelial Sodium Channel (ENaC) [23], inhibition of Calcium-Activated 
 
Figure 1.1 Structure of the CFTR protein. Figure shows the structure of the CFTR protein (green), an 
ATP-binding cassette transporter made up of five domains: the two transmembrane domains (TMD) 
that form the channel pore in the cell membrane (yellow), the two nucleotide binding domains (NBD) 
and one regulatory domain. The main function of the CFTR protein is the transport of chloride ions 
(grey). Figure from CF Education Steering Group (ESG), 2015 [22]. 
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Chloride Channels (CaCC) [1], activation of Outwardly Rectifying Chloride Channel (ORCC) 
[24], regulation of ATP channels[25] and bicarbonate-chloride exchange [26].  
CFTR is located on the long arm of human chromosome 7 [27] and over a thousand distinct 
mutations of the gene have been reported. For many of the mutations, the majority of which 
are very rare (only 20 have a allelic frequency >0.1% [28]), the phenotypic effects on the 
carrier are unknown or have been shown to be non-consequential [29, 30]. Ninety percent 
of CF patients carry a ΔF508 mutation involving a deletion of phenylalanine at position 508 
[31]. While the frequency of the different mutations vary by geographical region , no other 
single mutation accounts for more than 5% of the global CFTR mutations [32]. 
Approximately 80% of CFTR mutations are associated with CF disease and can be separated 
into 6 classes of mutations with varying degrees of CFTR function (Figure 1.2) [28].  
Mutations in CFTR give rise to the clinical manifestations of CF and that are observed in 
multiple organs. CF pathogenesis is characterized by the accumulation of thick, sticky mucus 
in organs producing mucin such as the lungs, sinuses, intestine, pancreas and reproductive 
organs. Clinical diagnosis of CF is partially based on one such manifestation, high sweat salt 
content due to the absence of functional CFTR in the sweat glands restricting chloride and 
sodium reabsorption [33]. If a baby has a positive result for CF during newborn screening, 
(raised levels of immunoreactive trypsinogen as an indirect consequence of CFTR 
mutations), or if a patient shows symptoms of CF, clinical diagnosis is carried out by CFTR 
mutation screening followed by the Gibson and Cooke sweat test when mutation screening 
identifies heterozygous results, [34, 35].  
The most significant clinical effects of CF are observed in the respiratory system and are a 
consequence of the inability of airways to channel chloride through CFTR. At birth, the lungs 
of CF infants appear normal. Yet, as early as four months of age, the lungs begin to show 
signs of infection and inflammation [36]. Infection initiates in early childhood with a 
progression of organisms including Staphylococcus aureus, Haemophilus influenzae, 
Streptococcus pneumoniae and, most significantly P. aeruginosa. Infections in CF are 
discussed further in section 1.1.4.2. 
CFTR is surface-expressed by ciliated epithelial cells in the airway and plays an important 
role in maintaining the hydrated periciliary mucus layer on the airway surface (airway 
surface liquid) required for adequate mucociliary clearance. Two main models of sodium 
and chloride reabsorption attempt to explain the resultant airway dehydration, viscous 
mucus and impaired mucociliary clearance observed in CF (Figure 1.3). The first, the low- 




Figure 1.2 CFTR Mutations. Mutations of the CFTR gene are categorized into 6 classes. The figure illustrates the mechanisms that differentiate between the 6 classes 
and the ability of CFTR in individual classes to mediate Cl– transport. Class I, II and III mutations generally result in a lack of functional CFTR, or CFTR 
expression/functionality is significantly reduced. Class I CFTR mutations typically result in truncated CFTR or its complete absence as a consequence of premature stop 
codons, nonsense, or frame-shift mutations and mRNA splicing defects [37]. The deletion of glycine at position 542 (G542X) is a common class I mutation with a 
premature stop codon. Class II mutations, including the prevalent ΔF508, result in defects in protein folding and maturation, so the proteins are not transported to the 
apical membrane and are instead prematurely degraded. The phenylalanine deletion in ΔF508 prevents it from being processed into its mature glycosylated form [38]. 
Class III mutations result in CFTR that is expressed at normal levels and transported to and inserted into the apical membrane but is non-functional. The relatively 
common G551D mutation, found in 4%–5% of CF patients [5, 39], has defective Cl– channel gating and is an example of a class III mutation [37]. Class IV mutations are 
similar to class III mutations in that CFTR is produced at normal levels, but unlike class III mutations, the CFTR displays aberrant and/or reduced function [37]. Class V 
mutations are the least severe and normally the result of splicing defects; they cause decreased production of functional CFTR. The relatively newly defined class VI 
mutations produce unstable but functional CFTR at the apical membrane as a result of C-terminal truncation [37, 40]. Figure from Derichs et al., 2013 [41]. 
  




Figure 1.3 Competing models explaining the airway dehydration, viscous mucus and impaired 
mucociliary clearance in the CF airway.  Panel A shows the transport of sodium and chloride ions 
through CFTR (blue) ENaC (red) and other ion channels (green) on the mucosal surface of healthy 
airway epithelia, together with the net luminal charge. The other two panels show how the action of 
these channels and the airway epithelia are affected in CF as explained by the low-volume (Panel B) 
and high-salt (Panel C) models. The low-volume model proposes a loss in regulation of sodium 
absorption by ENaC because of the absence of functional CFTR [42]. As a consequence, sodium and 
chloride are hyper-absorbed from the airway lumen and the resulting osmotic imbalance causes 
absorption of water into the cells, dehydrating the airway lumen. The second model, the high-salt 
model, postulates that without functional CFTR, sodium and chloride are not reabsorbed into the 
interstitium, allowing the ions to accumulate in the airway surface liquid [43]. Figure adapted from 
Rowe et al., 2005 [33].  
 
volume model, proposes that sodium and chloride hyper-absorption from the airway lumen 
results in an osmotic imbalance that dehydrates the airway lumen. The second model, the 
high salt model, postulates CFTR-dependent blockage of chloride reabsorption into the 
airway epithelia, which allows the ions to accumulate in the airway surface liquid [43]. 
Opinion is divided amongst researchers as to which model better explains the CF 
phenotype, but both models attribute an important role for the absence of functional CFTR 
in the development of the CF lung pathology. More importantly, both models also account 
for the most damaging consequence of the CFTR mutation in the airway, accumulation of 
dehydrated mucus leading to sustained bacterial infection. The low volume model allows for 
mucus on the epithelium to form plaques with hypoxic niches that can harbour bacteria [42, 
44]. The increased airway surface liquid chloride concentrations proposed in the high salt 
model, in combination with the resulting hyperpolarized epithelia, disrupt the production of 
innate immunity antimicrobial molecules, enabling bacteria to persist in the lung [43, 45, 
46]. It is therefore plausible that a combination of both models may be in effect in the CF 
airway. 
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Gastrointestinal complications are the other major pathology associated with CF. Around 
15% of CF patients are born with an obstructed ileum and almost 90% will develop 
pancreatic insufficiency because of defective secretion of digestive enzymes [1]. The 
thickened secretions in the pancreatic ducts cause blockages, and because of the resulting 
autolysis, the pancreatic tissue is replaced over time with fatty tissue. The glandular 
obstruction of bile canaliculi can cause clinically apparent cirrhosis in about 5% of patients 
[47]. The poor absorption of fat-soluble vitamins can also cause a number of complications 
including night blindness and bleeding disorders. Without adequate caloric intake and 
supplementation with fat-soluble vitamins, CF patients would not survive past the first few 
months. A major consequence of the gastrointestinal complications in CF is the development 
of CF-related diabetes, with almost 45% of individuals with CF aged above 35 diagnosed 
with this complication [5]. 
Almost 99% of adult males with CF are born with a congenital absence of the vas deferens, 
rendering them infertile [48]. This is frequently observed even in males heterozygous for 
CFTR mutations and who are otherwise asymptomatic [1]. Infertility is less serious in 
females and although not well understood, fertility complications are attributed to 
combinations of factors related to the CFTR mutation, including the thickening of the 
cervical mucus [49]. However, improvements in fertility medication and CF nutrition 
support means that men with CF have options to father children and women can have a 
healthy pregnancy. In the US, the number of women with CF who have successfully given 
birth almost doubled between 1997 and 2012 [5]. 
 
1.1.3 Cystic Fibrosis therapies 
 
Since the first comprehensive description of CF in the 1930s [50], the search for CF disease-
modifying therapies has been ongoing. As understanding of the disease pathophysiology has 
increased, we have begun to identify potential strategies to address the basic CF defect. Two 
main methods of addressing the basic CF defect have been identified. The first, gene 
therapy, involves strategies that modify or correct the abnormal expression of CFTR. Gene 
therapy became the primary focus of many CF researchers after the identification and 
cloning of the CFTR gene [51]. Early attempts at correcting CFTR defects were through the 
administration of CFTR DNA directly to the cells, which has up to now been largely 
unsuccessful. With the advent of the genomics era, gene therapy research has evolved for 
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the better. Researchers have since identified CF disease-modifying therapies through the 
use of novel drugs to target and correct defects arising from specific CF mutations. The 
second method of addressing the basic CF defect involves cell therapy, where live whole 
cells are administered. Cell therapy, using a variety of stem/progenitor cells and even a 
tissue-engineered lung may hold some promise, but this form of therapy is still an emerging 
field and further research is required. Because cell therapy research is in its infancy, the 
difficulty of transferring genes into the lungs, and the expense associated with large, 
meaningful clinical trials to test novel disease-modifying therapies, CF research has largely 
been restricted to further understanding the disease and providing strategies to increase 
life expectancy and quality of life. As a result of this research, the life expectancy of CF 
patients has steadily risen over the last 20 years. In the 1980s, the median life expectancy of 
a CF patient was around 25–30 years [1, 5, 6] but a child born with CF today is expected to 
live into their 50s [1, 6]. This increase in life expectancy has been coupled with marked 
improvements in a number of indicators of quality of life including body mass index, lung 
function and even live birth rates [5]. With the increase in CF patient life expectancy, the 
discovery of drugs and treatment strategies that improve the quality of life has important 
implications for health economics and is vital to the lives of people living with CF and their 
families. 
1.1.3.1 Current symptom-targeted CF therapies 
Current CF therapies are generally targeted towards preventing malnutrition and treating 
the lung pathophysiology. A list of common maintenance CF therapies is shown in Table 1.2. 
Pancreatic enzyme replacement to prevent malnutrition is essential for CF patients, and as 
for the large number of CF patients who develop pancreatic insufficiency, dietary 
Table 1.2 Common maintenance therapy drugs in CF. Adapted from Lubsch, 2007 [52]  
Drug Dosage 
Gastrointestinal Therapy 
Fat-soluble vitamins <1 year, 1 mL daily 
1 to 3 years, 1 mL, twice daily 
4 to 10 years, 1 capsule daily 
>10 years, 1 capsule, twice daily 
Pancreatic enzymes 1000 to 2500 lipase U/kg prior to meal and one half dose 
prior to each snack 
Pulmonary Therapy 
Dornase alpha 2.5 mg inhaled daily 
7% hypertonic saline 4 mL inhaled twice daily 
Tobramycin  300 mg inhaled twice daily, administered in 28 day cycles 
Azithromycin 500 mg, inhaled once every two days 
1. Introduction and literature review 
27 
 
supplementation of fat soluble vitamins is mandatory [6]. Patients who receive adequate 
nutrition not only have a survival advantage but also have improved lung function [53, 54]. 
The viscous mucus in the airways is particularly problematic for CF patients and is normally 
targeted with a number of drugs. The thick mucus contains large quantities of extracellular 
DNA and this is countered with aerosolized Dornase Alfa, a highly purified solution of 
recombinant human DNase. Hypertonic saline is administered as a hyper-osmolar agent to 
hydrate the airway lumen while inhaled β-agonists assist mucociliary clearance [1, 5, 55]. 
There is, however, limited evidence of the effectiveness of these therapies based on lung 
function improvement. Patients are also required on an almost daily basis to supplement 
these drugs with chest physiotherapy and the use of mechanical clearance devices to drain 
the tenacious airway mucus. 
Aggressive antibiotic therapy is the cornerstone of current CF therapy. Acute management 
in response to pulmonary exacerbation, particularly as a result of P. aeruginosa infection, 
involves combination high-dose intravenous antibiotic therapy to provide synergistic 
antimicrobial activity and to slow development of resistance. The combinations are 
individualized based on the microbial flora of the patient. As part of the daily maintenance 
therapies to keep chronic infections at bay, patients also receive inhaled tobramycin and 
azithromycin at regular intervals, tobramycin in 28 day cycles, and azithromycin on 
alternate days. [1, 52]. For patients with end-stage lung disease, the last resort is lung 
transplantation. For certain patients, this has the potential to vastly improve their quality of 
life, but deciding who gets transplants is contentious, and the availability of lungs limited. 
Some of the issues pertaining to CF lung transplantation are further elucidated in a recent 
review by Braun and Merlo [56]. 
There is considerable research being carried out on treatment of the symptoms of CF with 
the aim of improving the quality of and extending life. Treating specific symptoms will 
improve the chances of patients surviving long enough that a gene-targeted therapy may 
become available. The use of antibiotics to treat long-term infections has however, 
increased the levels of antibiotic resistance in individuals with CF. Consequently, the 
development of novel antimicrobial therapies has become an important area of CF research. 
1.1.3.2 Gene therapy and CFTR modulation on the horizon 
An increased understanding of CF disease and its associated genetics has allowed the 
discovery of a number of promising CFTR modulators specific to individual genetic 
mutations. Gentamicin, shown to be able to allow ribosomes to read through premature 
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mRNA stop codons (class I mutations), was the first such molecule, and caused small 
changes in the nasal potential difference, a test used to detect changes in CFTR function [57, 
58]. However, this was only observed when doses above safe levels were used that 
consequently caused adverse side effects such as nephrotoxicity. The compound PTC 124 or 
Ataluren has had promising results in in vitro  studies, and has been shown to restore CFTR 
function to a significant fraction of the normal level in mice with the class I G542X CFTR 
mutation [59]. Phase 2 trials in humans have shown positive changes in chloride transport 
and increases in lung function as measured by FEV1 (forced expiratory volume in 1 second) 
[60, 61]. Phase 3 trials are underway to determine the long-term efficacy and safety of this 
treatment, but concerns remain about the possibility of malignancies as a consequence of 
allowing ribosomes to read through native stop codons. So far, the drug seems specific to 
premature stop codons and could be effective in other diseases where premature stop 
codons are an issue (e.g., Duchenne Muscular Dystrophy [62].) 
The most successful of the recent CFTR-modulating compounds is VX-770 or Ivacaftor. This 
is a CFTR potentiator that increases the opening of CFTR channels, although its mechanisms 
of action are not completely understood. It has been shown in vitro to effectively increase 
CFTR opening of class III G551D mutations. A trial of Ivacaftor for 96 weeks at 150 mg twice 
daily in patients with the ΔF508 mutation aged 12 or above showed no significant increase 
in chloride transport or FEV1 [63]. When a similar dose was administered to patients with at 
least one G551D mutation in a randomized, double-blind, placebo-controlled, multicentre 
trial, marked improvements in disease symptoms were observed. By 48 weeks, 10% vs. 0% 
increase in FEV1 was observed in Ivacaftor vs. placebo groups. In the Ivacaftor group, 
increases were also observed in chloride transport, the patients gained more weight, and 
they scored their quality of life higher. In addition, the number of pulmonary exacerbations 
was almost halved in that time period for the treated group [64]. Because of these dramatic 
improvements in CFTR function, Ivacaftor has been approved by the FDA for patients with 
at least one G551D mutation. Although it was made available to Australian patients under 
the pharmaceutical benefits scheme in December 2014 [65], it does come at a significant 
cost: almost $300,000 per year per patient and is needed throughout their lifetime. A 
significant drawback of Ivacaftor is that it is only effective in individuals with the rare 
G511D mutation (present only in 4%–5% of CF patients [5, 39]). Another CFTR modulator, VX-
809 or Lumacaftor, has been shown in vitro to correct the folding and processing of CFTR in 
ΔF508 cell lines and to increase chloride secretions in human bronchial epithelial cells [66]. 
However, in a phase 2b study, no change in chloride transport, lung function or 
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exacerbation rate were observed [67]. Given these poor results, the use of Lumacaftor in 
conjunction with Ivacaftor was studied in a phase 2 study, because Lumacaftor could 
potentially correct CFTR folding and processing and Ivacaftor could then potentiate the 
opening of the CFTR. The study found a 7% increase in FEV1 compared with placebo  and a 
Phase 3 randomized, double blind, placebo controlled, parallel group study is currently 
being carried out to further establish the efficacy of this combination therapy [68]. 
There are also drugs that attempt to correct the biochemical defects in CF without 
influencing CFTR. Moli1901 or Lancovutide attempts to compensate for CFTR by 
stimulating an alternate chloride channel and has shown promising increases in FEV1 in 
early trials [69]. Phase 2b studies were completed in late 2013 but the results are yet to be 
published. Another drug, Denufosol, which attempts to reduce epithelial sodium 
reabsorption through ENaC, also showed promising initial results, but phase 3 trials 
determined that the drug failed to meet its primary endpoint, a significant increase in 
baseline FEV1 [70]. 
With the exception of Ivacaftor, which is limited in its use to only people with the rare 
G551D mutation, all other CFTR-modulating drugs require further research before they can 
be successfully applied to individuals with CF. Consequently, the use and development of 
symptom-targeted drugs and particularly of novel antimicrobial therapies remain essential 
to treating individuals with CF to enhancing their quality and length of life. 
 
1.1.4 Pathogens in Cystic Fibrosis lung infections 
 
1.1.4.1 Impaired immune response to pathogens in CF 
Human lungs process, on average, over 10,000 L of air a day, and are well equipped for 
coping with the associated barrage of microbes. The ciliated airway epithelial cells and 
mucus provide a physical barrier to prevent infection. The epithelial cells and closely 
associated cells involved in the immune system also have specialized receptors that allow 
them to detect the presence of a diverse multitude of pathogens. Upon detection of 
pathogens, the host cells, both epithelia and inflammatory cells, respond through a number 
of mechanisms including inflammation and induction of innate and adaptive immunity. The 
physical barriers and innate and adaptive immune responses to P. aeruginosa in human 
airways are summarized in Figure 1.4.  
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The normal immune response to pathogens is impaired in people with CF. A striking feature 
of the CF airway immune response is excessive inflammation, and is thought to contribute 
significantly to the declining pulmonary function. Neutrophils and cytokines are known to 
be found in high concentrations in the airway fluids of individuals with CF, even in young 
children [71].While the cytokines help in the recruitment of immune cells, the neutrophils 
themselves produce large quantities of proteases that can digest a diverse range of 
substrates, including host cell proteins. The excessive neutrophil infiltration of the airways 
seen in CF overwhelms the airway tissue, with the cleavage of structural proteins resulting 
in bronchiectasis [72]. Upon cell death the neutrophils release oxygen radicals that further 
contribute to airway damage [73]. There is also debate about whether the excessive 
inflammation in the airway is the result of inflammation that is disproportionate to 
infection, or if there is excessive inflammation independent of airway infections [Reviewed 
in 74, 75]. Much research has been aimed at understanding the mechanisms that link the 
CFTR function to modulated inflammation but these mechanisms are yet to be fully 
described. Regardless of the cause, correction of the inflammatory defects is a potential 
therapeutic target in individuals with CF.  




Figure 1.4 Outline of host immune responses to P. aeruginosa. The epithelial cells in the airway form a 
physical barrier to infection and employ various mechanisms to counter infection from pathogens like 
P. aeruginosa. The predominant cell type in the airways, the ciliated epithelial cell, has hair like 
extensions powered by mitochondria, which beat rhythmically in a unidirectional manner to force 
particulates out of the lungs, providing a mechanical mechanism to keep the airway free of pathogens. 
Interspersed among the ciliated epithelial cells are secretory cells producing surfactants and mucins. 
The surfactants, while playing an important role in maintaining the surface tension of the air-liquid 
interface and thus preventing the collapse of the airway, are also capable of binding and opsonizing 
microbial pathogens [76]. The mucins are high molecular weight glycolipids that trap foreign particles, 
which can then be transported out of the airway by cilia-mediated transport. The inter-cellular junction 
proteins play an important role in maintaining the structural integrity of the respiratory epithelium [77, 
78], making the epithelia less permeable to pathogens and their products. The airway also plays an 
important role in the initial identification of the pathogen and the regulation of the amplitude of the 
immune response to the pathogen. The activation of specific pattern recognition receptors 
(PAMPs)such as Toll-like Receptors (TLRs) and NOD-like receptors (NLRs) by P. aeruginosa initiate 
epithelial cell-intrinsic signalling pathways via nuclear factor κB (NF-κB), mitogen-activated protein 
kinase (MAPK) and interferon regulatory factors (IRF). This causes the production of various cytokines, 
chemokines, interferons, reactive oxygen species and antimicrobial proteins that help in the 
recruitment and activation of the innate and adaptive immune responses and assist in killing the 
pathogen. Multiple pathways that regulate apoptosis, the unfolded protein response and autophagy 
are also activated, and these pathways help to integrate the requirements to clear infection with cell 
survival. Alveolar macrophages are also recruited during infection and play a significant role in 
sequestering antigen and phagocytising foreign material. Dendritic cells in the basal lamina trigger the 
adaptive response, bringing B and T-cells into the picture. The degranulation of phagocytic cells also 
releases antimicrobial cationic molecules such as LL-37 and lactoferrin [79]. Figure adapted from 
Whitsett and Alenghat, 2015 [78] 
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1.1.4.2 Cystic Fibrosis lung microbiome and clinical significance 
 
CF lung infections are polymicrobial in nature and the pathogens vary between individuals 
and over time (Figure 1.5). Infections in CF children tend to be caused by Staphylococcus 
aureus and common airway commensals like Haemophilus influenzae [80, 81]. The effects of 
long-term colonization by S. aureus are not considered to be as severe as those of some of 
the other CF pathogens, but the emergence of particularly virulent strains of Methicillin 
resistant S.aureus (MRSA) is concerning to the CF community [81]. The prevalence of H. 
influenza infection wanes as patients get older and there is contention as to what role, if any, 
H. influenzae plays in pulmonary disease progression. Rosenfield and colleagues have 
shown that H. influenzae can induce inflammation in the airways, but a cross-sectional 
analysis of 7,010 European CF patients found no association between H. influenzae 
colonization and decreased FEV1 [81-83]. 
It is believed that these early infections damage the epithelial surfaces, and in conjunction 
with the inhibited mucociliary clearance mechanisms of the lungs and the aberrant 
inflammatory status, prime the airways for infections with opportunistic pathogens. The 
major pathogen in adult CF patients is P. aeruginosa. An estimated 80%–90% of adult CF 
 
Figure 1.5 Changing microbial ecology of the CF lung. Figure shows the prevalence of prominent CF 
pathogens in the lungs percentage of American CF patients (2012). * P.aeruginosa includes multi-drug 
resistant P.aeruginosa (** MDR-PA), ¥ S.aureus includes methicillin-resistant S.aureus (‡ MRSA). Figure 
from Patient Registry Annual Data Report of the US Cystic Fibrosis Foundation, 2012 [5] 
. 
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patients produce respiratory cultures containing P. aeruginosa, and infection with P. 
aeruginosa is associated with worse clinical progression of disease [5, 19]. The prevalence 
of multi-drug resistant P. aeruginosa (MDR-PA), has doubled in the US to 9.5% compared 
with CF respiratory cultures positive for (MDR-PA) in the decade preceding 2012 [5]. Other 
CF pathogens include Burkholderia cepacia complex (Bcc), Mycobacterium species, 
Pandoraea species and the nosocomial pathogens Stenotrophomonas maltophilia and 
Achromobacter xylosoxidan. The Bcc is a group of related bacteria consisting of a number of 
species. Despite their low prevalence, approximately 2.6% in the 2012 US CF population, 
infection with Bcc is linked to rapid decline in lung function and increased mortality, and is 
sometimes associated with necrotising pneumonia [5, 81, 84, 85]. Recent molecular studies 
indicate that there is a highly diverse bacterial community within the CF lung, with many 
different bacterial species, including anaerobes, also present [80, 86]. 
The most common fungus involved in CF respiratory disease is Aspergillus fumigatus [87]. A. 
fumigatus can cause a chronic allergy-associated inflammatory response in some CF 
patients and invasive infection after lung transplantation, but evidence correlating its 
prevalence with worse lung function is poor [80, 81]. A number of other fungal and yeast 
species including Exophiala (Wangiella) dermatitidis, Scedosporium species and the yeast 
species of Candida have also been recovered from CF respiratory cultures. Reported 
incidences vary dramatically from study to study, ranging from as low as 11% to as high as 
78%. This is attributed to the use of different culturing methods, but what is clear is that the 
incidence increases with patient age [80]. 
Individuals with CF also frequently acquire viral respiratory infections, but surprisingly, 
these do not occur any more frequently in CF patients than in the healthy population. 
However, viral respiratory infections in CF are usually more severe, last longer and often 
cause pulmonary exacerbations that may lead to hospitalization [81, 88, 89]. The most 
common virus seen in CF is respiratory syncytial virus, followed closely by influenza A and 
B viruses. Parainfluenza virus, rhinovirus and adenovirus infections are less frequently 
observed [90]. It is thought that virus infections have little long-term influence on declining 
lung function [81], but that they may predispose individuals with CF to more pathogenic 
bacteria such as P. aeruginosa [89]. 
CF patients will typically experience recurrent episodes of pulmonary symptoms called 
exacerbations, which present as increased respiratory symptoms including cough, 
pneumothorax, haemoptysis and increased sputum production and airway obstruction. 
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Quite often, these exacerbations require hospitalization. An increasing number of 
exacerbations is associated with worse lung function, because the persistent infections 
cause irreversible break down of the bronchial muscle and elastic tissue. The resulting 
pulmonary decline leads to eventual respiratory failure [91] 
Despite the advances in CF therapies in the last 3 decades and the increased life expectancy 
and quality of life, microbial infections still cause substantial damage to the CF lung. It 
remains important to develop our understanding of the mechanisms these microbes utilize 
to persist in the lung and the interactions among the microbes themselves and between the 
microbes and host cells, thereby allowing us to improve and refine therapies targeting these 
infections. 
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1.2 PSEUDOMONAS AERUGINOSA 
 
P. aeruginosa is a ubiquitous Gram-negative rod that is capable of causing severe 
opportunistic infections in immunocompromised individuals. Its metabolic diversity, overall 
adaptability and intrinsic ability to develop antibiotic resistance facilitates its survival on a 
diverse range of natural and artificial environments/surfaces. It is particularly troublesome 
on medical surfaces such as ventilators, and in the US, it is among the most common 
nosocomial pathogens and the second most frequently isolated pathogen from patients with 
ventilator-associated pneumonia [92]. Because it is the major CF pathogen and because of 
its association with increased clinical deterioration [5, 19], P. aeruginosa is the most widely 
studied pathogen, and eradication/ prevention of P. aeruginosa would have important 
implications for CF research and therapies and other P. aeruginosa infections. 
 
1.2.1 Genomic plasticity of P. aeruginosa 
P. aeruginosa has the largest genome of any disease-causing bacteria, ranging from 6.22 Mb 
to 6.91 Mb depending on the strain [93]. There are dozens of strains of P. aeruginosa, 32 of 
which had been completely or partially sequenced by late 2012 [92]. The sequencing of a 
number of strains shows that around 90% of the genomic content is conserved between 
strains. The remaining ‘regions of genomic plasticity’ contain genes unique to that strain or 
to a small subset of strains [94], suggesting that environmental selection pressures play an 
important role in the evolution of the P. aeruginosa genome [93]. Bacteria with higher 
proportions of regulatory proteins in their genomes are thought to be capable of surviving 
in diverse environments, and PAO1, the first of the P. aeruginosa strains to be sequenced, 
has 521 genes or nearly 10% of its genome dedicated to encoding regulatory proteins, far 
higher than most other bacteria [95].  
P. aeruginosa displays remarkable metabolic diversity, growing on/in various nutrient-poor 
environments/surfaces. The PAO1 sequencing identified genes involved in β-oxidation of 
various carbon compounds and approximately 300 cytoplasmic transport systems [95]. 
Studies of the P. aeruginosa genome have identified numerous other systems important to P. 
aeruginosa pathogenicity and persistence, including virulence factors, intrinsic drug efflux 
and resistance systems, and protein secretion systems [95]. In summary, its genomic 
plasticity enhances the potential of P. aeruginosa to adapt to, and survive in, a diverse range 
of environments. 
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1.2.2. Mechanisms of P. aeruginosa pathogenesis 
 
P.aeruginosa has a diverse range of virulence factors and associated mechanisms that 
contribute to respiratory pathogenesis. What follows is a description of such key virulence 
factors and pathogenic mechanisms and how they contribute to P. aeruginosa infections 
1.2.2.1 Flagella and pili 
Each P. aeruginosa cell has a single polar flagellum and any number of short type IV pili on 
the cell surface. Flagella are essential for the motility of the bacteria, but they also function 
as adhesins to epithelial membranes. Flagella mutants have been shown to be less invasive 
[96], and cause decreased mortality [97] in murine models of P. aeruginosa infection. 
Binding of flagella to the host epithelial cells elicits a potent neutrophilic inflammatory 
response, which can be detrimental to the airways during chronic infections because of 
persistent inflammation [98]. Flagella can also elicit a caspase-1-mediated response in host 
macrophages via the Nod-like receptor (NLR) IPAF [99]. Type IV pili are important adhesins 
of P. aeruginosa, they contribute to its swarming motility and facilitate aggregation of 
bacteria to form micro-colonies, a strategy that concentrates P. aeruginosa and potentially 
protects it from the host immune response [100, 101]. 
1.2.2.2 Type 3 secretion systems 
P. aeruginosa utilizes type 3 secretion systems (T3SS), where a needle-like structure on the 
cell surface, closely related to flagella, is used to secrete toxins directly into host cells. The 
two main P. aeruginosa exotoxins transported this way are exoU and exoS. These exotoxins 
target host-cell actin cytoskeletal organization, degrading the integrity of the plasma 
membrane and causing rapid host cell death. Death of the epithelial cells results in the loss 
of the physical barrier in the airway, aggravating P. aeruginosa infection, and is thought to 
lead to the symptoms observed during bacterial pneumonia, including haemoptysis, 
bronchiectasis, and necrosis of lung tissue [102]. 
1.2.2.3 Proteases 
P. aeruginosa produces a number or proteases that contribute to persistence in the lung. 
Alkaline protease and protease IV are both able to degrade host complement proteins, 
fibronectin, fibrinogen and immunoglobulins [103, 104]. Alkaline protease also helps P. 
aeruginosa to avoid detection by the immune system by interfering with flagella recognition 
through the host TLR5 [105]. LasA and LasB are elastases produced by P. aeruginosa. LasA 
has low elastolytic activity and is thought to instead enhance LasB activity [106]. LasB, 
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together with Protease IV, is thought to degrade the lung surfactants that assist in 
opsonizing bacteria, thus allowing P. aeruginosa to evade phagocytosis [104, 107]. 
1.2.2.4 Lipopolysaccharide 
The outer membrane of P. aeruginosa is coated with lipopolysaccharide (LPS), a complex 
glycolipid. P. aeruginosa LPS consists of three domains: the membrane bound lipid A that 
anchors LPS to the membrane, a polysaccharide core and a highly variable glycan polymer 
known as O-antigen that is exposed on the outer surface. LPS plays an important role in 
instigating the P. aeruginosa immune response and has a role in antigenicity [108]. Lipid A 
binds to host TLR4 and activates the nuclear factor kappa B (NFκB) pathway that triggers 
the IL-8 mediated neutrophilic infiltration characteristic of P. aeruginosa infections. The O-
antigen of the P. aeruginosa LPS is responsible for conferring serogroup specificity and it is 
believed that the polysaccharide nature of P. aeruginosa LPS O-antigen is responsible for the 
strong antibody response towards O-antigen [108]. 
1.2.2.5 Rhamnolipid 
The surfactant rhamnolipid is essential for P. aeruginosa swarming motility [109], 
influences biofilm formation [110] and has antimicrobial activities [111]. Rhamnolipid is 
also considered to have a role in protecting P. aeruginosa biofilms against the host immune 
system [112] and are classed as virulence factor as they disrupt tight junctions in host cells 
[113]. Disruption of the epithelia allows infiltration of P. aeruginosa, promoting 
development of infection. 
1.2.2.6 Alginate  
The production of the exopolysaccharide alginate is important in the colonization by P. 
aeruginosa of medical devices and cell surfaces, particularly in CF [114], and P. aeruginosa 
strains isolated from the CF lung typically overexpress alginate (mucoid variants). Though 
not essential for the formation of biofilms [115], alginate plays an important role in the 
maturation of biofilms and helps maintain hydration of bacterial cells in biofilms [116]. 
Alginate also offers protection by restricting the penetration of antibiotics and host 
molecules through the biofilm matrix and thus contributes to the pathogenesis of P. 
aeruginosa [117]. 
1.2.2.7 Other virulence factors 
P. aeruginosa colonies have a characteristic blue-green colour resulting from another 
virulence causing molecule, the pigment pyocyanin. Pyocyanin is capable of disrupting host 
catalase activity, inhibiting mitochondrial electron transport in the epithelia and causing 
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oxidative stress in host cells [118]. Other well characterized P. aeruginosa virulence factors 
include pyoverdine, which sequesters iron from the host to help establish infection and 
support biofilm formation [119, 120], endotoxin A, which can inhibit protein synthesis in 
host cells [121], hydrogen cyanide, a secondary metabolite that inhibits many host cellular 
processes [122], and lipases, which can break down opsonising surfactants in the airway 
[92]. P. aeruginosa itself is protected from cyanide as it possesses a cyanide-insensitive 
oxidase [123]. 
1.2.2.8 Quorum sensing 
An important mechanism that assists in P. aeruginosa persistence in the CF lung and 
contributes significantly to its pathogenesis is quorum sensing (QS). QS is mediated by small 
diffusible molecules produced by the bacteria that allow the coordination of community-
wide activities. Almost a quarter of the expressed P. aeruginosa proteome is controlled by 
QS [124]. In P. aeruginosa, QS plays an essential role in the expression  and regulation of 
numerous virulence determinants including, but not limited to, T3SSs, exotoxins, proteases, 
rhamnolipid, alginate, pyocyanin, pyoverdine, and hydrogen cyanide [Reviewed in 119]. QS 
also plays an important role in the formation of biofilms. Biofilms essentially envelop the 
bacterial community in an exopolymeric substance (EPS) matrix (mixture of 
polysaccharides, extracellular DNA and proteins), protecting it from the host’s immune 
responses and external antimicrobial agents like antibiotics, and facilitates survival of the P. 
aeruginosa. Bacteria enveloped in such biofilms are considered to be up to 1000 times more 
resistant to antibiotics than those in a planktonic state [125]. QS and biofilm formation is 
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1.2.3 P. aeruginosa infections in CF 
 
P. aeruginosa infections in CF evolve over-time. Initial P. aeruginosa infections occur 
intermittently during the first decade of life [126]. These infections are usually contracted 
from the environment, and may be eradicated through the aggressive early use of anti-
Pseudomonal antibiotics (median P. aeruginosa free period 18−19 months) [127, 128] [127, 
128] [127, 128] [127, 128] [127, 128] [127, 128]. However, P. aeruginosa generally recurs 
or persists leading to chronic infection [129]. During chronic infection P. aeruginosa is 
exposed to multiple stresses driving adaption to the lung environment. Mutation resulting 
in overproduction of alginate is characteristic of these adapted P. aeruginosa [116], and 
mucoidy offers significant protection to the bacteria from antibiotics and the host immune 
system [117]. The evolution of non-mucoid, and possibly easier to clear, early P. aeruginosa 
infections into the persistent chronic mucoid P. aeruginosa is detailed further in Figure 1.6. 
 
Figure 1.6 Evolution of P. aeruginosa infection in the CF lung. Initial colonization of the CF airway by P. 
aeruginosa from environmental sources is intermittent and considered to be more susceptible to anti-
Pseudomonal therapies [126, 130]. These early P. aeruginosa are exposed to a number of stresses in 
the airway, including antimicrobials, the immune response, nutrient and iron limitations, and hypoxia 
[131], and over time the P. aeruginosa in the airways develop mutations that allow them to persist in 
the airways [129]. These mutants typically express reduced levels of acute virulence factors but 
characteristically overproduce alginate. As a result, the biofilms produced by these mucoid P. 
aeruginosa have increased protection against the host immune response and conventional antibiotics 
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1.2.4 P. aeruginosa QS and biofilm formation 
 
1.2.4.1 P. aeruginosa QS signalling systems 
QS was first described in the 1970s, when researchers discovered that the expression of an 
endogenous luciferase by Vibrio fischeri was population density dependent [132]. We now 
understand that in a basic QS system (Figure 1.7), a bacterial inducer protein helps 
synthesize small, diffusible signalling molecules that are released into the extracellular 
space, and the concentration of the molecule increases in proportion to cell density. A 
cognate receptor protein, when bound to the signal molecule, functions as a transcriptional 
regulator of QS-dependent genes including that encoding the inducer protein, thereby 
allowing the molecule to also regulate its own expression. This biochemical mechanism 
allows cell density-dependent regulation of community-wide gene expression, and is 
conserved across many Gram-negative bacteria. 
QS in P. aeruginosa is a complex system that is used to monitor cell density, regulate 
virulence factor production, induce biofilm formation and monitor changes in the 
environment and availability of nutrients. The P. aeruginosa quorum signalling system 
consists of three such QS circuits arranged hierarchically, the Las, Rhl and PQS systems 
(Figure 1.8). At the top of the P. aeruginosa QS hierarchy is the Las system, which produces 
an acyl homoserine lactone (AHL) signalling molecule N-3-oxo-dodecanoyl-L-homoserine 
lactone (C12HSL), a fatty acyl chain linked to a homoserine lactone ring via an amine bond. 
The lactone rings are derived from S-adenosylmethionine, a common co-substrate involved 
in methyl group transfers, while the variable acyl chains are obtained from the cellular acyl-
acyl carrier protein pool [133]. C12HSL production is catalysed by the LasI synthase 
(inducer) and is recognized by its cognate receptor LasR, a transcriptional regulator. The 
Las system is directly involved in the regulation of a number of key virulence factors 
including the expression of alkaline proteases, exotoxins [134] and elastases LasA and LasB 
[135]. P. aeruginosa harbouring lasR mutations are avirulent in in vivo mouse models of 
infection [136, 137]. The Las system also regulates the Rhl system, because LasR bound to 
C12HSL up-regulates the expression of RhlR, the receptor for the Rhl system [138]. The Rhl 
system synthase RhlI is necessary for the production of another acylated homoserine 
lactone, N-butanoyl-L-homoserine lactone (C4HSL) which binds to its cognate receptor 
RhlR. The Rhl system is involved in the regulation of the T3SS [139] and production of 
rhamnolipid [135]. Both the Las and Rhl systems are intimately connected to the third QS 
system, the PQS system. LasR bound to C12HSL is required for synthesis of the PQS system  





Figure 1.8 The P. aeruginosa QS systems are hierarchically arranged. The P. aeruginosa QS systems 
includes three hierarchically arranged circuits. Black arrows represent positive regulation while red 
arrows indicate negative regulation. At the top of the hierarchy is the Las system, which utilizes the 
C12HSL signalling molecule and is capable of positively regulating itself and both the Rhl and PQS 
systems as well as genes in its regulon. The RhlR system utilizes C4HSL as its signalling molecule and 
regulates genes in the Rhl regulon while also positively regulating itself and negatively regulating the 




Figure 1.7 The basic quorum signalling system. Figure illustrates a basic QS system involving AHL 
(purple ball) as the signalling molecule. The bacterial inducer gene produces the inducer (orange oval) 
protein which helps to produces the small, diffusible signalling molecules (AHL) that diffuse into the 
extracellular space. As the bacterial population increases, the concentration of the molecule increases 
outside, and the signal molecule diffuses into surrounding bacteria. Once the concentration is high 
enough, a bacterial receptor protein (blue oval) modulates gene expression in the individual bacteria, 
expressing more inducer protein and effecting a population-wide change in gene expression. Figure 
from Lazdunski et al., 2005. [140]. 
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signalling molecule 2-heptyl-3-hydroxy-4-quinolone or Pseudomonas QS (PQS), which in 
turn influences the transcription of rhlI and rhlR [141, 142]. However, RhlR bound to C4HSL 
inhibits PQS synthesis [141, 142]. PQS plays an important role in the production of 
pyoverdine. It has been identified that, to keep these systems in check and provide a 
mechanism whereby a threshold for activation can be created, the quorum signalling 
control repressor (QscR) controls the timing of and repression of QS [143]. It forms 
complexes with LasR and RhlR, thereby by repressing P. aeruginosa virulence. To ensure 
that the bacteria does not QS beyond its energetic means, lasR and rhlR expression are 
under the control of Vfr, a protein that responds to the metabolic and energy status of the 
cell [140]. AlgR2, historically thought to regulate alginate biosynthesis, also regulates the QS 
in a similar way to Vfr [140, 144]. The QS system is further regulated by RsaL, a major Las 
transcriptional repressor[145], QteE, which prevents accumulation of both LasR and RhlR 
[146], and QslA, which ensures LasR does not initiate transcription prematurely [147].  
1.2.4.2 P. aeruginosa biofilms 
Biofilms can be defined as bacterial communities that are adherent to each other and/or to 
interfaces and surfaces while enveloped in extracellular polymeric substances [148]. P. 
aeruginosa biofilms consist of differentiated mushroom- and pillar-like structures 
composed of an exopolysaccharide matrix consisting of a mixture of polysaccharides, 
extracellular DNA, lipids and proteins. These structures are interconnected by fluid-filled 
channels that allow the transfer of nutrients and waste. 
In the development of lung infections, planktonic bacteria are ineffective in sustaining 
chronic infections [149]. Biofilm formation begins with cells attaching to each other and the 
supporting surface. At this point, the bacteria begin to switch their mode of growth. Bis-(3-
5,) cyclic dimeric guanosine monophosphate, an intracellular messenger, together with the 
GAC system, a two component regulatory system, play major roles in the establishment of 
biofilms [119, 150, 151]. QS plays an equally important role in the formation of biofilms. 
Davies and colleagues established this when they studied the biofilms formed by lasI 
mutants and found that the lasI mutants produced flat biofilms that were sensitive to a 
biocide agent, while wild-type P. aeruginosa formed the normal mushroom-shaped biofilms 
that were resistant to the biocide agent. These biofilms could be rescued to ones similar to 
wild-type with the application of exogenous C12HSL [152]. In addition, AHLs have been 
detected in the lungs of mice infected with P. aeruginosa [153]. Singh and colleagues have 
observed P. aeruginosa biofilms in sputum from CF patients and observed that the QS signal 
ratios in the sputa resembled the QS signal ratios seen in in vitro biofilms (almost equal  












Figure 1.9 The P. aeruginosa biofilm. A) Mucoid P. aeruginosa strain growing on a MacConkey agar 
plate over producing alginate. When stored upside down, the material will drip onto the plate lid. 
Figure from Pritt et al., 2007 [154]. B) The characteristic mushroom- and pillar-like structures are shown 
from a 6 day PAO1 biofilm using confocal scanning laser microscopy. The squares are 61 μM on a side. 
Figure from Banin et al., 2005 [155]. C) Illustration of planktonic biofilm developing into a mature 
biofilm. The planktonic bacteria on the left begin to attach to each other and a surface. They then 
switch to a mucoid phenotype and begin to produce the exopolysaccharide matrix. These colonies of 
bacteria mature into biofilms with fluid-filled channels that support the transport of nutrients and 
waste. Individual bacteria eventually disperse into the environment and restart the biofilm formation 
cycle. Figure adapted from Monroe et al., 2007[156]. 
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amounts of C12HSL and C4HSL in biofilms and sputa when compared with 3 to 10 times 
more C12HSL than C4HSL in mid-logarithmic P.aeruginosa broth cultures) [157]. QS has 
also been shown to play roles in the production of Psl, one of the polysaccharides that make 
up the biofilm EPS [158], and extracellular DNA[159]. 
Upon irreversible attachment of bacterial cells to each other and the supporting surface, the 
bacterial cells in the biofilms begin to produce the EPS matrix. The extracellular matrix is 
comprised of three main types of polysaccharide with varying functions, extracellular DNA, 
and a collection of proteins. The three main polysaccharides in the P. aeruginosa EPS are Psl, 
Pel and alginate. Psl and Pel are both scaffolding sugars in the EPS, allowing for the 
initiation of biofilm formation and adhesion of bacteria [160-162]. They also help provide a 
physical barrier from the host immune response and antibiotics [160, 162]. Mucoid P. 
aeruginosa strains in biofilms in the CF lung typically overproduce the EPS alginate because 
of mutations in the AlgU operon , the master regulator of alginate biosynthesis [Reviewed in 
116]. While not essential for biofilm formation [115], alginate plays significant roles in 
biofilm structure, protection and maintenance [163, 164] and is believed to offer P. 
aeruginosa the protection it requires to form chronic infections in the CF lung. Extracellular 
DNA is also a vital component of the EPS matrix, providing structural support and 
protection against host immunity, and is the most significant pro-inflammatory contributor 
to the EPS matrix [159, 165-167]. The proteins in the EPS mainly have supporting roles in 
structure and adhesion [168]. 
The maturing biofilm develops into the characteristic mushroom- and pillar-like structures 
supported by the EPS and interspersed with fluid-filled channels that allow for the exchange 
of nutrients and waste products [169] (Figure 1.9). These structures limit diffusion of 
oxygen, antibiotics and immune mediators, providing considerable protection to P. 
aeruginosa. P. aeruginosa in biofilms are considered to be 1000 times more resistant to 
antibiotics than their planktonic counterparts [125]. The biofilms also play an important 
role in the development of antibiotic resistance, as further described in section 1.2.5. 
Eventually, bacterial cells detach from the biofilm allowing dispersion of P. aeruginosa 
through the environment to form new biofilms 
 
 
1. Introduction and literature review 
45 
 
1.2.5 Antibiotic resistance in P. aeruginosa 
 
Once P. aeruginosa biofilms are established in the airways, they are virtually impossible to 
clear either by the host immune response or through the use of conventional antibiotics. 
There are three hypothesized mechanisms for the resistance that biofilms have against 
antibiotics. Firstly, the thickness of the biofilm prevents the penetration of the antibiotic 
into the biofilm where it can affect the bacteria, and consequently the bacteria are exposed 
to sub-inhibitory concentrations, resulting in decreased killing. Secondly, the zones of 
nutrient depletion and waste accumulation in the biofilms and the generally hypoxic 
conditions in biofilms inhibit antibiotic activity [170]. Finally, exposure to sub-inhibitory 
concentrations of antibiotics helps to select for bacteria that are more resistant to the 
antibiotics [170]. The biofilms also offer protection against the host immune cells. Freshly 
isolated neutrophils have been shown to be ineffective in phagocytising QS-proficient P. 
aeruginosa biofilms, but effective when exposed to a QS mutant biofilm [112, 171]. One of 
the ways that biofilms protect against host neutrophils is thought to be through utilizing a 
‘biofilm shield’, where the bipolar rhamnolipid is localized to the biofilm surface and lyses 
the invading neutrophils [172]. 
Of particular concern to CF physicians is the increased incidence of antibiotic-resistant P. 
aeruginosa. The prevalence of MDR-PA in the US has doubled from 4.2% in 2002 to 9.5% in 
2012 [5], and is thought to be highly associated with the increased use of antibiotics [173]. 
The increase in resistance rates and the absence of novel therapies have seen physicians 
resort to the use of older antibiotics, despite their toxicity [174]. 
P. aeruginosa demonstrates remarkable versatility in its mechanisms for developing 
resistance to antibiotics. Particularly useful are the two-component regulatory systems 
(TCSs) [92]. TCSs are comprised of a primitive signal transduction system, where a 
membrane-bound sensor protein monitors changes in the extracellular environment and 
then activates a transcriptional regulator to alter gene expression in response to stimulus. 
TCSs are generally used by bacteria to adapt to their environment, and particular P. 
aeruginosa TCSs such as GAC have been implicated as participating in biofilm formation and 
antibiotic resistance [119, 175]. 
Other mechanisms include the horizontal transfer of DNA [176]: the low permeability of the 
outer membrane of P. aeruginosa means that the uptake of small hydrophilic molecules, 
including particular antibiotics, is restricted [176], membrane efflux (Mex) pumps that 
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allow it to efflux a broad range of antibiotics including β-lactams [176], and AmpC in the 
periplasm, a β-lactamase that can efficiently hydrolyse a number of common antibiotics 
including penicillin [177]. 
Another issue contributing to antibiotic resistance is the way antibiotics are administered to 
patients. One such example is that of the commonly used CF antibiotic tobramycin, the use 
of which results in increased FEV1 and reduced morbidity [178]. However, translation of in 
vitro microbiological determinations of P. aeruginosa inhibitory antibiotic concentrations 
into clinically achievable concentrations is difficult. Poor penetration of the antibiotic into 
the bronchial secretions of CF patients impairs its antibiotic activity while increasing the 
development of antibiotic resistance [179]. Attempts to increase dosages must be balanced 
with the nephrotoxicity and ototoxicity of the antibiotic [179, 180]. In a study by Smith and 
colleagues, after 3 months of three times daily 600 mg doses of inhaled tobramycin, the 
proportion of CF patients with P. aeruginosa cultures that have a minimum inhibitory 
concentration of antibiotic of > 8 µg/mL had increased from 29% to 73%. Thus, care must 
be taken with the administration of antibiotics to CF patients. Tobramycin, as part of 
maintenance therapy, is typically administered intermittently (on a monthly basis) to CF 
patients. 
 
1.2.6 P. aeruginosa inter-kingdom signalling 
 
P. aeruginosa QS molecules co-ordinate bacterial virulence, but importantly they are also 
capable of modifying the immune response of their mammalian hosts in a process termed 
inter-kingdom signalling. In the CF lung, inter-kingdom signalling further exacerbates the 
already altered immune signalling. This bipartite attack on the host makes QS an important 
feature in P. aeruginosa pathogenesis. Williams and colleagues demonstrated that both 
major AHLs produced by P. aeruginosa could traverse mammalian cell membranes and, 
once inside the cell, they retain their biological activity [181]. It is thought that C12HSL 
enters the cells passively and that the lipophilic nature of the AHLs facilitates their 
transport across the plasma and nuclear membrane [182, 183]. 
Once inside the host cells, C12HSL is capable of influencing multiple cellular processes, as 
summarized in Table 1.3, including modulating multiple aspects of host immunity, inducing 
apoptosis in a range of cells, modulating calcium transport and inducing the unfolded 
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Table 1.3 Table of evidence on effects of C12HSL on the mammalian host 
Specific Feature Effect 
Immune system 
Peripheral Blood Mononuclear 
Cells 
(PBMC) 
 Immunosuppressive effect on human PBMC [184, 185] 
 Influences T-cell cytokine production [186] 
Lymphocytes  Inhibits mitogen-induced lymphocyte proliferation in murine macrophages [187] 
NF-κB  Disrupts NF-κB signalling in murine macrophages, fibroblasts and epithelia [188] 
 Significant over-representation of differentially expressed genes in the NF-κB pathway in a 
transcriptome array of human airway epithelial cells treated with C12HSL [189] 
 Significantly over-represented gene ontology of positive regulation of the NF-κB cascade in a 
transcriptome array of human airway epithelial cells treated with C12HSL [189] 
Tumor necrosis factor alpha 
(TNF-α) 
 Suppress LPS-induced TNF-α secretion in murine macrophages [187, 188, 190] and human 
macrophages [187] 
 Significant over-representation of differentially expressed genes in the TNF-α pathway in a 
transcriptome array of human airway epithelial cells treated with C12HSL [189] 
Interleukins (IL) IL-6, IL-8, IL-12  Increased IL-6 in CF airway epithelial cell lines (wild-type and ΔF508) [189] 
 Influences Il-6 in murine mast cells [191] 
 Increase in Il-6 and Il-8 gene expression in murine fibroblasts [192] 
 Increase in IL6 and IL8 gene expression in human vascular endothelial cells [192] 
 Increase in IL-8 neutrophil attractant in human airway epithelial cells [193] 
 Down-regulates LPS-induced proinflammatory cytokine Il-12 production in murine 
macrophages [187] 
 Significantly over-represented gene ontology of positive regulation of cytokine production in 
a transcriptome array of human airway epithelial cells treated with C12HSL [189] 
Cox-2  Increase in Cox2 gene expression in murine fibroblasts [192] 
 Increase in COX2 gene expression in human vascular endothelial cells [192] 
 Increased COX2 in human lung fibroblasts [194] 
Toll-Like Receptors (TLRs)  Regulate TLR expression in monocytes [195] 
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Specific Feature Effect 
Nod-Like Receptors (NLRs)  Significant over-representation of differentially expressed genes in the NLR signalling 
pathway in a transcriptome array of human airway epithelial cells treated with C12HSL [189] 
Mitogen-activated protein kinases 
(MAPK) 
 Stimulation of phagocytic activity through p38 MAPK pathway in human macrophages [196] 
 Significant over-representation of differentially expressed genes in the MAPK signalling 
pathway in a transcriptome array of human airway epithelial cells treated with C12HSL [189] 
 Significantly over-represented gene ontology of MAPK activity in a transcriptome array of 
human airway epithelial cells treated with C12HSL [189] 
c-Jun N-terminal kinases (JNK)  Significant over-representation of differentially expressed genes in the JNK cascade in a 
transcriptome array of human airway epithelial cells treated with C12HSL [189] 
Apoptosis 
  Murine macrophages[197, 198] and human macrophages [197] 
 Murine fibroblasts [192, 199] 
 Murine mast cells [191] 
 Human breast carcinoma cells [200] 
 Human epithelial colorectal adenocarcinoma cells [201] 
 Human Jurkat T lymphocytes [202] 
 Human vascular endothelial cells [192] 
 Human airway epithelia [203] 
ER stress and unfolded protein response 
  Activates PERK, an ER stress inducer, and inhibits protein synthesis in murine embryonic 
fibroblasts [204] 
 Increased UPR in human aortic endothelial cells [205] and mouse macrophages [206] 
 Depolarisation of mitochondrial membrane potential in human airway epithelial cells [203] 
Epithelial integrity 
  Impaired epithelial barrier function via delocalization of tight junction protein in human 
intestinal epithelia [207, 208] 
 Causes tight junction disassembly in airway epithelial cells [203] 
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Specific Feature Effect 
Calcium ion regulation 
  Calcium release from ER into cytosol in murine fibroblasts [192] 
 Increased intracellular calcium release in murine and human mast cells [191] 
 Significantly over-represented gene ontology of calcium signalling in the CD4+ T-cell receptor 
pathway in a transcriptome array of human airway epithelial cells treated with C12HSL [189] 
 Significantly over-represented gene ontology of response to calcium ions in a transcriptome 
array of human airway epithelial cells treated with C12HSL [189] 
 Significantly over-represented gene ontology of calcium sensitive transcription factors ATF-2, 
NFATC1 and NFATC2 in a transcriptome array of human airway epithelial cells treated with 
C12HSL [189] 
 Increased intracellular calcium release in human airway epithelial cell lines wild-type  [189, 
203] and ΔF508 [189] 
 
Others 
  Vasoconstriction in porcine coronary arteries [209] 
 Bradycardia in rats [210] 
 Induces damage to human spermatozoa [211] 




protein response [188, 192, 197, 205, 212]. In fact, microarray analysis of a human alveolar 
epithelial cell line, A549, showed that treatment with 50 μM C12HSL caused significant 
changes in expression of approximately 11% of the cell’s transcriptome (over 4000 genes) 
[213]. A similar experiment using C4HSL and 4,5-dihydroxy-2,3-pentanedione, a precursor 
to a family of signalling molecules widely used in the bacterial community, showed that 
expression of far fewer genes was affected, 105 and 116 genes respectively, indicating that 
the C4HSL molecule is far less effective at modulating host cell function. In addition, only 39 
genes were common between those with altered expression caused by the three compounds 
studied [213]. This indicates that the structure of C12HSL may be vitally important for 
modulating the host immune responses to facilitate infection. In the same study, the authors 
also observed an increase in mRNA levels of mammalian genes involved in xenobiotic 
sensing and drug efflux. They followed up this finding with radiolabeled auto-inducer 
uptake assays and concluded that the host cells may be up-regulating mechanisms to expel 
C12HSL [213].The mechanisms by which C12HSL causes these changes are poorly 
understood, and only recently some progress has been made into understanding how the 
AHLs influence mammalian cellular activities. 
In 2008, Jahoor and colleagues identified the mammalian nuclear hormone receptor and a 
major inflammatory regulator, peroxisome proliferator activated receptor γ (PPARγ) as a 
binding target for C12HSL [214]. PPARγ is a ligand-dependent transcription factor that 
binds to a specific peroxisome proliferator response element (PPRE) in the promoter region 
of a gene, in the form of a heterodimer with retinoid X receptor (RXR) [215, 216]. It then 
binds an agonist or antagonist that allows for a conformational change, enabling it to recruit 
co-activators or co-repressors and instigate or suppress transcription. Native PPARγ ligands 
are typically metabolic products of fatty acids, and are usually unsaturated fatty acids such 
as 15-hydroxy-eicosatetraenoic acid and prostaglandin J2. PPARs regulate inflammation by 
modulating NF-κB signalling and influencing the JAK/STAT (c-Jun activated kinase/Signal 
transducer and activator of transcription) and MAP kinase pathways [217]. C12HSL, 
through completive inhibition of binding of PPARγ ligands, prevents formation of PPARγ-
PPRE transcriptional complex, thereby inhibiting PPARγ-dependent gene expression. In in 
vitro models, C12HSL behaves as a weak PPARγ agonist. In the in vivo environment 
however, where multiple PPARγ ligands are present, the net effect of C12HSL on PPARγ is 
hypothesized to be negative, because it interferes with stronger endogenous PPARγ 
agonists [218] through the mechanism summarized in Figure 1.10.  




In CF patients, PPARγ activity is also affected by mutations in CFTR. Studies involving Cftr-
negative mice have shown decreased PPARγ nuclear localization, DNA binding and PPARγ 
co-activator recruitment [220, 221]. Treatment of the Cftr-deficient mice with a PPARγ 
agonist was able to reverse the effects of the mutation in the gut [220, 221]. Reduced PPARγ 
levels and/or function has also been demonstrated in CF airway epithelial cells [222], and 
reduced PPARγ expression was observed in bronchoalveolar lavage cells of children with CF 
infected with P. aeruginosa compared with those infected with other pathogens [223]. It is 
believed that CFTR defects result in increased oxidative stress that sustains tissue trans-
glutaminase-2 activation and inhibits PPARγ SUMOylation (Small Ubiquitin-like Modifier). 
This favours crosslinking and proteasomal degradation of PPARγ, preventing PPARγ activity 
[224]. This combined effect of low constitutive PPARγ functionality and bacterial C12HSL 
competing with PPARγ ligands to bind to PPARγ may help to explain why P. aeruginosa is 
able to persist in the CF lung. 
More recently, a second human C12HSL receptor molecule was identified, the GTPase-
activating scaffolding protein IQGAP1 [225]. Membrane-bound IQGAP1 plays an essential 
 
Figure 1.10 Hypothetical model for the disruption by C12HSL of PPARγ-mediated repression of NF-κB.  
LPS stimulates a neutrophilic response via NF-κB and ligand-bound PPARγ is responsible for the trans-
repression of NF-κB regulated genes, exerting an anti-inflammatory effect [219]. C12HSL interferes with 
binding of normal PPARγ ligands and exerts a net negative effect on PPARγ. This allows it to prevent 
trans-repression of NF-κB and promotes prolonged inflammation [214]. Figure adapted from Jahoor et 
al., 2008 [214]. 
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role in cell shape, vesicle trafficking, and directional migration [226]. C12HSL is thought to 
use IQGAP to trigger essential changes in the cytoskeletal network [225]. Reports into the 
consequences of C12HSL interacting with IQGAP are only beginning to emerge, but IQGAP 
contains a calmodulin (primary Ca2+ sensor)-binding motif, and has previously been 
described as providing a molecular integration of Ca2+/calmodulin signalling and the 
cytoskeleton [227]. 
Increased understanding of the effects of C12HSL on the airways and the mechanisms 
through which these effects occur is vital in the development of strategies against C12HSL-
induced inter-kingdom signalling effects on host cells. Such strategies could assist in 
reducing the morbidity and mortality associated with P. aeruginosa infection. 
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1.3 QUORUM SENSING INHIBITION 
 
1.3.1 Targeting of QS as a novel therapeutic strategy 
 
The reliance on inter-cellular communication to co-ordinate community wide activity 
represents an as yet underutilized mechanism through which pathogens can be targeted in 
the search for novel antibiotic therapies. QS is widely seen as a potential target for a new 
generation of antimicrobials, the quorum sensing inhibitors (QSI). By inhibiting QS, the 
control of major regulatory components of P. aeruginosa can be modulated, assisting 
targeted therapies against P. aeruginosa. Because many bacteria use QS systems to regulate 
multiple aspects of cellular function, increased understanding of the cell-to-cell 
communication in other CF pathogens may also allow for the use of QSI therapies against 
those pathogens. 
The classical QS system seen in Gram-negative bacteria has three components: a) an inducer 
protein that assists in synthesis of b) the QS signal, and c) a cognate receptor that, when 
bound to the signal molecule, induces QS dependent gene expression. This model allows 
three potential mechanisms for QSI.  
1.3.1.1 QSI of QS inducer protein 
A number of conventional antibiotics used to treat CF patients, including ceftazadime, 
ciprofloxacin and azithromycin, display strong QSI activity [228, 229]. Though not yet fully 
understood, their anti-QS activity is thought to operate via their ability to inhibit bacterial 
protein synthesis, which results in the inhibition of the formation of QS signals by affecting 
expression of the inducers in the QS circuit. Azithromycin in particular also inhibits alginate 
formation, and clinical studies have shown its use to be linked with good outcomes in CF 
patients despite azithromycin having ineffective bactericidal activity at clinically relevant 
concentrations [229-231]. 
1.3.1.2 QS inhibition through the QS receptor protein 
Competitive inhibition based on utilizing small molecules that mimic AHLs represents 
another promising QS inhibition strategy. One of the first naturally occurring class of 
compounds discovered to quench QS were the furanones [232]. Furanones compete with 
C12HSL to bind the LasR receptor [233], effectively interfering with C12HSL binding. Since 
the discovery of the furanones, chemically synthesized and structurally diverse furanones 
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have been shown to display QS inhibition to facilitate clearance of P. aeruginosa lung 
infection in a mouse model. However, there is concern about the toxicity of the furanones in 
mammals [234] and emerging evidence of P. aeruginosa resistance towards these molecules 
through up-regulation of efflux pumps [235, 236]. Another example of competitive 
inhibition through the QS receptor protein is the use of the synthetic AHL analogue, meta-
bromo-thiolactone, which inhibits P. aeruginosa biofilm growth and pyocyanin production, 
and protects human lung epithelial cells from P. aeruginosa induced cell death in vitro [237]. 
1.3.1.3 QS inhibition via QS signal molecule 
The most widely investigated QSI strategy is that of directly inactivating the signal molecule. 
One such strategy utilized antibodies against AHLs to encourage the host immune response 
to target AHLs and sequester the signalling molecule. Success with this strategy was initially 
limited because the relatively small size of the AHL molecules limits their immunogenicity. 
This issue was overcome by conjugating AHLs to larger proteins, and antibodies generated 
by this means have shown some promising results in protecting against P. aeruginosa in 
mice [238, 239]. However, research into the use of such immunopharmacotherapeutic 
strategies for QSI is still in its infancy and more research is required to establish its efficacy. 
An alternate strategy to inactivate the signalling molecule involves enzymatic degradation. 
Three main types of enzymes capable of degrading AHLs have been reported in the 
literature: acylases, oxidoreductases and lactonases. The P. aeruginosa AHL acylase PvdQ 
cleaves the amide bond linking the acyl chain and the homoserine lactone ring, and has been 
shown to reduce the severity of P. aeruginosa infections in a nematode model of P. 
aeruginosa infection [240]. Oxidoreductases, including CYP102A1, a cytochrome from 
Bacillus megaterium, are able to oxidize C12HSL in vitro, although further investigation is 
required to establish how this oxidation affects C12HSL bioactivity and efficacy in in vivo 
[241]. 
The third type of enzymes capable of degrading QS signals, the lactonases, are perhaps the 
best studied and the most promising of the potential QS inhibitors. They function by 
hydrolysing the lactone ring of AHLs, a feature thought to be important in the binding of 
AHLs to their cognate receptors [242, 243]. Hydrolysis of the lactone ring effectively 
renders the AHLs incapable of participating in QS. Lactonases capable of degrading various 
AHLs have been found in a number of bacterial species including Bacillus sp. [242], 
Agrobacterium tumefaciens [244], Ochrobactrum sp [245] and Microbacterium testaceum 
[246]. More importantly however, a family of mammalian enzymes has been identified as 
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capable of specific lactonase activity towards AHLs, and particularly towards C12HSL. The 
paraoxonase (PON) family of enzymes have been shown to display lactonase activity in vitro 
[247, 248] and appear to attenuate P. aeruginosa virulence in vivo in drosophila and 
knockout mice models of infection [249, 250]. Because they are lactonase enzymes that are 
endogenous to mammals, the PONs warrant further scrutiny for their potential role as a 
component of the host immune response towards bacterial QS. 
 
1.3.2 The paraoxonases 
 
The PONs are a family of mammalian enzymes that consists of three proteins that play roles 
in inflammatory diseases and are known to hydrolyse bacterial AHLs. The first member of 
the PON family to be identified was PON1. In 1946, Mazur observed that extracts from a 
number of human and rabbit tissues were able to hydrolyse the organophosphate di-
isopropyl fluorophosphates [251]. Aldridge extended the study by looking at the ability of 
sera from a number of animals to hydrolyse the organophosphate toxin paraoxon and found 
an esterase that could catalytically hydrolyse paraoxon, hence the name paraoxonase [252]. 
It wasn’t until the 1996 that the other two PONs were identified by Primo-Parmo and 
colleagues by searching human cDNA libraries for PON1 analogues [253]. They found that 
the PON sequences shared ~70% homology and were positioned adjacent to each other on 
chromosome 7. In addition, they identified PON2 and PON3 in other mammalian species 
including mouse, turkey and chicken. The PONs are glycosylated proteins with an apparent 
mass of 40–48 kDa. The protein structure of PON1 has been elucidated and is considered to 
be a 6-bladed β-propeller. The overall active site structure and catalytic machinery are 
thought to be conserved in PON2 and PON3 [254]. Much of the research on the PONs is 
focused on their ability to function as anti-artherogenic agents in both in in vitro and in vivo 
models. However, there are numerous reports of the ability of PON to hydrolyse AHLs and 
also provide protection against oxidative stress. 
PON1 and PON3 are primarily expressed in the liver and PON1 is found in the serum, bound 
to high-density lipoproteins [255-257]. PON2 in contrast is ubiquitously expressed as a 
membrane-bound protein, mainly associated with the nuclear membrane, mitochondrial 
membrane and endoplasmic reticulum [258, 259].  
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1.3.2.1 Mammalian paraoxonases as QSI 
From a bacterial infection perspective, the ability of the PONs to hydrolyse AHLs is 
significant, because it represents an endogenous mechanism through which the immune 
system counters bacterial QS. PONs are lactonase enzymes, capable of hydrolysing the 
lactone ring of AHLs. In the absence of the lactone ring, AHLs are incapable of mediating 
cognate receptor-bound regulation of QS-dependent gene expression [242, 243]. 
Chun and colleagues in 2004 were the first to observe the inactivation of C12HSL, but not 
C4HSL, in primary cultures of human airway epithelia and a cultured human 
bronchoalveolar cell line A549. Upon fractionating the A549 lysates and comparing the 
soluble cytosolic fraction with the membrane-containing particulate fraction, the authors 
found that the insoluble membrane fraction contained the majority of the C12HSL-
hydrolysing activity. This indicated that the activity was more likely to be membrane 
associated, but they were unable to identify what was causing this activity [260]. Two 
subsequent studies showed that sera from humans, mice and a number of other mammals 
all hydrolysed C12HSL [247, 261]. Ozer and colleagues showed that treatment with PON 
inhibitors impaired the ability of human serum to hydrolyse C12HSL [247]. A later study 
showed that almost 90% of the C12HSL hydrolytic activity of human sera can be attributed 
to PON1 [262]. Ozer and colleagues also grew P. aeruginosa biofilms in the presence of sera 
from wild-type and PON1-KO mice and found that the biofilms grown with the wild-type 
sera were half the size of the biofilms grown with PON1-KO sera. PON1 has also been shown 
to have a protective effect against P. aeruginosa infection in a Drosophila melanogaster 
model of infection [263].  
Draganov and colleagues tested the ability of recombinant PONs to hydrolyse a variety of 
AHLs, including C12HSL. They discovered that while all the PONs were able to hydrolyse 
AHLs to some extent, PON2 was far superior in hydrolysing all the AHLs tested [248]. A later 
study by Teiber and colleagues found that the specific activity of recombinant PON2 for 
C12HSL was ~25 more than that of PON1 and ~75 more than that of PON3 [262]. 
There is an increasing body of evidence, as detailed in Table 1.4, that PON2 has the ability to 
counter P. aeruginosa QS and confer in vivo protection against P. aeruginosa infection and 
virulence. Consequently, PON2 has potential as a novel therapy against P. aeruginosa. In 
contrast to PON1 and PON3 which are primarily expressed in the liver serum, [255-257], 
PON2 is ubiquitously expressed, and at particularly high levels in the lungs [264]. This 
strong expression further strengthens the hypothesis that PON2 may represent an  




endogenous mechanism through which the immune system counters bacterial QS. However, 
there are no reports that PON2 can exist as a secreted enzyme, and the intracellular 
localization of PON2 would indicate that any PON2-mediated hydrolysis of AHLs would be 
restricted to AHLs that have entered host cells. To target QS by P. aeruginosa in the airways, 
PON2 would need to be delivered to the airways as a purified, recombinant, extracellular 
protein. A combination of both exogenous rhPON2 and increased endogenous native PON2 
would allow targeting of both the regulation of P. aeruginosa QS to susceptibility to 
antibiotics and host immune responses, and of C12HSL-mediated effects on host cells to 
allow host responses to deal effectively with infection. There are, however, no reports to 
date of the effects of recombinant human PON2 on in vitro P.aeruginosa cultures, and the 
use of rhPON2 in models of P. aeruginosa infection warrant further attention. In addition, 
the regulation of PON2 expression is poorly understood.  
 
Table 1.4 Table of evidence for role of PON2 as a QSI and protector against P. 
aeruginosa infection  
Evidence provided Model tested Reference 
Lysates of murine tracheal epithelial cells from wild-






PON2-KO derived macrophages show significant 




Decreased C12HSL hydrolysis in endothelial cell lines 
when PON2 expression is inhibited by siRNA 




A human airway epithelial cell line uses PON2 to 
hydrolyse C12HSL 
Human airway 
epithelial cell line 
A549 
[265] 
PON2 hydrolyses C12HSL and protects human 




Rapid intracellular hydrolysis of C12HSL in cell lines 
from airway epithelia and accumulation of 





Increased QS in PON2-KO mouse lungs using QS 
reporter strains 
PON2-KO mice [264] 
PON2-KO mice cleared P. aeruginosa much more 
slowly than their wild-type counterparts 
Acute systemic 
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There are reports that PON2 expression is regulated via PPARγ in murine macrophages 
[268], and that PON2 expression increases as a result of increased oxidative stress through 
the PI3K pathway involved in cellular functions such as cell growth, proliferation, 
differentiation, motility, survival and intracellular trafficking [269-271]. Any attempt to 
pharmacologically increase endogenous PON2 expression will require further elucidation of 
the regulatory mechanisms of PON2 expression. 
1.3.2.3 PON2 has anti-oxidant and anti-apoptotic activity 
PON2 is thought to also protect against oxidative stress by reducing reactive oxygen species 
(ROS). Nuclear membrane- and endoplasmic reticulum-bound PON2 is thought to prevent 
the formation in and leakage of superoxides from the mitochondria, most likely by 
modulating Coenzyme Q on the inner mitochondrial membrane and consequently 
preventing superoxide production [259, 272, 273]. Neutrophils require ROS for the efficient 
clearance of microbes. During sustained infections, such as those seen in chronic P. 
aeruginosa infections, the accumulation of ROS from the protracted and overwhelming 
immune response towards persistent P. aeruginosa can damage host cells. It is important to 
note that while PON2 was able to prevent the generation of ROS in a human endothelial cell 
line, it was ineffective against existing free radicals, indicating that the anti-oxidative role of 
PON2 is not likely to function via enzymatic clearance of ROS. Therefore, increasing 
expression of PON2 may not be capable of reducing extracellular neutrophil derived ROS 
[273]. Further research is needed to better understand the ability of PON2 to protect 
against ROS, particularly in an infection setting, such as in macrophages or airway epithelia, 
before PON2 can be considered to protect against extracellular neutrophil derived ROS. 
However, detection of microbes in the airways by TLRs on host cells results in increased 
intracellular oxidative stress, and PON2 may play a valuable role in protecting host cells 
against this increased oxidative stress during infection [78]. 
One of the major effects of the P. aeruginosa QS molecule C12SHL on host cells is its ability 
to induce ER stress and subsequent cell death through the UPR. Horke and colleagues have 
shown in a human aortic endothelial cell line that PON2 expression is induced by the UPR 
and that PON2 can protect against UPR-stimulated apoptosis [259]. These observations 
were further corroborated by knocking down PON2 in human aortic endothelial cells [205]. 
Devarajan and colleagues investigated the ability of macrophages from PON2-KO mice to 
protect against ER stress, and found that PON2 is capable of regulating calcium homeostasis, 
another feature of the cell affected by C12HSL [189, 192], and facilitates cell survival under 
ER stress [274]. 
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Furthermore, the anti-apoptotic and anti-oxidative capabilities of PON2 were shown by 
Altenhöfer and colleagues to be independent of its lactonase activity. These investigators 
found that abrogation of the lactonase activity of PON2 did not appear to affect the ability of 
PON2 to protect against ROS and apoptosis [273]. This adds to the complexity of the actions 
of PON2 and suggests that PON2 exerts dual, distinct, protective influences on host cells 
exposed to P. aeruginosa and its QS signals. When considering therapies that would involve 
increasing endogenous, native PON2, the additional anti-oxidative and anti-apoptotic roles 
of PON2 could provide an added layer of protection against C12HSL-mediated effects on 
host cells. 
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1.4 HYPOTHESIS AND AIMS 
 
We hypothesized that PON2, the mammalian enzyme capable of hydrolysing the P. 
aeruginosa QS AHL signal molecules, can inhibit P. aeruginosa QS, and thereby protect host 
cells infected with P. aeruginosa from AHL-regulated bacterial virulence and AHL-mediated 
mammalian immunomodulatory activity and cytotoxicity. Consequently, PON2 could be a 
novel anti-Pseudomonal therapy. 
The proposed use of PON2 as an anti-Pseudomonal therapy would involve pharmaceutically 
increased expression of endogenous native PON2, to provide protection to host cells against 
C12HSL-mediated effects, and/or application of extracellular rhPON2 to inhibit QS and 
thereby increase the susceptibility of P. aeruginosa to conventional antibiotics and the host 
immune response. Application of rhPON2 would also offer protection to mammalian cells 
against AHL-mediated modulation of gene expression by hydrolysing AHLs, thus preventing 
their accumulation in the extracellular environment and diffusion into host cells. 
The work described in this thesis investigates multiple aspects of the use of PON2 as a novel 
anti-Pseudomonal therapy. Firstly, the effects of C12HSL, the AHL at the top of the P. 
aeruginosa QS hierarchy, on airway epithelial cells was further investigated to add to the 
already established literature on the topic. Next, we investigated the regulation of PON2 to 
determine the mechanisms through which endogenous, native PON2 could be up-regulated 
to provide protection to host cells against intracellular C12HSL-mediated effects. We then 
synthesized rhPON2 for extracellular application. Using this rhPON2, we investigated the 
ability of rhPON2 to inhibit P. aeruginosa QS and synergize with an antibiotic in vitro. 
Finally, we attempted to establish a murine model of chronic P. aeruginosa infection, one 
that closely mimics the CF phenotype, for in vivo investigations on the potential of PON2 as a 
































2.1 MAMMALIAN CELL CULTURE 
 
2.1.1 Cells used 
 
Details of the mammalian cell lines used are listed in Table 2.1. 
Table 2.1 Mammalian cell lines used in this study 
Cell Line Description Source Medium 
BEAS-2B Adherent non-cancerous 
human bronchial epithelial 






NuLi-1 Adherent human bronchial 
epithelial cell line from 
healthy individual 
ATCC® CRl-4011 Bronchial 
epithelial cell 
growth medium 
CuFi-1 Adherent human bronchial 
epithelial cell line from 
individual with CF. 
Homozygous for ΔF508 
CFTR mutation 




2.1.2. Cell culture methods 
2.1.2.1 Media used 
2.1.2.1.1 Complete cell culture medium 
Cells were grown in complete cell culture medium (CCCM) which consisted of Dulbecco’s 
Modified Eagle Medium (DMEM) (Life Technologies, Carlsbad, CA) supplemented with 10% 
(v/v) Australian origin foetal bovine serum(FBS; Bovogen, VIC, Australia), 500 U/mL 
penicillin (Life Technologies), 500 μg/mL streptomycin (Life Technologies) and 4 mM L-
glutamine (Life Technologies). 
2.1.2.1.2 Bronchial epithelial cell growth medium 
Serum free bronchial epithelial cell growth medium (BEGM; Lonza, Walkersville, MD) was 
supplemented according to manufacturer’s instructions with provided growth factors, 
cytokines and supplements. In addition, 500 U/mL penicillin (Life Technologies), 500 
μg/mL streptomycin (Life Technologies) and 4 mM L-glutamine (Life Technologies) were 
added to the culture media.  




2.1.2.2 Coating of cell culture surfaces 
2.1.2.3.1 BEAS-2B cells 
Flasks and plates for BEAS-2B culture were coated with cell culture coating medium 
prepared in CCCM (Section 2.1.2.1.1) consisting of 0.001 mg/mL bovine plasma fibronectin 
(Life Technologies), 0.03 mg/mL bovine collagen type-I (Life Technologies), 0.01 mg/mL 
bovine serum albumin (BSA) and Cohn Fraction V (Sigma, St. Louis, MO) made in Dulbecco’s 
phosphate buffered saline (DPBS; Life Technologies). 
Tissue culture surfaces were incubated in cell culture coating medium in a humidified 37°C 
incubator for 30 minutes before discarding the medium. Table 2.2 shows volumes required 
to completely coat the surfaces of regularly used culture flasks and dishes. Plates were air 
dried and stored in sealed bags at room temperature. 
 
 
2.1.2.3.2 NuLi and CuFi cells  
Flasks and plates for NuLi-1 and CuFi-1 culture were also coated using the volumes 
specified in Table 2.2. Cell culture surfaces were incubated 18 hours at 37°C in 60 µg/mL 
human placental collagen Type IV (Sigma) made up in DPBS, before the collagen solution 
was removed. The surfaces were rinsing three times with ice-cold PBS before being air-
dried in a sterile environment overnight. Plates were stored at 4°C. 
2.1.2.3 Normal cell growth, counting and passaging 
2.1.2.3.1 BEAS-2B 
Cells were grown in a humidified incubator at 37°C with 5% CO2. At each passage, cells were 
seeded at ~2  104 cells/cm2. When the cells reached 90% confluency (density of ~1.5  105 
cells/cm2; 2–3 days after seeding), the cells were passaged. Care was taken to avoid 




Minimum Volume to cover surface 
T-75 flask 75 cm2 3 mL 
T-25 flask 25 cm2 1 mL 
6 well plate 9.5 cm2 300 μL 
12 well plate 3.8  cm2 100 μL 
96 well plate 0.15 cm2 20 μL 




allowing cells to grow beyond confluency. Passaging involved removal of the medium from 
the flask before washing the cells in pre warmed (37°C) DPBS (Life Technologies). The cells 
were then trypsinized with 0.25% Trypsin-EDTA (Life Technologies; 1 mL for T-25, 3 mL 
for T-75) for five minutes at 37°C or until the adherent cells had detached. An equal volume 
of CCCM was then added to deactivate the trypsin. The cells were subsequently counted by 
trypan blue exclusion using a haemocytometer. Next, the cells were centrifuged at 500  g 
for five minutes. Finally, the supernatant was discarded, and the cells resuspended in fresh 
medium to appropriate cell density. 
2.1.2.3.2 NuLi and CuFi 
Cells were grown in a humidified incubator at 37°C with 5% CO2. At each passage, cells were 
seeded at ~1  104 cells/cm2. When the cells reached 90% confluency (density of ~5  104 
cells/cm2; 2–3 days after seeding), the cells were passaged. This involved removal of the 
medium from the flask before washing the cells in pre warmed (37°C) DPBS (Life 
Technologies). The cells were then trypsinized with 0.25% Trypsin-EDTA (Life 
Technologies (1 mL for T-25, 3 mL for T-75) for five minutes at 37°C or until the adherent 
cells had detached. An equal volume of BGEM, supplemented with 1% FBS, was then added 
to deactivate the trypsin. The cells were subsequently counted by trypan blue exclusion 
using a haemocytometer. Next, the cells were centrifuged at 500  g for five minutes. Finally, 
the supernatant was discarded, and the cells resuspended in fresh medium to appropriate 
cell density. 
 




2.2 REAL TIME QUANTITATIVE PCR (qPCR) 
2.2.1 Primers  
2.2.1.1 Primer design for qPCR 
Primers were designed using Primer-Blast (http://www.ncbi.nlm.nih.gov/tools/primer-
blast/index.cgi?LINK_L°C=BlastHome) from the National Centre for Biotechnology 
Information (NCBI) website. Amplicon lengths were kept below 200 bp and primer melting 
temperatures in a 3°C range around 60°C. Primers were designed to avoid amplification of 
contaminating genomic DNA by selecting the ‘primers must span an exon-exon junction’ 
option. Primers were then picked against cDNA sequences of the genes in question. Primers 
selected typically had a C or G nucleotide at the 3 end, an even mix of GC and AT residues 
and a low self-complementary score.  
2.2.1.2 Primers used 
 
Table 2.3 DNA primers used in study 




5’-TGCCACAAATGACCACTACTTCT-3’ 5’-GGTGAAATATTGATCCCATTTGCTG-3’ This study 
pUC/M13 5’-CCCAGTCACGACGTTGTAAAACG-3’ 5’-AGCGGATAACAATTTCACACAGG-3’ [275] 
 
Table 2.4 P. aeruginosa qPCR primers used in study 
Gene Forward Sequence Reverse Sequence Source 
psd7 5-CAAAACTACTGAGCTAGAGTACG-3 5-TAAGATCTCAAGGATCCCAACGGCT-3 [276] 
lasI 5-CAAGTGTTCAAGGAGCGC-3 5-GCCAGCAACCGAAAACC-3 This study 
rhlI 5-GCTGGAAGGGCTTTCCG-3 5-GGATGGTCGAACTGGTCG-3 This study 
pqsA 5-CCCGATACCGCCGTTTATCA-3 5-CTGGCCTGGGAGAGAATGTAG-3 This study 
lasR 5-CCCTGTGGATGCTCAAGGACTAC-3 5-GCTTCCGAGCAGTTGCAGATAAC-3 This study 
lasB 5-GCCGCAAGACCGAGAATG-3 5-TCAGGTAGGAGACGTTGTAGAC-3 This study 
algD 5-GCGACCTGGACCTGGGCT-3 5-TCCTCGATCAGCGGGATC-3 [277] 
hcnB 5-CGGTCGGCTATGGCTTCATC-3 5-GCTGCCAGACGTTGCATTC-3 This study 
phz1 5-ATTCCCAATGCACGCAGTTTC-3 5-GAATTCCTGTTCCGCCAGGG-3 This study 
vfr 5-GCGAAACGCTGTTCTTCATC-3 5-AATCACCGCTGTTGAGGTAG-3 This study 
 




Table 2.5 Human qPCR primers used in study 
Gene Forward Sequence Reverse Sequence Source 
PON2 5-GCCAACAATGGGTCTGTTCTCC-3 5-CAGCTTCCCATCATACACTGAGGC-3 [223] 
PPARG 5-AGCTGAACCACCCTGAGTCC-3 5-TCATGTCTGTCTCCGTCTTCTTG-3 [223] 




IL8 5-TGCTAGCCAGGATCCACAAG-3 5-GCTTCCACATGTCCTCACAAC-3 This 
study 






ABCF1 5-GCCGGAAGCGGAAATAGCAC-3 5-ACTTTGTCTGATGGGCTCGTG-3 This 
study 
MST1 5-CACTCCTGCTGCTTCTGACT-3 5-GAAGGCCCGGCAGTCCATTA-3 This 
study 
MUC2 5-CTACTGGTGTGAGTCCAAGG-3 5-GGCACTTGGAGGAATAAACTG-3 [279] 
USP40 5-ACTGGCAGTTTCAAGAGGAAAA-3 5-GATTGCTTTTAGAATCATCAGTGGA-3 This 
study 
XBP1 5-CCATGGATTCTGGCGGTATTGACT-3 5-CCACATTAGCTTGGCTCTCTGTCT-3 [278] 
ATF3 5-TTGCAGAGCTAAGCAGTCGTGGTA-3 5-ATGGTTCTCTGCTGCTGGGATTCT-3 [278] 
CASP3 5-CATCCAGCCGGAGGCCAGAGC-3 5-GCAGTGACGGCTCCGCACCTG-3 This 
study 
CASP7 5-TTCAAAGCTGAGGGAGCGTC-3 5-ATCATCTGCCATCCCACAAGG-3 This 
study 
CASP8 5-ACACTTGGATGCAGGGTTTGA-3 5-TAGCTGGATTCTGCAGGCTT-3 This 
study 
NGFR 5- GAGGCACCTCCAGAACAAGAC-3 5-GCTGTTCCACCTCTTGAAGGC-3 This 
study 
2.2.1.3 Primer validation 
Primers were validated by measuring the PCR efficiency of serial dilutions of cDNA 
prepared from RNA that contained gene of interest transcripts. The cDNA was diluted 1/4, 
1/16, 1/64 and 1/256 and the qPCR carried out using the primers. The cycle crossing 
threshold (CT) of the product for each reaction was then noted. The natural logarithm of the 
cDNA dilution factor was plotted against the CT. (See method in Table 2.6). The efficiency of 
the PCR was calculated from the gradient of the line plotted between the natural logarithm 
of cDNA dilution and the CT. An efficiency of 2 suggested that there was a doubling of DNA 
at each PCR cycle and that the primers were highly efficient at amplifying the target cDNA. 
Primers with efficiencies between 1.7 and 2.1 were acceptable, provided the melt curves of 
the PCR products did not show primer dimerization and were consistent with one PCR 
product being amplified. Finally, amplicon size was checked by separating PCR products by 
agarose gel electrophoresis followed by staining with SYBR-II DNA gel stain (Life 
Technologies). 





2.2.2 RNA isolation by phenol–chloroform  
 
RNA isolation by phenol–chloroform was carried out using TRIzol® (Life Technologies), 
following the manufacturer’s instructions with minor modifications as detailed below. 
2.2.2.1 Cell lysis for RNA isolation 
For cells grown in a six well plate, 1 mL of TRIzol® was sufficient per well. Medium was first 
removed from the cells and the cells rinsed with DPBS. TRIzol® was added directly to the 
culture dish and the surface of the well scraped with pipette tip immediately after TRIzol® 
application. The cells were then lysed in the wells by pipetting up and down several times 
until homogenous. The lysate was then collected and transferred to a microcentrifuge tube 
for RNA extraction. Lysates could also be stored at –80°C at this stage for later RNA isolation 
2.2.2.2 RNA isolation 
The cell lysates were incubated at room temperature for five minutes before 200 L of 
chloroform (Merck) was added per mL of cell lysate. The mixture was shaken vigorously by 
hand for 15 seconds and then incubated at room temperature for three minutes before 
centrifuging at 12,000  g for 15 minutes at 4°C. This separated the mixture into three 
distinct phases, with the upper aqueous phase exclusively containing the RNA. The aqueous 
Table 2.6 Method of qPCR primer efficiency determination 
cDNA dilution 
Plot these two 
ln (cDNA dilution) CT 

















Gradient Linear regression of the line to find gradient 










phase was carefully aspirated without disturbing the other phases and transferred to a fresh 
microcentrifuge tube. 
When isolating RNA from cells with an expected low yield, 5 g glycogen was used as an 
RNA carrier and added at this stage. For every mL of cells homogenized in TRIzol®, 500 L 
of 100% isopropanol (Merck) was added to precipitate the RNA. The mixture was shaken 
and incubated for 10 minutes at room temperature before being centrifuged at 12,000  g 
for 10 minutes at 4°C.  
The supernatant was removed from the tube, leaving only the RNA precipitate. The RNA 
pellet was rinsed with ice-cold 75% ethanol prepared in nuclease-free water, 1 mL per mL 
of cell homogenate. Once the 75% ethanol was added, the tubes were briefly vortexed 
before centrifuging at 7,500  g for five minutes at 4°C. The supernatant was then carefully 
removed without disturbing the pellet before repeating the rinse step. Once the supernatant 
was removed, the tube was air dried in a sterile cabinet, though care was taken to not 
completely dry out the RNA pellet. The pellet was then resuspended in an appropriate 
volume of nuclease-free water and heated at 65°C for 10 minutes. RNA solution was stored 
at –80°C for further use. 
2.2.2.3 DNase treatment of isolated RNA 
DNase treatment of recovered RNA was performed using TURBO DNA-free™ Kit (Life 
Technologies) according to the manufacturer’s instructions. A typical reaction consisted of 
50 L of RNA solution with <10 g total RNA. Briefly, the 10 DNase I buffer was added, 
followed by 1 L of TURBO™ DNase (2 units). The reaction was incubated at 37°C for 30 
minutes. A 1/10 volume of DNase inactivation reagent was then added to stop the DNase 
reaction. After a five minute incubation at room temperature with periodic mixing, the tube 
was centrifuged at 10,000  g for 90 seconds at room temperature. The supernatant 
containing the RNA was transferred to a fresh tube for quantification, storage and 









2.2.3 R NA extraction by spin column 
 
RNA was also extracted from cells stored in RNALater (Life Technologies) using the 
ReliaPrep™ RNA Cell Miniprep System (Promega, Madison, WI). Cells in RNALater (Life 
Technologies) were pelleted by centrifugation at 500  g for five minutes. The supernatant 
was discarded and the pellet carefully rinsed with ice-cold sterile 1 DPBS (Life 
Technologies). The cells were then pelleted by centrifugation at 500  g for five minutes and 
the supernatant discarded. Five hundred microlitres of fresh BL+TG buffer (32.5 L 1-
Thioglycerol (TG) to 3.25 mL BL buffer) was added to the pellet. The pellet was pipetted 7–
10 times and then incubated at 4°C for five minutes before pipetting a further 7–10 times to 
ensure complete lysis of the cells. Then, 170 L of isopropanol was added to the lysate and 
mixed by vortexing. The lysate was transferred to a ReliaPrep™ minicolumn assembled 
according to the manufacturer’s specifications and centrifuged at 14,000  g for 30 seconds 
at room temperature. The liquid in the collection tube was discarded and then 500 L RNA 
wash solution was added. The columns were then centrifuged at 14,000  g for 30 seconds 
at room temperature. 
Next, the RNA was DNase-treated by adding 30 L of DNase I incubation mix (24 L Yellow 
Core buffer, 3 L 0.09 M MnCl2 and 3 L of DNase I enzyme) to the membrane inside the 
minicolumn. The membrane was allowed to incubate at room temperature for 15 minutes 
before 200 L of column wash buffer solution was added to the minicolumn. The 
minicolumn was then centrifuged at 14,000  g for 30 seconds. Next, 500 L of RNA wash 
solution was added to the minicolumn and centrifuged at 14,000  g for 30 seconds. The 
collection tube was discarded and the minicolumn moved to a fresh collection tube. A 
further 300 L of RNA wash solution was added to the minicolumn and centrifuged at 
14,000  g for two minutes. The minicolumn was then transferred to an elution tube and 
allowed to dry for two minutes.  
Finally, to elute the RNA, 20 L of nuclease free water was added to the minicolumn 
membrane and the minicolumn centrifuged at 14,000  g for one minute at room 
temperature. The collected RNA was quantified and then stored at –80°C. 
 




2.2.4 Nucleic acid quantification and quality determination 
 
All purified nucleic acids were quantified using a NanoDrop 1000 spectrophotometer 
(Thermo Scientific, Waltman, MA, USA). The instrument was blanked with the appropriate 
diluent before 1.5 L of nucleic acid sample was loaded for measurement using the ‘nucleic 
acid’ setting to determine concentration by measuring absorbance at 260 nm. By comparing 
the ratios of absorbance at 260/280 nm, the quality of the nucleic acid was determined. For 
subsequent cDNA synthesis and qPCR, only RNA with absorbance 260/280 nm ratios of 1.8–
2.2 were used. 
 
2.2.5 cDNA synthesis 
 
cDNA was synthesized using Transcriptor First Strand cDNA Synthesis Kit (Roche, 
Mannheim, Germany) according to the manufacturer’s instructions. cDNA was synthesized 
in 20 L reactions. A maximum of 1 g of RNA was included, up to a maximum volume of 8 
L in PCR-grade water.  
For mammalian RNA, anchored-oligo(dT)18 primers, 50 pmol/L were added to a final 
concentration of 2.5 M. The template-primer mixture was then heated at 65°C for 10 
minutes to denature secondary RNA structures before immediately cooling on ice. Next, 4 
L of 5 Transcriptor reverse transcriptase reaction buffer, 0.5 L of Protector RNase 
inhibitor, 2 L of 10 mM deoxynucleotide mix and 0.5 L of Transcriptor reverse 
transcriptase were added to the reaction tube. The tube was centrifuged briefly and then 
incubated 30 minutes at 55°C, then 85°C for 10 minutes before finally chilling on ice. The 
cDNA was stored at –80°C, or used for qPCR. 
For bacterial RNA, random hexamer primers, 600 pmol/L were added to a final 
concentration of 60 M. The template-primer mixture was then heated at 65°C for 10 
minutes to denature secondary RNA structures before immediately cooling on ice. Next, 4 
L of 5 Transcriptor reverse transcriptase reaction buffer, 0.5 L of Protector RNase 
inhibitor, 2 L of 10 mM deoxynucleotide mix and 0.5 L of Transcriptor reverse 
transcriptase were added to the reaction tube. The tube was centrifuged briefly and then 




incubated 10 minutes at 25°C, then 50°C for 60 minutes before finally chilling on ice. The 
cDNA was also stored at –80°C, or used for qPCR. 
 
2.2.6 Quantitative PCR 
 
Real time quantitative PCR (qPCR) was carried out on the LightCycler® 480 II instrument 
(Roche) using LightCycler® 480 SYBR Green 1 Master Mix (Roche). Reaction volumes were 
typically 10 L and prepared in 96 or 384 well plates using a CAS-1200N liquid handling 
robot (Corbett Robotics, Sydney, NSW, Australia). A typical 10 L reaction consisted of 5 L 
of 2 master mix, 2 L of primer mix to a final concentration of 0.5 M, 1 L of PCR grade 
water and 2 L of cDNA template. The plates were sealed with LightCycler® 480 multi-well 
sealing foil (Roche) before being centrifuged briefly to collect the reactions at the bottom of 
the wells, at 1500  g at room temperature for two minutes. A typical run used the run 
conditions outlined in Table 2.7. 











Pre-incubation (1 cycle) 
95 None 600 4.8 - 
Amplification (45 cycles) 
95 None 10 4.8 - 
60 None 10 2.5 - 
72 Single 30 4.8 - 
Melting Curves (1 cycle) 
95 None 5 4.8 - 
65 None 60 2.5 - 
97 Continuous - - 10 
Cooling ( 1 cycle) 










2.2.6.1 qPCR Data analysis 
The fluorescence data from the qPCR was interpreted by the LightCycler® Software 
(Roche). The cycle threshold (CT) was determined using the absolute/second derivative 
maximum method. The raw CT values were exported into Excel (Microsoft) spreadsheets for 
analysis. Melt curves were generated using the melting temperature (Tm) calling analysis. 
To calculate fold change of gene expression, the following formula, developed by Livak and 
Schmittgen, was used [280]. 
 
Fold Change in target gene expression relative to untreated sample, relative to reference 
=
𝑷𝑪𝑹 𝑬𝒇𝒇𝒊𝒄𝒊𝒆𝒏𝒄𝒚 𝒐𝒇 𝒕𝒂𝒓𝒈𝒆𝒕 𝒈𝒆𝒏𝒆 (𝑪𝑻 
𝑪𝒐𝒏𝒕𝒓𝒐𝒍 𝑺𝒂𝒎𝒑𝒍𝒆 − 𝑪𝑻𝑬𝒙𝒑𝒆𝒓𝒊𝒎𝒆𝒏𝒕𝒂𝒍 𝑺𝒂𝒎𝒑𝒍𝒆   )
𝑷𝑪𝑹 𝑬𝒇𝒇𝒊𝒄𝒊𝒆𝒏𝒄𝒚 𝒐𝒇 𝒓𝒆𝒇𝒆𝒓𝒆𝒏𝒄𝒆 𝒈𝒆𝒏𝒆 (𝑪𝑻 









2.3 PROTEIN IMMUNOBLOTTING AND DETECTION 
 
2.3.1 Buffers and solutions 
 
2.3.1.1 Cell lysis buffer 
Cell lysis buffer consisted of 50 mM Tris-HCl at pH 7.5, 138 mM NaCl, 5 mM EDTA and 1% 
Triton™ X-100 (Sigma). Prior to use, one tablet of complete, mini, EDTA-free protease 
inhibitor cocktail (Roche) was added to 10 mL of cell lysis buffer and the complete buffer 
was stored for up to 3 months at –20°C until use.  
2.3.1.2 10% resolving gel solution 
The resolving, lower gel for sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) was a 10% gel capable of resolving proteins with a size of 15–100 kDa. It 
consisted of 10% (v/v) acrylamide/bis solution 37.5:1 (Bio-Rad) in degassed distilled water 
with 375 mM Tris-HCl (pH 8.8) and 0.1% (w/v) SDS. To initialize the polymerization of the 
gel, 0.1% (w/v) ammonium persulphate (Sigma) and 1  10–4 % (v/v) TEMED (Sigma) were 
added.  
2.3.1.3 5% stacking gel solution 
The stacking upper gel for SDS-PAGE consisted of 5% (v/v) acrylamide/bis solution 37.5:1 
(Bio-Rad) in degassed distilled water with 125 mM Tris-HCl (pH 6.8) and 0.1% (w/v) SDS. 
To initialize the polymerization of the gel, 0.1% (w/v) ammonium persulphate (Sigma) and 
0.01% (v/v) TEMED (Sigma) were added. 
2.3.1.4 10 tris-glycine running buffer 
The 10 tris-glycine running buffer consisted of 250 mM Tris base (Sigma), 14.4 % (w/v) 
glycine (Sigma), and 1% (w/v) SDS in Milli-Q water. 
2.3.1.5 Coomassie stain solution 
Coomassie stain solution contained 10% acetic acid, 50% methanol with 0.25% (w/v) 
Coomassie Brilliant Blue R-250 (Bio-Rad) in Milli-Q water. 
2.3.1.6 Coomassie de-stain solution 
Coomassie de-stain solution was 10% acetic acid, 30% methanol in Milli-Q water. 




2.3.1.7 10 transfer buffer  
The 10 transfer buffer consisted of 250 mM (w/v) Tris base (Sigma), 14.4 % (w/v) glycine 
(Sigma) in Milli-Q water. 
2.3.1.8 1 protein transfer buffer  
The 1 protein transfer buffer was made by diluting 10 transfer buffer ten-fold in Milli-Q 
water with 20% methanol. 
2.3.1.9 Phosphate-buffered saline 
Phosphate-buffered saline (PBS) was prepared by dissolving 1 PBS tablet (Thermo 
Scientific) in 100 mL of Milli-Q water. 
2.3.1.10 Blocking buffer  
Blocking buffer was a 2% (w/v) solution of skim milk powder (Devondale, WA, Australia) in 
PBS. The buffer was filtered prior to use to prevent spotting downstream. 
2.3.1.11 Antibody incubation buffer 
Antibody incubation buffer was a 2% (w/v) solution of skim milk powder (Devondale) in 
PBS with the addition of 0.1% (v/v) Tween 20 (Sigma). The buffer was filtered prior to the 
addition of detergent to prevent spotting downstream. 
2.3.1.12 Membrane wash buffer 
Membrane wash buffer was PBS with the addition of 0.1% (v/v) Tween 20 (Sigma). 
2.3.1.13 Membrane stripping buffer 
Membrane stripping buffer was made up in Milli-Q water and contained 1.5% (w/v) glycine, 
0.1% (w/v) SDS and 1% (v/v) Tween-20 (Sigma). The pH was adjusted to 2.2 with HCl. 
2.3.2 Preparation of cell lysates for protein analysis 
 
Medium was removed from cells before washing the cells with ice-cold DPBS (Life 
Technologies). Cell lysis buffer (section 2.3.1.1) was then added to the cells. For six-well 
plates, 300 L of ice-cold cell lysis buffer was added per well while for a T-25 flask, 1 mL 
was used. The cells were incubated at 4°C for 20 minutes, while rocking. Any remaining 
adherent cells were then scraped off and the cell homogenates transferred to a 
microcentrifuge tube. The lysates were subjected to ultra-sonication with Microson™ 
Misonix XL sonicator (Misonix, NY, USA) at the ‘high’ setting, 20 cycles of five seconds on, 




five seconds off, on ice. The homogenized cells were then centrifuged at 2,000  g for 30 
seconds at 4°C to pellet cellular debris. The supernatant was collected and stored at –80°C 
or used for analysis.  
 
2.3.3 Protein quantification 
 
Protein quantification by a modified Lowry assay was carried out using DC™ Protein Assay 
(Bio-Rad), providing a detergent-compatible solution for protein quantification. The 
microplate assay protocol was used according to the manufacturer’s instructions. Protein 
standards were prepared using BSA in cell lysis buffer, with five concentrations in a range of 
200 to 1500 g/mL. After incubating at room temperature for15 minutes, the absorbance of 
the samples was determined at 750 nm on a SpectraMax M2 plate-reader (Molecular 
Devices, Sunnyvale, California). Concentrations of protein were determined against the BSA 
standards. Second-order polynomial correlation coefficients were typically 0.99 or higher. 
2.3.4 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
 
2.3.4.1 SDS-PAGE gels 
Where possible, 4%–12% Bis-Tris polyacrylamide gels (Bolt® Mini; Life Technologies) 
were used. When not convenient, Tris-glycine gels were prepared as follows. Gels were 
prepared in 1.0 mm empty gel cassettes (Life Technologies). Six millilitres of 10% resolving 
gel solution (Section 2.3.1.2) was added into the gel cassettes. A layer of 0.1% SDS was then 
carefully layered on top of the resolving gel and the gel allowed to set (~15 minutes). Once 
it was set, the SDS layer was poured off and a volume of stacking gel (2.3.1.3) applied such 
that it filled the cassette (~2 mL). An appropriate comb was then slotted into the top and 
the gel allowed to set. Once set, the cassettes were moved to an XCell SureLock™ Mini-Cell 
(Life Technologies) electrophoresis apparatus filled with 1 Tris-glycine running buffer for 
SDS-PAGE (10 SDS PAGE Tris-glycine running buffer dissolved ten-fold in distilled water). 
2.3.4.2 Preparation of samples and electrophoresis conditions 
Typically, the sample volume loaded into an SDS-polyacrylamide gel was 20 L, consisting 
of between 20–40 µg of total protein. Deionized water and protein together made up 13 L 
of the sample volume. Five microlitres of Novex LDS sample buffer (Life Technologies) and 2 
L of Novex reducing agent (Life Technologies) were added to make up the volume to 20 L. 




Samples were then heated at 70°C for 10 minutes before being loaded into the wells of 
prepared Tris-glycine gel or precast Bolt® Mini gels (Life Technologies). Five microlitres of 
SeeBlue® Plus2 pre-stained protein standard (Life Technologies) were loaded as molecular 
weight markers. Electrophoresis was carried out in 1 Tris-glycine running buffer for 
prepared Tris-glycine gels and MES buffer (Life Technologies) or MOPS buffer (Life 
Technologies) for the precast Bolt® minigels. The electrophoresis gels were run at the 
voltages shown in Table 2.8 for the desired times or until the leading dye front reached the 
bottom. 
Table 2.8 Run conditions for SDS-PAGE gels 
Type of Gel Running Buffer Voltage Running Time 
Poured Tris-glycine 1 Tris-glycine running buffer 100 V 80 minutes 
Precast Bis-Tris 1 MES (Life Technologies) 165 V 35 minutes 
1 MOPS (Life Technologies) 165 V 45 minutes 
 
2.3.5 Transfer of protein to nitrocellulose 
 
Wet transfers were carried out when immunoblotting was necessary for precise 
identification of the protein of interest. Once the SDS-PAGE was complete, the gel was 
removed from the tank, rinsed in Milli-Q and transferred to a fresh container with pre 
chilled 1 protein transfer buffer (Section 2.3.1.8). Wet transfers were performed using the 
Mini Trans-Blot® cell (Bio-Rad) apparatus. The wet transfer assembly was set up as shown 
in Figure 2.1, submerged in ice-cold 1 protein transfer buffer using nitrocellulose 
membrane (Hybond-C Extra; Amersham, Arlington Heights IL). Transfer was carried out 
with 1 protein transfer buffer for 80 minutes at 100 V at room temperature, or overnight 
at 4°C at 20 V. 





Figure 2.1 Mini Trans-Blot® cell apparatus wet transfer assembly 
2.3.6 Visualization of separated proteins on polyacrylamide gels 
2.3.6.1 Coomassie staining 
Once the SDS-PAGE was completed, the gels were rinsed for one minute in Milli-Q water 
before the addition of Coomassie stain solution (Section 2.3.1.6). The gels were incubated 
for 4 hours (or overnight) at room temperature on a shaker, rotating at 40 revolutions per 
minute (RPM) in an enclosed container. The gels were then transferred to Coomassie de-
stain solution and placed on a shaker at 40 RPM. The de-stain solution was replaced 
regularly until all excess dye had been removed and the protein bands of interest were 
clearly visible. De-stained gels were visualized on a light box and photographed using a 
flatbed scanner (Epson 880F; Epson, Suwa, Japan). 
2.3.6.2 Silver staining 
The more sensitive method for protein detection, silver staining, was carried out using the 
Silver Stain Plus kit (Bio-Rad). Briefly, each gel was fixed for 20 minutes using 50 mL of 
fixative enhancer solution containing 50% (v/v) methanol, 10% (v/v) acetic acid, and 10% 
supplied fixative enhancer concentrate in Milli-Q water. The gel was rinsed in water twice, 
10 minutes each time, using fresh Milli-Q water. Next, the gels were stained in 25 mL of 
staining solution prepared according to the manufacturer’s instructions. Silver stains 
typically took 20 minutes to develop to the desired intensity. Before excessive background 




could develop, the development of the stain was stopped by discarding the stain solution 
and adding 30 mL of 5% acetic acid solution in Milli-Q water. After incubating for 15 
minutes in the stop solution, the gels were transferred to Milli-Q water and visualized on a 
light box or photographed using a flatbed scanner (Epson 880F; Epson). 
2.3.6.3 Immunoblotting of membrane 
2.3.6.3.1 Immunoblotting procedure 
Once the proteins had been transferred, the membrane was rinsed in Milli-Q water. In order 
to prevent nonspecific background, the membranes were first incubated for one hour at 
room temperature (or at 4°C overnight) in blocking buffer. Once blocking was complete, the 
membranes were transferred to a fresh container containing primary antibody (See Table 
2.9 for full list of antibodies used) at the required dilution in antibody incubation buffer. The 
membrane was incubated for 2 hours at room temperature (or overnight at 4°C). Once 
again, the membrane was washed in membrane wash buffer, four times, 5 minutes each, 
using fresh buffer each time. The membrane was then incubated in the appropriate 
secondary biotinylated antibody in antibody incubation buffer for 1 hour at room 
temperature. The membrane was then washed again, in membrane wash buffer, four times 
for 5 minutes each. The membrane was next incubated with the Streptavidin–horse radish 
peroxidase (HRP; 1:5000 dilution; AbD Serotech, Oxford, UK) conjugate in antibody 
incubation buffer for 1 hour at room temperature. Finally, the membrane was washed again, 
in membrane wash buffer, four times, 5 minutes each, using fresh buffer each time.  
Table 2.9 Antibodies and dilutions used in study 
Antibody Name Source Use Dilution for 
use 
Company 
PON2 (C-5) Mouse 
Monoclonal 





















Streptavidin: HRP - Binding to biotin-
labelled antibody, 








The washed membrane was allowed to dry before chemiluminescent detection of the 
protein. Chemiluminescent detection was carried out using Immobilon Western 
Chemiluminescent HRP substrate (Millipore, ThermoFisher). Working HRP substrate was 
prepared by mixing in equal quantities the luminol reagent and peroxide solution. 
Approximately, 100 L of the working HRP substrate was required per cm2 of membrane. 
The working substrate was allowed to warm up to room temperature before being applied 
to the membrane, ensuring complete and equal coverage. The membrane was incubated for 
5 minutes at room temperature before chemiluminescent detection using Carestream Image 
Station 2000 (Carestream Molecular Imaging; Rochester, NY). 
2.3.6.3.2 Stripping membranes 
When investigating more than one protein on the same blot, membranes were stripped 
prior to re-staining for the second protein. The membranes were incubated at room 
temperature for 15 minutes with the membrane stripping buffer before the buffer was 
discarded. The process was then repeated. Next the membrane was rinsed twice with 
antibody incubation buffer, 10 minutes each time. The membrane could then be blocked and 
immunoblotted again as per section 2.3.6.3.1. 
2.3.6.3.3 Dot blot 
Dot blots were used for rapid detection of protein without the use of SDS-PAGE. Protein 
samples were directly applied to nitrocellulose membranes (Hybond-C Extra; Amersham) in 
pre-marked 2 cm2 boxes, a maximum of 5 L per box. Whole cells could also be applied to 
the membrane but were boiled first. The membrane was then allowed to air dry for 30 
minutes. Once dry, the membrane was rinsed with Milli-Q water before the immunoblotting 
method described in section 2.3.6.3.1 was used to detect the protein. 
 




2.4 TRANSFECTIONS AND LUCIFERASE ASSAYS 
 
2.4.1 Preparation of mammalian cells for transfection 
 
BEAS-2B cells were seeded at 1.5  105 cells per well in a 12 well plate or 1.5  104 cells per 
well in a 96 well plate in CCCM without antibiotics. The cells were allowed to recover 
overnight in a humidified incubator at 37°C with 5% CO2 prior to transfection. 
 
2.4.2 Mini/midi preps 
 
To obtain large quantities of plasmid DNA, mini/midi preps were required. The preps were 
carried out using PureYield™ Plasmid Mini-prep/Midi-prep System (Promega) following the 
manufacturer’s instructions for standard DNA purification by centrifugation. The eluted 
DNA was quantified using the nucleic acid quantification method described in section 2.2.4 
and stored at 4°C. 
 
2.4.3 Transfection of mammalian cells 
 
Transfection-quality DNA from mini/midi preps was used for the transfections and the 
A260/280 ratios were confirmed to be between 1.7–1.9. The medium used for transfections 
was Opti-MEM® (Life Technologies). Transfection complexes were prepared in 60 L 
reactions. Opti-MEM® was added to a fresh microcentrifuge tube so that upon the addition 
of transfection reagent and DNA, the final volume would be 60 L. A total of 1 g of DNA 
was added to the Opti-MEM® and vortexed to mix. For co-transfections, the total DNA 
comprised a predefined ratio of the plasmid DNAs being transfected. The transfection 
reagent FuGENE® HD (Promega) was then added drop wise, directly into the medium. The 
reagent was not allowed to make contact with the side of the tube. Three microlitres of the 
transfection reagent were used per g of DNA. The complexes were mixed immediately and 
allowed to incubate at room temperature for 15 minutes. Sixty microlitres of the complex 




was then added to each well of a 12 well plate. For 96 well plates, 6 L were used per well. 
The cells were then returned to the humidified 37°C incubators. 
All transfected plasmids were co-transfected with a plasmid constitutively expressing 
Renilla luciferase (pGL4.75 (hRLUC/CMV) to normalize for transfection efficiency (For list 
of plasmids used, refer to Table 3.2.1).  
 
2.4.4 Luciferase assay 
 
Luciferase expression in the transfected cells was measured using the Dual-Luciferase® 
Reporter assay system (Promega). At the time of measurement, the medium was removed 
from the cells and the cells rinsed with DPBS. All liquid was removed from the well and the 
supplied passive lysis buffer added to the cells, 100 L per well, in 12 well plates. The plate 
was incubated for 2 minutes at room temperature before the cells were scraped with a 
pipette tip and then aspirated into a fresh microcentrifuge tube. Care was taken to minimize 
the generation of bubbles. The cells were frozen at –20°C immediately and then allowed to 
thaw. The thawed lysates were then frozen overnight at –80°C prior to assay. 
Once two freeze-thaw cycles had been achieved, 10 L of the samples were added to each 
well of a white flat-bottomed 96-well microplate. LARII reagent was prepared according to 
the manufacturer’s instructions and 50 L added to each well. The firefly luciferase activity 
was measured using the GlowMax® (Promega) instrument. The Stop & Glow® reagent was 
then prepared according to the manufacturer’s instructions and 50 L added to each well. 
This time, the Renilla luciferase activity was measured using the GlowMax® (Promega) 
instrument. 
 




2.5 BACTERIAL CULTURE 
 
2.5.1 Buffers and Media 
 
2.5.1.1 Lysogeny broth (LB) (Lennox) 
LB was prepared using the Lennox formulation, with 1% (w/v) tryptone (Thermo Fisher), 
0.5% (w/v) yeast extract (Thermo Fisher) and 0.5% (w/v) NaCl (Thermo Fisher) in distilled 
water. The broth was then sterilized by autoclaving at 121°C. 
2.5.1.2 LB agar with/without antibiotics 
LB agar was prepared using the same formulation as LB, with the addition of 1% (w/v) 
bacto-agar (Thermo Fisher). The solution was autoclaved at 121°C to sterilize before 
cooling to 50°C. At this point any relevant antibiotics (ampicillin at 100 g/mL and 
kanamycin at 50 g/mL; Sigma) were added to the medium. The medium was then poured 
into sterile 90 mm petri dishes, ~15 mL per dish, and allowed to cool before storing at 4°C. 
2.5.1.3 0.85% saline 
The 0.85% saline solution was prepared by dissolving NaCl (Thermo Fisher) 0.85% (w/v) in 
distilled water and autoclaving at 121°C to sterilize. 
2.5.1.4 2 glycerol freezing medium 
Glycerol freezing medium for storage of bacterial cultures was prepared by mixing glycerol 
(manufacturer) 50% (v/v) in LB medium. The medium was then autoclaved at 121°C to 
sterilize. 
2.5.1.5 Crystal violet biofilm stain 










2.5.2 Culture methods 
 
2.5.2.1 Streaking plates  
Using a sterile inoculation loop, a single colony from a petri dish, or revived from a glycerol 
stock, was transferred to a fresh agar medium plate. The plates were then inverted and 
allowed to incubate in the appropriate growth conditions. Typically, for Escherichia coli and 
P. aeruginosa, this was 37°C. 
 
2.5.2.2 Spread plating 
A known volume (typically 100 L) of bacterial culture was transferred to a fresh agar 
medium plate. Using a sterile spreader, the inoculum was spread over the plate to ensure 
complete coverage. The plates were then inverted and allowed to incubate under the 
appropriate growth conditions. Typically, for E. coli and P. aeruginosa, this was 37C. 
2.5.2.3 Overnight culture 
To grow bacteria to stationary phase overnight, an overnight broth was used. A 2 mL 
volume of sterile culture medium in a 15 mL loosely capped polypropylene (BD Falcon, 
Bedford, MA) centrifuge tube was inoculated with a single colony of bacteria and grown 
overnight (~18 hours). The culture was then incubated in the appropriate growth 
conditions. Typically, for E. coli and P. aeruginosa, this was 37°C, with shaking at 220 RPM. 
2.5.2.4 Planktonic growth 
For the planktonic growth of cultures, a sterile flask with the desired volume of media was 
inoculated with the desired number of bacteria. The volume of media was less than 40% of 
the volume of the flask to provide adequate aeration of the medium during growth. The 
culture was then incubated in the appropriate growth conditions. Typically, for E. coli and P. 
aeruginosa, this was 37°C, with shaking at 220 RPM. 
2.5.2.5 Glycerol stocks 
Glycerol stocks were prepared in LB broth using 2 glycerol freezing media. Cultures were 
grown to stationary phase in LB and then mixed 1:1 in 2 glycerol freezing media. This gave 
a final glycerol concentration of 25%. Stocks were then stored at –80°C. 
 






2.5.3.1 Optical density 
To determine the optical density at 600 nm (OD600nm) of a culture, 100 L was transferred in 
triplicate to a three wells of a 96 well microplate and the absorbance at 600 nm was read 
using a SpectraMax M2 plate-reader (Molecular Devices). 
2.5.3.2 Determination of colony forming units (CFU)  
In order to enumerate the CFU in a culture, 100 L aliquots were removed from culture and 
serially diluted ten-fold in sterile 0.85% saline. Each dilution was then spread-plated onto 
agar medium plates, 100 L per plate, in triplicate. The plates were inverted and incubated 
at 37°C overnight. The spread plates where the number of colonies were between 30 and 
300 were counted, averaged and the final CFU established by accounting for the dilution 
factor. When the cell density of cultures could be estimated, only those dilutions expected to 
have between 30 and 300 colonies were spread-plated. 
2.5.3.2 qPCR 
The bacterial strains were grown to stationary phase in a 10 mL overnight culture. The 
OD600nm was measured and then the cultures ten-fold serially diluted to 10–4 in triplicate, in 
1.1 mL volumes. A 100 L aliquot was taken from each dilution for CFU determination by 
spread plating. RNA was extracted from the remaining volume by centrifuging at 500  g for 
5 minutes to remove the culture medium and resuspending in TRIzol®. The RNA was 
extracted using TRIzol®, DNase treated, cDNA synthesized and then qPCR carried out on 
the cDNA using primers specific for the bacteria using the LightCyler platform (Roche) as 
described in section 2.2. For P. aeruginosa, the primer target was the 16S ribosomal RNA, 
using psd7 primers designed by Matsuda and colleagues[276] (sequence in Table 2.3). The 
cell counts were used to generate a standard with their corresponding CT values and 
OD600nm, the slope of which allowed enumeration of bacteria from a given CT value or 
OD600nm. 
 




2.6 INSECT CELL CULTURE 
 
2.6.1 Cell lines 
 
Details of the insect cell lines used are listed in Table 2.10. 
Table 2.10 Insect cell lines used 
Cell Line Details Source Source 
(Lot Number) 
Medium 




AE cell line  
Pupal ovarian 












4 cell line 











2.6.2 Culture media and methods 
 
2.6.2.1 - Complete High Five culture medium 
Complete High Five culture medium consisted of Express Five™ medium containing 10 
g/mL gentamycin (Sigma) and 20 mM L-glutamine (Life Technologies).  
2.6.2.2 Microscopic visualisation of cells 
Insect cells were regularly monitored for growth, confluency and signs of infection using 
microscopic visualisation. In addition, during baculovirus infection, progress of infections 
was monitored by microscopic imaging of cultures at intervals. Microscopic visualisation 
and photography was carried out using a Leica DM IL inverted microscope (Leica 
Microsystems, Wetzlar, Germany) with a Leica DFC320 camera (Leica Microsystems). 
 
 




2.6.3 Culturing insect cells 
 
2.6.3.1 Resuscitating cells from cryostorage 
2.6.3.1.1 Sf9 cells in Sf900III 
Sf9 cells were resuscitated from storage in liquid nitrogen as follows. Vials containing cells 
were thawed rapidly before the contents were transferred to a 250 mL flat-bottom 
polycarbonate Erlenmeyer shaker flask with vented polypropylene cap (Corning, Corning, 
NY)) containing 28.5 mL Sf-900-III medium (Life Technologies) pre-warmed to 28°C. The 
shaker flask was then moved to an orbital shaker at 28°C under atmospheric conditions and 
shaken at 130 RPM in the dark. 
2.6.3.1.2 High Five™ cells 
High Five™ cells were resuscitated from storage in liquid nitrogen as follows. Vials 
containing cells were thawed rapidly before the contents were transferred to 15 mL 
polypropylene centrifuge tubes (BD Flacon) containing 4 mL of pre warmed complete High 
Five™ culture medium. The tube was centrifuged at room temperature for 5 minutes at 500 
 g. The supernatant was discarded and the cells resuspended in 5 mL complete High Five™ 
culture medium. 
A frozen vial of High Five™ cells was rapidly thawed by rolling between the palms of the 
hand. One millilitre of cells at 3  106 cells/mL was transferred to a 15 mL centrifuge tube 
containing 4 mL of pre-warmed complete High Five™ culture medium. The tube was 
centrifuged at room temperature for 5 minutes at 500  g. The supernatant was discarded 
and the cells resuspended in 5 mL complete High Five™ culture medium. This was done to 
remove the cytotoxic DMSO in the freezing medium. The mixture was used to seed a T-25 
tissue culture flask (vented lid) at cell density of 2.5  104 cells/cm2 and the flask incubated 
in a humidified incubator at 28°C under atmospheric conditions.  
2.6.3.2 Adherent cell culture and passage 
Once the adherent High Five™ cells had reached a density of 1.5  105 cells/cm2, the cultures 
were passaged. High Five™ cells have an approximate doubling time of 18–24 hours and 
this, along with observing the cultures under a microscope for signs of confluency, allowed 
establishment of the best time to passage the cells. The cells were also monitored daily for 
signs of distress and microbial contamination. 




The cells were detached by sloughing the adherent monolayer. All but 1 mL of medium was 
removed from the flask (5 mL when growing cells in T-75s). The flask was tilted on its side 
so that the medium collected in one corner. Some media was drawn up with a sterile 
Pasteur (or plastic dropper) pipette and starting from the bottom corner of the flask, media 
was gently streamed across the cells in a side to side motion, moving upwards each time. 
This process was repeated as gently as possible until all the cells were dislodged. The cells 
were then counted by trypan blue exclusion, and the viability determined. The cells were 
diluted to 5  105 cells/mL and 5 mL transferred to a fresh T-25 flask. When expanding the 
culture to a T-75 flask, 15 mL of 5  105 cells/mL were used. A seeding density of 2.5  104 
cells/cm2 was maintained. The flasks were then incubated in a humidified incubator at 28°C 
under atmospheric conditions. 
2.6.3.3 Adapting cells to suspension culture 
High Five™ cells needed to be adapted to suspension growth before they could be infected 
with PON2-expressing baculovirus. Before they could be moved to suspension culture, the 
High Five cells needed to be growing healthily in a monolayer. Once consistent passages of 
>90% viability were obtained from the adherent cultures, the cells could be transferred to a 
suspension culture. A minimum total volume of 40 mL of 7  105 cells/mL were required to 
initiate the culture. Once enough cells were available in adherent culture, the cells were 
detached, quantified and concentration adjusted to 7  105 cells/mL. 
Forty millilitres of cells were then transferred to a 250 mL flat-bottom polycarbonate 
Erlenmeyer shaker flask with a vented polypropylene cap (Corning). The medium was 
supplemented with 10 units/mL of porcine heparin (Sigma) to prevent cell aggregation. The 
shaker flask was then moved to an orbital shaker at 28°C and shaken at 130 RPM in the 
dark. The cells were monitored for viability and doubling time at each passage. The cells 
were considered to be adapted to suspension culture once the viability was >98% and the 
cells were doubling every 18–24 hours. Once adapted, the cells were weaned off the heparin 
by adding medium with decreasing heparin concentrations when passaging cells. High 
Five™ cells were typically weaned off heparin in 2–3 passages. 
2.6.3.4 Passaging suspension cultures 
During normal growth, and during infections, both Sf9 and High Five ™ cells were grown in 
suspension cultures, in the dark, in an orbital shaker. The cells were grown at 28°C under 
atmospheric conditions in 250 mL flat-bottomed polycarbonate Erlenmeyer shaker flasks 
with vented polypropylene caps (Corning). Confluency of the shaker cultures was 




approximately 2  106 cells/mL. The Sf9 cells doubled every 72 hours and High Five cells 
doubled every 18–24 hours. Once the cultures were estimated to be confluent, they were 
passaged. Firstly, the cells were enumerated by trypan blue exclusion and the viability of the 
cells determined. The cells were then diluted to 5  105cells/mL in the appropriate medium 
in fresh culture flasks and returned to the orbital shaker. 
2.6.3.5 Cryostorage of insect cells 
Cells were stored in liquid nitrogen at the densities indicated in Table 2.9 below. The cells 
were centrifuged at 500  g at room temperature for 10 minutes. The supernatant was 
removed and used as conditioned medium for preparing the freezing medium. The cells 
were then resuspended at the appropriate concentration in the freezing medium as per 
Table 2.11 and the appropriate volume dispensed into sterile, pre chilled cryovials. The 




2.6.4 Baculovirus titre determination 
 
Viral titres were determined using the end-point dilution method [281], based on 
estimation of the dilution of virus that would infect 50% of cultures. Briefly, ten-fold serial 
dilutions of virus stock were prepared and dilutions of 10–5–10–9 were appropriate for most. 
Ten microliter aliquots of each dilution was mixed with 100 L aliquots of Sf9 cell 
suspensions (in SF900 III medium; 1  105 cells/mL) and used to seed wells in 96-well cell 
culture plates (Corning). Each viral dilution along with Sf9 cells was seeded with 12 
Table 2.11 Cryostorage conditions for cultured insect cells 






46.25% conditioned Sf900 III medium 
46.25 fresh Sf900 III medium 
7.5% DMSO 
 





42.5% conditioned High Five medium 




3  106 
 
1.0 mL 




technical replicates (one row on 96 well plates). Sf9 cells without virus were used as a 
control. Plates were incubated in the dark at 28°C in a humidified environment to prevent 
dehydration. Cells were examined by light microscopy for virus replication and resultant Sf9 
cell death after three days. All wells that showed signs of infection were scored as positive, 
and the results tabulated. The plaque forming units were determined as described by 
O’Reilly and colleagues [281]. An example of the calculation of the viral titre based on the 
endpoint dilution method can be found in Appendix 8.1 
 
2.7 DATA HANDLING AND STATISTICS 
 
Digital images were processed with the GIMP2 software (v 2.8; http://www.gimp.org). 
Immunoblot intensities were analysed by densitometry using ImageJ (v.146; NIH, Bethesda, 






























CHAPTER THREE – P. AERUGINOSA QS SIGNAL 
C12HSL EXERTS CONCENTRATION-
DEPENDENT EFFECTS ON HUMAN AIRWAY 
















Many Gram-negative bacteria produce acylated homoserine lactone (AHL) molecules, to 
sense and co-ordinate their population growth via the quorum sensing (QS) mechanism. In 
P. aeruginosa, N-3-oxo-dodecanoyl-L-homoserine lactone (C12HSL) is the principal 
signalling molecule in this organisms hierarchical QS systems.  
C12HSL consists of a homoserine lactone ring with a fatty N-acyl group, and its intracellular 
and extracellular concentrations have been shown to vary in response to the growth phase 
of bacterial cells.  Thus for example, during its planktonic growth phase, P. aeruginosa has 
been shown to secrete sub-micromolar (M) amounts of C12HSL, while concentrations as 
high as 600 µM have been detected in mature biofilms produced by this organism [283]. 
Importantly, for the purposes of this study, the C12HSL produced by P. aeruginosa during 
infection has been shown to readily traverse mammalian cell membranes and to influence 
the normal functions of multiple cellular processes. C12HSL has been shown to inhibit T-
lymphocyte proliferation and function [184, 186, 187, 284], as well as modulate antibody 
production by B-lymphocytes [186, 187, 284]. In addition, C12HSL has been demonstrated 
to affect host protein synthesis by inducing endoplasmic reticulum stress, modulating 
calcium transport [192] and modifying ER structures [212]. C12HSL also appears to be a 
potent inducer of genes whose protein products are involved in the unfolded protein 
response (UPR) and apoptosis [192, 197, 202, 203]. The precise intracellular concentrations 
of C12HSL required to elicit these multiple cellular responses in the host is not known. 
Moreover, intracellular concentrations of C12HSL are also likely to be influenced by host 
proteins and varying pH levels, which all together often make it difficult for investigators to 
determine the precise biologically relevant dose of C12HSL to use in in vitro studies. In line 
with this, it is also generally realised that the in vitro effects of C12HSL on inflammation are 
dependent upon the concentration of C12HSL. Concentrations as low as one pico molar 
C12HSL have been shown to have immunomodulatory activity, at least in in vitro 
experiments [285], whereas 10-100 µM, or else higher concentrations of C12HSL,  have 
been widely used by investigators interested in provoking more pronounced 
immunomodulatory responses [187, 188, 192, 197, 205, 212]. In this context, it is important 
to point out that concentrations of C12HSL below 10 μM, appear to induce anti-
inflammatory responses, while concentrations above 20 μM seem to activate pro-
inflammatory and pro-apoptotic mechanisms [217].  




To gain further insight into the cellular pathways induced by C12HSL, Bryan and colleagues 
(2010) performed a whole transcriptome analysis in human alveolar epithelial (A549) cells 
exposed to 50 μM C12HSL. These authors observed significant changes in the expression 
levels of over 4000 genes, representing ~ 11% of the transcriptome of the alveolar 
epithelial cells. [213]. In addition, the results of their study seemed to suggest that 50 μM 
C12HSL  induced proinflammatory responses in  treated cells [15], which is consistent with 
a previous report showing that high concentrations (above 20M) of  C12HSL are pro-
inflammatory and pro-apoptotic [14]. On this line, research in our laboratory recently 
performed a whole transcriptome study in human bronchial epithelial cells being exposed 
to a concentration of C12HSL (10 μM), largely assumed only to trigger anti-inflammatory 
responses. [Unpublished Honours Thesis [286]](Table, 3.1; Appendix 8.2 for complete data 
set).  
 
Table 3.1 Selected details of an array probed with RNA extracted from  airway 
epithelia treated with 10 µM C12HSL [Unpublished honours thesis [286]].  See Appendix 
8.2 for complete data set 
Array Details 
Array platform GeneChip Human Transcriptome array 2.0 (Affymetrix) 
Array details High-resolution array consisting over six million probes 
encompassing coding regions and non-coding transcripts/exon-
exon splice junctions. 
Experimental Details 
Cell type Human Airway Epithelial Cell line – BEAS-2B 
Treatment Treatment – Six hour exposure to 10 μM C12HSL dissolved in 1% 
DMSO (v/v) in cell culture medium  
Control – Six hour exposure to 1% DMSO (v/v) in cell culture 
medium 1% DMSO (v/v) in cell culture media for six hours 




2941 (cut-off - greater than two fold with p < 0.05) 
Selected altered 
pathways 
(as determined by 
Ingenuity Pathway 
Analysis) 
Ingenuity Canonical Pathways –Log (P-value) 
(>1.3 = 
significant) 
Protein kinase Signalling 3.47 
3-phosphoinositide biosynthesis 2.56 
Calcium signalling 2.44 
PPAR signalling 2.38 
NF-κB signalling 1.68 




Surprisingly, that study produced similar results to those reported by Bryan and colleagues, 
in so far as genes involved in  calcium signalling, cell cycling, apoptosis, and the UPR 
pathway were all found to be differentially expressed in 10M C12HSL- treated bronchial 
epithelial cells compared to control (Table 3.1). Up until this point, however, the results of 
the whole transcriptome study [Unpublished Honours Thesis 286]] have not been validated. 
In this section of the thesis, an attempt was made to validate some of the results obtained in 
the whole transcriptome study involving human bronchial epithelial cells (with and without 
functional CFTR) being exposed to 10 µM C12HSL[Unpublished Honours Thesis [286]]. The 
ability of C12HSL to induce apoptosis in respiratory epithelial cells, as well as its effects on 




















3.2 MATERIALS AND METHODS 
 
A description of the materials and methods for this chapter is provided in chapter two. 
Additional materials and methods specific to this chapter are described below. 
 
3.2.1 Cell lines  
 
The respiratory epithelial cell lines BEAS-2B (wild-type CFTR), Nuli-1 (wild-type CFTR) 
[287], and CuFi-1 (ΔF508/ΔF508 CFTR) [287] were cultured as described previously 
(chapter two). 
 
3.2.2 Microarray validation by RT-qPCR 
 
To validate the gene expression changes observed in our transcriptome study in human 
bronchial epithelial cells exposed to 10 µM C12HSL, RT-qPCR was performed as described 
in chapter two to measure the expression levels of various genes (Table 3.2). The primers 
used are shown in Table 2.5. Complimentary DNA synthesis was carried out on the total 
RNA samples used in our initial transcriptome study, as described in chapter two. Gene 
expression measured by RT-qPCR was normalized to the commonly used reference gene 
ACTB which codes for the human β-actin protein. This reference gene is widely used in the 
literature to study changes in gene expression of epithelial cells and results in our lab show 
that the gene is stably expressed in the studied cell lines. 
 
3.2.3 Flow cytometry detection of apoptosis 
 
Apoptosis was detected using FITC-Annexin V (BD Biosciences, Mountainview, CA) antibody 
and propidium iodide (PI) dye. Annexin V detects the apoptosis-specific cell surface marker 
phosphatidylserine (PS). BEAS-2B cells were seeded in six well plates at 2  105 cells/well 
24 hours prior to treatment. The growth medium was then changed, and fresh medium was 




added containing either 1% DMSO as a vehicle control, or else varying concentrations of 
C12HSL (10, or 50 µM) also prepared in 1% DMSO. Solubility of C12HSL was checked by 
dissolving C12HSL to both concentrations and then measuring against pre-prepared 
standard using UPLC-MS. After six hours of treatment, the growth medium was removed, 
and cultured cells trypsinized and pelleted at 500  g for five minutes before the pellet was 
washed twice in ice cold PBS. Cells were then resuspended in ice cold 1 binding buffer 
(0.01 M HEPES (pH 7.4), 0.14 M NaCl, and 2.5 mM CaCl2) at a concentration of 1  106 
cells/mL. Next, a 100 µL aliquot of cells was removed and mixed with 5 µL of FITC Annexin 
V and 10 µL of PI (50 µg/mL stock). The FITC-conjugated Annexin V binds PS to the surface 
of apoptotic cells, while PI dye enters cells that have lost their membrane integrity; in turn, 
this assay can successfully differentiate between early apoptotic (Annexin V positive, PI 
negative cells) and necrotic/late apoptotic cells (Annexin V and PI positive) cells. The tubes 
were gently vortexed and incubated at 25 C in the dark for 15 minutes. A further 400 µL of 
1  binding buffer was then added; the cells passed through a nylon filter; and analysis 
carried out using a BD FACS Canto II flow cytometer (BD Biosciences). Ten thousand cells 
were counted for each sample. FITC and PE compensation controls were used for software 
compensation of spectra overlap for FITC and PE fluorescence. Software compensation and 
analysis of the results was carried out using FlowJo (TreeStar, San Carlos, CA) and GraphPad 
prism (La Jolla, CA). Apoptotic cells were considered to be those that stained FITC Annexin V 
positive and PI negative. 
 
3.2.4 Effects of C12HSL on cytotoxicity and cell metabolism 
 
To determine the cytotoxic effects of C12HSL on airway epithelia, the CellTox Green 
Cytotoxicity assay (Promega) was used. The assay employs a proprietary asymmetric 
cyanine dye that is usually excluded from viable cells and preferentially stains the DNA from 
dead cells. This assay was multiplexed with RealTime-Glo™ MT Cell Viability assay 
(Promega), which is a bioluminescent assay that measures the reducing potential of cells, 
thereby allowing the effects of C12HSL on the metabolic activity of the cell lines also to be 
determined. Cells were seeded at 1  104 cells/well in a 96 well plate for 24 hours prior to 
treatment. The growth medium was then changed and fresh medium supplemented with 
varying concentrations of C12HSL, along with the manufacturer-specified amount of dye, 
and luciferase and substrate added. The fluorescence (485 nm excitation and 525 nm 




emission) and luminescence were measured over 20 hour period using a SpectraMax M2 
plate-reader (Molecular Devices, Sunnyvale, California). To measure cell toxicity, the blank 
corrected fluorescence was normalized against the fluorescence of the non-treated cells for 
each time point, while in the case of assessing the metabolic activity of the cells; the blank 
corrected luminescence was normalized against the luminescence of each treatment group 
at time zero. 
3.2.6 Effects of C12HSL on gene expression of NuLi (wt CFTR) and CuFi (CFTR-
deficient) cells 
 
NuLi and CuFi cells were seeded in six well plates at 2  105 cells/well 24 hours prior to 
treatment. The growth medium was then changed and fresh medium was added containing 
either 10 μM C12HSL in 1% DMSO or 1% DMSO as a vehicle control. Solubility of C12HSL 
was checked by dissolving C12HSL to both concentrations and then measuring against pre-
prepared standard using UPLC-MS. After six hours of treatment, the cells were harvested, 
the RNA extracted and cDNA synthesized as previously described in chapter two (Section 
2.2) Quantitative PCR was carried out as previously described in chapter two . For analysis 










3.3.1 Validation of whole transcriptome microarray data 
 
Previously, a whole transcriptome study in airway epithelial cells (BEAS-2B) treated with 
10 μM C12HSL, found that ~ 3000 genes were differentially expressed, including those 
involved in immune signalling and apoptosis [Unpublished Honours Thesis 286]]. In the 
present study, RT-qPCR was used to validate certain results. The changes in gene expression 
obtained by RT-qPCR were then compared to those changes captured by the whole 
transcriptome array (Table 3.2). 
Changes in gene expression levels of five (TANK, MUC2, USP40, XBP1 and ATF3) out of 15 
selected genes from the microarray panel (Table 3.2) were validated (t-test, p < 0.05) 
successfully using RT-qPCR. (Table 3.2). Although the expression levels of four additional 
genes (ABCF1, MST1, CASP8 and IL6) measured by RT-qPCR were similar to those obtained 
in the microarray study, the results were not statistically significant. Of the five genes whose 
expression failed to reach statistical significance, ABCF1 showed a trend toward significance 
(-4.97 fold change in microarray vs. -5.12 fold change in RT-qPCR, p=0.0570). In all, the 
expression levels of only two of the 15 genes, as measured by RT-qPCR, were different to 
those obtained on the microarray platform. On the basis of these results, it seems that the 
microarray data [Unpublished Honours Thesis [286]] provides a significant and robust 
insight into the likely effects of 10 μM C12HSL on the BEAS-2B transcriptome.  
The results of the transcriptome study showed that the expression of two important UPR 
genes, namely, XBP1 and ATF3 were significantly diminished, in response to treatment with 
10 μM C12HSL, which was validated by RT-qPCR (p < 0.05) (Table 3.2). Although 
dysregulation of the UPR could be suspected to lead to apoptosis, up-regulation of two 
genes (CASP3 and CASP7) involved in apoptosis as captured by the microarray could not be 
validated by RT-qPCR (Table 3.2). Instead, the results of the RT-PCR analysis would seem to 
suggest that 10 μM C12HSL did not induce the expression of apoptotic pathways in BEAS-2B 
cells.  
Since the whole genome expression study also indicated that 10 μM C12HSL modulated 
immune signalling it was decide to verify changes in gene expression of some of these 
immune-responsive genes by RT-qPCR. RT-qPCR confirmed the down regulation of TANK 
and MAP3K2, which are involved in NF-κB signalling. In addition, while no change in the 










(Treated: Vehicle Control) 
Microarray 
(p < 0.05) 
RT-qPCR 




ABCF1 ATP-binding cassette, 




-4.97 -5.12 0.0570 
PPARG Peroxisome proliferator-
activated receptor gamma 
Immune 
Inflammation 
+3.43 -1.23 0.6742 






-4.33 -7.36* 0.0094 
MAP3K2 Mitogen-activated protein 




+2.02 -3.49* 0.0170 




in lung epithelia 
+3.19 +19.54 0.3957 




-3.11 -7.39* 0.0045 




-5.16 11.31*** 0.0002 
XBP1 Xbox binding protein UPR -1.47 -2.73* 0.0051 
ATF3 Activating transcription 
factor 3 
UPR 
-1.86 -3.55* 0.0046 
CASP3 Caspase 3, apoptosis 
related cysteine peptidase 
Apoptosis 
+4.55 -3.71* 0.0045 
CASP7 Caspase 7, apoptosis 
related cysteine peptidase 
Apoptosis 
+2.17 -1.10 0.7599 
CASP8 Caspase 8, apoptosis 
related cysteine peptidase 
Apoptosis 
-2.81 -2.97 0.3080 
IL6 Interleukin 6 Inflammatory 
cytokine 
-1.07 -1.18 0.1840 
IL8 Interleukin 8 Inflammatory 
cytokine 
No change -1.49* 0.0297 
TNF Tumor necrosis factor Immune 
Cell Signalling 
No change +2.46 0.3100 
Genes whose change in expression as indicated by microarray was validated by RT-qPCR are 
highlighted in bold. Mean of three independent experiments.  * = p < 0.05, *** = p < 0.001 
based on unpaired t-test. 




expression level of the inflammatory cytokine IL8 gene was observed in the transcriptome 
study, RT-qPCR showed a small decrease in IL8 expression (-1.49 fold). Taken together, the 
RT-qPCR analysis of the whole transcriptome study seems to suggest that 10μM C12HSL 
treatment has an anti-inflammatory effect on BEAS-2B cells. 
 
3.3.2 C12HSL induces apoptosis in BEAS-2B cells in a concentration-dependent 
manner 
 
Although C12HSL has been reported to be able to induce apoptosis in a number of different 
cell types, including lymphocytes, macrophages, and aortic endothelial cells [192, 197, 202], 
there appears to be some debate in the literature on whether human epithelial cells are 
similarly affected by treatment with C12HSL. Tateda and colleagues showed that apoptosis 
was not induced in human epithelial cell lines exposed to up to 24 µM C12HSL [197]. In 
contrast, Schwarzer and colleagues reported activation of caspase 3/7 (the executing 
caspases in apoptosis), in human airway epithelia upon treatment with C12HSL 
concentrations greater than 10 µM [288]. To test whether C12HSL induces apoptosis in 
airway epithelial cells, the BEAS-2B airway epithelial cell line was exposed to 10 μM and 50 
μM C12HSL and subjected to a flow cytometry-based apoptosis assay (Section 3.2.3).  
The results of the flow cytometry analysis of BEAS-2B cells treated with varying 
concentrations of C12HSL for six hours show an induction of apoptosis in these cells. 
Importantly, apoptosis was induced in a C12HSL dose-dependent manner (Figure 3.1). It is 
clear from the results that after a six hours exposure to 10 µM C12HSL, no difference in the 
overall numbers of apoptotic cells able to be detected between C12HSL-treated and vehicle 
control-treated BEAS-2B cells. In contrast, treating BEAS-2B cells with 50 µM C12HSL for six 
hours induced a greater than two-fold increase in the percentage of early apoptotic cells 















Figure 3.1 Induction of apoptosis in respiratory epithelial cells by C12HSL is concentration 
dependent.  
BEAS-2B cells were treated with 10 µM and 50 µM C12HSL for six hours before being collected and 
stained with FITC-Annexin V and PI. The induction of apoptosis was measured by flow cytometry. 
Three biological replicates were run and representative flow cytometry plots are shown in (A). 
Apoptotic cells stain positive for Annexin V and can be seen in the quadrants on the right. The mean 
% of apoptotic cells from three experiments are shown in (B). Error bars represent S.D; *** p < 0.001 
(One way ANOVA). 




3.3.3 The cytotoxic and metabolic effects of C12HSL on airway epithelial cells 
 
Given that apoptosis was observed in BEASE-2B cells treated with 50 µM C12HSL, the 
cytotoxic effects of 10 μM and 50 μM C12HSL (over a period of 20 hours) on BEAS-2B cells 
was investigated using the CellTox Green Cytotoxicity assay (Promega). In addition, changes 
in cellular metabolism across the same time period was also determined concurrently using 
a separate assay. Three airway epithelial cell lines were used: BEAS-2B (wild-type CFTR); 
CuFi, an airway epithelial cell line with homozygous ΔF508 CFTR mutation and NuLi, an 
identically transformed (to CuFi) cell line which possesses wild-type CFTR [287]. By both 
NuLi and CuFi cells the effect(s), if any, of the CFTR mutation on the response of these cells 
to C12HSL treatment could be determined. 
A C12HSL-dose-dependent cytotoxic effect was observed in our airway epithelial cells 
(Figure 3.2). Of the three airway epithelial cells tested, C12HSL induced the greater 
cytotoxic effects on BEAS-2B cells, while the NuLi and CuFi cells appeared less susceptible to 
the cytotoxic effects of C12HSL. The CFTR-deficient CuFi cells appeared to be the most 
protected from C12HSL-mediated cytotoxicity. Treatment with 10 μM C12HSL did not 
increase cell toxicity when compared to the (vehicle treated) control in any of the three 
airway epithelial cell lines. Treatment with 50 μM C12HSL, however, caused immediate 
(within two hours of treatment) significant (p < 0.05) increases in cell cytotoxicity in three 
airway epithelial cells tested. CFTR-deficient CuFi cells appeared to be less susceptible to 
C12HSL mediated toxicity when compared to the wild-type CFTR NuLi cells. In CuFi cells, 
there was no discernable increase in cytotoxicity over the 20 hours with 10 μM C12HSL. 
With the higher concentration of 50 μM C12HSL, the cytotoxicity effects were similar but 
less pronounced in CuFi cells when compared to the wild-type CFTR cells. 
Ten micromolar C12HSL did not have any effect on cell metabolism in any of the cell lines 
(Figure 3.3). Typically, as cell toxicity increases, cell metabolic activity is expected to 
decrease [289-292]. However, the BEAS-2B cells, in which C12HSL caused the greatest 
increase in cytotoxicity (50 μM C12HSL) did not display a corresponding decrease in cell 
metabolic activity. In fact, within 30 minutes of treatment of BEAS2-B with 50 µM C12 HSL, 
there was an increase in cell metabolism compared with the vehicle-treated cells (p<0.05). 
After two hours of treatment, metabolic activity still remained elevated. After four hours of 
50 µM 12HSL treatment, cell metabolic activity began to fall. By 10 hours, there was no 




difference in metabolic activity (p>0.05) and by 24 hours there was a trend to decreased 
metabolic activity when compared with the (vehicle treated) control.  
The increase in cytotoxicity in the NuLi cells in response to 50 µM C12HSL treatment 
coincided with a decrease in cell metabolic activity. There was an immediate but modest 
decrease in metabolic activity with 50 µM C12HSL treatment (p<0.05 after 30 minutes), 
further supporting that the NuLi cells are less affected by C12HSL-mediated cytotoxicity 
than the BEAS-2B cells. The metabolic activity remained consistently lower than the 
(vehicle treated) control throughout the 20 hour treatment of 50 µM C12HSL.












Figure 3.2 C12HSL-induced cell toxicity in BEAS-2B, NuLi and CuFi cells. BEAS-2B (A), NuLi (B) and CuFi (C) cells were treated with 10 μM  and 50 µM C12HSL and then 
assayed for cell toxicity for 20 hours using the Cell-Tox Green assay (Promega). Cell toxicity is shown as relative fluorescence units (RFU), the blank corrected 
fluorescence relative to the blank corrected fluorescence of an untreated control. The mean of four independent experiments is shown. Error bars show SD. * p<0.05 
based on Holm multiple t-tests.  
 










Figure 3.3 Effect of C12HSL on BEAS-2B, NuLi and CuFi cell metabolism. BEAS-2B (A), NuLi (B) and CuFi (C) cells were treated with 10 μM and 50 µM C12HSL and then 
assayed for cell metabolism for 20 hours using the RealTime-Glo MT Cell Viability assay (Promega). Cell metabolism is shown as fold change of luminescence units 








The CuFi cells once again appeared to be the most resistant to the effects of C12HSL, with a 
very small decrease in metabolic activity after two hours (p< 0.05) but this effect was not 
persistent, since by four hours, there was little to no difference between the treated cells 
and vehicle control. 
 
3.3.4 CFTR-dependent effects of C12HSL on airway epithelia gene expression 
 
Even 10 μM C12HSL, was able to dramatically impact gene expression in the BEAS-2B 
bronchial epithelial cells. In order to investigate how mutations in CFTR influences C12HSL-
mediated gene expression in airway epithelial cells, RT-qPCR was used to investigate 
changes in the same panel of genes used to validate the microarray results, as well as 
several other genes of interest.  
 
Table 3.3 Change in gene expression (by RT-qPCR) in NuLi and CuFi treated with 10 µM 




Description of Gene 
Relative Expression 







MAP3K2 Immune, NF-κB Signalling +1.71 0.174 +1.38 0.602 
TANK Immune, NF-κB Signalling +1.39 0.241 +1.11 0.745 
ABCF1 Immune, Inflammation +1.12 0.713 -2.20 0.317 
MST1 Cilliary Motility in lung epithelia +1.08 0.870 -1.69 0.402 
MUC2 Mucin Production -1.14 0.662 -2.22 0.245 
USP40 Deubiquinating enzyme +1.71* 0.035 +1.52 0.252 
XBP1 UPR +1.72 0.442 -1.86 0.468 
ATF3 UPR +1.34 0.082 -2.38 0.232 
CASP3 Apoptosis +1.08 0.704 -1.31 0.517 
CASP7 Apoptosis +1.04 0.909 -2.90 0.474 
CASP8 Apoptosis -2.77 0.138 -2.27 0.317 
NGFR Apoptosis +2.88 0.181 -1.33 0.662 
IL6 Inflammatory cytokine +1.07 0.753 -1.70 0.095 
IL8 Inflammatory cytokine +1.22 0.301 +1.15 0.600 
TNF Immune, Cell Signalling -1.938 0.278 -2.51 0.059 
Mean of three independent experiments; * = p < 0.05, based on unpaired t-test. 




From the panel of genes listed in Table 3.3, only USP40 was significantly up-regulated in the 
NuLi cells (+1.71 fold, p<0.05). Two genes showed a trend to significance, ATF3 in NuLi cells 
(+1.34 fold up-regulation, p=0.0820) and TNF in CuFi cells (-2.51 fold up-regulation, 
p=0.059).  
When the relative expression of the treated cells to untreated cells is compared between the 
two cell lines, the results showed that all of the NF-κB signalling genes examined showed 
the same directional regulation, however the expression of inflammation, UPR and 
apoptosis genes were up-regulated in NuLi cell and down-regulated in CuFi cells, suggesting 





Figure 3.4 CFTR dependent effects of C12HSL on NuLi and CuFi gene expression. NuLi (wild-type CFTR, 
solid bars) and CuFi (ΔF508, spotted bars) cells were treated with 10 μM C12HSL for six hours and the 
RNA extracted to measure change in gene expression in response to treatment. The expression of each 
gene was normalized to reference gene ACTB and then the fold change of C12HSL treated/vehicle 
control treated cells calculated. The bars show fold change of each gene relative to vehicle control with 
associated standard error bars. 






In this section of the thesis, 15 differentially expressed genes reported in an earlier 
transcriptome study [286] were chosen for validation, based on their biological significance 
and on their expression levels. Transcriptome-wide analyses provide a valuable insight into 
change in global gene expression levels of numerous genes change between varying tissues 
and cell types, and across different disease states, as well as in response to varying 
environmental stimuli. DNA microarrays are widely accepted as powerful tools to capture 
genome wide changes in transcription patterns; in turn, and with the advent of 
bioinformatics tools such as pathway analysis, network analysis and systems biology, DNA 
microarrays now allow investigators to generate testable hypotheses. However, the quality 
of the data obtained in microarray-based studies can be highly variable, owing in part at 
least to variations in the types of microarray platforms used; the quality of the starting RNA 
material [293]; and the bioinformatics programs used to perform the microarray analysis 
[294]. In order to translate microarray data into biologically significant findings, other gene 
expression technologies are often used to validate data obtained in microarray studies.  In 
this context, there is no universally agreed upon method to validate microarray data, 
however, RT-qPCR has long been considered the gold-standard method to investigate 
differential gene expression in biological studies [295, 296]. 
Investigators typically approach validation in one of two ways: validating (i) a set of top hits 
based on biological and statistical significance, or else (ii) large random subset of results 
[297]. Given that the results of the RT-PCR experiments performed in this study were 
mostly consistent with those obtained in our microarray analysis, it seemed reasonable to 
conclude that the microarray results broadly represented the likely cellular changes being 
triggered in BEAS-2B cells by 10 μM C12HSL exposure. The data from both the 
transcriptome array and RT-qPCR analysis show that C12HSL, even at the relatively low 
concentration of 10 μM, was capable of influencing the expression levels of a number of 
genes involved in the host immune response. In this context, numerous in vitro studies have 
described the immunomodulatory effects of C12HSL on the human airway [184, 186, 197, 
reviewed in 217, 284]. The results described here show the strong down-regulation of TANK 
by 10 μM C12HSL. TANK encodes a protein that stimulates NF-κB activation [298] and 
thereby, the immune response. The suppression of inflammation found in this study is 
consistent with reports showing C12HSL having anti-inflammatory effects at concentrations 
below 10 μM [187, 217].  




The change in expression of the pro-inflammatory cytokine genes IL6 and IL8 was also 
investigated, given that both genes have been reported to be up-regulated in airway 
epithelia in response to >25μM C12HSL [189, 299]. While there was no change in 
expression of IL6, 10 μM C12HSL down-regulated IL8 expression, suggesting that this 
concentration of C12HSL may have a suppressive effect on inflammation, possibly through 
the suppression of neutrophil chemotaxis [193]. These results lend further support to the 
hypothesis that concentrations of C12HSL below 10 μM provoke anti-inflammatory 
responses [217]. 
Jahoor and colleagues identified the transcription factors PPARβ/δ and PPARγ as putative 
mammalian C12HSL receptors through which C12HSL could modulate mammalian host 
responses [214]. The microarray data indicated that in response to C12HSL PPAR signalling, 
and that PPARγ expression was up-regulated. However, RT-PCR analysis failed to validate 
this change in PPARγ expression. While there is some indication that PPARγ may regulate its 
own expression [300], antagonism by relatively low levels of C12HSL may only affect PPARγ 
protein activity and not its expression thus a transcript-based method like RT-qPCR may 
not be the ideal technique with which to validate the C12HSL dependent effects on PPAR 
signalling. The results from chapter four, using a functional promoter assay, shows that 10 
μM C12HSL was able to competitively bind to PPARγ and increase PPARγ activity. This is a 
small increase in activity, however, and under normal cellular conditions could be expected 
to be balanced by inhibition of binding of C12HSL by stronger endogenous agonists. Given 
the proposed role of PPARγ as a mammalian C12HSL receptor, PPARγ-dependent immune 
signalling in response to C12HSL will require further investigation.  
The microarray data also indicated that C12HSL might be inducing cellular stress by altering 
the expression levels of genes involved in the UPR and ubiquination. The expression of three 
genes involved in the UPR and ubiquination was validated by RT-qPCR. The expression of 
XBP1 and ATF3, two key UPR genes, was down-regulated in response to C12HSL treatment. 
Increased XBP1 usually indicates a shift towards a protective response to misfolded 
proteins, while decreased ATF3 usually indicates a shift to a deleterious, apoptotic response 
to misfolded proteins. The reduced expression of both genes indicates a shift towards ATF3 
dependent induction of apoptosis. Although no increase in cytotoxicity was observed in 
BEAS-2B cells six hours after treating with 10 μM C12HSL (compared to control treated 
cells), this decreased ATF3 offers a potential mechanistic explanation for how C12HSL might 
be able to induce cytotoxicity. The expression of USP40, a peptidase specific to ubiquitin, is 
also down-regulated. Deubiquinating enzymes are not merely ubiquitin recyclers, as there 




are emerging reports of their involvement in DNA replication, cell division and cell death 
[301, 302]. The accumulation of misfolded proteins, as caused by the disruption of the UPR 
by C12HSL, results in cytotoxicity. By also affecting deubiquinating enzymes, it is tempting 
to speculate that C12HSL could possibly further hamper the ability of a cell to respond to 
misfolded proteins, thereby exacerbating the cytotoxic effects of C12HSL on the cells. 
Given the down-regulation of the UPR by C12HSL in BEAS-2B, increased cytotoxicity was 
expected. It is widely reported that C12HSL is able to induce apoptosis in a number of cell 
types including airway epithelia [192, 200, 202, 203]. As a result, the apoptotic effect of 
C12HSL in the BEAS-2B cells was further investigated. The transcriptome study indicated 
that the expression of some of the caspase genes were affected by 10 μM C12HSL. However, 
none of the changes in expression of the caspase genes could be validated by RT-qPCR. In 
fact, the results of the RT-qPCR analysis indicated that the expression of CASP3 was down-
regulated by 10 μM C12HSL after six hours. Another independent method of investigating 
the apoptotic effect of C12HSL on the BEAS-2B cells was therefore used. The results of the 
flow cytometry analysis of induction of apoptosis showed that 10 μM C12HSL did not induce 
apoptosis in the cells following six hours of treatment. Increasing the C12HSL concentration 
to 50 μM induced apoptosis in the cells, implying C12HSL has a concentration-dependent 
ability to induce apoptosis in BEAS-2B cells. Schwarzer and colleagues also investigated the 
induction of apoptosis by C12HSL in airway epithelial cells and found a concentration-
dependent effect of C12HSL on induction of caspase 3/7 activity in airway epithelial cells. 
However, their methodology showed that concentrations of 10 µM C12HSL increased 
caspase 3/7 activity.[288]  
Investigations of the effects of C12HSL was extended to the effect of C12HSL on the viability 
and metabolic activity of airway epithelial cells. At the lower concentration, the two wild-
type CFTR cell lines showed a small decrease in viability after 20 hours but at higher 
concentrations, an immediate (within two hours) decrease in cell viability was observed. 
This further confirmed the C12HSL-dose dependent induction of apoptosis. The two wild-
type CFTR bronchial epithelial cell lines (BEAS-2B and NuLi) behaved similarly in regards to 
viability, although the NuLi cells were less affected by C12HSL.  
The processes of cell metabolism and apoptosis are intertwined but the mechanisms 
through which cell metabolism and apoptosis are linked remain to be fully elucidated. The 
triggering of apoptosis is thought to result in an overall decrease in cellular metabolic 
activity [289-292]. In the wild-type CFTR NuLi cell line, as expected, there was a marked 




decrease in cell viability in the cells that displayed increased cell cytotoxicity in response to 
C12HSL treatment. However, BEAS-2B cells treated with 50 μM C12HSL demonstrated an 
increase in cell metabolic activity. The initiation of apoptosis is a metabolically taxing 
activity with ATP being required for the activation of caspases, enzymatic activity, bleb 
formation and chromatin condensation [291]. The observed increase in BEAS-2B cell 
metabolism could be a result of the cells initiating the apoptotic processes. Such an increase 
may not have been observed in the NuLi cells because they appear to be more resistant to 
the effects of C12HSL, and perhaps a greater concentration of C12HSL is needed to induce 
the apoptotic processes being observed in the BEAS-2B cells. However, in order to 
completely reconcile the differences between the BEAS-2B and NuLi cells the possibility 
that these observations may be due to the cells being in different growth phases and at 
different cell densities needed to be eliminated. Even though the cell lines were seeded at 
the same density, any differences in growth rates of the cell lines may need to be 
determined to ensure that these factors do not contribute to the effects seen with the BEAS-
2B and NuLi cells. 
What is clear, is that C12HSL is able to influence the airway epithelia in a number of 
different ways, and that these effects vary in magnitude and direction depending on the 
concentration of C12HSL. Ten micromolar C12HSL, a concentration lower than that 
generally studied in the literature, still dramatically affected airway epithelial cells. While 
this concentration did not elicit apoptosis or affect cell metabolic activity, it was still able to 
induce significant changes in expression of a number of important genes. Thus, these 
findings provide further support for the notion thatC12HSL plays important roles in P. 
aeruginosa pathogenesis.  
The whole transcriptome study identified altered calcium signalling as another major 
change effected by 10 μM C12HSL-treated BEAS-2B cells. Interestingly, the microarray 
reported the down-regulation of the GTPase-activating protein IQGAP1. Briefly, and with 
the exception of PPAR’s, IQGAP1 is the only other identified mammalian C12HSL receptor 
[225]. C12HSL is thought to use IQGAP to trigger essential changes in the cytoskeletal 
network [225]. IQGAP1is a scaffolding protein that plays an essential role in cell shape, 
vesicle trafficking, and directional migration [226]. It contains a calmodulin-binding motif, 
and calmodulin is a major Ca2+ sensor. Although it is unknown whether C12HSL directly 
interacts with calmodulin-binding motif, C12HSL may use IQGAP1 to affect intracellular Ca2+ 
levels. Furthermore, the presence of CFTR mutations modulates the influence C12HSL has 
on intracellular calcium [303, 304]. Schwarzer and colleagues investigated the effects of 




C12HSL on intracellular and endoplasmic reticulum (ER) Ca2+ concentrations in the wild-
type CFTR Calu-3 airway epithelial cell line. They found increasing intracellular and 
decreasing ER Ca2+ with C12HSL concentrations as low as 10 μM [305], while cells with 
defective CFTR demonstrated a considerably increased release of Ca2+ when treated with 
100 μM C12HSL [189]. This movement of Ca2+ has been linked to apoptosis in murine 
fibroblasts [192] and is thought to affect host defence mechanisms against P. aeruginosa 
[265]. Thus it is difficult to tease apart whether the C12HSL-mediated effects on BEAS-2B 
result from C12HSL acting through PPARγ or IQGAP1 or even through another as yet 
unidentified C12HSL receptor. Clearly, further investigations are required to determine how 
exposure to C12HSL treatment induces changes in intracellular Ca2+ levels. 
We investigated further which of the effects of C12HSL are influenced by the CFTR mutation. 
RT-qPCR was used to measure changes in gene expression in NuLi and CuFi cells treated 
with 10 M C12HSL for 6 hours to isolate CFTR-dependent effects of 10 μM C12HSL. Only 
one gene showed a significant change in expression: USP40 in the wild-type CFTR NuLi cell 
line, which showed an increase (<2 fold) in expression. It is difficult to draw any conclusions 
from such a small change in expression of only one gene, particularly since USP-40 
expression was strongly down-regulated in another wild-type CFTR cell line (BEAS-2B). 
Instead changes in gene expression between the wild-type CFTR and CFTR-deficient cell 
lines were compared to elucidate any CFTR-dependent effects.NF-κB signalling is 
considered to be PPARγ dependent [214], and PPARγ protein activity is believed to 
impaired by CFTR mutation [224]. As a result, we would expect the gene expression profiles 
of genes involved in NFκB signalling in wild-type CFTR to be different to that of CFTR-
deficient cells. However, RT-qPCR results showed similar trends in change in expression of 
NF-κB signalling genes in both wild-type CFTR and CFTR-deficient cells. As expected, genes 
involved in the UPR, a process that can be activated by both PPARγ[306] and modulated by 
calcium signalling induced ER stress [307], showed opposing trends in change in 
expression. Without statistically significant results it is difficult to draw conclusions from 
these findings, however it is possible that C12HSL-dependent effects on inflammation and 
apoptosis may occur through independent mechanisms. Research into novel receptors of 
C12HSL is required. 
The experiments were therefore extended to analyse changes in cell toxicity and metabolic 
activity in the CuFi cells in response to C12HSL treatments. The CFTR deficient CuFi cells 
appeared to be protected against C12HSL mediated changes in cell toxicity and metabolic 
activity, even more so than the NuLi cells. This is consistent with another study [189] where 




concentrations of 100 μM C12HSL were required to elicit a hyperinflammatory response in 
CFTR-deficient cell cultures. Further understanding of the protective mechanisms of 
increased intracellular Ca2+ is required before any protective effect(s) of C12HSL can be 
attributed to disrupted calcium signalling. One possible explanation of the protective effect 
of the ΔF508 mutation is to consider the effect of the mutation on the inflammatory 
regulator PPARγ. PPARγ has a net suppressive effect on inflammation and CFTR mutations 
are thought to decrease its expression and activity [221, 222, 224]. Since PPARγ has been 
reported to be a mammalian C12HSL receptor, decreased PPARγ expression/function in 
CFTR deficient cell lines may render them less sensitive to the effects of C12HSL. Given the 
already hyper-inflammatory nature of the CF cell line, any pro-inflammatory and apoptotic 
effects of C12HSL would be muted. However, the differences between the wild-type CFTR 
and CFTR-deficient cell lines in our experiments were small, possibly due to decreased CFTR 
in the wild-type as a consequence of C12HSL treatment (transcriptome array indicates 
decreased CFTR expression in response to C12HSL treatment) although there is some 
evidence that C12HSL-induced apoptosis may be independent of CFTR mutations [288, 
308].  
One factor to consider is that the CuFi cells may have an underlying proinflammatory bias. 
Voisin et al 2014 [309] demonstrated (using microarrays) a general up-regulation of 
inflammatory genes in the CuFi cells even in the absence of a pathogen compared to NuLi 
cells. Therefore there may be an underlying immune bias associated with a dysfunctional 
CFTR protein. They also demonstrated that under conditions of oxidative stress CuFi cells 
are more resistant to apoptosis than NuLi cells which fits with the results in this thesis. In 
the data analysis NuLi data was compared to NuLi control and the same for CuFi, and 
thereby negates this bias. Both the NuLi and CuFi cells appear to be more protected against 
C12HSL mediated effects when compared to the BEAS-2B cells and it is difficult to establish 
which cells, the NuLi or the BEAS-2B most closely reflect C12HSL mediated effects in the 
airway. The use of primary cell cultures, which more accurately reflect the in vivo 
characteristics of airway epithelia, may enable the determination of which cell line more 
closely represents the airway and proves most valuable in future studies involving C12HSL. 
Another consideration for future studies would be to accurately determine the LD50 of 
C12HSL when studying cytotoxicity, for each individual cell line. Such determination would 
lead to improved understanding of the varying effects of C12HSL at different concentrations 
when compared to studying the effects of C12HSL at established anti/pro inflammatory 
concentrations. 




The results in this chapter show that even at low concentrations (10µM) C12HSL 
significantly affects airway epithelial cells, the first point of contact in the establishment of 
P. aeruginosa infection. These effects of C12HSL appear to be concentration dependent. The 
results described here suggest that at low concentrations of C12HSL appear to be anti-
inflammatory and deregulates the UPR but does not induce apoptosis. In addition, the CFTR 
mutation seems to offer some protection to C12HSL-mediated effects, but better 
understanding of the mechanisms through which CFTR mutations may facilitate chronic P. 
aeruginosa infections on a cellular level. With increased understanding of how C12HSL 

































The three members of the human paraoxonase enzyme family, PON1, PON2 and PON3, are 
found adjacent to each other on chromosome 7 and possess significant homology [310]. 
PON1 and PON3 are primarily found bound to high-density lipoproteins in circulation [257, 
311], while PON2 is absent from plasma, but is expressed by most human tissue and 
functions as an intracellular enzyme [258]. All the PONs display anti-artherogenic 
properties in murine models [312-314] and an ability to hydrolyse varying types of lactones 
in vitro [248]. PON2 also displays anti-oxidative and anti-apoptotic properties but it is 
thought that these processes are mechanistically independent of its lactonase activity. [259, 
315]. PON2 lactonase activity is generally much lower than that of other PONs with the 
exception of its activity against acyl homoserine lactone (AHL) substrates, where PON2 
activity is orders of magnitude higher in comparison with PON1 and PON3 [248]. 
AHLs are widely recognized as important quorum sensing (QS) signals in many Gram-
deficient bacteria. Of particular interest to this project is the P. aeruginosa QS signalling 
molecule C12HSL. C12HSL is the signal molecule at the top of the P. aeruginosa QS hierarchy 
and is integral to the bacterium’s virulence, in particular to the formation of biofilms, which 
afford P. aeruginosa significant protection against host immune responses and conventional 
antibiotics [125, 157, 316, 317]. P. aeruginosa is particularly problematic in people with 
cystic fibrosis (CF) where it is the major lung pathogen in adults, and causes chronic 
infections leading to much of the CF-related morbidity and mortality. Of the paraoxonases, 
PON2 has the highest lactonase activity against C12HSL. As a result, C12HSL is widely 
considered to be the natural substrate of PON2 [248, 262]. PON2 deficiency hinders P. 
aeruginosa clearance and enhances its quorum sensing in murine models [249, 264] 
suggesting that PON2 must play a protective role against co-ordinated bacterial virulence 
and infection. 
Apart from its bacterial signalling function, C12HSL is also able to modulate mammalian 
cellular function, because its lipophilic tail structure facilitates entry into mammalian cells. 
C12HSL interferes with inflammatory pathways involving NF-B [188] by acting as a weak 
agonist of the anti-inflammatory nuclear transcription factor PPARγ (peroxisome 
proliferator activated receptor  ) [214]. PPAR is a ligand-dependent transcription factor 
that binds to a specific peroxisome proliferator response element (PPRE) as a heterodimer 
with a retinoid X receptor (RXR) [215, 216]. It can then bind an agonist that allows for a 
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conformational change enabling it to recruit co-activators and/or co-repressers and 
modulate transcription. PPAR influences inflammation by the modulation of signalling 
through toll-like receptors (3,4 & 9), NF-B signalling and by inducing phosphorylation of 
p38 MAPK [217, 318, 319], producing a net suppressive effect on inflammation. C12HSL 
competes with unknown endogenous PPAR agonists and exerts a net antagonistic effect on 
PPAR activity, possibly allowing for sustained inflammation when the host is infected with 
P. aeruginosa [214, 217]. 
In people with CF, PPAR function is affected by mutations in the cystic fibrosis 
transmembrane conductance regulator (CFTR) gene and Cftr-deficient mice display 
decreased PPAR nuclear localization, PPAR DNA binding, PPAR co-activator recruitment 
and overall gene expression [221]. Reduced PPAR levels and/or function have also been 
demonstrated in CF human airway epithelial cell lines [222]. It is believed that CFTR defects 
generate oxidative stress that sustains tissue trans-glutaminase 2 activation. This inhibits 
PPAR SUMOylation, favouring PPAR crosslinking and proteasomal degradation [224]. 
Consequently, there is decreased PPAR functionality, which may explain, in part, the 
hyperinflammatory nature of the CF lung. 
 The regulation of PON2 expression is as yet poorly understood. Investigations into PON2 
regulation have been mostly limited to macrophages, where PON2 expression is influenced 
greatly by a number of factors induced by oxidative stress [268-271, 321, 322]. In 
endothelial cells, PON2 transcript and protein expression was induced via the unfolded 
protein response to endoplasmic reticulum stress [259], while in cultured airway epithelial 
cells, C12HSL has been shown to down-regulate expression of PON2 [265]. Several studies 
have shown that PON1 is activated by PPAR agonism [323-326] and PPAR agonism by 
rosiglitazone leads to up-regulation of PON2 transcript and protein in mouse macrophages 




Relative to hPON2 







Binding site Start Stop 
1. –66 –88 Forward 0.916 Yes 
2. –719 –813 Reverse 0.839 No 
Putative PPARγ binding sites were identified within the 1100 bp up-stream of human PON2 
transcription start with ‘good’ matrix similarity score. Matrix similarity scores of 0.8 or more 
are considered to be a ‘good’ score. Analysis done using the in silico transcription factor 
binding site analysis in Genomatix MatInspector [320]. 
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in a dose-dependent manner [268]. The mechanisms behind PPAR regulation of PON2 are 
less clear. PPAR functions as a transcription factor and unpublished results in our lab 
indicate the presence of putative PPREs in the PON2 promoter (Table 4.1) [320]. Results 
from our lab have also indicated that PPAR and PON2 expression is correlated in the lungs 
of CF patients (Figure 4.1). These findings strongly suggest that PPAR transcriptionally 
regulates PON2. 
The transcriptional regulation of PON2 by PPAR has important implications for individuals 
with CF. The combined suppression of PPAR function by defective CFTR and P. aeruginosa 
QS signal may hamper the protective functions of PON2. The cells in the airway would then 
be unable to degrade intracellular P. aeruginosa QS signal, allowing P. aeruginosa to 
establish the chronic infections characteristic of CF patients. In addition, with decreased 
PON2, the airways also are less protected from cellular stresses induced by defective CFTR 
and the oxidative damage associated with infection and the hyperinflammatory conditions.  
 
 
Figure 4.1 Correlation between PON2 and PPAR expression in children with CF. Figure shows log2 
expression of PON2 and PPAR in RNA extracted from bronchoalveolar lavage from 80 CF patients 
showing a correlation (p<0.0001) (Spearman r = 0.5152) between expression of the two genes. 
[Unpublished] 
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Pharmaceutical regulation of PON2 expression by PPAR agonism might allow for the 
correction of decreased PON2 by treatment with known PPAR agonists. Such a therapy 
would protect host cells against the intracellular effects of C12HSL. In this study, we 
investigate the ability of PPAR to regulate PON2 expression 
 
.
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4.2 MATERIALS AND METHODS  
 
The materials and methods for this chapter are described in chapter two. Additional 
materials and methods specific for this chapter are described below.  
 
4.2.1 Plasmids used 
 
To measure PPAR transactivation of PON2, the plasmid pXP1-hPON2p1000 with 1098 bp 
of the human PON2 promoter cloned into the promoter-less luciferase reporter vector pXP1 
was used [Honours Thesis, Naseem Ali 320]. The pcDNA3-PPAR1 plasmid was used to 
overexpress PPAR because of the reported low expression of PPARγ in BEAS-2B, the cell 
line used in these experiments [327, 328], while the PPAR-responsive PPRE3x-TK-LUC 
plasmid was used to detect the presence of activated PPAR. The pGL4.75 (hRLUC/CMV) 
plasmid expressing renilla luciferase was used to normalize transfections and the empty 
vector pcDNA3.1 and firefly luciferase expressing pGL3 were used as controls. These 
plasmids are summarized in table 4.2.  
Table 4.2 Plasmids used in transfection experiments 


















stream from start) 




SV40 5.3 kb Ampicillin 
PPRE3x-TK-LUC [330] 
3 PPAR response 
element driving 
luciferase expression 











CMV 4.3 kb Ampicillin 
Schematic representations of pxXP1, pXP1-hPON2p1000 and PPRE3x-TK-LUC plasmids, are shown in 
Figure 7a. 
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4.2.2 Transient transfections 
 
BEAS-2B cells were transfected with the plasmids listed in table 4.2 using FugeneHD 
(Promega) as described in chapter 2 (Section 2.4) . For co-transfections using two genes, a 
7:3 ratio of luciferase-expressing plasmid:secondary plasmid was used. This has previously 
been shown to be optimal for our experiments [320]. For co-transfections, a range of ratios 
were tested for optimum expression and a ratio of 7:2:1 of firefly luciferase-expressing 
plasmid: renilla luciferase-expressing plasmid: tertiary plasmid was then used in 
experiments. Transfected cells were incubated for six hours and media changed prior to 
treatments. 
 
4.2.3 Treatment of BEAS-2B cells 
 
The compounds listed in table 4.3 were used to treat BEAS-2B cells. Powdered stocks were 
dissolved in ethanol and aliquoted into working stocks. The ethanol was then evaporated in 
a hood before storage at –20 C. Prior to experiments, the compounds were dissolved in cell 
culture buffer and added to the cells at the desired concentrations. For treatments with 
more than one compound, the cells were pre-treated with one compound for 30 minutes 
prior to addition of the second compound. Transfected cells were typically treated for 16 
hours prior to lysis and analysis of luciferase activity. 
 
Table 4.3 PPAR agonists and antagonists used in study 
Name Source Effect on PPAR activity 
Rosiglitazone (RG) Cayman Chemicals, MI, USA Agonist 
Pioglitazone (PIO) Cayman Chemicals, MI, USA Agonist 
C12HSL  Cayman Chemicals, MI, USA Weak Agonist 









 4.3.1 Determination of optimum ratio for three-plasmid co-transfections  
 
 When co-transfecting cells, it is important to account for varying transfection efficiencies. 
This is particularly important when transfecting different experimental groups with 
different plasmids with the intention of making comparisons between the groups. In our 
experiments, we used the renilla luciferase-expressing plasmid pGL4 to normalize luciferase 
expression to transfection efficiency. Because we were transfecting with two different 
luciferase reporters, we needed to optimize the ratios of the plasmids being transfected in 




Figure 4.2 Expression of firefly and renilla luciferase and relative luminescence in co-transfections 
with three plasmids at a range of ratios. BEAS-2B cells were transiently co-transfected for 72 hours 
with varying ratios of pGL3 firefly luciferase expression vector, pGL4.75 renilla luciferase expression 
vector and pcDNA3.1 empty vector. Luminescence units of firefly and renilla luciferase were assayed 
from cell lysates. Results expressed as firefly luciferase expression (right axis) and firefly luciferase 
expression relative to renilla luciferase expression (left axis). Error bars represent S.D.; n = 3. 
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 The BEAS-2B cells were transfected with five different ratios of firefly luciferase: renilla 
luciferase: reporter-less pcDNA3.1 (Figure 4.2) for 72 hours to allow for luciferase to 
accumulate. The lysates of the cells were assayed for both firefly and renilla luciferase 
expression and the firefly-to-renilla luciferase ratio calculated for each group. The mean of 
three biological replicates is shown (Figure 4.2) and demonstrates that a continuous, but 
modest, decrease in renilla luciferase expression was observed as the percent of renilla 
plasmid decreased from 50% to 10%. As the percent firefly luciferase increased from 30% 
to 70%, the firefly luciferase expression increased modestly. The levels remained fairly 
constant between 70% and 80% firefly luciferase plasmid. A ratio of 70%:20%:10% firefly 
luciferase: renilla luciferase: pcDNA3.1 was considered to be the optimum, because no 
major increase in firefly luciferase expression could be obtained by increasing further the 
percent firefly luciferase. This ratio was used in all further experiments. 
 
4.3.2 BEAS-2B cells require PPAR overexpression  
 
 PPAR is widely recognized to be expressed in the airway, but studies have reported 
different expression levels in BEAS-2B [327, 328]. It was important to firstly establish that 
the known PPAR agonist rosiglitazone could activate PPAR-dependent signalling in our 
BEAS-2B. BEAS-2B cells were transfected with the PPAR-sensitive A-Ox3-TKSL-PPRE 
plasmid [330], a reporter plasmid with three PPREs that can bind activated PPAR. The cells 
were co-transfected with either a reporter-less plasmid pcDNA3 or the PPAR expression 
plasmid pcDNA3-PPAR1 [331]. The cells were then treated with 50 nM, 100 nM or 280 nM 
rosiglitazone for 16 hours before cell lysates were assayed for luciferase expression. The 
mean results of three biological replicates are shown in figure 4.3. In cells without PPAR 
overexpression, 50 nM rosiglitazone did not activate luciferase expression, while treatment 
with 100 nM and 280 nM rosiglitazone elicited modest increases in luciferase expression. 
When PPAR was overexpressed in cells, we observed significant increases in luciferase 
expression with all three concentrations of rosiglitazone treatment compared with the cells 
without PPAR overexpression and the vehicle control (p < 0.05). 
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4.3.3 Characterising PPAR activation in BEAS-2B cells overexpressing PPAR 
 
 As we were over-expressing PPAR in the cells and using the increasing luciferase 
expression of the A-Ox3-TKSL-PPRE plasmid in response to PPAR activation as a measure 
of PPAR activation, we needed to demonstrate modulation of PPAR activation using 
known PPAR agonists and antagonists. The BEAS-2B cells were co-transfected with the 
PPAR-sensitive A-Ox3-TKSL-PPRE and PPAR-expressing pcDNA3-PPAR1 plasmids. The 
cells were then treated for 16 hours with a range of concentrations and combinations of 
known modulators of PPAR activity. The lysates of the cells were then assayed for 
luciferase expression. The mean results (n = 3–7) are shown in Figure 4.4. Rosiglitazone, the 
most potent of the PPAR agonists used in this study, at 50 nM and 100 nM produced 
significant dose-dependent increases in luciferase expression compared with vehicle- 
 
Figure 4 3 Dose response of PPAR activation in cells transfected with PPRE-containing reporter. 
BEAS-2B cells were transiently co-transfected with A-Ox3-TKSL-PPRE, a PPAR-responsive 
luciferase expression vector, pGL4 to normalize for transfection efficiency and one of either 
pcDNA3.1 empty vector or pcDNA3-PPAR1, a PPAR expression vector. The cells were then 
treated for 16 hours with varying concentrations of rosiglitazone (RG) and the lysates assayed for 
luminescence. Results expressed as firefly luciferase expression relative to renilla luciferase 
expression. Error bars represent S.D.; n = 3. *p < 0.05, t-tests comparing two groups. 
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treated transfected cells, suggesting increased PPAR activation (p < 0.001). PPAR 
activation could be irreversibly prevented by pre-incubating the cells with 1 M GW9662, a 
known PPAR antagonist [332] for 30 minutes prior to treating with 100 nM rosiglitazone. 
Treating with 500 nM pioglitazone, another PPAR agonist, did not increase luciferase 
expression. However, a small but significant (p < 0.05) increase in PPAR activation was 
observed when the cells were treated with 1 M pioglitazone. The P. aeruginosa signalling 
molecule C12HSL is also reported to agonize PPAR and treatment of cells with 10 M 
C12HSL produced a small but significant increase in PPAR activation. We also investigated 
the ability of C12HSL to prevent rosiglitazone from activating PPAR by pre-incubating the 
cells with 10 M C12HSL for 30 min prior to treating with 100 nM rosiglitazone. C12HSL 
was unable to completely prevent rosiglitazone-mediated PPAR activation, but a 20% 
decrease in PPAR activation was observed with C12HSL pre-treatment. 
 
Figure 4.4 PPAR activation by a number of PPAR agonists and antagonists. BEAS-2B cells were 
transiently co-transfected with A-Ox3-TKSL-PPRE, a PPAR-responsive luciferase expression vector and 
pcDNA3-PPAR1, a PPAR expression vector. The cells were then treated for 16 hours with varying 
doses of the agonists rosiglitazone (RG), pioglitazone (Pio) and C12HSL. Cells were also pre-treated with 
GW9662 (GW) and C12HSL for 30 minutes prior to rosiglitazone treatment. The lysates were assayed 
for luminescence. Results expressed as firefly luciferase expression relative to renilla luciferase 
expression. Error bars represent S.D.; n = 3–7. *p < 0.05; ***p < 0.001 relative to vehicle control (t-
test). 
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4.3.4 PON2 gene and protein expression induced by PPAR activation 
 
The correlation of PPAR and PON2 gene expression in CF lungs (Figure 4.1) prompted the 
investigation of whether PON2 expression is directly induced by PPAR activation. The 
known PPAR agonist rosiglitazone was used to activate PPAR in the BEAS-2B human 
airway epithelial cell line. After treatment with 100 nM rosiglitazone, changes in PON2 gene 
and protein expression were measured by quantitative PCR (n = 4) and western blot 
analysis, respectively, over a period of 16 hours. 
The changes in PON2 gene expression in BEAS-2B cells over 16 hours treatment with 
rosiglitazone are shown in figure 4.5. There is an immediate trend towards an increase in 
PON2 transcription after one hour of PPAR activation. By four hours, PON2 expression in 
rosiglitazone-treated BEAS-2B cells is significantly higher than that in the vehicle control 
(p<0.05). A similar increase in PON2 protein expression was observed in response to 
rosiglitazone treatment (Figure 4.6). By 16 hours, PON2 gene expression was significantly 
down-regulated (p < 0.05) and the increase in PON2 protein had also diminished by 16 
hours (Figure 4.6). 
PPARγ expression remained more stable than PON2 following rosiglitazone treatment. A 
significant increase in PPARγ expression was observed at four hours post treatment (p < 
0.05) (Figure 5), similar to the rosiglitazone effect on PON2 gene expression, but this was 
not apparent by 16 hours, when there was a trend towards down-regulation of PPARγ 

















Figure 4.5 Change in relative gene expression of PON2 and PPARG in BEAS-2B cells treated with 
rosiglitazone. BEAS-2B cells treated for 16 hour with 100 nM rosiglitazone (RG) (black) or vehicle (grey). 
Total RNA extracted from cells and PON2 (A) and PPARG (B) gene expression relative to -actin 
expression measured using real time quantitative PCR. Results expressed as log10 expression relative to 
-actin. The log10 expression of PON2 (solid line) and PPARG (dashed line) in RG-treated cells relative to 
vehicle-treated cells is shown in (C). Error bars represent S.D; n = 4. * p < 0.05, t-test comparing 
rosiglitazone-treated to vehicle-treated at each time point. 
  













Figure 4.6 Change in PON2 protein expression in BEAS-2B cells treated with rosiglitazone (RG). 
Change in PON2 protein expression over time period observed by a) western blot analysis of cell lysates 
and b) densitometry of western blots. Error bars represent S.E.M; n = 2. 
Hours of treatment 
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4.3.5 PPAR does not transactivate PON2 via the first 1100 bp of its promoter 
 
To investigate the ability of PPAR to transactivate PON2 expression, the pXP1-
hPON2p1000 reporter vector was used [320]. The pXP1-hPON2p1000 reporter vector 
contains the first 1100 bp immediately up-stream of the human PON2 transcription start, 
the section containing the putative PPREs (Table 4.1). The activation of PPAR by treatment 
of the cells with 100 nM rosiglitazone for 16 hours was detected using the PPAR-
responsive A-Ox3-TKSL-PPRE plasmid. When PPAR is activated it binds to the PPREs and 
initiates the transcription of luciferase, which can then be assayed (Figure 4.7A). PPAR 




Figure 4.7 Activated PPAR does not transactivate the human PON2 promoter within the first 1100bp. 
BEAS-2B cells were transiently transfected with pXP1 (promoter-less vector into which hPON2 promoter 
was cloned), A-Ox3-TKSL-PPRE (PPAR responsive vector), human PON2 promoter vector and PGL4 (renilla 
luciferase expressing vector). A. Schematic representation of the three plasmid constructs used to assay 
PON2 promoter transactivation. B. Transfected cells were treated with vehicle or 100 nM rosiglitazone 
(RG) for 16 hours or 1M GW9662 (GW) for 30 minutes prior to 16 hours with 100 nM rosiglitazone. Cell 
lysates were collected and luciferase expression assayed. Results expressed as firefly luciferase relative to 
renilla luciferase. Error bars represent S.D.; n = 5. * = p < 0.05, t-test comparing two groups. 
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prior to rosiglitazone treatment. Cells were also transfected with the promoter-less pXP1 
vector to control for leaky luciferase expression from the plasmid. All the cells were co-
transfected with the PPAR expression plasmid pcDNA3-PPAR1[331] to ensure adequate 
PPAR was present and with pGL4 to normalize luciferase expression to assess transfection 
efficiency. 
 When cells were transiently transfected with the promoter-less pXP1 vector, pcDNA3-
PPAR1 and pGL4, no change in relative luciferase expression was observed after treatment 
with PPAR agonist or antagonist (Figure 4.7B). In the positive control, where cells were 
transiently transfected with the PPAR-responsive A-Ox3-TKSL-PPRE, pcDNA3-PPAR1 and 
pGL4, a significant increase in luciferase expression relative to the vehicle-treated cells was 
observed when PPAR was activated by treatment with 100 nM rosiglitazone for 16 hours 
(p < 0.05). When cells were treated with GW9662, this effect was abolished and no 
difference was observed between the vehicle-treated and GW9662-treated cells. When the 
cells were transiently transfected with hPON2 promoter reporter vector containing putative 
PPREs, activating PPAR in the cells with 100 nM rosiglitazone did not lead to 
transactivation of the PON2 promoter. Similarly, no effect was observed in response to 
treatment with PPAR antagonist GW9662. 
 
 





This is the first study that describes PPARγ-mediated modulation of PON2 gene and protein 
expression in human airway epithelial cells. Much of the research into PON2 regulation has 
primarily focused on the ability of PON2 in macrophages to protect against oxidative stress. 
The first point of contact for the establishment of P. aeruginosa infection in the lungs is the 
airways, where bacteria establish and begin producing QS molecules. As acyl homoserine 
lactones, including P. aeruginosa QS molecules, are widely considered to be the natural 
substrate of PON2, it is appropriate to improve our understanding of the regulation of PON2 
in the airways in response to infection, as a component of the innate defence mechanisms. 
We observed an increase in PON2 mRNA and protein expression within 4 hours post 
treatment with100 nm rosiglitazone, a concentration previously shown to activate PPAR 
[218]. This effect had essentially disappeared by 16 hours of treatment. Shiner and 
colleagues found that PPAR activation by rosiglitazone induced PON2 mRNA and protein in 
the J774A.1 mouse macrophage cell line [268]. The authors observed a significant increase 
in PON2 mRNA, but not PON2 protein, after 18 hours treatment with 10 M rosiglitazone, 
although both PON2 mRNA and protein were increased after 18 hours treatment with at 
least 25 μM rosiglitazone. This group did not study earlier time points, so we cannot directly 
compare our results with theirs, but it is possible that higher concentrations of rosiglitazone 
are required to sustain increased PON2 levels for a prolonged time. What is striking about 
our findings is the early (within 2 hours) increase in PON2 mRNA and protein expression in 
response to PPAR activation. This suggests the regulatory relationship between the two is 
direct or very close. Our in silico identification of ‘good’ putative PPREs in the PON2 
promoter [320] further strengthens the hypothesis that PPAR transcriptionally regulates 
PON2. In silico based methods of transcription factor binding site analysis such as 
MatInspector are useful in identifying the potential of a site to bind the protein in question. 
However, it is the context of the site that separates a functional regulatory region from a 
physical sequence. The presence of binding sites for dimers is one such factor. The context 
of the PPREs we identified by MatInspector is deserving of consideration. Their close 
proximity to the PON2 start codon coupled with the presence of an adjacent RXR binding 
site makes them ideal candidates to explore experimentally. 
We also observed an increase in PPARG expression when PPAR was activated. This was 
unexpected, as rosiglitazone is a PPAR ligand which, upon binding to PPAR, instigates the 
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conformational changes required for the complex to recruit co-activators or co-repressors 
and alter transcription. It should not necessarily increase PPAR mRNA, however, increased 
PPAR mRNA and protein have been reported in BEAS-2B cells and other airway epithelial 
cells in response to rosiglitazone treatment [300], suggesting that a positive feedback loop 
exists. A marked increase in PPARG expression 16 hours post rosiglitazone treatment was 
observed but not found statistically significant. While this observation may call into 
question, the validity of the assay, in reality, this anomaly was caused by an outlier in the 
biological replicates that could not be excluded and only applies to this time point and only 
for the PPARG gene. 
When using transfection based reporter assays, it is important to have a well-characterized 
assay system. The use of a second constitutively expressed reporter to normalize 
transfections is important to control for the potential differences in transfection efficiency. 
We optimized our assay system to achieve optimum expression of luciferases from both 
reporters and we established that BEAS-2B cells express endogenous PPAR that could be 
activated by rosiglitazone and detected by our PPAR-responsive reporter. However, this 
activation of PPAR was modest, and only seen after treatment with higher concentration of 
rosiglitazone (100 nM and 280 nM). Pawliczak and colleagues carried out western blot 
analysis of PPAR isoforms in four human airway epithelial cell lines (NHBE, BEAS-2B, A549, 
and H292 cells), and found that BEAS-2B cells expressed the least amount of PPAR protein. 
Because our studies are based on PPAR-mediated signalling, we needed to ensure that 
enough PPAR was present to observe any PPAR-mediated effects on PON2 expression. 
When we overexpressed PPAR in our cells, we observed strong activation of PPAR after 
rosiglitazone treatment at all the tested concentrations, underlining the importance for our 
experiments of overexpressing PPAR. The highly selective PPAR agonists rosiglitazone 
and pioglitazone [333] were both able to induce PPAR activation as predicted. When our 
cells were pre-treated with the PPAR antagonist GW9662 prior to rosiglitazone treatment, 
we observed an irreversible inhibition of PPAR activation, as reported previously in the 
literature [332]. We also demonstrated the weak agonist activity of 10 M C12HSL on 
PPAR and its ability to interfere with rosiglitazone-mediated activation of PPAR, as 
reported by Cooley and colleagues [218]. GW9962 is thought to modify cysteine residues is 
the ligand binding domain of PPARγ when bound to PPARγ [332] and thereby preventing 
further ligand binding. C12HSL interference with PPARγ ligand binding does not appear to 
be irreversible, so the mechanisms of antagonistic activity of GW9662 and C12HSL are likely 
to be distinct. 
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Our transcription factor reporter assays indicate that PPAR does not transactivate the 
expression of PON2 by binding within the first 1000 bp of the human PON2 promoter. 
However, direct transactivation of PON2 by PPAR is still the most likely explanation for the 
speed with which activation of PPAR leads to PON2 expression. It may be that the 
functional PPAR binding site in the PON2 promoter is further up-stream or down-stream 
than investigated in our transcription factor reporter assays. Functional PPREs have been 
located as far as 3300 bp up-stream from the transcription start [334]. Co-regulatory 
elements can be involved in transcription irrespective of their location in regards to the 
promoter [Reviewed in 335] and can be as much as 1 Mb from the promoter, as is the case 
with the limb bud enhancer for the mouse sonic hedgehog (Shh) gene [336]. Perhaps a 
PPAR-mediated regulation of PON2 could then be observed if a larger section of the PON2 
promoter was studied that could be identified based on a better understanding of the 
regulatory elements involved in PON2 transcription. 
It is also possible that PPAR activation of PON2 gene expression is indirect rather than 
directly linked. The effects of PPAR activation on the immune system are numerous and far 
reaching, and a number of down-stream factors may be involved in subsequent regulation 
of PON2, especially given the roles that PON2 plays as an anti-oxidant, anti-artherogenic and 
anti-apoptotic agent. 
Interestingly, rosiglitazone has also been shown using microarrays in murine PPAR–/– 
macrophages to have PPAR-independent effects, and it is impossible to disregard the 
possibility of a rosiglitazone-mediated, PPAR-independent effect on PON2 expression [337-
340]. Rosiglitazone is a class of medications that contain a thiazolidine functional group 
which serves as a dione known as thiazolidinediones (TZD’s). Perez-Ortiz and colleagues 
have demonstrated PPAR-independent effects of another member of the family of TZDs, 
ciglitazone, also a known PPAR agonist. Ciglitazone was able to induce PPAR-independent 
cellular toxicity by producing reactive oxygen species and rapidly depolarizing the 
mitochondrial membrane in primary murine astrocytes [341]. As PON2 protects against 
oxidative stress, the TZDs may induce PON2 expression by a PPAR-independent pathway. 
Further research is needed into these PPAR-independent effects to identify a possible 
mechanism by which rosiglitazone-mediated PPAR-independent up regulation of PON2 
would be possible. This could be done by using GW9662, a well-characterized selective and 
irreversible PPAR antagonist, to observe PPAR-independent effects of rosiglitazone. 
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As the modulation of PPAR expression/activity in the CF lung, both as a consequence of 
defective CFTR and of possible antagonism by C12HSL becomes clearer, our need to 
understand the influence of PON2 in lung and airways becomes more pressing. Decreased 
PPAR expression has been observed in human CF cell lines and Cftr-deficient mice [220, 
222, 342], while we have previously observed that P. aeruginosa infection is correlated with 
low PPAR expression in the bronchoalveolar lavage fluid of people with CF [223]. Given the 
suggested protective role of PON2 against C12HSL-mediated signalling in bacteria and its 
effects on respiratory epithelium, and our observation that PPAR activation increases 
expression of PON2, the modulation of PPAR in CF may have important consequences in 
terms of innate defence mechanisms and disease progression. 
Increased levels of PON2 expression in airway cells in response to rosiglitazone treatment 
would be beneficial from the perspective of preventing/ameliorating infection. PON2- 
deficient mice have been shown to be less adept than wild-type mice at clearing 
Pseudomonas infections [249], and the ability of PON2 to degrade P. aeruginosa QS signals is 
well established [248, 260, 262, 264]. PON2 may also protect the airways themselves from 
the oxidative stress and proapoptotic effects of the P. aeruginosa QS C12HSL. In a CF setting, 
an increase in PPAR activity with rosiglitazone treatment may go some way into correcting 
the detrimental effects the CFTR mutations have on PPAR activity, including modulation of 
the immune response. Treating Cftr-deficient mice with a synthetic PPAR agonist reversed 
some of the effects of the CFTR deficiency and reduced disease severity in the gut [220]. In 
Cftr-deficient mice acutely infected with P. aeruginosa, administration of a synthetic PPAR 
agonist protected against the exaggerated inflammatory response in the airways that is 
usually seen in P. aeruginosa infected Cftr-deficient mice [222, 343].  
Rosiglitazone is a member of the TZD group of chemicals. A number of TZDs have been 
approved for clinical use, mostly to treat insulin resistance, but numerous severe side 
effects have since been discovered. Troglitazone has been withdrawn from the market 
because of liver toxicity in some patients [344], while the use of both rosiglitazone and 
pioglitazone have been associated with an increased risk of heart failure and increased fluid 
retention, meaning that their use is now limited [345, 346]. In late 2013, the FDA released a 
statement removing the prescribing and dispensing restrictions for rosiglitazone and it can 
once again be used to improve control of blood sugar in patients with type 2 diabetes 
mellitus [347]. The use of TZDs to increase endogenous PON2 expression is a therapeutic 
strategy that needs to be balanced with the risks it poses. Instead of using TZDs, we could 
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also focus our attention on increasing PON2 in the lungs by alternate methods such as 
extracellular application of recombinant protein, a proposal that will be explored further in 













CHAPTER FIVE – RECOMBINANT HUMAN PON2 
















P. aeruginosa utilises a cell-density dependent and intercellular communication system, 
called quorum sensing (QS), to co-ordinate and regulate virulence factor production, as well 
as biofilm formation. P. aeruginosa has multiple, hierarchically arranged QS systems, as 
described in Section 1.2.4.1. At the top of the P. aeruginosa QS hierarchy is the Las system, 
which utilizes C12HSL, an acyl homoserine lactone (AHL) signalling molecule. In addition, 
the Las system also regulates the activity of the Rhl system. The Rhl system also utilizes an 
AHL, C4-HSL as its signalling molecule [Reviewed in 119, 140, 348]. Together, the Las and 
Rhl systems regulate the third P. aeruginosa QS system, PQS. These three QS systems play an 
important role in the regulation of a number of virulence determinants including the 
biosynthesis of elastase, alginate, hydrogen cyanide, rhamnolipid and pyoverdine. There are 
also overarching regulators of QS, including the virulence factor regulator Vfr and the 
GacS/GacA two component regulatory system, which transcriptionally and post-
transcriptionally regulate the QS systems [119, 140, 348].  
As QS is important for P. aeruginosa virulence and biofilm formation, and responsible for 
regulating virulence of many other Gram-negative bacteria, it is seen by many investigators 
to represent a target for novel antimicrobial therapies. One potential mechanism for QS 
inhibition is degradation of the QS signal molecules themselves. Enzymatic degradation of 
the QS signal, particularly through the hydrolysis of lactone rings of AHLs is perhaps one of 
 
Figure 5.1 Lactonolysis of AHL’s. Acyl homoserine lactones (AHL’s) comprise of a five-membered 
homoserine lactone ring amide-linked to a variable acyl chain. In nature, the AHL’s have N-acyl moieties 
that range from 4 to 14 carbons atoms in length (R2). The acyl chains may be saturated or unsaturated 
and also may contain a hydroxy or oxo substituent (R1). The lactone ring of the AHL’s can be 
spontaneously hydrolysed (and condensed once hydrolysed) in a pH and temperature dependent 
manner to the hydrolysed acid form [243].The lactonolysis of AHL’s by paraoxonases also involves 
hydrolysis of the lactone ring. The resultant molecule is the acid form of the AHL.  
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the more promising forms of QS inhibition (Figure 5.1). Hydrolysis of the lactone ring 
effectively inactivates AHLs, thereby rendering them unable to signal through their cognate 
receptors [242, 243]. A number of lactonases have been identified in several bacterial 
species [242, 244-246]. Interestingly, mammals also produce enzymes with intrinsic 
lactonase activity, the so-called paraoxonases, which have been reported to exhibit highly 
specific in situ hydrolytic activity against certain bacterial AHLs [247, 248, 262, 264]. Some 
of these mammalian paraoxonases have been demonstrated to attenuate P. aeruginosa 
virulence in KO-mice and Drosophila models of P. aeruginosa infection [249, 250], 
underscoring their potential as QS inhibitors. 
The paraoxonase family consists of three distinct proteins, PON1, PON2 and PON3, which 
display considerable sequence homology [253]. While PON1 and PON3 are primarily 
expressed in the liver and sera, PON2 is ubiquitously expressed, especially in respiratory 
epithelia, as an intracellular membrane-bound protein, mainly associated with nuclear and 
mitochondrial membranes and the endoplasmic reticulum [253, 255-259]. Of the three 
PONs, PON2 has the highest recorded AHL lactonase activity of all the paraoxonases tested, 
and has been demonstrated to have maximal activity against C12HSL [248, 262]. 
To date, PON2 studies have largely been confined to over expression and knockout models. 
However, simply augmenting native PON2 expression might prove less useful 
therapeutically against Pseudomonas because PON2 is an intracellular protein, whereas the 
bacterial QS signals accumulate mostly in the extracellular environment. A more effective 
therapeutic approach might instead involve the application of a recombinant human form of 
PON2 (rhPON2) into the P. aeruginosa infected airways, where PON2 would be expected to 
disrupt QS through lactonolysis of bacterially produced C12HSL. In turn, inactivation of the 
C12HSL would prevent bacterial QS and associated biofilm formation and virulence and as a 
result could be expected to increase the susceptibility of P. aeruginosa to conventional 
antimicrobial therapies already in use in CF clinics such as tobramycin. Importantly, known 
C12HSL-mediated effects on host cells could also be prevented. 
Tobramycin, while not considered to not have anti-QS activity, is an important component 
of the CF antibiotic regime. Study of anti-QS therapies, in combination with tobramycin, 
allow for the isolation of the specific effects of the anti-QS therapy and as such, tobramycin 
was selected for use in this study. 
Whilst there are a number of studies involving rhPON2 [248, 258, 262, 272, 273, 349, 350], 
there are few, if any, studies in the literature documenting the effects of recombinant PON2 
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on growth, QS and virulence of P. aeruginosa. Instead, there are some studies describing the 
effects of recombinant bacterial acylases on P. aeruginosa QS and virulence. Bacterial 
acylases are another class of enzymes that degrade C12HSL via hydrolysis of the amide 
bond between the acyl chain and the homoserine lactone ring. Recombinant acylases have 
been shown to be effective in decreasing the accumulation of C12HSL produced by P. 
aeruginosa and have been reported to decrease QS and QS-dependent virulence of this 
organism in vitro [351-355]and in vivo [352, 353]. There are, however, several advantages 
to using a mammalian therapeutic protein instead of a bacteria-derived C12HSL hydrolysing 
enzyme, the most important of which concerns safety. Given that human PON2 is normally 
expressed in the mammalian host, a recombinant hPON2 protein is far less likely to be 
immunogenic, reducing the likelihood of both inactivation and adverse effects of the hPON2 
protein, and thereby increasing the likelihood of regulatory approval.  
Active rhPON2 has usually been cloned and purified using three independent methods: i) 
directed evolution in Escherichia coli followed by purification using a GST tag [258], ii) 
baculovirus infection of Trichoplusia ni insect cells and subsequent purification using liquid 
chromatography techniques [248, 262], and iii) expression in mammalian cells followed by 
the use of either clarified cell lysates [349] or else further purification using affinity 
chromatography [273]. 
Certain considerations must be kept in mind when attempting to produce rhPON2. First, a 
polymorphism has been reported in PON2 that alters its lactonase activity. Substitution of 
cysteine for serine at codon 311 diminished but did not eliminate rhPON2 lactonase activity 
[349]. Second, the paraoxonases are glycoproteins, and carbohydrates account for around a 
sixth of their molecular mass [356]. rhPON2 being produced in insect or mammalian cells, 
unlike that produced in bacteria such as E. coli, is usually glycosylated, even though insect 
cells do not glycosylate the protein to the same extent as human cells [262]. Glycosylation 
has been reported by some investigators to be critical to the lactonase activity of rhPON2 
[273, 349], while others have described glycosylation as being important for the stability 
but not the hydrolytic activity of paraoxonases [357, 358].  
In the studies described in this chapter, rhPON2 was synthesized by infecting Trichoplusia ni 
insect cells with a baculovirus made to express human PON2 (Ser311 variant). The lactonase 
activity of the purified rhPON2 was then tested against C12HSL. We hypothesized that 
rhPON2 would inhibit P. aeruginosa QS by inactivating C12HSL and as a consequence, 
increase the susceptibility of P. aeruginosa to conventional antibiotic therapy. 
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The results of this chapter demonstrate that (i) rhPON2 was effective at preventing P. 
aeruginosa QS, and (ii) exposing cells of P. aeruginosa to rhPON2 increased the susceptibility 
of P. aeruginosa to the antibiotic tobramycin. Taken together, the data presented in this 
chapter lend strong support to the idea of using rhPON2 as a novel QS inhibitor. 
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5.2 MATERIALS AND METHODS 
 
The materials and methods for this chapter are described in Chapter 2. Additional materials 
and methods specific to this chapter are described below. 
 
5.2.1 Generation of a recombinant human PON2-expressing baculovirus 
5.2.1.1 Generation of recombinant human PON2 vector. 
The human PON2 transcript (isoform 1, NCBI accession NM_000305.2, Ser311 variant) was 
codon optimized for expression in insect cells and synthesized by DNA2.0 (Menlo Park, 
California, US) (Figure 5.2). The transcript included a BamHI restriction enzyme site seven 
bp upstream from the PON2 translation start codon, and a NotI restriction site immediately 
following the translation stop codon. Following restriction digestion, the PON2 transcript 
was ligated into the multiple cloning site of the pFastBac1 vector (Life Technologies, 
Carlsbad, California) using the BamHI and NotI restriction sites to generate the recombinant 
human PON2 vector pFastBac1.hPON2 (Figure 5.3). 
 
Figure 5.2 Nucleotide and protein sequence of synthesised human PON2 transcript. Figure shows 
human PON2 transcript (isoform 1, NCBI accession NM_000305.2, with Ser311) (top line) and 
translated AA sequence (middle line), with codon optimization for insect cell protein synthesis by 
DNA2.0. The transcript includes a BamHI restriction site seven bp upstream from the PON2 translation 
start codon, and a NotI restriction site immediately downstream from the translation stop codon. 




Figure 5.3 Vector map of pFastBac.hPON2, a hPON2-containing plasmid vector. The synthesized 
hPON2 sequence was inserted into the MCS of pFastBac to give pFastBac-hPON2, a 5797 bp plasmid 
with SV40 promoter and ampicillin and gentamycin resistance cassettes. 
 
The pFastBac1.hPON2 construct was transformed into One Shot® TOP10 Competent Cells 
(Life Technologies) following to the manufacturer’s recommended chemical transformation 
protocol. Briefly, 5 μL of construct DNA was added to one vial of OneShot® TOP10 
Competent Cells. The mixture was incubated on ice for 30 minutes, heat-shocked for 45 
seconds at 42°C without agitation, and immediately chilled on ice for a further two minutes. 
A 250 μL aliquot of S.O.C. medium was added and the mixture shaken at 150 RPM at 37°C 
for one hour.  
Transformed cells (20 μL, 50 μL and 120 μL aliquots) were then spread-plated on LB agar 
plates supplemented with 100 μg/mL ampicillin. The plates were incubated at 37°C 
overnight. The following day, single colonies were isolated from the plates and used to 
inoculate fresh LB-ampicillin plates. Selected colonies were used to inoculate 2 mL LB 
medium and grown overnight at 37°C, with shaking at 220 RPM. DNA from overnight 
cultures was isolated using a plasmid mini-prep kit (Promega, Madison, WI) (Chapter 2.4.2) 
and subjected to PCR using hPON2 primers (sequences in table 2.3) and gel electrophoresis 
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used to verify correct insertion. DNA and glycerol stocks of pFastBac1.hPON2 were stored at 
−80°C for future use. 
5.2.1.2 Generation of recombinant hPON2 bacmid and isolation of 
recombinant hPON2 bacmid DNA 
The hPON2 bacmid was generated using the Bac-to-Bac® Baculovirus expression system 
(Life Technologies) according to the manufacturer’s protocols. The pFastBac1 vector’s 
expression cassette recombines with the parent bacmid in the MAX Efficiency® DH10Bac 
cells to form an expression bacmid. Briefly, 5 µL of pFastBac1.hPON2 DNA (200 pg/µL in TE, 
pH 8.0) was added to 100 µL of MAX Efficiency® DH10Bac™ in a pre-chilled 15-mL 
polypropylene tube. The cell-DNA mixture was incubated on ice for 30 mins, heat shocked 
for 45 seconds at 42°C, then immediately chilled on ice for a further two minutes. Finally 10-
fold serial dilutions were prepared in S.O.C medium before being plated onto LB plates 
supplemented with 50 μg/mL kanamycin, 7 μg/mL gentamicin, 10 μg/mL tetracycline, 40 
μg/mL X-gal, and 40 μg/mL IPTG. The plates were incubated for 48 hours at 37°C after 
which time several white colonies were picked and struck onto fresh selective medium to 
obtain single colonies. A single colony was used to inoculate LB containing 50 μg/mL 
kanamycin, 7 μg/mL gentamicin and 10 μg/mL tetracycline and grown overnight at 37°C 
with shaking at 220 RPM. Bacmid DNA was then isolated using plasmid mini-preps 
(Promega) (Section 2.4.2.3) and PCR and gel electrophoresis was used to verify the 
presence of recombinant hPON2 constructs using primers: pUC/M13 primers (Table 2.3) 
The DNA and glycerol stocks of pFastBac1.hPON2 bacmid were stored at −80°C for future 
use. 
5.2.1.3 Generation of recombinant hPON2 baculovirus stocks 
Baculovirus stocks were generated in Spodoptera frugiperda Sf9 cells (Life Technologies), 
which were transfected with recombinant bacmid DNA using the Cellfectin® reagent 
supplied with the Bac-to-Bac® Baculovirus expression system (Life Technologies) and 
following the manufacturer’s instructions. Briefly, recombinant hPON2 bacmid DNA was 
diluted to 500 ng/μL in TE Buffer, pH 8.0. Stationary phase Sf9 cells (~1  107 cells/mL) 
were diluted to 2  106 cells/mL. In six-well plates, 2 mL of unsupplemented Grace’s Insect 
Medium was added to each well followed by the addition 8  105 Sf9 cells in SF900III 
medium. The cells were allowed to rest and attach to plates at room temperature for 15 
minutes. The DNA–transfection reagent complexes were prepared at various ratios of DNA 
to transfection reagent in unsupplemented Grace’s Insect Medium to determine the 
optimum DNA to transfection reagent ratio. The DNA–transfection reagent complexes were 
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added drop-wise to the cells. The cells were then incubated in a humidified incubator at 
27°C for 6 hours before growth medium was replaced with SF900-III serum-free medium 
and further incubated in a humidified incubator at 27°C. Cells were monitored daily for 
signs of viral infection (Table 5.1). Once cells showed signs of late infection (Table 5.1), the 
growth medium from the wells was removed and centrifuged at 500  g for five minutes to 
remove any cells and debris. The supernatant containing virus particle was collected and 
FBS was added to a final concentration of 2% (v/v). This yielded the P1 baculoviral stock. 
P1 baculoviral stock was stored short-term at 4°C, protected from light, or at −80°C for long-
term storage. Immunoblot analysis of cell lysates was carried out with PON2 antibody to 
establish the presence of rhPON2 protein and viral titre determined by the endpoint titre 
method as described in Chapter 2 (Section 2.6.4). For long-term storage, the P1 baculoviral 
stock was stored at −80°C.  
The baculoviral stock was further amplified by infecting more Sf9 cells. Stationary phase Sf9 
cells were diluted to 2  106 cells/mL in 50mL in a vented, flat-bottom polycarbonate 
Erlenmeyer flask. P1 baculovirus was added to the cells at a multiplicity of infection (MOI) 
of 0.1. The inoculum required was calculated using the following formula: 
Inoculum required (mL)  =  
MOI (
pfu
cell) × number of cells  




The inoculated Sf9 cells were incubated at 27°C, with shaking at 120 RPM in the dark. After 
48 hours, the cell suspension was collected and centrifuged at 500  g for five minutes to 
remove any cells and debris. The supernatant was collected and FBS added to a final 
concentration of 2% (v/v), which constituted the P2 baculoviral stock. P2 baculoviral stock 
Table 5.1 Characteristics of viral infection in Sf9 and High Five™ insect cells. 
Adapted from Bac-to-Bac baculovirus expression system user guide, 2013. [275] 
Signs of Infection Phenotype Description 
Early 
(First 24 hours) 
Increased cell diameter A 25%–50% increase in cell 
diameter may be seen. 
Increase in cell nuclei size Nuclei may appear to "fill" the cells. 
Late  
(24–72 hours) 
Cessation of cell growth Cells appear to stop growing when 
compared to a cell-only control. 
Granular appearance Signs of viral budding; vesicular 
appearance of cells. 
Detachment Cells release from the plate or flask. 
Very late 
 (>72 hours) 
Cell lysis Cells appear lysed, and show signs of 
clearing in the monolayer. 
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was stored as described for P1 stocks and viral titre was determined by the endpoint titre 
method.  
5.2.2 Expression of recombinant hPON2 
The Trichoplusia ni cell line High Five™ (Life Technologies) has been reported to allow up to 
five-fold higher expression of recombinant paraoxonases than Sf9 cells [248, 356], and 
hence was used exclusively to express rhPON2 for purification. Stationary phase High Five™ 
cells were diluted to 1  106 cells/mL in Express Five medium and inoculated with P2 
baculovirus at MOIs ranging from 0.5 pfu/cell to 5.0 pfu/cell to determine the optimum MOI 
for rhPON2 expression. The cells were monitored daily for signs of viral infection and 
harvested at the earliest signs of late infection (~48–72 hours). To harvest cells, the cell 
suspension was centrifuged at 1,000  g for 5 minutes at 4°C. The cell pellet was collected 
and stored at −80°C and later used for immunoblotting, activity determination and further 
protein purification.  
 
5.2.3 Purification of recombinant hPON2 
 
Recombinant hPON2 was purified via a three-step purification protocol as described by 
Draganov and colleagues [248]. Differential centrifugation was used to isolate the crude 
membrane fraction of infected High Five™ cells, followed by diethylaminoethyl (DEAE) 
anion exchange chromatography and Concanavalin A affinity chromatography. Purification 
was initially optimised and performed in our lab, but because of technical difficulties 
(equipment failure), cell pellets from hPON2 baculovirus infected High Five™ cells were sent 
to Monash Protein Production Unit (Monash University, Victoria, Australia) for large-scale 
rhPON2 purification.  
5.2.3.1 Buffers 
All buffers were filter sterilized and degassed with a 0.22 µm filter under vacuum prior to 
use. 
5.2.3.1.1 Homogenization buffer 
Homogenization buffer was 5 mM Tris/HCl at pH 7.4, 1 mM CaCl2, 2 µg/mL leupeptin (Sigma 
Aldrich, St Louis, MO, US) and two tablets of EDTA-free protease inhibitors/100 mL buffer 
(Roche, Mannheim, Germany).  
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5.2.3.1.2 Extraction buffer 
Extraction buffer was 25 mM Tris/HCl at pH 7.4, 1 mM CaCl2, 10% glycerol, 1% n-dodecyl--
D-maltoside (DDM) (Anatrace, Maumee, OH, US), 2 µg/mL leupeptin (Sigma) and one tablet 
of mini-EDTA-free protease inhibitors/10 mL buffer (Roche).  
5.2.3.1.3 DEAE column buffer and DEAE elution buffer 
DEAE column buffer was 25 mM Tris/HCL at pH 7.4, 1mM CaCl2, 10% glycerol and 0.05% 
DDM (Anatrace). DEAE elution buffer was DEAE column buffer supplemented with 1 M 
NaCl.  
5.2.3.1.4 Concanavalin A column equilibration buffer 
Concanavalin A column equilibration buffer was 25 mM Tris/HCl at pH 7.4, 2 mM CaCl2, 1 
mM MgCl2, 0.5 M NaCl and 0.05% DDM (Anatrace). 
5.2.3.1.5 Concanavalin A column wash buffer and Concanavalin A column elution 
buffer 
Concanavalin A column washing buffer was 25 mM Tris/HCl, pH 7.4, 1 mM CaCl2, 10% 
glycerol and 0.05% DDM (Anatrace). Concanavalin A column elution buffer was 
Concanavalin A column wash buffer supplemented with 200 mM methyl- -D-
mannopyranoside (Sigma). 
5.2.3.2 Isolation of crude membrane fractions from rhPON2 baculovirus-
infected High Five cells. 
Cell pellets from 150 mL rhPON2 baculovirus-infected High Five were thawed in 30 mL ice-
cold homogenization buffer, lysed with 20  five-second passes with a Teflon homogenizer 
and centrifuged at 2,000  g at 4°C for 10 minutes. The supernatant was discarded and the 
cell pellet resuspended in a further 30 mL ice-cold homogenization buffer and the 
homogenization process repeated twice more. The final resuspended cell pellet was 
centrifuged at 20,000  g for 30 minutes at 4°C and the supernatant was discarded. The 
pellet containing the membrane-bound rhPON2 was resuspended in 20 mL ice-cold 
extraction buffer and solubilized overnight at 4°C on a rolling platform, and centrifuged at 
2,000  g at 4°C for five minutes to remove debris. The supernatant containing rhPON2 was 
centrifuged at 100,000  g for one hour and filtered using a 0.22 µm syringe filtration unit. 
5.2.3.3 DEAE anion exchange chromatography 
The isolated rhPON2 containing membrane fraction was loaded onto a 5 mL DEAE-
Sepharose HiTrap FF Column (GE Healthcare Life Science, Chalfont UK) at 0.5 mL/min in 
5. rhPON2 as an anti-Pseudomonal therapy 
147 
 
DEAE column buffer on an AKTA pure FPLC system (GE). The column was washed in DEAE 
column buffer with 10%–50% DEAE elution buffer over 30 column volumes. Fractions were 
collected and the presence of rhPON2 determined by immunoblot analysis with PON2 
antibody and SDS-PAGE. The SDS-PAGE gels were imaged with a Criterion Stain Free™ Gel 
Imaging system (BioRad, Hercules, CA, US). The PON2-containing fractions were pooled. 
5.2.3.4 Concanavalin A affinity chromatography 
The pooled rhPON2-containing fractions from the DEAE chromatography were mixed by 
rotating overnight with 1 mL of loose Concanavalin A Sepharose (GE) equilibrated with 
Concanavalin A column equilibration buffer by rotation at 4°C. After overnight incubation, 
the resin was poured into a column and washed with five column volumes of Concanavalin 
A column wash buffer. The bound protein was eluted with 15 column volumes of 
Concanavalin A column elution buffer and 2 mL fractions were collected. Following the 
collection of the first, second and third fractions, flow was stopped for 30, 20 and 10 
minutes, respectively, to maximise recovery of rhPON2. The eluted fractions were analysed 
for the presence of rhPON2 by immunoblotting with anti-PON2 antibody and SDS-PAGE. 
SDS-PAGE gels were imaged with silver staining as described in Chapter 2 (Section 2.3). The 
protein concentration of individual fractions was determined according to a BSA standard 
curve using the BioRad protein assay. Second-order polynomial correlation coefficients 
were typically 0.998 or above. Because the DDM detergent was predicted to interact with 
the protein assay dye, all diluents contained the appropriate buffer detergent concentration 
and individual standard curves were prepared for each of the buffers used.  
The purified protein was stored at 4°C in the Concanavalin A column elution buffer. These 
storage conditions resulted in minimal loss of activity over a four month period.  
 
5.2.4 Characterizing rhPON2 lactonase activity 
 
Recombinant human PON2 lactonase activity was measured at defined intervals in vitro 
using a PON2 C12HSL hydrolysis reaction buffer as described by Teiber and Draganov 
[359]. The reactions were then stopped, and the proportions of C12HSL lactone and acid 
were measured by UPLC-MS at the UTAS Central Science Laboratory as described below. 




5.2.4.1.1 PON2 C12HSL hydrolysis reaction buffer 
The reaction buffer was 2.5 mM Tris/HCl (pH 7.4) and 1 mM CaCl2. The buffer was sterilised 
by passing through a 0.22 µm filter prior to use. 
5.2.4.1.2 PON2 C12HSL hydrolysis inhibitory reaction buffer 
The reaction buffer was 2.5 mM Tris/HCl (pH 7.4) and 0.5 mM EDTA. The buffer was 
sterilised by passing the mixture through a 0.22 µm filter. 
5.2.4.2 C12HSL hydrolysis by rhPON2 
Recombinant human PON2 was resuspended in hydrolysis reaction buffer, (5 µL rhPON2 in 
94 µL hydrolysis reaction buffer). To start the reaction, 1 µL of 10 mM C12HSL (Cayman 
Chemicals, Ann Arbor MI) in HPLC grade acetonitrile (Sigma) was added to the reaction 
mixture to give a starting C12HSL concentration of 100 µM. The reactions were incubated 
for 5, 30, 45 and 60 minutes. To stop the reaction, 100 µL of ice-cold HPLC grade acetonitrile 
was added and the mixture stored on ice for further analysis. rhPON2 has Ca2+-dependent 
lactonase activity. To verify that C12HSL hydrolysis was dependent on rhPON2, a separate 
reaction involving inhibitory buffer (5.2.4.1.2), containing the metal ion-chelating EDTA and 
lacking Ca2+, was prepared. 
5.2.4.3 Analysis of rhPON2-mediated C12HSL hydrolysis 
5.2.4.3.1 Standard mixture for instrument calibration 
rhPON2 hydrolysis reactions were diluted and analysed by UPLC-MS. The instrument was 
calibrated using an external standard curve consisting of mixtures, in equal proportions, of 
C12HSL (closed lactone ring) and C12HSL-acid (open ring).  
The C12HSL-acid form was synthesized from the lactone form as follows. Ten millimolar 
C12HSL (Cayman Chemicals) in HPLC grade acetonitrile (Sigma) was diluted to a final 
concentration of 100 µM in an aqueous 1 mM NaOH solution by adding 1 µL of the C12HSL 
to 99 µL of the 1 mM NaOH. The reaction was mixed by vortexing and incubated at room 
temperature for 30 minutes. Finally, the reaction was stopped by adding and mixing 100 µL 
of HPLC grade acetonitrile (Sigma) containing 1 mM HCl. This mixture now contained 50 µM 
C12HSL-acid.  
Next, 1 µL of 10 mM C12HSL (Cayman Chemicals) in HPLC grade acetonitrile (Sigma) was 
added to 99 µL of degassed, distilled H2O. One hundred millilitres of HPLC grade acetonitrile 
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with 1 mM NaOH and 1 mM HCl was immediately added to the reaction mixture to give a 50 
µM C12HSL mixture.  
The 50µM solutions of C12HSL and C12HSL-acid were mixed in equal proportion and the 
resulting solution diluted to the following concentrations: 5.0 µM, 2.5 µM, 1.25 µM, 625 nm, 
312.5 nM, 104 nM and 52 nM. A 50:50 solution of degassed, distilled H2O and HPLC-grade 
acetonitrile was used as the diluent when preparing these mixtures.  
5.2.4.3.2 UPLC-MS of C12HSL solutions 
Samples were analysed by UPLC-MS using a Waters Acquity H-series UPLC coupled to a 
Waters Xevo triple quadrupole mass spectrometer (Waters Inc., Manchester UK). A Waters 
Acquity UPLC BEH C18 column (2.1 x 100mm x 1.7 micron particles) was used. The solvents 
were 1% acetic acid (Solvent A) and acetonitrile (Solvent B). 
The UPLC program was 50% A: 50% B to 10% A: 90% B at 4 minutes, followed by 
immediate re-equilibration to starting conditions for 3 minutes. The flow rate was 0.35 
mL/min, the column was held at 35°C and the injection volume was 10 μL. 
The mass spectrometer was operated in positive-ion electrospray mode with a needle 
voltage of three kV, and multiple reaction monitoring (MRM) mode was used to detect and 
quantify the analytes. The ion source temperature was 130°C, the desolvation gas was 
nitrogen at 950 L/hour, the cone gas flow was 100/hour and the desolvation temperature 
was 450°C. All data was analysed using MassLynx software (Waters Inc.). 
The MRM channels were: 
C12HSL-acid — m/z 316.2 to 95.0, m/z 316.2 to 144.05 and m/z 316.2 to 197.1. 
C12HSL-lactone — m/z 298.2 to 95.0, m/z 298.2 to 102.0, m/z 298.2 to 197.1.  
Cone voltage was 30 V and collision energy 20 V for all channels. Dwell time was 50 ms per 
channel. 
Calibration was against an external standard calibration mixture of the two analytes at 
seven different concentrations ranging from 53 nM to 5000 nM as outlined in Section 
5.2.4.3.1. Second-order polynomial correlation coefficients were typically 0.9998 or higher 
in all cases. Samples were bracketed by full standard curves run after every ten samples, 
and a single quality control calibration point (625 nM) was also acquired in the middle of 
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each set of ten samples. Quantification was carried out using the sum of the three MRM 
channels for each compound. 
5.2.4.3 Activity calculation 
From the UPLC-MS determined concentrations of C12HSL, the total amount of C12HSL 
hydrolysed was calculated in nMol. One activity unit (U) was defined as 1 nMol of C12HSL 
hydrolysed per minute. Total activity was defined as activity units from the total protein 
sample while the specific activity was defined as U per mg of protein. 
Activity Unit (U)=
amount of  C12HSL hydrolysed (nMol)
Time taken (minutes)
 





Volume of sample used to determine activity units (mL)
 











amount of C12HSL hydrolysed (nMol)
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5.2.5 Determination of the effects of rhPON2 on PAO1 growth, C12HSL 
accumulation and QS-dependent gene expression 
 
Overnight stationary-phase cultures of P. aeruginosa strain PAO1 strain ATCC 15692 were 
diluted to approximately 5  105 cells in LB media. Cultures were treated at time of dilution 
(pre-exponential) or after six hours incubation (mid-exponential) at 37°C with shaking at 
220 RPM. The Concanavalin A elution buffer (buffer in which rhPON2 is dissolved and 
contains 0.05% DDM) was used as a control. Treatments were (i) 5 U/mL rhPON2, (ii) 25 
U/mL rhPON2, (iii)10 µg/mL tobramycin, (iv) 5 U/mL rhPON2 + 10 µg/mL tobramycin and 
(v) 25 U/mL rhPON2 + 10 µg/mL tobramycin. All cultures included a final concentration of 
0.0005% (w/v) DDM. Cells were incubated at 37°C with shaking at 220 RPM. At intervals, 
aliquots were removed for bacterial enumeration, pH determination, determination of 
C12HSL lactonolysis and concentration, and RNA extraction for subsequent gene expression 
analysis by RT-qPCR. 
5.2.5.1.1 Bacterial enumeration and pH determination 
At intervals, 100 µL aliquots of cultures were ten-fold serially diluted and colony forming 
units (CFU) per mL determined by plating as described in Chapter 2. (Section 3.5.3.2) The 
pH of 1 mL aliquots of PAO1 cultures was determined. 
5.2.5.2 Analysis of C12HSL accumulation and lactonolysis 
One-millilitre aliquots of bacterial cultures were taken at intervals and centrifuged at 500  
g for five minutes to clarify the supernatant. The cell pellets were preserved in RNALater 
(Life Technologies) at −20°C for subsequent RNA extraction (5.2.5.3). The culture 
supernatants collected were used to analyse the concentration of C12HSL (lactone and acid 
forms). Stored supernatants were thawed and diluted 1:4 into acetonitrile: water (2:1, both 
solvents HPLC grade) to give a final ratio of solvents of 1:1 organic: aqueous. The samples 
were then analysed by UPLC as described in Section 5.2.4.3.2. 
5.2.5.3 RT-qPCR Analysis of QS and QS-dependent gene expression 
RNA was extracted from stored pellets using the ReliaPrep RNA Cell Miniprep kit (Promega) 
and complimentary DNA was synthesised for quantitative-PCR; all methods and primer 
sequences are described in Chapter 2 (Section 2.2). The genes analysed (psd7, lasI, rhlI, 
pqsA, lasR, lasB, algD, hcnB, phz1, and vfr) are described in Table 5.2. Gene expression was 
normalized to the reference gene psd7, which encodes P. aeruginosa 16S ribosomal RNA. 
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Table 5.2 P. aeruginosa QS genes analysed by RT-qPCR and their role in QS 
Gene Description Involvement in QS 
lasI Catalyses production of C12HSL 
Catalyses production of 
C12HSL, the main P. 
aeruginosa QS signal. 
Regulates the other two 
major P. aeruginosa QS 
systems. 
rhlI Catalyses production of C4HSL 
Catalyses production of 
C4HSL, the signal molecule of 
the second P. aeruginosa QS 
system. The Rhl system is 
induced by the Las system. 
pqsA 
Catalyses production of 2 heptyl-3-hydroxy-4-
quinolone. 
Catalyses production of 2 
heptyl-3-hydroxy-4-
quinolone the signal molecule 
of the third P. aeruginosa QS 
system. Regulated by both the 
Las (positive) and Rhl 
(negative) systems 
lasR Cognate receptor of C12HSL 
Transcriptional regulator 
which drives LasI expression 
when bound to C12HSL. 
lasB 
In the production of the virulence factor 
production 
Expression regulated by both 
the Las and Rhl systems 
algD 
Alginate biosynthesis. Responsible for the 
mucoid phenotype and biofilm formation 
Expression regulated partly 
by LasI 
hcnB 
Produces the virulence factor hydrogen 
cyanide. 
Expression regulated partly 
by RhlI 
phz1 
Involved in biosynthesis of the phenazines, 
including the virulence factor pyocyanin 
Expression regulated by RhlI 
and Pqs. 
vfr Virulence factor regulator 
Regulates P. aeruginosa 
virulence factor production, 








5.2.5.4 Determination of the minimal inhibitory concentration (MIC) of 
tobramycin for PAO1 
Overnight cultures of PAO1 were diluted to approximately 5  105 cells in LB medium 
supplemented with increasing concentrations (1, 2.5, 4, 5, 7, 8.5, 10, 12, 15 µg/mL) 
tobramycin (Sigma-Aldrich). The cultures were incubated for 24 hours at 37°C with shaking 
at 220 RPM. The optical density of the cultures at 600 nm was then measured to determine 
MIC, which was defined as the lowest concentration of tobramycin that inhibited detectable 
growth of PAO1. 
 





5.3.1 Successful cloning of human PON2 into bacmid expression vector.  
 
To express hPON2 in insect cells, hPON2 transcript was cloned into a bacmid vector to 
produce a baculovirus stock capable of infecting insect cells and producing rhPON2. Figure 
5.4 depicts agarose gel electrophoresis of the PCR products derived from amplification of 
the rhPON2 bacmid DNA using pUC/M13 primers. 
 
 
5.3.2 Production of high-titre, rhPON2-expressing baculovirus stock. 
 
Baculovirus stocks were created by transfection and subsequent infection of the SF9 insect 
cell line. To obtain high titres of hPON2-expressing baculovirus stock, the optimum DNA: 
transfection reagent ratio was determined. A range of ratios of DNA: transfection reagent 
was used for transfecting SF9 cells with the DNA of the hPON2 vector. Using immunoblot 
analysis (Figure 5.5) and microscopic visualization of baculovirus infected SF9 cells (result 
not shown), the optimum DNA: transfection reagent ratio was determined to be 4.0 µg DNA  
 
Figure 5.4 PCR verification of cloning of hPON2 transcript into baculoviral expression vector. PCR 
was carried out on baculovirus DNA to verify recombination of hPON2 transcript into the baculovirus 
expression vector. Successful recombination produced a 3,400 bp PCR product. Baculovirus that did 
not undergo recombination would produce a 300 bp product. 
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per 8 µL transfection reagent. Using this optimum ratio of DNA:transfection reagent, SF9 cells 
were transfected with hPON2-expressing baculovirus to produce passage one (P1) stock with a 
titre of 2.19  106 pfu/mL. P1 stock was used to infect fresh SF9 cells to produce passage two 
(P2) baculovirus stock with a titre of 1.89  107 pfu/mL (Table 5.3). The titres were determined 
using the end-point dilution method and were similar to those titres indicated in  the Bac-to-Bac 
manufacturer’s instructions [275].  
Table 5.3 Titres of baculovirus stock calculated by end-point dilution  
End-Point Dilution Counts 













10–4 20 1 95.20 10–4 23 0 100 
10–5 7 7 50.00 10–5 11 3 75.57 
10–6 1 18 5.26 10–6 2 13 13.33 
10–7 0 30 0.00 10–7 0 25 0 
Calculated Viral Titres 
Virus passage Titre (plaque forming units/mL) Used to infect 
P1 2.19  106 Sf9 Cells – generate P2 stock 
P2 1.89  107 Sf9 cells – Test hPON2 expression 
Hi-Five – Express hPON2 
 
Figure 5.5 Optimizing transfection of Sf9 cells with hPON2-expressing baculovirus DNA using 
immunoblot analysis. Sf9 cells were transfected with DNA from the hPON2-expressing baculovirus 
vector with varying ratios of DNA:transfection reagent (Cellfectin). Immunoblot analysis of lysed 
cells, using a hPON2 antibody, determined the optimum ratio of DNA: transfection reagent to be 4 
µg DNA:8 µl Cellfectin.  
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5.3.3 Determination of High Five insect cell infection conditions for maximal 
rhPON2 expression. 
 
To ensure maximal production of rhPON2 in the High Five insect cell line, the optimal 
multiplicity of infection (MOI) and duration of infection were determined. The amount of 
rhPON2 in the infected insect cells varies over time as the infection progresses, and 
baculovirus infection eventually causes cell death. Too little baculovirus usually results in 
lower rhPON2 production, while too much virus usually causes immediate cell lysis and 
hence reduced protein yield. The optimum MOI was determined by immunoblot analysis of 
lysates of cells infected with rhPON2 baculovirus expression vector (Figure 5.6 and by 
microscopic visualization of infected cells. (Figures 5.7 and 5.8) of the lysates of the infected 
High Five cells. These analyses determined that the optimum MOI and duration of infection 
required for maximal production of rhPON2 was 3–4 days of infection with a MOI of 2.5. 
Using lower MOIs did not yield as much PON2, while MOI of 5 resulted in quick cell death 
hence yielding reduced rhPON2.  
MOI Non-infected 0.5 1.0 2.5 5.0 
Day 2 
     
Day 3 
     
Day 4 
     
Day 5 
     
Figure 5.6 Optimizing infection of High Five cells with hPON2-expressing baculovirus using immunoblot 
analysis. Figure shows immunoblot analysis, using hPON2 antibody, of High Five cell lysates infected with 
varying MOI of hPON2-expressing baculovirus and the progress of infection over five days, with increasing 
MOIs.  
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MOI Non-infected 0.5 1.0 2.5 5.0 
Day 2 
     
Day 3 
     
Day 4 
     
Day 5 
     
Figure 5.7 Progression of infection of HIgh Five cellswith hPON2-expressing baculovirus observed at 40 magnification. Figure shows High Five cells infected with varying MOIs of hPON2-
expressing baculovirus and the progress of infection was monitored using light microscopy at 40 magnification starting at day two post infection. At this magnification, the cessation of 
growth and the clearing of the adherent cell monolayer can be observed starting at day two in High Five cells treated with MOI ≥ 2.5. With the progression of infection the cessation of 
growth and the clearing of the adherent cell monolayer can also be observed with MOI ≤ 1. Scale bar represents 500 µm. 
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MOI Uninfected 0.5 1.0 2.5 5.0 
Day 2 
     
Day 3 
     
Day 4 
     
Day 5 
    c 
Figure 5.8 Progression of infection of High Five cells with hPON2-expressing baculovirus observed at 400 magnification. Figure shows High Five cells infected with 
varying MOI of hPON2 expressing baculovirus and the progress of infection was monitored using light microscopy at 400 magnification, starting at day two post 
infection At this magnification, the increase in cell size, nuclear diameter, granular appearance and lysis of the cell can be observed starting at day two in High Five cells 
treated with MOI ≥ 2.5. With the progression of infection the increase in cell size, nuclear diameter, granular appearance can also be observed with MOI ≤ 1. Scale bar 
represents 50 µm. 
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5.3.4 Purification and characterization of rhPON2 
Recombinant human PON2 was purified by differential centrifugation and using a two-step 
liquid chromatography protocol as previously described by Draganov and colleagues. 
Firstly, the membrane fractions from High Five cells infected with the rhPON2 baculovirus 
were purified by differential centrifugation. This step increased the purity of rhPON2 12-
fold and resulted in a membrane fraction with a specific lactonase activity (64.656 units/mg 
protein) towards C12HSL (Table 5.4, Figure 5.9).  
The membrane fractions were then further purified using DEAE anion chromatography. The 
eluted fractions were analysed by Coomassie-stained SDS-PAGE to detect the 
presence/absence of rhPON2 (Figure 5.10). The rhPON2 eluted as a broad peak at a NaCl 
concentration between 100 mM and 300 mM NaCl. This purification step resulted in a 27-
fold increase in purification from crude lysates and the pooled fractions had a specific 
activity of 148.213 U/mg (Table 5.4, Figure 5.9).  
The final purification step involved concanavalin A affinity chromatography. The 
concanavalin A binds glycosylated rhPON2 and the protein was eluted by a 
mannopyranoside sugar containing buffer that disrupted the concanavalin A lectin binding. 
The eluted fractions were analysed by SDS-PAGE and immunoblot analysis to detect the 
presence/absence of rhPON2 (Figure 5.11). Pooled rhPON2 fractions had a specific activity 
towards C12HSL of 323 U/mg (nMols min–1 mg–1) (Table 5.4, Figure 5.9), representing a 59-
fold purification of specific activity compared with whole cell lysates. 


















Whole-cell lysate 300 897.00 4920 5.485 100 1 
Membrane fraction 20 61.00 3944 64.656 80.2 12 
DEAE anion exchange 
(pooled) 
12 24.88 3682 148.213 74.8 27 
Concanavalin A affinity 
purification (pooled) 
6 6.96 2251 323.448 45.7 59 
Results are given for representative purifications. Activity was calculated against 100 µM C12HSL, as 
described in Section 5.2.4. Units are defined as nMols of C12HSL hydrolysed per minute. Yield = (Total 
activity of fractions at step)/ (Total activity of whole cell lysate). Fold purification is the change in 
specific activity at each step relative to the specific activity of the whole-cell lysate. 
 




Figure 5.9 Recombinant human PON2 lactonolysis of C12HSL. 100 µM C12HSL was incubated for 60 
min with rhPON2 from each purification step and the percentage of remaining C12HSL determined 
using UPLC-MS. Figure shows the mean percentage of un-hydrolysed C12HSL remaining from three 
independent reactions. A buffer-only control (Concanavalin A column elution buffer, black line) or a 5 µl 
aliquot of each rhPON2 sample was used; whole cell lysates (purple line), membrane fraction (red line), 
pooled DEAE anion exchange purified rhPON2 (blue line), first eluted fraction of Concanavalin A 
purified rhPON2 (green line). Error bars indicate S.D.  
 
The purified rhPON2 mix contained three major protein bands, as revealed by SDS-PAGE 
analysis (Figure 5.10). Two of these proteins differed in size by ~5 KDa but both were 
identified as rhPON2, as demonstrated by immunoblot analysis (Figure 5.12). These two 
forms of rhPON2 most likely differed in their extent of post-translational glycosylation 
[described previously in 248]. A third protein was a contaminating protein of ~25 KDa. 
No C12HSL hydrolysis was observed when reactions were carried out in the presence of the 
metal ion chelating agent EDTA and absence of Ca2+, indicating that purified rhPON2 had 
Ca2+dependent lactonase activity, consistent with previous reports [262]. Furthermore, 
lysates or purified fractions derived from not-infected insect cells showed no lactonase 
activity towards C12HSL (Figure 5.13), demonstrating that the lactonase activity was indeed 
associated with rhPON2. 











Figure 5.10 Purification of membrane fractions of lysates from infected High Five cells by anion exchange chromatography. The membrane fractions of lysates from hPON2-
expressing baculovirus-infected High Five cells were purified using DEAE anion exchange liquid chromatography. A) Traces of UV absorbance from FPLC system (purple) overlaid 
with elution buffer NaCl concentration (green) and the fractions in which the eluted samples were collected (red). Figure indicates which peak contained proteins with a size 
similar to that of PON2 as determined by SDS-PAGE. B) Magnified peak of UV absorbance indicating where proteins with a size similar to PON2, as determined by SDS-PAGE, were 
eluted. C) Stained SDS-PAGE of fractions obtained from DEAE purification of hPON2 baculovirus-infected High Five cell membrane fractions.  




Figure 5.11 Affinity purification of rhPON2. The pooled rhPON2-containing 
fractions from DEAE anion exchange chromatography were purified further 
using Concanavalin A affinity chromatography and the eluted fractions 





Figure 5.12 Immunoblot of purified hPON2 fractions. SDS-PAGE was carried 
out on the membrane fractions isolated from crude lysates of hPON2-
expressing baculovirus-infected High Five cells, along with the pooled fractions 
from the DEAE anion exchange chromatography and the Concanavalin A affinity 
chromatography. Figure shows immunoblot analysis with a hPON2 antibody. 
rhPON2 can be observed as a doublet of bands at ~39 kDa (lanes 1–3). 
 
 













Figure 5.13 SDS-PAGE gels, immunoblot analysis and lactonase activity of High Five cells not infected with 
rhPON2. Lysates of uninfected High Five cells underwent the same protein purification protocol as infected 
High Five cells. A) Figure shows SDS-PAGE (lanes 1, 2) and immunoblotting (lanes 3, 4) of purified lysates 
from uninfected High Five cells (lanes 1, 3) and infected cells (lanes 2, 4). B) Mean lactonase activity of 
purified lysates from uninfected and infected cells, in the presence and absence of EDTA and Ca2+ from 
three independent experiments. Errors bars indicate S.D., * p < 0.05.  
5. rhPON2 as an anti-Pseudomonal therapy 
164 
 
5.3.5 Effect of rhPON2 on P. aeruginosa strain PAO1 growth, QS and virulence 
5.3.5.1 Determination of rate of PA01 growth and C12HSL accumulation and 
hydrolysis. 
Cultures of bacteria undergo four distinct growth phases, each with different characteristics. 
We hypothesized that the effect of rhPON2 on P. aeruginosa QS and virulence would differ 
depending upon which growth phase the bacteria were in at the time of exposure to the 
paraoxonase. A previous report demonstrated the accumulation and disappearance of 
C12HSL during exponential phase and stationary phase, respectively [243]. To determine 
the rate of growth and the cell density associated with each growth phase of PA01, bacterial 
growth was monitored by determining CFU/mL at specific time points (2, 6, 10, 14, 24 
hours). As depicted in Figure 5.14A, following a short lag phase, strain PAO1 rapidly entered 
exponential growth with growth peaking at approximately 12 hours (~1  109 CFU/mL), 
followed by stationary-phase growth as nutrients became limited. 
The stability and associated activity of C12HSL are influenced by the pH of the media [243]. 
At high pH, ring opening occurs by hydroxide ion-mediated hydrolysis, while at low pH, ring 
closure is predominant. Therefore, the pH of the growth medium inoculated with PAO1 was 
monitored during the different stages of growth. As depicted in Figure 5.14A, the pH of the 
growth medium decreased during growth from 7.6 to 7.0 over 24 hours, conditions that 
should favour ring closure. 
Accumulation and hydrolysis of C12HSL was also measured during the growth of PAO1. 
Figure 5.14B shows that initial levels of C12HSL were below detectable limits. This was 
followed by rapid accumulation of C12HSL-acid (open-ring form) during exponential 
growth, with a peak concentration of 800 nm. There was little detectable C12HSL open-ring 
form until mid-exponential growth (around six hours). The C12HSL disappearance during 
stationary-phase is associated with ring opening, as demonstrated by the parallel increase 














Figure 5.14  Growth curve of PAO1 at 37C in LB media LB media was inoculated with 5  105 colony 
forming units per mL (CFU/mL) of PAO1 and samples collected at various intervals to count cell 
numbers, measure media pH and determine C12HSL (lactone and acid) concentrations over a 24 hour 
period. A) Figure shows the mean CFU/mL of PAO1 (black line) and pH of media (dotted red line) from 
three independent experiments. The exponential and stationary growth phases are bracketed (dotted 
blue). B) Figure shows C12HSL lactone (blue-dashed line), C12HSL acid (red-dashed line) and C12HSL 
lactone + acid (black solid line) concentrations in the culture supernatants as determined at 0, 2, 6, 10, 
14 and 24 hours. Error bars show S.D. from three independent cultures. 
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5.3.5.2 Determination of PAO1 tobramycin minimal inhibitory concentration 
To study the effects of tobramycin on the growth of PAO1, the MIC of tobramycin was 
determined. A stationary phase PAO1 culture was diluted to 5  105 colony forming units 
per mL (CFU/mL) in LB medium supplemented with 0,1, 2.5, 4, 5, 7, 8.5, 10, 12, 15 µg/mL of 
tobramycin.. The cultures were grown for 24 hours and the absorbance at 600 nm 
measured for three independent cultures. The concentration of tobramycin required to 
completely inhibit growth was determined to be ~5 µg/mL (Figure 5.15). 
 
 
Figure 5.15 Dose-dependent killing of PA01 by tobramycin. LB media was inoculated with 5  105 
colony forming units per mL (CFU/mL) of PAO1 and tobramycin (0–15 μg/mL). The cultures were grown 
at 37C for 24 hours with shaking and absorbance at 600 nm measured. Figure shows mean optical 
density of cultures from three independent experiments after 24 hours. Error bars show S.D. 
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5.3.5.3 Recombinant human PON2-mediated lactonolysis of C12HSL during 
PAO1 growth increases PAO1 antibiotic susceptibility 
To quantitatively investigate the effects of rhPON2 on PAO1 growth, QS, virulence and 
tobramycin susceptibility, PAO1 cultures were co-treated with rhPON2 and tobramycin. 
PAO1 cultures either in pre-exponential growth-phase (Figure 5.16) or mid-exponential 
growth (Figure 5.17) were treated with 0, 5 or 25 U/mL rhPON2 and either with 0 or 10 
µg/mL (2 MIC) tobramycin. We hypothesised that treatment of pre-exponential cultures 
would prevent bacterial QS and that treatment of mid-exponential phase cultures would 
dampen QS-mediated virulence. Samples were collected from three independent 
experiments at 0, 2, 6, 12, 14 and 24 hours and analysed to determine the CFU/ml and 
C12HSL concentration (both open and closed ring forms). 
Treatment of pre-exponential phase cultures of PAO1 with 5 U/mL rhPON2-alone did not 
affect bacterial growth (as seen in Figure 5.16A) but prevented accumulation of C12HSL 
(closed-ring form) presumably by promoting C12 HSL lactonolysis (open-ring form, Figure 
5.16B). The maximum amount of C12HSL (closed-ring form) occurred during exponential 
growth and was significantly reduced in the presence of rhPON2. There was a 
corresponding increase in concentration of the C12HSL-acid (open-ring form) that reflected 
the extensive activity of rhPON2 over the entire 24 hour period. The increased C12HSL-acid 
detected in rhPON2-treated culture supernatants compared to those collected from not-
infected controls suggested that the bacteria might be compensating for the lack of C12HSL 
in their growth environment by increasing their overall production of C12HSL, which in 
would have been hydrolysed to the acid form being detected (Fig. 5.16B) 
When pre-exponential growth phase cultures were treated with 2 MIC tobramycin, no 
viable bacterial cells were able to be recovered 24 hours post treatment. There also 
appeared to be little, if any, effect on the rate of antibiotic-mediated killing when cultures 
were co-treated with 5 U/mL rhPON2 and 2 MIC tobramycin and no detectable C12HSL 
(open- or closed-ring form, data not shown), most likely as a consequence of the rapid 
bacterial cell death. In summary, treatment of pre-exponential phase cultures had no 
detectable effect on bacterial growth, prevented accumulation of C12HSL (by rapid 
hydrolysis to form C12HSL-acid) and did not alter bacterial susceptibility to tobramycin (2 
MIC) most likely because of rapid killing of the cells by tobramycin. 
 








Figure 5.16 Time-dependent effect of rhPON2 in combination with tobramycin on pre-exponential phase PAO1. LB media was inoculated with 5  105 colony forming 
units per mL (CFU/mL) of PAO1. Recombinant hPON2 (5 U/ml) with or without tobramycin (2 MIC) was added at the time of inoculation and the cultures were grown at 
37C for 24 hours. Bacteria were enumerated and the C12HSL (lactone and acid) concentrations in the culture supernatants were determined at 0, 2, 6, 10, 14 and 24 
hours. Figure shows A) Bacterial growth rate and B) C12HSL-lactone (solid line) and C12HSL-acid (dotted line) concentration. Error bars represent S.D. from three 
independent experiments.  
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Figure 5.17 Time-dependent effect of rhPON2 in combination with tobramycin on mid-exponential phase PAO1. LB media was inoculated with 5  105 colony 
forming units per mL (CFU/mL) of PAO1. Recombinant hPON2 (5 U/ml) with or without tobramycin (2 MIC) was added six hours post-inoculation (mid-exponential 
growth) and the cultures were grown at 37C for 24 hours. Bacteria were enumerated and the C12HSL (lactone and acid) concentrations in the culture supernatants 
were determined at 0, 1, 6 and 24 hours. Figure shows A) Bacterial growth rate, B) C12HSL-lactone concentration and C) C12HSL-acid concentration. Error bars 
represent S.D. from three independent experiments.  
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When mid-exponential phase cultures of PAO1 that had already accumulated significant 
levels of C12HSL (~800 nm) were treated with either 5 U/mL or 25 U/mL rhPON2, bacterial 
growth was unaffected (Figure 5.17A). There was, however, rapid (over 10-fold decrease 
within the first hour of treatment) and almost complete hydrolysis of the accumulated 
C12HSL (less than 5 nM C12HSL remaining, Figure 5.17B) to the open-ring C12HSL acid 
form (Figure 5.17C).  
These mid-exponential cultures were also resistant to complete killing by 2 MIC 
tobramycin (Figure 5.17A). Tobramycin treatment alone decreases C12HSL concentration 
because of the decrease in cell numbers, as seen in Figure 5.17B, without substantial 
increases in the open-ring C12HSL acid form (Figure 5.17C). This is most likely the result of 
rapid bacterial killing causing a decrease in C12HSL production. However, when these 
cultures were co-treated with rhPON2 and 2 MIC tobramycin there was a significant (t-
test, p < 0.05) dose-dependent increase in bacterial killing in the presence of rhPON2, which 
coincided with hydrolysis of C12HSL (Figure 5.17C).  
5.3.5.4 Effect of rhPON2 with or without antibiotics on strain PAO1 QS and 
virulence gene expression 
Treatment of mid-exponential phase PAO1 cultures with either 5 or 25 U/mL rhPON2 did 
not affect bacterial growth but rapidly converted accumulated C12HSL to the open-ring 
form, with a concomitant increase in the susceptibility of the bacterial cells to tobramycin. 
To investigate the effects of rhPON2 treatment on QS signalling, the expression levels of 
nine QS regulatory and QS-dependent genes were measured (Table 5.5 lists the genes) in 
bacteria treated with rhPON2 with and without 2 MIC tobramycin. 
In the cultures treated with rhPON2 (5 or 25 U/mL) alone, there were no significant 
changes in gene expression (Figure 5.18). One hour post-treatment there was, however, a 
general trend towards decreased expression of QS-regulatory and QS-dependent gene 
expression in cultures treated with 5 U/mL rhPON2 but not in those treated with 25 U/mL 
rhPON2. After six hours of exposure to rhPON2, both 5 and 25 U of rhPON2 caused a general 
decrease in expression of all of the QS-related genes tested.  
Treatment of cultures with 2 MIC tobramycin resulted in rapid but incomplete bacterial 
killing. Surviving bacteria had significantly (t-test, p < 0.05) increased expression of all the 
QS-related genes compared with no antibiotic treatment controls (Figure 5.19). Up-
regulation of the expression of algD, hcnB and phz was observed at both time-points, while 
an increase in vfr expression was only observed one hour post treatment, and lasB 
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expression was up-regulated six hours post treatment. Although it was not significant, there 
was a trend towards increased expression of lasI and rhlI, the two genes catalysing the 
production of the two QS signal molecules at the top of the P. aeruginosa QS hierarchy, 
compared with the control treated cells, while significant up-regulation of pqsA compared 
with the control treated cells was observed six hours post treatment with tobramycin. 
When mid-exponential phase cultures were co-treated with 5 or 25 U/mL rhPON2 and 
2MIC tobramycin there was an increased susceptibility to tobramycin, however, bacterial 
killing was still incomplete. One hour post treatment surviving cells showed little to no 
change in gene expression compared with untreated controls, regardless of the dose of 
rhPON2 used (Figure 5.19). This is in contrast to the general up-regulation of these genes 
that occurs following one hour of tobramycin treatment alone, suggesting that rhPON2 
treatment prevents the early tobramycin-associated up-regulation of QS-associated genes. 
In contrast, at six hours post-treatment there was a general trend towards up-regulation of 
all genes tested. However, only the higher concentration of rhPON2 (25 U/mL), in 
conjunction with tobramycin, elicited significant increases (Figure 5.19). A greater than 10-
fold up-regulation of the C12HSL synthase lasI was observed with a similar increase in 
expression of lasR. There was also strong and significant, up-regulation of the QS-dependent 
virulence factor-encoding genes lasB and algD and the QS regulator vfr. The strong up-
regulation of lasI in response to treatment with 25 U/ml rhPON2 and tobramycin seem to 
indicate that when the bacterial cells were placed under stress (by the addition of 
tobramycin) they responded by attempting to up-regulate lasI. However, almost all the 
C12HSL released into the intercellular environment would be expected to be hydrolysed by 
the extracellular added rhPON2. In spite of the relative absence of C12HSL, expression of the 
associated QS-dependent genes were nonetheless up-regulated. 
 





Figure 5.18 Effect of rhPON2 on PAO1 QS-associated gene expression. LB media was inoculated with 5  105 CFU/mL PAO1. Six hours post-inoculation (mid 
exponential phase), the cultures were treated with recombinant hPON2 at either 5 U/mL (dark-red) or 25 U/mL (solid-red) and grown at 37C with shaking. RNA was 
extracted from cultures at one hour and six hours post-treatment to measure expression of nine QS-associated genes by RT-qPCR. Figure shows the average change 
in gene expression relative to expression of 16S rRNA (psd7) and relative to expression of the same gene at the start of treatment (time 0). Error bars represent S.D. 
from three independent experiments. 
 





Figure 5.19 Effect of combined rhPON2 and tobramycin treatment on PAO1 QS-associated gene expression. LB media was inoculated with 5  105 CFU/mL PAO1. 
Six hours post-inoculation (mid exponential phase), the cultures were treated with tobramycin (2 MIC; solid blue) alone or in combination with recombinant 
hPON2 at either 5 U/mL (shaded green) or 25 U/mL (solid green) and grown at 37C with shaking. RNA was extracted from cultures at one hour and six hours post-
treatment to measure gene expression of nine QS-associated genes by RT-qPCR. Figure shows the average change in gene expression relative to expression of 16S 
rRNA (psd7) and relative to expression of the same gene at the start of treatment (time 0). Error bars represent S.D. from three independent experiments.  
* p < 0.05 by Students t-test. 
 





Recombinant human PON2 was successfully expressed via a baculovirus infection system 
and purified using the method described by Draganov and colleagues [248]. The purity of 
the final protein preparation was ~70%. A contaminating ~25kDa protein found in the 
protein preparation was also similarly reported by Draganov and colleagues [248]. 
Importantly, the 25kDa protein did not have detectable PON2-associated lactonase activity. 
When the cell lysates from non-infected insect cells underwent the same purification 
protocol, the ~25 kDa protein was once again detected, suggesting that this protein was 
endogenous to the Trichoplusia ni insect cells. Removal of this contaminating protein might 
be possible with inclusion of an additional purification step, perhaps one involving gel 
filtration chromatography to separate the proteins based on their molecular mass. However, 
each additional purification step comes at the cost of decreased protein yield, and because 
there was no detectable PON2 activity associated with lysates prepared from non-infected 
insect cells (since insects do not possess PON2) the benefits of any additional purification is 
expected to be minimal. 
The specific activity of the rhPON2 preparation towards C12HSL was Ca2+-dependent and 
was determined to be 323 U/mg total protein. This was comparable to the rhPON2 specific 
activity reported by Draganov and colleagues (459 U/mg total protein) [248]. Teiber and 
colleagues also produced rhPON2 using a similar method to that described by Draganov and 
colleagues but reported a much higher specific activity, 7647 U/mg [262]. The reason(s) for 
these discrepancies are not understood.  
Next the hypothesis that rhPON2 treatment of P. aeruginosa would decrease bacterial QS 
and QS-associated virulence and increase bacterial susceptibility to tobramycin was tested. 
While synthetic rhPON2 was produced in this study laboratory and its lactonase activity 
verified, this hypothesis was tested using rhPON2 that had been produced by a large scale 
preparation at the Monash Protein Production Unit. 
The results presented in Figure 5.16 are the first demonstration that an extracellularly 
applied mammalian lactonase is capable of hydrolysing C12HSL produced during the 
growth of P .aeruginosa. In control PAO1 cultures, C12HSL-lactone accumulated in culture 
supernatants during the early exponential phase, peaking at the end of the exponential 
phase before decreasing to a stable level during the stationary phase. Treatment of pre-
exponential PAO1 with rhPON2 largely prevented C12HSL-lactone from being detected in 
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culture supernatants, as indicated by the sustained accumulation of the acid form of C12HSL 
in rhPON2 treated cultures. Treatment of mid-exponential cultures with rhPON2 led to 
rapid and almost complete hydrolysis of C12HSL-lactone. This observation indicated that, in 
addition to preventing the accumulation of C12HSL in early cultures, rhPON2 was also able 
to hydrolyse C12HSL being produced by older cultures. Sustained (24 hours) prevention of 
C12HSL accumulation by rhPON2 also indicated that the rhPON2 was reasonably stable in 
treated bacterial cultures. Taken together, these findings demonstrate the ability of rhPON2 
to hydrolyse and prevent accumulation of C12HSL-lactone in P. aeruginosa cultures. It 
seems reasonable to suspect that a significant proportion of C4HSL, the signalling molecule 
of the second P. aeruginosa QS system, also undergoes lactonolysis. While this phenomenon 
was not directly measured in this study, rhPON2 reportedly displays similar lactonase 
activity towards C4HSL [248]. 
Interestingly, C12HSL-acid was also detected in control cultures, indicating that C12HSL 
hydrolysis occurred in P. aeruginosa cultures even in the absence of rhPON2 treatment. 
Yates and colleagues also observed the accumulation of C12HSL-acid in P. aeruginosa 
cultures during their experimentation [243].These authors found that hydrolysis of C12HSL 
in cultures was not enzyme-dependent but instead pH dependent. Unlike the observations 
of Yates and colleagues, the present study found that the pH decreased only slightly during 
growth of the bacterial cells but most importantly remained neutral. There are no reports 
describing native P. aeruginosa enzymes able to hydrolyse C12HSL. Thus the reason for 
spontaneous hydrolysis of C12HSL in P. aeruginosa cultures is not known. As the acid form 
accumulates during PAO1 exponential growth, preceding the accumulation of the lactone 
form, one explanation could be that C12HSL was being hydrolysed after binding to its 
cognate receptor as part of a hitherto unknown self-regulating mechanism of QS. One such 
proposed self-regulating mechanism of QS is thought to be through PvdQ QS [360]. PvdQ is 
an acylase that inactivates AHLs by cleaving the acyl chain from the homoserine lactone, 
rendering the molecule inactive [361]. Whether this sort of system is responsible for the 
"spontaneous" hydrolysis C12HSL observed in the absence of rhPON2 treatment remains to 
be determined. While the treatment with rhPON2 did not affect the growth of P. aeruginosa, 
the expression of most QS-associated genes, however, showed a trend towards decreased 
expression six hours post-treatment with rhPON2. Higher doses of rhPON2 may have 
initially (after one hour) increased QS and QS-dependent virulence, most likely through 
stress, but these effects were no longer evident six hours post treatment. Decreased QS and 
QS-dependent virulence as a result of hydrolysis of C12HSL is consistent with the findings of 
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other studies where C12HSL-dependent signalling was prohibited either through QS 
knockout studies [135, 316, 362, 363] or treatment with C12HSL degrading enzymes [351-
353, 355]. 
P. aeruginosa cultures were treated with the CF-relevant aminoglycoside antibiotic 
tobramycin. Treatment with 2 MIC tobramycin completely killed pre-exponential but not 
mid-exponential cultures within 24 hours. This was not unexpected as growth rates are 
known to influence susceptibility to antibiotics. Mid-exponential cultures treated with 
tobramycin alone yielded lower C12HSL concentrations compared with controls, most likely 
as a consequence of antibiotic-mediated cell death. Treatment with tobramycin alone also 
seemed to induce QS and QS-dependent virulence gene expression. For example, the 
expression of QS-dependent virulence genes involved in elastase biosynthesis (lasB), 
alginate synthesis (algD), hydrogen cyanide production (hcnB) and phenzine production 
(phz) were all significantly up-regulated at certain time points in response to tobramycin 
treatment alone. Intriguingly, tobramycin treatment had a lesser effect on the expression of 
genes coding for the QS signals. While there appeared to be a trend towards increased 
expression of lasI and rhlI in response to tobramycin treatment at both one and six hours 
post treatment, the expression of pqsA only seemed to increase six hours post treatment. 
The general increase in virulence gene expression in PAO1 in response to tobramycin 
treatment, was most likely the result of the stress induced by tobramycin. Tobramycin binds 
to the 30S and 50S bacterial ribosomes, preventing formation of the 70S complex, which 
eventually causes inhibition of mRNA translation inducing ribosomal stress [364]. 
Ribosomal stress is known to induce the P. aeruginosa stress response via the MexXY-OprM 
multidrug efflux system [365, 366]. The MexXY-OprM efflux system is thought to influence 
the expression of a number of virulence genes also normally regulated by QS [367]. A 
number of studies have reported that in P. aeruginosa, QS forms part of the cellular 
response to various stresses including antibiotics [368-372]. In addition, bacteria seem to 
increase their biofilm formation, a QS-determinant, in response to antibiotic stress [373]. 
To investigate whether rhPON2-mediated C12HSL hydrolysis might increase the 
susceptibility of P. aeruginosa to the inhibitory effects of antibiotics, P. aeruginosa cultures 
were treated with varying concentrations of rhPON2 together with tobramycin at 2 MIC. 
Treatment of mid-exponential cultures, but not pre-exponential cultures, showed that 
rhPON2 treatment increased the susceptibility of the bacterial cells to tobramycin. At 2 
MIC, tobramycin effectively killed most of the bacterial cells in pre-exponential cultures, 
making it difficult to observe whether co-treatment with rhPON2 increased their 
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susceptibility to the antibiotic treatment. In contrast, mid-exponential cultures treated with 
both rhPON2 and tobramycin showed a rhPON2-dose-dependent increase in the 
susceptibility of PAO1 to tobramycin. These results are consistent with those studies 
showing QS deficient P. aeruginosa strains [171] and those treated with QS inhibitors are 
more susceptible to tobramycin than control [171, 374]. However, complete killing was not 
achieved, even with combined rhPON2+tobramycin treatment. Remarkably, some 
populations of bacterial cells seemed to up-regulate the expression of QS and QS-dependent 
virulence gene expression. In particular, there was a strong up-regulation of lasI, indicating 
that some bacterial cells at least were attempting to compensate for the decreased 
extracellular C12HSL concentration by up-regulating LasI, most likely to co-ordinate a 
response to the antibiotic stress. The attempt was futile however, as rhPON2 degrades the 
QS signal. This up-regulation of QS-dependent virulence genes must be independent of 
C12HSL. However, the expression levels of QS-dependent virulence genes can be regulated 
independently of QS. Thus for example, las and rhl mutants are still capable of producing 
low levels of elastase [135, 362, 363] and pyocyanin [362] despite being unable to use these 
two systems to co-ordinate expression. In addition, the major transcriptional repressor of 
the Las system, RsaL, can regulate pyocyanin and hydrogen cyanide synthesis 
independently of Las system, [375]. In fact, emerging evidence indicates that there is added 
complexity in the QS systems of P. aeruginosa. It is proposed that the expression of the QS 
virulence determinants may be regulated independently of QS under sub-optimal 
conditions. One such example is the recent discovery of a new QS signal, IQS, which, during 
growth in nutrient rich media, was regulated by the Las system [376]. However, under 
phosphate depletion stress, IQS can be produced independent of the Las system, and still 
signal the Rhl and PQS QS systems and stimulate gene expression of virulence determinants 
usually regulated by QS. As a result, it is plausible that up-regulation of lasI and the QS-
dependent virulence genes in the absence of C12HSL could take place via a C12HSL/Las 
independent mechanism. Further investigations will be required to establish the 
mechanism through which this occurs. Global gene expression analysis using microarrays 
may be an ideal method to further explore the mechanisms by which P. aeruginosa responds 
to antibiotic stress in the absence of C12HSL.  
Treatment of mid-exponential cultures with both rhPON2 and tobramycin resulted in rapid 
hydrolysis of C12HSL, faster than that observed with tobramycin-treatment alone. This 
difference in rates of hydrolysis further supports the hypothesis that the tobramycin 
treatment-associated decrease in C12HSL was predominantly due to increased cell death.  
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In summary, rhPON2 was capable of hydrolysing C12HSL able to be produced in P. 
aeruginosa cultures, and although it did not affect bacterial growth, it did appear to 
decrease QS and QS-dependent virulence gene expression in this organism. More 
importantly, when used in combination with tobramycin, rhPON2 increased the bactericidal 
effects of the tobramycin. Overall, the results described in this chapter suggest that rhPON2 
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The ubiquitous bacteria P. aeruginosa is a common pathogen in nosocomial infections, 
burns, people with immune deficiencies and people with cystic fibrosis (CF). CF is the most 
common life-limiting single gene disorder in Caucasians and is characterized by chronic 
respiratory infections. These respiratory infections severely compromise lung function in 
patients and are a major contributor to morbidity and mortality in CF [5, 19, 377]. CF is the 
result of mutations to the CF transmembrane conductance regulator (CFTR) gene. These 
mutations facilitate the establishment of chronic infections in young people with CF by 
pathogens thought to be acquired from the environment. A number of theories attempt to 
explain why CF patients have a high incidence of chronic lung infections and these include 
impaired mucociliary clearance [43, 378, 379] and compromised immune function[380]. 
Once P. aeruginosa is in the airway, bacterial cellular components such as 
lipopolysaccharides (LPS), flagella and pili facilitate attachment to host cells. This then 
stimulates the pathogen to produce virulence factors such as toxins and proteases and to 
trigger a host immune response. Healthy hosts clear the infection through a combination of 
an effective immune response and mechanical forms of protection such as mucociliary 
clearance, preventing the pathogen from establishing an infection. The impaired 
mucociliary clearance and compromised immune function in people with CF allows the 
pathogen to persist in the airway. Over time, P. aeruginosa begins to produce more 
virulence factors and uses quorum sensing to establish biofilms. The increased bacterial 
virulence has a detrimental effect on the airways while the biofilms aid the pathogen to 
shield itself from the host immune response. The immune response of the host, and 
conventional antibiotics, find it almost impossible to penetrate these biofilms, facilitating 
the establishment of a persistent bacterial infection [170, 171]. 
While the holy grail of CF research is ultimately correction of the defective CFTR channel, 
research has traditionally been focused on improving the quality of life of patients by 
countering the pulmonary, pancreatic and gastrointestinal manifestations of the disease. 
Developing drugs and novel therapies relies on the use of cell- and animal-based models of 
CF to test efficacy and provide a more comprehensive understanding of the mechanisms 
involved in the disease. These models provide us with an insight into how pathogens such 
as P. aeruginosa colonize and persist in the CF lung. There exist a number of in vitro CF 
models including primary, wild-type and CFTR-deficient cell lines. However, the 
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invasiveness of obtaining tissues from CF patients limits the use of primary cell lines [381] 
and cultured cell  
 
lines rarely maintain epithelial cell properties and cellular differentiation for prolonged 
periods. Cell lines are also hardly representative of the complex relationships seen in intact 
organs or whole animals, a feature that is important when studying a multi-organ disease 
like CF. Thus animal models remain a valuable tool in understanding the pathophysiology of 
the CF phenotype. No natural animal models that mimic human CF have yet been described 
[388] and instead a number of models have been developed to represent different aspects of 
the disease, particularly respiratory complications associated with infections by P. 
aeruginosa, and are summarized in Table 6.1.  With recent advances in techniques, more 
appropriate transgenic animals have also been developed, including CFTR-deficient ferrets 
[385] and the promising CFTR-deficient pigs [386]. However, murine models have featured 
prominently due to their ease of use, availability and the increasing number of available 
transgenic variants. 
With the mapping of the human CFTR gene as the defect present in CF [27] and subsequent 
identification of its murine equivalent [389], Snouwaert and colleagues were able to 
develop the first transgenic mouse by incorporating a null mutation of Cftr. This resulted in 
Cftr-/- mice with numerous pathological changes similar to those in humans with CF [390]. 
However, gastrointestinal complications shortened the lifespan of these mice and this was 
consistent across all the early null mutation based Cftr-deficient mice [391-393]. When mice 
were created with the clinically relevant mutations F508 [394], G551D [395] and G480C 
Table 6.1 Non-murine animal models of CF and chronic P. aeruginosa infection 
Animal  Type of Infection 
Rhesus Monkey Chronic endobronchitis by intrabronchial instillation of P. 
aeruginosa agar beads [382] 
Cat Pneumonia by repeated intrapulmonary inoculation of viable P. 
aeruginosa [383] 
Guinea pig Pneumonia by tracheobronchial instillation of P. aeruginosa agar 
beads [384] 
Ferrets CFTR-deficient with multiple characteristics of human CF including 
gastrointestinal abnormalities and predisposition to lung infection 
(but not chronic infections and not P. aeruginosa) [385] 
Pigs CFTR -deficient [386]that develop CF like lung disease with 
spontaneous lung infection (but not with P. aeruginosa) and exhibit 
difficulty in clearing bacterial infection from birth [387] 
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[396] the mortality rate due to the gastrointestinal complications decreased but was still a 
major hindrance towards using these models. In order to overcome this complication, a Cftr-
deficient mouse with the transgenic expression of human CFTR in the gut epithelium was 
created, Cftrtm1Unc-Tg(FABPCFTR)1Jaw/J, which displayed a significantly improved survival 
rate [397]. Another promising transgenic mouse strain for studying CF is the Scnn1 mutant 
in which specific airway epithelial Na+ channels are over expressed. This increases Na+ 
absorption and produces a CF like lung disease in the mice [42]. While a number of authors 
have claimed that under challenge with bacterial pathogens, CF mice find it more difficult to 
clear infection [377, 398, 399], the establishment of the most challenging phenotype of CF, 
chronic P. aeruginosa infection, has been difficult under standard laboratory conditions and 
even when infections do develop, they do not completely resemble those of human CF [400]. 
A number of reasons for this have been put forward, all suggesting that the physiology of 
mice allows them to be intrinsically more capable of clearing bacterial infections by 
mechanisms including compensation for the CFTR defect by other ion channels. A further 
factor limiting the experimental use of transgenic mice is the expense associated with 
maintaining the animals. Breeding pairs are normally heterozygous and thus offspring have 
to be typed and only a limited number of animals per litter can be used in the experiments. 
While transgenic Cftr-deficient mice are the best available analogues of CF lung disease 
amongst murine models, the strains currently available need to be better characterized and 
adjusted to give us models more typical of human CF. 
P. aeruginosa infections were first successfully established in inbred mice in 1968 to 
facilitate the study of lung infection [401], with the establishment of acute infections 
achieved by aerosolization of bacteria into the lung. While aerosolized challenges remain 
popular, acute infections can now also be established intranasally, [402] and intratracheally 
[403]. P. aeruginosa, upon establishing infection in a human CF host, initiate biofilm 
formation. Biofilm growth affords P. aeruginosa significant protection against host defence 
mechanisms and conventional antibiotics, facilitating the establishment of chronic 
infections. Chronic infections are difficult to establish in mice as the mice mechanically clear 
the infection[404] and aerosol challenges have had limited success in aiding their 
establishment, even under controlled conditions and using immunocompromised mice 
[405, 406]. Instead investigators generally embed P. aeruginosa into a bead-shaped artificial 
matrix such as agar or alginate and then infuse it intratracheally into mice [407-409]. Two 
studies using intratracheal challenges [410, 411] have largely succeeded in mimicking the 
persistent P. aeruginosa infections seen in the CF lung. Both studies demonstrate the 
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persistence and proliferation of P. aeruginosa in the lungs with a bacterial load of 1  105 
CFU/lung 7–21 days post infection. Hoffman and colleagues demonstrated foci of P. 
aeruginosa biofilms in the alveoli of CF mice infected intratracheally with P. aeruginosa 
[410] and histological analysis of the samples from the lungs showed damage to the airway 
similar to that seen in CF patients. However, both authors conceded that the use of 
intratracheal challenges does not reflect the natural history of Pseudomonas infection in CF 
and the use of beads may cause blockages and mechanical damage to the airway of the mice 
resulting in added inflammation. 
Intranasal infection strategies represent an easy and more natural way of establishing 
infections. Tang and colleagues adapted a neonatal model of acute pulmonary infection by 
Bordetella pertussis [412] to establish acute P. aeruginosa pneumonia in neonatal BALB/c 
mice [402]. They placed bacterial suspensions onto the nares of seven-day-old mice and 
allowed the pups to inhale the bacteria. They demonstrated evidence of pulmonary infection 
within 4 h post inoculation. All mortalities occurred in the first 24 hours and, of the animals 
that survived, most had cleared the infection by 48 hours and by 96 hours, P. aeruginosa 
was undetectable. The authors also showed that adult mice tolerated several orders of 
magnitude of bacterial load higher than infant mice without obvious signs of pneumonia or 
bacteraemia. This increased susceptibility to bacterial infection in infant mice was 
attributed to the naive immune system in the neonates. Further research on the 
susceptibility of neonatal mice to infection by Diavatopoulos and colleagues enabled the 
establishment of a chronic bacterial infection in a neonatal murine model by intranasal 
application by initially priming the mice with influenza A virus [413]. The authors infected 5 
day old C57BL/6 mice with 2  103 colony forming units (CFU) of Streptococcus pneumoniae 
and the infants retained the bacteria with the nasopharangeal carriage at 9 days post 
infection increasing to 1  105 CFU in the nasopharynx. An intranasal neonatal model of 
chronic P. aeruginosa would have a number of advantages. Firstly, it would not necessitate 
the sedation of the animal as required for intratracheal inoculation. Secondly, it can be done 
quite quickly. Tang and colleagues were able to inoculate each pup in less than 1 minute 
[402]. More importantly though, CF patients acquire pathogens from the environment by 
inhaling them and then develop chronic infections, partially due to the limitations placed on 
them by their immune deficiencies. The under-developed immune systems of the neonates 
offer a similar setting to establish and study chronic bacterial infections. Finally, there are 
significant cost savings in using more conventional non-transgenic models, and using well-
characterized strains of mice allows us to better understand the implications of any 
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infection. In this study, we attempt to establish intranasal chronic P. aeruginosa infection in 
inbred BALB/c neonates. Establishment of such a model will enable the investigation the 
potential of rhPON2 as an anti-Pseudomonal in an in vivo infection model. 
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6.2 MATERIALS AND METHODS 
 
Most of the materials and methods for this chapter are described in Chapter 2. Any 
additional materials and methods specific for this chapter are described below. 
 
6.2.1 Ethics statement 
 
Animal experiments were approved by the University of Tasmania (A0012571) and 
complied with the Prevention of Cruelty to Animals Act (1986) and the National Health and 
Medical Research Council (NHMRC) Australian Code of Practice for the Care and Use of 
Animals for Scientific Purposes 2004. 
 
6.2.2 Bacterial strain and culture conditions 
 
PAO1 (ATCC 15692) was grown in LB media, shaking at 37 C overnight until stationary 
phase as measured by optical density at 600 nm (OD600 = 1–2). They were diluted in LB 
media to OD600 of 0.05 and grown at 37 C for eight hours with shaking at 200 RPM. Aliquots 
were taken at regular intervals to determine CFU/mL at particular OD600 levels and 
standard curve generated. A mid-log phase aliquot (OD600 = 0.2–0.4) was then serially 
diluted and aliquots of each dilution were frozen in LB supplemented with 8% glycerol at –
20 C for infecting mice. Additional aliquots of each dilution were either stored in RNAlater 
(Life Technologies, Carlsbad CA) for quantitative PCR, or plated for CFU determination. 
Bacterial suspensions for mouse infection were prepared by thawing glycerol stocks and 
diluting in PBS to the desired CFU/mL with reference to a standard curve. Bacteria were 
then washed once with PBS and diluted 2:1 in 6 mg/mL Evans Blue dye (Life Technologies, 
Carlsbad CA) in PBS. In addition, the bacterial load was determined as described in chapter 
two (Section 2.5.3).  
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6.2.3 Neonatal mouse model of infection 
 
Visibly pregnant BALB/c mice (UTAS breeding colony) were housed in individual cages 
containing Pure-o’Cel bedding (Able Scientific, Canning Vale WA, Australia). Following birth, 
the cages were issued to the experimental room where they were housed in an Optimice 
microisolated ventilated rack system. Five-day-old mice (5–9 mice per group depending on 
litter size) were inoculated with 3 L of PAO1 suspensions at different bacterial 
concentrations (103 to 108 CFU), one treatment concentration per litter. The pups were 
inoculated by applying the 3 L of suspension directly to the nares of pups while they were 
being restrained gently in the hand. The pups reflexively inhaled the bacteria and care was 
taken to ensure that pups completely inhaled the suspensions. Pups were then returned to 
the mother and monitored for signs of infection and/or distress.  At 12 hours, two days, five 
days and 12 days post-inoculation; mice were euthanized by CO2 asphyxiation. In a sterile 
environment, the chest was opened and the lungs carefully harvested and transferred to 1 
mL of RNAlater (Life Technologies, Carlsbad CA). The lungs were cut into smaller pieces to 
ensure complete permeation of RNAlater, then weighed and stored at –20 C for subsequent 
RNA extraction. 
 
6.2.4 Tissue homogenization, RNA extraction and quantitative PCR 
 
RNAlater was drained from lung tissue and the lung tissue transferred to 750 mL Trizol 
(Life Technologies, Carlsbad CA) in a 2 mL tube containing 1 mL of 0.1 mm zirconia/silica 
beads (Daintree Scientific, St Helens, TAS, Australia). Another 650 mL of Trizol was then 
added to fill the tube and the tissue homogenized by bead-beating for 1 minute using a bead 
beater (Daintree Scientific). Bead-beating was repeated until the lung tissue was completely 
homogenised. Beads and cellular debris were pelleted by centrifugation at 10,000  g for 10 
min at 4 C and the clarified supernatant transferred to a fresh tube for RNA extraction 
using Trizol and for subsequent cDNA synthesis as described in chapter 2 (Section 2.2). 
PCR was carried out on the LightCycler480 instrument using LightCYcler480TM SYBR Green 
I Mastermix (Roche) as described in Chapter 2 (Section 2.2.6), with one exception. PCR 
conditions were as follows, 95 C (5 minutes) then 55 cycles instead of 45 cycles (as 
described in chapter two) of 95 C (10 seconds), 60 C (10 seconds) and 72 C (30 seconds) 
followed by melt curve analysis. Bacterial concentration was determined using primers 
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specific for P. aeruginosa 16s rRNA [276]. Expression of bacterial genes was determined 
using primers described in chapter 2 (Table 2.4).  





6.3.1 Observational assessment of animal behaviour in response to intranasal 
infection with bacteria. 
 
Observations made of the behaviour animals in response to the intranasal applications are 
summarized in Table 6.2. Briefly, it was difficult to apply a consistent dose to each animal as 
not all pups reflexively inhaled the inoculum. Some pups initially exhaled the inoculum 
before re-inhaling, presumably resulting in them receiving a lower dose than the pups that 
completely inhaled the inoculum without exhaling. No other signs of distress from the 
experimental procedure were observed. No mortality associated with infection was 
observed. 
 
6.3.2 Neonatal mice developed low-level chronic infections via intranasal 
inoculation 
 
When infecting mice with bacteria, the dosage needs to carefully considered, especially if 
attempting to establish a chronic infection. Too few bacteria, and a sufficiently robust 
infection will not develop. Too many bacteria, and the mice may succumb to bacterial 
pneumonia. We first attempted to establish an optimum dose of infection by infecting five 
day old BALB/c mice with doses of PAO1 ranging from 1  103 to 1  107 CFU. The mice 
were euthanized two days post inoculation, the lungs harvested and the CFU remaining in  
Table 6.2 Observational assessment of animal behaviour in response to intranasal 
application of bacteria 
Assessment Criteria Observations 
Viscosity of inoculum Inoculum containing higher doses of bacteria were more 
viscous 
Efficacy of intranasal 
application of bacteria 
Some pups reflexively inhale the complete inoculum 
while others initially exhaled before re-inhaling.  
Signs of distress No major indicators of distress upon application of 
inoculum. Some pups rested for a few minutes before 
freely moving around 
Mortality None associated with infection 
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 the lungs was enumerated by qPCR of the bacterial 16srRNA gene (psd7). The CFU was 
calculated by comparing the cycle threshold (CT) of psd7 expression in lung tissue with a 
standard curve relating CT to PAO1 CFU (Figure 6.1). A linear relationship was observed (R2 
= 0.9693) allowing us to relate CT of psd7 expression to number of CFU. The CFU 
enumerated in each mouse are displayed in Figure 6.2, along with the mean CFU (n = 5–8) of 
each treatment dose. 
No dose dependent effects were observed relating to bacterial load of infected mice. In 
addition, none of the mice had enough CFU in the lungs to be considered to have an infection 
as decided by our arbitrary cut-off of >103 CFU/ml. In fact, for between 2-4 mice in each 
group of 5-8 mice we found no detectible P. aeruginosa in their lungs. The mice that 
received the highest dose of P. aeruginosa, 1  107 CFU, were the most capable of clearing 
the infection with 4/5 mice having no detectible P. aeruginosa in their lungs two days post 
infection. 
In order to determine if establishment of chronic infection is possible using this model, five 
day old mice were infected with 1  108 CFU of PAO1. This dose was used because the lower 
doses were unable to cause infection with >105 CFU/mL that persisted two days post 
infection, and did not have any obvious detrimental effects on the animals. PAO1 CFU in the 
lungs was enumerated by qPCR from lungs harvested from the mice 12 hours, five days and 
12 days post infection. The number of CFU in the lungs of each mouse and the mean CFU (n 
= 6–9) in the lungs of mice for each time point are displayed in Figure 6.3. At the earliest  
 
Figure 6.1 Relationship between qPCR cycle threshold (CT) of psd7 expression and log10 PAO1 
CFU. Cycle threshold of psd7 expression of RNA extracted from PAO1 cultures compared to the 
number of CFU in those cultures. n = 2 
 




Figure 6.2 Bacterial load of P. aeruginosa infected mice lungs two days post infection. Five day old 
neonatal mice infected with a range of CFU’s of PAO1 and bacterial load two days post infection of 
individual calculated by qPCR. Results expressed as log10 CFU recovered from whole lung. Mean CFU 
recovered indicated by horizontal line, while error bars represent S.E.M. Significant differences 
assessed using Kruskal–Wallis non-parametric test with Dunn’s post-test. n = 5–8. Mice with no 
detectible P. aeruginosa shown on logarithmic scale as 1.  
 
Figure 6.3 Bacterial load of P. aeruginosa infected mice lungs over 12 days. Five day old neonatal mice 
infected with 1 108 CFU of PAO1 and bacterial load 12 hours, five days and 12 days post infection 
determined by qPCR. Results expressed as log10 CFU recovered from whole lung. Mean CFU recovered 
indicated by horizontal line, while error bars represent S.E.M. Significant differences assessed using 
Kruskal–Wallis non-parametric test with Dunn’s post-test.* p < 0.05. n = 6–9. Mice with no detectible P. 
aeruginosa shown on logarithmic scale as 1. 
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time point, 12 hours post infection, the P. aeruginosa load was highest, with 1/6 mice having 
>103 CFU in the lung. However, the mice cleared most of the bacteria within this short time 
period suggesting that an immediate acute infection was not established. The numbers of 
CFU detected in the lungs decreased significantly (p < 0.05) by day five to less than <102 
CFU. The number of CFU detected in the lungs by day 12 post infection remained similar, 
demonstrating that small numbers of bacteria were persisting in the lungs.  
However, 3/ 9 mice had completely cleared the infection. Though the number of P. 
aeruginosa detected at the later time points were inconsistent, and orders of magnitude 
lower than the infection dose, the persistence of low levels of bacteria is consistent with 
establishment of a low-level chronic infection in 30% of the mice. 
To investigate whether a virulent infection had been established, we measured the 
expression of a number of bacterial QS and virulence genes summarized in Table 6.3. We 
used qPCR to quantify gene expression in the mouse lung tissue from two mice from each 
group with the highest reported bacteria loads. However, there was no detectable 





Table 6.3 Expression of bacterial virulence and QS genes in two mice from each 
group with highest bacterial carriage by qPCR 
Genes Role Expression 




lasB Elastase B synthesis No detectable 
expression 
rhlI QS signal (C4-HSL inducer) synthesis  No detectable 
expression 
algD Alginate biosynthesis  No detectable 
expression 
pqsA Pseudomonas quinolone signal synthesis No detectable 
expression 





Establishment of an intranasal chronic P. aeruginosa infection model will enable the in vivo 
investigation of rhPON2 as a novel anti-Pseudomonal therapy. The intranasal method of P. 
aeruginosa bacterial delivery to the neonatal mouse lung investigated in this chapter 
enabled the development of a low-level chronic infection. Chronic infections are 
characterized by surviving animals having a stable bacterial load, often with 
intrapulmonary replication, in the airway, typically for at least two weeks. In our study we 
saw persistence of a relatively small numbers of bacteria (102–103 CFU) 12 days post 
infection. This rate of PAO1 carriage in the mouse lungs is on the lower end of the scale of 
carriage rates reported by other authors who have established chronic P. aeruginosa 
infections in BALB/c mice. Hoffmann and colleagues intratracheally challenged 12–14 week 
old BALB/c with 5  107 CFU of a mucoid P. aeruginosa strain and recovered between 103 
and 109 CFU/mouse seven days post infection and between 105 and 107 CFU/mouse 13 days 
post infection [410]. Lazenby and colleagues intratracheally challenged 8–12 week old 
BALB/c with 1  106 CFU PAO1 and the investigators recovered between 103–104 CFU/g 
lung tissue 24 hours post challenge and ~ 104 CFU/g lung tissue 10 days post challenge 
(average weight of 8–12 week mouse lung 200 mg–400 mg) in their study. [362]. We were 
however unable to establish whether this level of infection is physiologically relevant, as 
there was no detectable expression of Pseudomonas virulence and QS genes. This inability to 
detect expression of Pseudomonas virulence and QS genes may be a result of the low 
bacterial numbers. Without histopathological analysis of the lungs, it is difficult to 
determine whether this level of bacteria can be considered to be pathological.  
It must also be noted that the mice were monitored for signs of distress and none was 
evident. In comparable studies, intratracheal challenges with the higher doses of PAO1, such 
as those used in our study (108), have normally resulted in neutrophilic pneumonia, 
bacteraemia and death within the first 24–48 hours in neonates [402, 404, 410]. The fact 
that all the mice survived suggests the bacteria were unable to produce sufficient virulence 
to harm the mice. Our mice were challenged with 108 CFU of PAO1 but 12 hours post 
infection only ~103 CFU were detected. It is plausible that the majority of the bacteria were 
cleared mechanically by the mice before any infection was initiated. Intranasal infections 
have generally displayed a lower effectiveness at delivering bacteria to the lungs than more 
invasive methods such intratracheal infection or a tracheotomy [414]. This raises the 
prospect that our delivery method for bacteria may need to be further developed to reduce 
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the mechanical clearance of the bacteria perhaps through application of smaller volume of, 
but multiple doses of bacterial suspensions. 
The low bacterial loads in the mice poses some intriguing questions. Tang and colleagues 
were successfully able to establish an acute Pseudomonas infection in BALB/c neonates. 
Upon application of 1  105 CFU, 12/15 mice had increased CFU 24 hours post infection. By 
96 hours, no bacteria remained in the lungs [402]. Morissette and colleagues infected a 
number of inbred mouse strains with low doses (104 CFU) of P. aeruginosa and found 
BALB/c to be resistant to infection based on both their mortality and bacterial load post 
infection [409]. This suggests that the BALB/c strain has high resistance to P. aeruginosa 
infection. The authors considered the C57BL/6 mouse strain to be of an intermediate 
phenotype while the DBA/2 strain was the most susceptible to infection. Tam and 
colleagues investigated the susceptibility of BALB/c and C57BL/6 mice to chronic P. 
aeruginosa and observed two thirds of their BALB/c mice cleared the infection by 28 days 
post inoculation [415]. However, almost 80% of the C57BL/6 mice had persistent infections. 
These differences have been attributed to the differing intrinsic inflammatory and immune 
response in the two strains, particularly the lower tumour necrosis factor- gene 
expression and protein secretion [416, 417], increased nitric oxide production [417], and 
reduced proliferative responses from lung T cells [408]. Sapru and colleagues reported a 
considerably stronger immune response in C57BL/6 mice when compared to the BALB/c 
mice, with a higher count of polymorphonuclear cells in the bronchoalveolar lavage fluid 
and this correlated with increased susceptibility to infection [417]. An exaggerated 
inflammatory response may thus predispose the C57BL/6 mouse to infection and also more 
accurately mimic the CF disease pathophysiology. It is therefore possible that the strain of 
mouse selected for this study may have contributed to the inability to establish chronic 
high-level colonization of the lungs by P. aeruginosa and that this could be overcome by 
using an alternate mouse strain. It may also be still possible to use the current mouse strain 
but prime the immune system using microbial ligands such as LPS, flagellin [418, 419] or 
protein from pili [402] to stimulate the immune response. We could also adopt a strategy 
whereby we initially challenge the mice with an intermediate dose (106 CFU/mL) before re-
challenging the mice with a higher dose (108) 24 hours later. 
Given the low levels of bacteria persisting in the lungs in this study, the use of a PCR based 
method to quantify bacteria is validated. Numerous studies have investigated the suitability 
of real-time quantitative PCR to quantify bacterial load. Provided sensitive methods are 
used to detect the bacteria, such as quantifying high expression genes like 16S ribosomal 
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RNA, as in this study, bacteria can be reliably enumerated down to a single colony forming 
unit [276]. While there are studies that indicate that PCR may be less sensitive than 
conventional culture methods [420], most studies generally agree that PCR is as good as if 
not more sensitive than culture based methods for enumerating bacteria [276, 421-423]. 
The inability to detect the expression of QS and virulence genes explored in this study can 
most likely be attributed to the low levels of bacteria present in the mouse lungs. 
A promising development in imaging technology has been the advent of in vivo imaging of 
mice infected with a GFP- or luciferase-tagged P. aeruginosa. This enables the real-time, 
sensitive monitoring of infection in mice without the need to use multiple groups to study 
multiple treatment conditions, thereby reducing inter-animal variations [424, 425]. There is 
the added advantage of the ability to monitor the progression of bacteria from the nares 
into the lower lung, and give a good indication of where the mice establish the infection. 
Further studies will be required to develop a suitable intranasal murine model of P. 
aeruginosa infection. This study has provided some important insight into how this could be 
achievable. Such a model would have numerous advantages, particularly the ability to 
rapidly check the effectiveness of novel therapies such as rhPON2 and better understand 
































This thesis investigates human PON2 as a quorum sensing inhibitor of P. aeruginosa. The 
inhibition of QS is of particular interest because conventional antibiotic therapy is 
ineffective against chronic P. aeruginosa infections. The efficacy of these antibiotics might be 
rescued using a therapeutic approach that combines conventional antibiotic therapy with 
anti-virulence therapy. Anti-virulence therapies have the advantage of targeting the 
pathogenicity of bacteria in an infection setting without necessarily affecting viability. With 
attenuated virulence, the bacteria are unable to cause pathological infections, allowing the 
host immune response to respond effectively. In addition, because anti-virulence therapies 
do not affect microbial growth, the general consensus amongst researchers is that such 
therapies are less likely to exert selective pressures towards resistance development [426]. 
The C12HSL QS molecule is a potent signalling molecule produced by P. aeruginosa during 
infection. C12HSL induces the production of many bacterial host-damaging virulence factors 
and is involved in biofilm formation by this organism. C12HSL also has important roles in 
conditioning host cells for infection and even at low concentrations induces host-cell 
immune pathways, the unfolded-protein stress-responses, as well as intra-cellular calcium 
signalling. Consequently, C12HSL represents a potential target for novel anti-virulence 
therapies. The results described in thesis demonstrate the potential usefulness of human 
PON2 as an anti-Pseudomonal therapy, with the added advantage of abrogating the negative 
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7.2 THE IMPORTANCE OF C12HSL-BASED QUORUM SENSING IN P. 
AERUGINOSA INFECTION IS NOT YET FULLY UNDERSTOOD  
 
The combination of the high prevalence of P. aeruginosa lung infections in individuals with 
CF, together with the extensive associated lung damage have made P. aeruginosa the most 
widely studied CF-related pathogen. Yet, once P. aeruginosa infections become established 
in the CF lung it is virtually impossible to clear, and currently available eradication therapies 
have thus far proven to be ultimately unsuccessful [5, 140, 348]. These sustained P. 
aeruginosa infections are widely thought to stem from the ability of this pathogen to form 
biofilms. Cell-to-cell communication by QS is considered to be important in the formation of 
biofilms in addition to its role in the regulation of virulence factor production.  
The most important QS molecule of P. aeruginosa is C12HSL whose synthesis is catalysed by 
the LasI protein, and whose signalling-effects are relayed through its cognate receptor LasR. 
There is however some debate about the importance of the role of the Las system in P. 
aeruginosa infections. Involvement of the QS circuitry in the regulation of biofilm formation, 
important for P. aeruginosa persistence, was originally reported by Davies and colleagues 
[152]. Mutations to lasI result in flat, undifferentiated biofilms compared to the complex 
structures formed by the wild-type. Importantly, the lasI mutant biofilms were more 
susceptible to a biocide than those of the wild type [152]. Subsequently, the Las system was 
implicated in an important role in the later stages of biofilm development and lasI mutants 
showed reduced in vivo virulence in mouse burn wound models of P. aeruginosa infection 
[427, 428]. In contrast, other studies observed no difference in biofilm formation and 
structure in lasI mutants [135, 429, 430]. These differences were attributed by some 
authors to  variations in experimental conditions [431] but more detailed consideration is 
required. Despite using a strain in which both the inducer and receptors of both the top P. 
aeruginosa QS systems (i.e. lasIRrhlIR quadruple mutant) were knocked out, Lazenby and 
colleagues observed no difference between the mutant and wild type P. aeruginosa in 
immunogenicity, infectiveness or persistence of infection, in an acute mouse model of P. 
aeruginosa infection [362]. This, however, does not suggest that QS has no role in chronic 
infection, where a loss of QS can only confer an advantage to a minority sub-population of 
bacteria. In lung cell assays, O’Loughlin and colleagues observed that the lasR, rhlR double 
mutant was more virulent than wild type, possibly because of misregulation of virulence 
factors [237]. It is possible that QS alone is not a definitive determinant of P. aeruginosa 
pathogenesis and biofilm formation. Further investigation is required to define the role of 
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QS in both in vitro and in vivo biofilm development. However, it is unquestionable that QS is 
essential to the regulation of many virulence determinants of P. aeruginosa [136, 137]. 
Studies involving the inhibition rather than the knockout of the Las system have proved 
quite successful in attenuating P. aeruginosa virulence, pathogenicity and biofilm formation 
(Table 7.1).  
 
Table 7.1 Table of evidence that QSI attenuates P. aeruginosa virulence, 
pathogenicity and biofilm formation 
QS inhibitor Description of QSI Effect on P. aeruginosa Reference 
mBTL LasR, RhlR inhibitor Inhibits production of 
pyocyanin virulence factor in 
in vitro biofilm formation 
Protects human epithelial 
cells lines and nematodes 




LasR inhibitor Inhibit biofilm formation,  








LasR inhibitor Inhibits QS gene expression  
Inhibits biofilm formation by 
reducing extracellular DNA 
release (controlled by PQS 
system) 




Hydrolyse QS signal Reduced virulence factor 
production, 
Reduced severity of infection 





Bacterial lactonases Hydrolyse QS signal Reduced virulence factor 
production and biofilm 
production of UTI P. 







reaction to QS 
signal 
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Importantly, QS AHL signals have been detected in CF sputum (in the pico- to nano-molar 
range)
 
[157, 436] and lung tissue [437]. Thus, QS is relevant in clinical P. aeruginosa 
infections. However, the level of dependence on QS that P. aeruginosa has during chronic 
human lung infections, is still unclear. It is understood that QS plays an important role in the 
early stages of development of chronic infection [438]. However, QS mutants accumulate 
during chronic infection. In particular lasR mutations (able to produce C12HSL but unable to 
respond to it), accumulate in the colonizing bacteria, most likely as an adaptation to the 
specific nutrient conditions of the lung [439-441]. The occurrence of QS mutants can be 
explained by the concept of ‘QS cheaters’, the idea that some individuals in a bacterial 
population derive an advantage from bacterial cooperation in cell-to-cell communication 
without themselves participating in the metabolically expensive production of public goods 
[442]. The implication is that QS-inactive members of the biofilm communities avoid the 
cost of participating in cooperative behaviour and can therefore spread [443]. Over time, as 
chronic infections develop, the requirement for virulence production is reduced, allowing 
cheaters to become more prominent. The accumulation of QS mutants means that 
therapeutic QS inhibition (QSI) is likely to be more effective when administered prior to, or 
in the early stages of, establishment of chronic infections. More research into bacterial 
interactions during infection and the role of QS would be beneficial when developing clinical 
therapies that target QS. 
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7.3 BACTERIALLY PRODUCED C12HSL MODULATES GENE EXPRESSION 
IN HOST RESPIRATORY EPITHELIAL CELLS IN A CONCENTRATION-
DEPENDENT MANNER  
 
The effects of QS are not restricted to the bacteria alone. The primary P. aeruginosa QS 
signal molecule, C12HSL, is able to enter mammalian host cells during infection and 
modulate the host immune system and induce host cytotoxicity (covered in detail in Chapter 
1, Section 1.2.6). As it is difficult to determine the precise concentrations of C12HSL that are 
present in situ during P. aeruginosa infection, studies into the effects of C12HSL have used a 
range of concentrations. Typically, the effects of C12HSL in vitro on host cells appear to be 
concentration-dependent. Concentrations of C12HSL above 20 µM are generally 
proinflammatory, while concentrations below 10 µM are considered to be anti-
inflammatory. It has been suggested that AHL concentrations localized around biofilm cells 
are higher than those detected in clinical samples. On the other hand, away from the P. 
aeruginosa cells, the C12HSL concentration would be expected to be lower. The existence of 
an AHL concentration gradient is an important consideration when the effects of C12HSL on 
host cells are examined. Immediately adjacent to P. aeruginosa cell clusters, C12HSL could 
be proinflammatory and cause damage or death of the closely associated epithelia and 
immune cells. Away from the pockets of infection, the anti-inflammatory effect may hamper 
the recruitment of immune cells to the site of infection. Therefore, it is important to further 
develop our understanding of C12HSL-mediated effects on host cells. 
The results described in this thesis support and augment the previous reports of 
concentration-dependent effects of C12HSL on host cells by demonstrating that low-
concentration (10 µM) C12HSL affects airway epithelial cell gene expression differently to 
the gene modulation at higher concentrations (50 µM) of C12HSL. In particular, the effects 
on expression of genes involved in immune signalling, the unfolded protein response (UPR) 
and intra-cellular calcium signalling was significantly altered.  
The results described in this thesis confirmed the ability of C12HSL to competitively 
interfere with the binding of ligands to PPARγ, a major regulator of inflammation. 
Therefore, the decreased immune signalling seen in response to 10 µM C12HSL is most 
likely to be PPARγ-dependent. PPARγ agonism/antagonism is known to modulate the 
expression of numerous genes in mammalian cells [444].  
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Gene expression analysis of two key UPR genes, XBP1 and ATF3, indicated that endoplasmic 
reticulum stress was induced by the deregulation of the UPR with 10 μM C12HSL. This 
would cause accumulation of misfolded proteins in the host cell and subsequently result in 
cytotoxicity. However, when the apoptosis and the cytotoxic effects of C12HSL were 
investigated, the results indicated a concentration-dependent effect, with high 
concentrations (50 µM) but not low (10 µM) concentrations inducing apoptosis. On the 
basis of these results, and in the context of local C12HSL concentrations in the airway, cells 
close to the site of infection would undergo apoptosis whereas, cells more distal to the site 
of infection and therefore exposed to lower C12HSL concentrations, would show induction 
of the UPR but not undergo apoptosis. As a result there would be an accumulation of cells 
(including immune cells) distal from the infection site, whose function is compromised 
because of the build-up of misfolded proteins, thereby further compromising the 
recruitment of immune cells to the site of infection.  
Finally the CFTR-dependent effects of C12HSL were investigated by comparing the cytotoxic 
and metabolic effects of C12HSL in a wild-type and CFTR-negative cell line, the later of 
which is thought to be defective in calcium signalling [351] but also to have impaired PPARγ 
function [224]. In addition, the effects of C12HSL on expression of immune, apoptosis and 
UPR genes in CFTR-negative cells was also investigated. Surprisingly, we found that CFTR-
negative cell lines were more resistant to the harmful effects of C12HSL than wild-type cells. 
In the CF lung, it is thought that the UPR may be triggered by the ΔF508 mutation [445]. 
C12HSL produced by P. aeruginosa during infection can also trigger the UPR. The combined 
result of these factors in cells in the airway should be an exaggerated induction of the UPR 
and subsequent cytotoxicity. However, the results described in this thesis indicate that 
CFTR-negative cells appear to be protected from the cytotoxic effects of C12HSL. This can be 
explained by an observation of Bartoszewski and colleagues, who showed that UPR 
activation in airway epithelial cells overexpressing ΔF508 CFTR preceded reduced 
expression of endogenous wild-type CFTR [445]. This finding would suggest that the 
triggering of UPR by C12HSL in CFTR-negative cells reduces subsequent CFTR expression 
and thereby dampens any further CFTR-dependent C12HSL-mediated effects on the cell. 
The ΔF508 mutation is also thought to contribute to impaired function of PPARγ [224], 
which is also a mammalian receptor for C12HSL. Impaired PPARγ function in the CFTR-
negative cells would also explain why the CFTR-negative cells are generally protected from 
C12HSL-mediated effects. 
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Intriguingly, changes in gene expression revealed that C12HSL influenced the wild-type and 
CFTR-negative cell line differently in regards to UPR and apoptosis genes but less so with 
the immune genes. We postulated that modulation of immune signalling and apoptosis may 
be distinct consequences of C12HSL, possibly through the C12HSL interacting with different 
cellular receptors. There are two identified mammalian C12HSL receptors, PPARγ (immune 
signalling) [214] and IQGAP (may influence calcium signalling) [354], However, more 
detailed understanding of the effects of C12HSL on mammalian cells is required before we 
can fully appreciate how C12HSL causes the reported and observed detrimental effects on 
mammalian cells.   
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7.4 THERAPUETIC USE OF PARAOXONASE 2 (PON2) 
 
PON2 demonstrates lactonase activity towards multiple lactones, but it displays the highest 
activity towards AHL’s, the family of lactones that includes the two most important P. 
aeruginosa QS signalling molecules C12HSL and C4HSL [248]. This specific ability of PON2 
to hydrolyse AHL’s in vitro, along with the fact that its expression is widely conserved 
amongst mammals [352], have lead many researchers to speculate that PON2 may be a 
component of the mammalian innate immune response towards P. aeruginosa and other 
Gram-negative AHL-producing pathogens. A recent study shows that PON2, an intracellular, 
membrane-bound protein, rapidly causes C12HSL hydrolysis in airway epithelial cells and 
the researchers proposed a central regulatory role for PON2 against host cell C12HSL-
mediated effects [267]. Previous studies have shown that PON2 plays a role in protecting 
against P. aeruginosa infections. Horke and colleagues observed that PON2 attenuates ROS 
production induced by the P. aeruginosa virulence factor pyocyanin [265], while 
importantly, Devarajan and colleagues observed significantly impaired clearance of P. 
aeruginosa from the lungs of PON2-deficient mice [249]. These findings are suggestive that 
PON2 has potential as anti-Pseudomonal therapy. 
 
7.4.1 Up-regulation of endogenous PON2 could protect host cells from C12HSL-
mediated effects 
 
Increasing endogenous PON2 expression could protect host cells from C12HSL-mediated 
effects by hydrolysing intracellular (host cell) C12HSL. The work presented in this thesis 
demonstrates, for the first time, that endogenous PON2 expression can be up-regulated in 
respiratory epithelial cells by agonism of PPARγ. Fortunately, the PPARγ agonist used in the 
study is already approved for pharmaceutical use as an anti-inflammatory drug and could 
relatively easily be used in a CF clinical setting. 
Furthermore, preliminary data from our laboratory demonstrates that lactonolysis of 
C12HSL can abolish the C12HSL-dependent cytotoxic and immune modulatory effects in 
human cells (unpublished data). This therapy however, would not protect host cells against 
the accumulation of C12HSL acid in cell organelles which was recently demonstrated to 
exert pH-dependent effects [267]. The authors of the study noted a PON2-dependent 
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hydrolysis of C12HSL in airway epithelial cell organelles. However, the resultant 
accumulation of C12HSL acid in the organelles caused acidification of the cytosol,  an 
associated release of Ca2+ into the cytosol and an increase in a marker of cellular stress. 
Therefore, it remains to be elucidated for host cells how effective the hydrolysis of C12HSL 
will be in reducing C12HSL-mediated cytotoxic and immune modulatory effects.  
Importantly, the protective roles of PON2 are not solely restricted to lactonolysis of C12HSL. 
PON2 has anti-oxidative activity independent of its lactonase activity [273]. Such anti-
oxidant activity is likely to dampen the oxidative stress associated with hyperinflammatory 
environments, providing to the host cells an added layer of protection from P. aeruginosa 
infection. CFTR mutations in CF contributes to increased intracellular oxidative stress [446]. 
The anti-oxidant activity of PON2 could thus also help to reduce the oxidative-stress burden 
in the CF lung. Protection of host cell from the effects of P. aeruginosa infection would mean 
that, the host immune response is better able to respond to the infection.  
Pharmaceutically increasing endogenous PON2 would benefit all host cells exposed to 
C12HSL during P. aeruginosa infection, because of the ubiquitous nature of PON2 expression 
in humans. There have been reports of increased PON2 mRNA and protein in murine 
macrophages in response to agonism of the C12HSL receptor PPARγ [268]. We used a 
potent synthetic PPARγ agonist in an airway epithelial cell line and PPARγ agonism, 
resulted in an almost immediate increased PON2 mRNA and protein. The swiftness of the 
increase in PON2 in response to PPARγ agonism, together with the fact that PPARγ is a well-
described transcription factor regulating the immune system, lead us to hypothesize that 
PPARγ may be transcriptionally regulating PON2 expression. Our hypothesis was further 
strengthened by the identification of putative PPAR response elements in the human PON2 
promoter through in silico analysis. We therefore investigated, using functional promoter 
assays, whether PPARγ transcriptionally regulates PON2 expression. However, the results 
indicate that the region of the human PON2 promoter studied does not appear to be 
involved in PPARγ-dependent PON2 gene expression. Therefore either PPARγ agonist-
mediated up-regulation of PON2 operates via a PPARγ-independent mechanism or our 
reporter construct did not fully encapsulate all the regulatory elements required for PPARγ-
mediated PON2 transcription. It is not uncommon for regulatory elements such as 
enhancers to be widely dispersed and thus making it difficult to capture in a single reporter 
construct [359]. Further study is required into other factors that may be involved in PON2 
regulation including the regulatory elements involved in its PPARγ-dependent expression. 
Most importantly though, we were able to identify a mechanism through which PON2 
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expression could be regulated, i.e. through PPARγ agonism. An added advantage of PPARγ 
agonists may be alleviation of the hyperinflammatory state of the CF lungs because 
decreased PPARγ activity in the CF lung is thought to contribute to the chronic 
hyperinflammatory state.  
 
7.4.2 Treatment with extracellular rhPON2 could protect host cells from 
C12HSL-mediated effects and prevent bacterial QS and virulence 
 
There are no reports of PON2 being secreted from mammalian cells. Through the use of 
PON2 siRNA inhibition and overexpression, investigators have determined that lysates of 
human epithelial cells and murine macrophages can hydrolyse C12HSL [249, 262, 264]. 
However, intact cells were not able to do so, suggesting that the PON2-mediated hydrolysis 
of C12HSL is restricted to the intra-cellular environment [264]. Therefore, the efficacy of 
pharmaceutically boosting endogenous intracellular PON2 would be limited by the amount 
of C12HSL that enters cells, and is unlikely to significantly affect the extracellular 
concentration of C12HSL that is critical to QS. As a result, such a therapy would offer no 
protection against P. aeruginosa QS and virulence. In addition, intracellular PON2-mediated 
hydrolysis of C12HSL would result in accumulation of C12HSL acid in the organelles, 
causing pH-mediated effects in the cells. Application of extracellular rhPON2 as a 
therapeutic approach would instead have the benefit of hydrolysing C12HSL in the bacterial 
environment, working as a QSI and preventing autoinduction of bacterial C12HSL synthesis. 
With reduced C12HSL in the bacterial environment, less C12HSL would enter host cells, 
reducing C12HSL-mediated effects on host cells and the excess accumulation of hydrolysed 
C12HSL inside the host cell. By combining the effects of extracellular rhPON2 and increased 
endogenous native PON2 (Figure 7.1), we could address both prevention of bacterial QS and 
virulence and protect against host cell modulation. Such a therapy could be prescribed as a 
prophylactic to CF patients to target P. aeruginosa before the pathogen has a chance to 
establish chronic infections. 
This study demonstrated for the first time that rhPON2-mediated prevention of C12HSL 
accumulation during P. aeruginosa growth in culture was combined with a trend towards 
reduced expression of QS-associated virulence genes without affecting bacterial growth. 
Because rhPON2 is reported to also have high specific activity towards C4HSL [248], then 
presumably C4HSL is also prevented from accumulating during P. aeruginosa growth, and   




Figure 7.1 The potential of PON2 as a novel anti-Pseudomonal therapy. 1) P. aeruginosa, in the 
airways of infected hosts, utilizes QS to co-ordinate cell-density-dependent virulence factor 
production. Diffusible signalling molecules, the most important of which is C12HSL, mediate QS.. These 
virulence factors help to sustain bacterial infection and in the process, harm host cells, particularly the 
host epithelia but also macrophages, neutrophils, fibroblasts and the endothelial cells of capillaries 
closely associated with lung tissue. In addition, the QS molecule C12HSL is able to enter these cells 
through passive diffusion. Once inside, C12HSL has multiple negative effects on the cell, particularly 
modulated immune signalling and cytotoxicity. 2) The proposed PON2 therapy would address both the 
extracellular and intracellular consequences of C12HSL. In the extracellular environment through the 
use of recombinant human PON2 (rhPON2) and intracellularly through the increased expression of 
native PON2. In the extracellular environment, i.e. the host airway, recombinant human PON2 can 
hydrolyse C12HSL, preventing accumulation of the signal. Consequently, there would be reduced QS 
and subsequent attenuation of QS-mediated virulence determinants. The hydrolysis of C12HSL would 
also decrease the accumulation of C12HSL in the extracellular environment, substantially reducing the 
amount of C12HSL passively diffusing into host cells. In the intracellular environment, including host 
airway epithelia, increased native PON2 expression would offer protection against the detrimental 
effects of C12HSL. The hydrolysis of endogenous QS signal by PON2 and abrogation of the effects of 
C12HSL through its lactonase activity-independent anti-apoptotic and anti-oxidative properties 
contribute to the effectiveness of increased endogenous, native PON2.  
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although we did not specifically measure C4HSL levels, expression of C4HSL-mediated 
genes also tended to decrease with rhPON2 treatment. Importantly, in addition to 
quenching QS, rhPON2 therapy significantly increased the susceptibility to tobramycin of 
actively proliferating P. aeruginosa in a dose-dependent manner. Cells surviving tobramycin 
treatment alone and combined tobramycin and rhPON2 treatment had significantly 
increased expression of QS-associated genes, presumably as a stress response. The 
expression of QS-dependent virulence genes, in the absence of C12HSL was unexpected, 
because the expression of C12HSL’s cognate receptor, the LasR transcription factor, was 
virtually undetectable in cultures, therefore the stress response is presumably co-ordinated 
independently of LasR. This would also explain the observation by O’Loughlin and 
colleagues that in lung cell assays the lasR, rhlR double mutant was more virulent than wild 
type [237]. Of note, is that bacterial intracellular levels of C12HSL were not measured in our 
study and as rhPON2 cannot enter the bacterial cells, intracellular C12HSL would be 
unaffected by rhPON2. Intracellular C12HSL could potentially bind to its cognate receptor 
LasR causing regulation of the operon in a mechanism that does not involve community-
wide coordination. It is therefore important in future studies to determine the intracellular 
(bacterial) levels of C12HSL and to elucidate LasIR-independent virulence mechanisms. 
The level of tobramycin used in these experiments was well above the levels that are 
clinically achievable, so artificial over-activation of stress response pathways may have 
occurred. If rhPON2 and tobramycin are to be used as an anti-Pseudomonal therapy, 
another avenue for further investigation is the use of a more clinically-relevant tobramycin 
concentration. In this study, tobramycin was used at a concentration of 10 µg/mL. The 
MIC50 (minimum inhibitory concentration that inhibits 50% of P. aeruginosa) of 
tobramycin for P. aeruginosa in CF sputum was determined to be 2 µg/mL although this 
value may vary between different strains of P. aeruginosa [447] while the clinically 
achievable dose of tobramycin in the epithelial lining fluid of the CF lung is estimated to be 
between 75 and 90 µg/mL under standard CF dosing conditions [448]. While this 
concentration may be much higher than 10 µg/mL used in this study, only a small 
proportion of the tobramycin dose is bioavailable in the CF lung [449, 450]. In addition, 
long-term serum tobramycin concentrations of >4 µg/mL may be nephrotoxic and ototoxic 
[451]. Furthermore, 10 µg/mL tobramycin treatment of PAO1 cultures prior to the cultures 
reaching exponential growth resulted in complete killing of the bacteria and thus no 
rhPON2-dependent effects could be studied. Therefore, it would be informative if the 
treatment of PAO1 with rhPON2 combined with tobramycin was carried out with sub-
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inhibitory concentrations of tobramycin, perhaps a concentration that is more relevant to 
that seen in the CF lung and even in conjunction with a second antibiotic. It is also essential 
that these experiments are repeated using clinically achievable levels of tobramycin and 
other relevant antibiotics, such as azithromycin. In addition, in this study rhPON2 was 
applied only once to bacterial cultures and was able to increase antibiotic susceptibility but 
did not eliminate the bacteria. However, in the therapeutic context, rhPON2 would be 
applied at regular intervals, perhaps even daily. It is likely that sustained treatment of 
rhPON2 may be more effective at completely clearing the infection than the application of a 
single dose.  
 
7.4.3 Regulation of QS and virulence in vivo may differ to regulation of QS and 
virulence in vitro 
 
The experiments in this study using rhPON2 to treat P. aeruginosa were carried out in 
nutrient-rich medium. However, the CF lung is known to be deficient in nutrients and 
inorganic ions such as iron [452]. Nutrient limitations may greatly affect how QS is 
regulated, and therefore, need to be investigated further. Furthermore, P. aeruginosa is 
often found in the CF lung growing in hypoxic niches [379]. As a consequence, the ability of 
rhPON2 to prevent QS and QS-associated virulence in anaerobically growing P. aeruginosa 
also requires further investigation. 
Other studies with QS-inhibitors and QS knockout bacteria have shown that QSI typically 
results in inferior biofilms, that are easier to target with antibiotics [152, 273, 434, 435]. It is 
vital that future studies establish the ability of rhPON2 to interfere with biofilm formation 
both in vitro using defined media and artificial sputum and in vivo during both acute and 
chronic lung infection.    
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7.4.4 Therapeutic advantages of rhPON2 as an anti-Pseudomonal 
 
There are a number of advantages of using PON2 as an anti-Pseudomonal therapy that were 
demonstrated by this study, as well as a number of perceived advantages: 
i) rhPON2 caused prevention of accumulation of the major P. aeruginosa QS signal 
C12HSL and associated C12HSL-mediated virulence expression and should prevent 
robust biofilm formation; 
ii) rhPON2 increased P. aeruginosa susceptibility to antibiotics; 
iii) rhPON2 therapy by itself does not affect bacterial growth, and consequently there 
would be little selection pressure driving the development of resistance; 
a. rhPON2 is not internalised into bacterial cells, so efflux pumps could not 
contribute to resistance development; 
b. because rhPON2 does not interact with bacterial receptor proteins, mutations of 
bacterial receptors will not provide a resistance mechanism; 
iv) a recombinant human enzyme is unlikely to elicit an immune response that would 
interfere with its function; 
v) rhPON2 would prevent the proinflammatory effects of C12HSL on mammalian cells, 
decreasing host inflammatory cell-mediated lung damage    
This type of therapy would add a new type of weapon to the arsenal of antimicrobials 
(whether antibiotics, anti-inflammatories, or other QS inhibitors) that could be used in 
combination to fight infectious disease. 
 
7.4.5 Delivery of rhPON2 
 
To efficiently deliver the rhPON2 to the airways, the recombinant protein will need to be 
nebulized or inhaled as a dry powder. CF patients are already subjected to inhaled 
antibiotics and recombinant protein therapy, for example Tobramycin and Dornase alfa 
respectively [5]. Dornase alfa is a licensed recombinant human DNase whose primary target 
is the high levels of neutrophil-derived DNA in the CF sputum to reduce sputum viscosity. 
Dornase alfa can also target the extracellular matrix surrounding the P. aeruginosa biofilms 
and the use of Dornase Alfa establishes a precedent for the delivery of a therapeutic 
recombinant human protein directly into the airways.  
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There are three important factors that would need to be considered during formulation of 
the rhPON2 for application to the lung (nebulized or in powdered form):  
i) Accounting for the Ca2+-dependence of rhPON2 lactonase activity. Dornase alfa 
stability is also dependent on calcium concentration [453]. The calcium 
composition of sputum is estimated to be ~3 mM [454], a concentration 
conducive to PON2 lactonase activity [262] and Dornase alfa stability [453]. 
However, Dornase alfa is still delivered to the airways with 0.15 mg/mL calcium 
chloride [455] to ensure stability. Requirement of supplementation of calcium 
will therefore need to be established when investigating the delivery of rhPON2 
as a therapy. 
ii) rhPON2 stability and activity in the lung environment. Our study found 
minimum detectable C12HSL 24 hours post-treatment in bacterial culture 
supernatants known to contain proteases, suggesting that rhPON2 is stable in 
this environment. Were there to be problems with rhPON2 stability, molecular 
dynamics simulations of PON2 structure may identify flexible regions that can 
be targeted for engineering to enhance stability and activity. 
iii) Minimizing droplet particle size during nebulization, to efficiently deliver the 
rhPON2 peripherally to small airways.  
All of these considerations can be investigated using in vivo infection models. 
 
7.4.6 Testing rhPON2 therapy in vivo using animal models of infection 
 
To date, there are no animal models that completely mimic the chronic P. aeruginosa 
infections in human CF [388] and the best representations of human CF disease are seen in 
transgenic CFTR-knockout pigs [386]. The CFTR-knockout pigs, unlike humans, do not 
spontaneously acquire P. aeruginosa lung infections, are expensive to house and time-
consuming to rear and thus their use is restricted to specialized labs. For this reason, 
murine models feature prominently in the literature, because of their ease of use, 
availability and the increasing number of available transgenic variants. To allow the study of 
the effects of rhPON2 in an in vivo setting, this study demonstrated for the first time the 
development of sustained P. aeruginosa infection (>12 days post infection) in mice without 
installation of P. aeruginosa in agar or extracellular material mimicking a biofilm, but using 
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an intranasal challenge, a method similar to the one developed by Diavatopoulos and 
colleagues for investigating S. aureus infection [413]. Unlike the Diavatopoulos study, the 
method described in this thesis did not incorporate priming the murine host for P. 
aeruginosa infection by pre-infecting with human influenza virus. However the infections 
established were low-level (< 103 CFU detected) and priming the immune system may 
increase bacterial carriage. The intranasal challenge model of sustained P. aeruginosa 
infection has the advantages of ease of infection of the animal without the need for 
intubation, sedatives or a tracheotomy, cost-effectiveness and most importantly, the use of 
neonatal mice with an underdeveloped immune system that more closely represents the 
compromised immune function of the CF lung than do adult mice, increasing the likelihood 
of the development of a chronic infection.  
Using in vivo models of chronic P. aeruginosa infection the efficacious dose of rhPON2,the 
ideal intervals of treatment and the best combinations of antibiotics that will maximise the 
therapeutic potential of rhPON2 can be elucidated. Additionally, using both acute and 
chronic infection models will help determine the effectiveness of rhPON2 in prevention and 
eradication of P. aeruginosa infections, respectively. Study of acute infection models will 
help elucidate the ability of rhPON2 to prevent the initial establishment of infections, while 
the study of chronic infection models will help determine whether rhPON2 can be 
successfully used to eradicate already-established P. aeruginosa infection.  
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7.5 FUTURE PROSPECTS 
 
CF lung infections are polymicrobial and include a number of other Gram-negative 
pathogens that utilize AHLs for QS. This provides an opportunity to potentially extend 
beyond P. aeruginosa, the use of inhibition of QS by rhPON2. Bacteria belonging to the 
Burkholderia cepacia complex utilize AHLs (predominantly C8HSL) in a QS system 
homologous to that observed in P. aeruginosa [456, 457], while the emerging CF pathogen 
Pandoraea pnomenusa is also reported to utilise an AHL to regulate QS [458].  
P. aeruginosa is a major opportunistic human pathogen and a significant source of 
bacteraemia. Its ability to cause infections is not restricted to people with CF. In the US, it is 
among the most common nosocomial pathogens and the second most frequently isolated 
pathogen from patients with ventilator-associated pneumonia [92]. Infections with P. 
aeruginosa are also commonly associated with burns [459], microbial keratitis in contact 
lens wearers [459], urinary tract infections in catheterized patients [459] and pulmonary 
infections in chronic obstructive pulmonary disease [460], HIV infections [461] and 
immunocompromised individuals such as patients on chemotherapy [462] and 
immunosuppressive drugs [459]. rhPON2 therapy may aid in the control of these infections. 
For pulmonary infections, nebulized rhPON2 therapy could be applied. For other infections, 
the method of delivery of rhPON2 may need to be adjusted: for example, in burns, topical 
application of rhPON2 in cream may be the most appropriate method of delivery. 
PON2 needs much more research before it can be established as an anti-virulence therapy. 
However, there are multiple advantages of the therapy over other proposed anti-virulence 
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7.6 CONCLUDING REMARKS 
 
The work described in this thesis sheds new light on the potential of using the mammalian 
enzyme PON2 as a novel anti-Pseudomonal therapy. By investigating the effects of C12HSL 
on the airway, we confirmed and augmented established research on the effects that 
C12HSL has on infected host cells, thus allowing us to understand better the C12HSL-
mediated modulation of host cell gene expression. Through further investigation of the 
regulation of human PON2 expression, this study was able to determine a mechanism 
through which endogenous, intracellular PON2 expression could be increased. This finding 
enabled us to suggest a mechanism by which the cells of P. aeruginosa-infected host could 
be protected from the detrimental effects of C12HSL. Using rhPON2 produced in this study, 
in situ lactonolysis of C12HSL by rhPON2 in actively growing P. aeruginosa cultures was 
demonstrated. This allowed us to investigate the effects that the unavailability of C12HSL in 
the bacterial cell environment has on QS by the bacteria, showing that the absence of 
C12HSL may attenuate P. aeruginosa pathogenicity. By treating bacteria with a combination 
of rhPON2 and a CF-relevant antibiotic, we were able to demonstrate a rhPON2-dose-
dependent increase in P. aeruginosa antibiotic susceptibility. These findings strengthened 
the notion that rhPON2 can be effective when applied extracellularly as a recombinant 
protein. Finally, we described a novel mouse model, which, after further development, may 
be a useful tool for in vivo studies to further investigate PON2 as a therapy. 
Taken together, the results suggest that treatment with PON2, in both its recombinant and 
native forms, offers substantial protection from P. aeruginosa by hydrolysing P. aeruginosa-
produced AHL signals and decreasing C12HSL-mediated effects on host cells. Therefore, the 
work described in this thesis strongly indicates that PON2 should be further investigated as 
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8.1 EXAMPLE CALCULATION OF BACULOVIRUS TITRE BY END-POINT 
DILUTION METHOD 
 
Dilution Infected wells Uninfected wells 
10-5 12 0 
10-6 8 4 
10-7 1 11 
10-8 0 12 
 
At the 10-5, all 12 wells were infected. However, at the 10-6 dilution, 8 weeks were infected 
and only one well at 10-7. Assuming that these wells would also have been infected by 10-5 
dilution, the total number of infected wells is taken to be 21 (12 + 8 + 1). Similarly, the same 
could be said about the uninfected cells and hence the total number of uninfected wells at 10-
8 would be 27 (4+11+12). Extending this, the following results were obtained. 
 
Dilution Infected Uninfected % Infected 
10-5 21 0 100.0 
10-6 9 4 69.2 
10-7 1 15 6.3 
10-8 0 27 0.0 
 
In this case, the dilution that would have given 50% infection lies between 10-6 and 10-7. This 
dilution is calculated by linear interpolation between infection rates observed at these 
dilutions. 
First, the proportionate distance (PD) of a 50% response from the response above 50% is 
calculated using the following formula: 
PD = (A-50)/(A-B) 
Where A is the % response above 50%, and B is the % response below 50%. In the above 
example, 
PD = (69.2-50)/(69.2-6.3) 







The dose that would give a 50% response, the TCID50, is then calculated using the following 
formula: 
Log TCID50 = log of the dilution giving a response greater than 50% - PD of that response 
Thus, 
Log TCID50 = - 6 - 0.305 
Log TCID50 = - 6.305 
Therefore, TCID50 = 4.95 x 10-7 
The titre of virus (TCID50 / 10 µL) =(1/ TCID50) = 1 / 4.95 x 10-7 = 2.02 x 106 TCID50 / µL 
The titre of virus (TCID50 / 10 mL) = 2.02 x 106 TCID50 / µL X 100 = 2.02 x 108 TCID50 / mL 
Next,  
The titre of virus (pfu/ mL) = The titre of virus (TCID50 / mL) x 0.69 (constant based on Poisson 
distribution ), therefore 
The titre of virus (pfu/ mL) = 2.02 x 108 TCID50 / mL x 0.69 
The titre of virus (pfu/ mL) =  1.4 x 108 pfu/mL 
 
Figure 8.1 Example calculation of baculovirus titre by end-point dilution method. Example adapted 







8.2 COMPLETE TRANSCRIPTOM ARRAY GENE EXPRESSION DATA SET 
 
 
Table 8.2 Complete transcriptome array gene expression data.  
Array data arranged from highest fold change to lowest. The Affymetrix GeneChip Human 






CHD5 chromodomain helicase DNA binding protein 5 9.94 
POLN polymerase (DNA directed) nu 9.85 
PRAM1 PML-RARA regulated adaptor molecule 1 8.62 
RC3H1 ring finger and CCCH-type domains 1 8.12 
FRMD4B FERM domain containing 4B 7.77 
MUC19 mucin 19, oligomeric 7.43 
SORBS2 sorbin and SH3 domain containing 2 7.38 
LDHB lactate dehydrogenase B 7.34 
VPS13A vacuolar protein sorting 13 homolog A (S. cerevisiae) 7.15 
TDRKH tudor and KH domain containing 7.09 
PNPT1 polyribonucleotide nucleotidyltransferase 1 7 
ASIC4 acid-sensing (proton-gated) ion channel family member 4 6.76 
RCOR3 REST corepressor 3 6.41 
NIPBL Nipped-B homolog (Drosophila) 6.35 
TAPT1 transmembrane anterior posterior transformation 1 6.33 
CCDC38 coiled-coil domain containing 38 6.12 
SLC3A1 solute carrier family 3 member 1 6.08 
LRRCC1 leucine rich repeat and coiled-coil centrosomal protein 1 5.9 
FAM82A1 family with sequence similarity 82, member A1 5.81 
ZFAND6 zinc finger, AN1-type domain 6 5.7 
SLC30A8 solute carrier family 30 (zinc transporter), member 8 5.65 
NRCAM neuronal cell adhesion molecule 5.62 
MEIS1 Meis homeobox 1 5.53 
SERPINI1 serpin peptidase inhibitor, clade I (neuroserpin), member 1 5.5 
UVSSA UV-stimulated scaffold protein A 5.45 
ADAM2 ADAM metallopeptidase domain 2 5.43 
GRHL1 grainyhead-like 1 (Drosophila) 5.42 
AK5 adenylate kinase 5 5.41 
MAP3K2 mitogen-activated protein kinase kinase kinase 2 5.41 
RBM26-AS1 RBM26 antisense RNA 1 (non-protein coding) 5.38 
POLN polymerase (DNA directed) nu 5.37 
PLCB4 phospholipase C, beta 4 5.31 




RERE arginine-glutamic acid dipeptide (RE) repeats 5.27 
C1orf222, 
KIAA1751 chromosome 1 open reading frame 222, KIAA1751 5.17 
TTLL5 tubulin tyrosine ligase-like family, member 5 5.15 
KLRG1 killer cell lectin-like receptor subfamily G, member 1 5.14 
DNAH6 dynein, axonemal, heavy chain 6 5.1 
WNK3 WNK lysine deficient protein kinase 3 5.08 
C1orf222, 
KIAA1751 chromosome 1 open reading frame 222, KIAA1751 5.04 
RAD17 RAD17 homolog (S. pombe) 5.03 
ATP13A2 ATPase type 13A2 5.01 
GSTCD glutathione S-transferase, C-terminal domain containing 5.01 
PDE8A phosphodiesterase 8A 4.99 
TRHDE-AS1 TRHDE antisense RNA 1 (non-protein coding) 4.94 
CSTF2 cleavage stimulation factor, 3' pre-RNA, subunit 2, 64kDa 4.92 
AKAP7 A kinase (PRKA) anchor protein 7 4.85 
DDHD2 DDHD domain containing 2 4.82 
GPR97 G protein-coupled receptor 97 4.82 
MDH1B malate dehydrogenase 1B, NAD (soluble) 4.79 
NGFR nerve growth factor receptor 4.77 
ARHGEF6 Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6 4.76 
C17orf104 chromosome 17 open reading frame 104 4.75 
VPS13B vacuolar protein sorting 13 homolog B (yeast) 4.72 
CGN cingulin 4.65 
FRYL FRY-like 4.64 
FSD1L fibronectin type III and SPRY domain containing 1-like 4.64 
MTUS1 microtubule associated tumor suppressor 1 4.61 
CASP3 caspase 3, apoptosis-related cysteine peptidase 4.55 
NEDD1 neural precursor cell expressed, developmentally down-regulated 1 4.54 
FSD2 fibronectin type III and SPRY domain containing 2 4.5 
LOC100302640 uncharacterized LOC100302640 4.5 
SNCAIP synuclein, alpha interacting protein 4.5 
KANK1 KN motif and ankyrin repeat domains 1 4.48 
MLLT4 myeloid/lymphoid or mixed-lineage leukemia 4 4.47 
FAM135A family with sequence similarity 135, member A 4.44 
LAMA4 laminin, alpha 4 4.44 
TOP2B topoisomerase (DNA) II beta 180kDa 4.42 
LARP7 La ribonucleoprotein domain family, member 7 4.41 
SORBS2 sorbin and SH3 domain containing 2 4.38 
MARK1 MAP/microtubule affinity-regulating kinase 1 4.37 
TM9SF4 transmembrane 9 superfamily protein member 4 4.37 
LAMA2 laminin, alpha 2 4.36 
F8 coagulation factor VIII, procoagulant component 4.35 
SCLY, UBE2F 
selenocysteine lyase, ubiquitin-conjugating enzyme E2F (putative), UBE2F-




NLGN1 neuroligin 1 4.34 
EPHA7 EPH receptor A7 4.33 
TPTE2P5 
transmembrane phosphoinositide 3-phosphatase and tensin homolog 2 
pseudogene 5 4.33 
AGBL5 ATP/GTP binding protein-like 5 4.3 
DMXL1 Dmx-like 1 4.29 
ZNF277 zinc finger protein 277 4.24 
CEACAM5 carcinoembryonic antigen-related cell adhesion molecule 5 4.23 
ENPP1 ectonucleotide pyrophosphatase/phosphodiesterase 1 4.23 
UBE2E1 ubiquitin-conjugating enzyme E2E 1 4.22 
DST dystonin, dystonin-like 4.21 
CEP170,171 centrosomal protein 170kDa, centrosomal protein 170kDa pseudogene 1 4.2 
KIAA0319L KIAA0319-like 4.17 
EPS8 epidermal growth factor receptor pathway substrate 8 4.14 
ME3 malic enzyme 3, NADP(+)-dependent, mitochondrial 4.14 
GANC, CAPN3 glucosidase, alpha; neutral C, calpain 3, (p94) 4.12 
NF1 neurofibromin 1 4.1 
ZC3H6 zinc finger CCCH-type containing 6 4.1 
LTA4H leukotriene A4 hydrolase 4.09 
MYO5B myosin VB 4.07 
TAS1R1 taste receptor, type 1, member 1 4.07 
ARAP2 ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 2 4.05 
FAM160B1 family with sequence similarity 160, member B1 4.04 
PNPT1 polyribonucleotide nucleotidyltransferase 1 4.04 
Mar-01 mitochondrial amidoxime reducing component 1 4.02 
HCLS1 hematopoietic cell-specific Lyn substrate 1 4.01 
POU2F1 POU class 2 homeobox 1 4.01 
C10orf57 chromosome 10 open reading frame 57 4 
CDKL4 cyclin-dependent kinase-like 4 4 
LRP2 low density lipoprotein receptor-related protein 2 4 
CEP192 centrosomal protein 192kDa 3.99 
FNTA farnesyltransferase, CAAX box, alpha 3.99 
DDX43 DEAD (Asp-Glu-Ala-Asp) box polypeptide 43 3.98 
ANKRD11 ankyrin repeat domain 11 3.97 
LDB2 LIM domain binding 2 3.94 
FAM114A2 family with sequence similarity 114, member A2 3.93 
TTC8 tetratricopeptide repeat domain 8 3.93 
SLC12A2 
solute carrier family 12 (sodium/potassium/chloride transporters), member 
2 3.92 
EP400 E1A binding protein p400 3.91 
FBN1 fibrillin 1 3.89 
KIAA0146 KIAA0146 3.89 
POLA1 polymerase (DNA directed), alpha 1, catalytic subunit 3.89 
ARFGEF2 





CDKL5 cyclin-dependent kinase-like 5 3.87 
SLA Src-like-adaptor 3.87 
STAT4 signal transducer and activator of transcription 4 3.87 
ZCCHC11 zinc finger, CCHC domain containing 11 3.87 
SLC19A3 solute carrier family 19, member 3 3.86 
KCNH7 potassium voltage-gated channel, subfamily H (eag-related), member 7 3.85 
NEMF nuclear export mediator factor 3.85 
SUN1 Sad1 and UNC84 domain containing 1 3.85 
CAB39L calcium binding protein 39-like 3.84 
SYNE1 spectrin repeat containing, nuclear envelope 1 3.84 
ACAA1 acetyl-CoA acyltransferase 1 3.83 
CYP2F1 cytochrome P450, family 2, subfamily F, polypeptide 1 3.83 
PARVB parvin, beta 3.83 
ADAM7 ADAM metallopeptidase domain 7 3.82 
ATXN7 ataxin 7 3.81 
DECR1 2,4-dienoyl CoA reductase 1, mitochondrial 3.81 
FBXL13 F-box and leucine-rich repeat protein 13 3.81 
CA7 carbonic anhydrase VII 3.8 
BIN3 bridging integrator 3 3.78 
RUFY2 RUN and FYVE domain containing 2 3.77 
SLC9A9 
solute carrier family 9, subfamily A (NHE9, cation proton antiporter 9), 
member 9 3.77 
STC1 stanniocalcin 1 3.77 
ALOX15B arachidonate 15-lipoxygenase, type B 3.76 
DNAH8 dynein, axonemal, heavy chain 8 3.76 
ZNF451 zinc finger protein 451 3.76 
FLJ37644 uncharacterized LOC400618 3.75 
OSBPL5 oxysterol binding protein-like 5 3.75 
TMX3 thioredoxin-related transmembrane protein 3 3.74 
WNK3 WNK lysine deficient protein kinase 3 3.74 
COL14A1 collagen, type XIV, alpha 1 3.73 
FLJ22763 uncharacterized LOC401081 3.73 
C17orf57, 
ITGB3 
chromosome 17 open reading frame 57, integrin, beta 3 (platelet 
glycoprotein IIIa, antigen CD61) 3.72 
LRRCC1 leucine rich repeat and coiled-coil centrosomal protein 1 3.72 
DIAPH3 diaphanous homolog 3 (Drosophila) 3.71 
PPM1L protein phosphatase, Mg2+/Mn2+ dependent, 1L 3.71 
SMARCE1 
SWI/SNF related, actin dependent regulator of chromatin, subfamily e, 
member 1 3.71 
TAB3 TGF-beta activated kinase 1/MAP3K7 binding protein 3 3.71 
ZSWIM5 zinc finger, SWIM-type containing 5 3.71 
GAL galanin prepropeptide 3.7 
RNF32 ring finger protein 32 3.7 
ANTXR2 anthrax toxin receptor 2 3.69 





MIR3610 RAD21 homolog (S. pombe), microRNA 3610 3.68 
UACA uveal autoantigen with coiled-coil domains and ankyrin repeats 3.68 
EPB41L3 erythrocyte membrane protein band 4.1-like 3 3.66 
KIAA0368 KIAA0368 3.66 
KIF27 kinesin family member 27 3.66 
VGLL4 vestigial like 4 (Drosophila) 3.66 
RNF150 ring finger protein 150 3.64 
SYNE2 spectrin repeat containing, nuclear envelope 2 3.64 
ADAM2 ADAM metallopeptidase domain 2 3.63 
STAT5B signal transducer and activator of transcription 5B 3.63 
SYTL2 synaptotagmin-like 2 3.63 
TMOD3 tropomodulin 3 (ubiquitous) 3.63 
HERC5 HECT and RLD domain containing E3 ubiquitin protein ligase 5 3.62 
ADAM7 ADAM metallopeptidase domain 7 3.61 
CALB1 calbindin 1, 28kDa 3.59 
KIAA1199 KIAA1199 3.59 
NEO1 neogenin 1 3.59 
CADPS2 Ca++-dependent secretion activator 2 3.58 
LYST lysosomal trafficking regulator 3.58 
NUMA1 nuclear mitotic apparatus protein 1 3.58 
AP1S3 adaptor-related protein complex 1, sigma 3 subunit 3.57 
ZCCHC4 zinc finger, CCHC domain containing 4 3.56 
AKNAD1 AKNA domain containing 1 3.55 
ARHGAP22 Rho GTPase activating protein 22 3.55 
CCDC39 coiled-coil domain containing 39 3.55 
CACNA2D2 calcium channel, voltage-dependent, alpha 2/delta subunit 2 3.54 
GRIN3A glutamate receptor, ionotropic, N-methyl-D-aspartate 3A 3.54 
SLC28A1 solute carrier family 28 (sodium-coupled nucleoside transporter), member 1 3.54 
YPEL1 yippee-like 1 (Drosophila) 3.54 
AEBP2 AE binding protein 2 3.53 
MYH15 myosin, heavy chain 15 3.53 
PLXDC1 plexin domain containing 1 3.51 
TPTE transmembrane phosphatase with tensin homology 3.51 
LARP4 La ribonucleoprotein domain family, member 4 3.5 
SLC6A5 solute carrier family 6 (neurotransmitter transporter, glycine), member 5 3.5 
APBB3 amyloid beta (A4) precursor protein-binding, family B, member 3 3.49 
ATM, NPAT ataxia telangiectasia mutated, nuclear protein, ataxia-telangiectasia locus 3.49 
PPP1R9A protein phosphatase 1, regulatory subunit 9A 3.49 
ADAM7 ADAM metallopeptidase domain 7 3.48 
C1orf228 chromosome 1 open reading frame 228 3.48 
CAGE1 cancer antigen 1 3.48 
ODZ1 odz, odd Oz/ten-m homolog 1 (Drosophila) 3.48 




PCSK6, proprotein convertase subtilisin/kexin type 6 3.48 
PCLO piccolo (presynaptic cytomatrix protein) 3.47 
CCDC144C, B 
coiled-coil domain containing 144C, coiled-coil domain containing 144B 
(pseudogene) 3.46 
FBXO41 F-box protein 41 3.46 
NELL2 NEL-like 2 (chicken) 3.46 
RAP1B RAP1B, member of RAS oncogene family 3.46 
LRP2BP LRP2 binding protein 3.45 
TSPAN9 tetraspanin 9 3.45 
ANKH ankylosis, progressive homolog (mouse) 3.44 
CCDC11 coiled-coil domain containing 11 3.44 
MAST4 microtubule associated serine/threonine kinase family member 4 3.44 
ATP2A2 ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 3.43 
COL28A1 collagen, type XXVIII, alpha 1 3.43 
PLXNC1 plexin C1 3.43 
PPARG peroxisome proliferator-activated receptor gamma 3.43 
COL22A1 collagen, type XXII, alpha 1 3.42 
FAM190A family with sequence similarity 190, member A 3.42 
FAM227B family with sequence similarity 227, member B 3.42 
LRRC34 leucine rich repeat containing 34 3.42 
CLEC16A C-type lectin domain family 16, member A 3.41 
ITGAX integrin, alpha X (complement component 3 receptor 4 subunit) 3.41 
KAT7 K(lysine) acetyltransferase 7 3.4 
PTCHD2 patched domain containing 2 3.4 
SYNE1 spectrin repeat containing, nuclear envelope 1 3.4 
TARBP1 TAR (HIV-1) RNA binding protein 1 3.4 
ZNF345 zinc finger protein 345 3.39 
NTRK2 neurotrophic tyrosine kinase, receptor, type 2 3.38 
SKAP2 src kinase associated phosphoprotein 2 3.38 
SSBP3 single stranded DNA binding protein 3 3.38 
DNAH1 dynein, axonemal, heavy chain 1 3.37 
PWRN1 Prader-Willi region non-protein coding RNA 1 3.36 
CP ceruloplasmin (ferroxidase) 3.35 
SLC1A3 solute carrier family 1 (glial high affinity glutamate transporter), member 3 3.35 
ZEB1 zinc finger E-box binding homeobox 1 3.35 
F7 coagulation factor VII (serum prothrombin conversion accelerator) 3.34 
RPS23 ribosomal protein S23 3.34 
CNTRL centriolin 3.33 
ENTPD5 ectonucleoside triphosphate diphosphohydrolase 5 3.33 
TTC17 tetratricopeptide repeat domain 17 3.33 
CSGALNACT1 chondroitin sulfate N-acetylgalactosaminyltransferase 1 3.32 
DUSP11 dual specificity phosphatase 11 (RNA/RNP complex 1-interacting) 3.32 
HIVEP1 human immunodeficiency virus type I enhancer binding protein 1 3.32 




COL24A1 collagen, type XXIV, alpha 1 3.31 
GTF2I general transcription factor IIi 3.31 
NPAS2 neuronal PAS domain protein 2 3.3 
SNX2 sorting nexin 2 3.3 
DOCK5 dedicator of cytokinesis 5 3.29 
NAB1 NGFI-A binding protein 1 (EGR1 binding protein 1) 3.29 
WDR17 WD repeat domain 17 3.29 
DLEU2 deleted in lymphocytic leukemia 2 (non-protein coding) 3.27 
LRSAM1 leucine rich repeat and sterile alpha motif containing 1 3.27 
LRTOMT leucine rich transmembrane and 0-methyltransferase domain containing 3.27 
ATG13 autophagy related 13 3.26 
KALRN kalirin, RhoGEF kinase 3.25 
FAM135A family with sequence similarity 135, member A 3.24 
TFAP2A transcription factor AP-2 alpha (activating enhancer binding protein 2 alpha) 3.23 
ACOXL acyl-CoA oxidase-like 3.22 
C14orf118 chromosome 14 open reading frame 118 3.22 
F8 coagulation factor VIII, procoagulant component 3.22 
GAD2 glutamate decarboxylase 2 (pancreatic islets and brain, 65kDa) 3.22 
PPFIA3 
protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), 
interacting protein (liprin), alpha 3 3.22 
CYFIP2 cytoplasmic FMR1 interacting protein 2 3.2 
KMO kynurenine 3-monooxygenase (kynurenine 3-hydroxylase) 3.2 
PIK3C3 phosphoinositide-3-kinase, class 3 3.2 
PLA2G4A phospholipase A2, group IVA (cytosolic, calcium-dependent) 3.2 
POLK polymerase (DNA directed) kappa 3.2 
TNS1 tensin 1 3.2 
ADAM22 ADAM metallopeptidase domain 22 3.19 
BRE, MRPL33 
brain and reproductive organ-expressed (TNFRSF1A modulator), 
mitochondrial ribosomal protein L33 3.19 
C9orf84 chromosome 9 open reading frame 84 3.19 
GLT8D2 glycosyltransferase 8 domain containing 2 3.19 
MST1 macrophage stimulating 1 (hepatocyte growth factor-like) 3.19 
NDRG2 NDRG family member 2 3.19 
ARHGAP9 Rho GTPase activating protein 9 3.18 
FAM198B family with sequence similarity 198, member B 3.18 
FN1 fibronectin 1 3.18 
GYS2 glycogen synthase 2 (liver) 3.18 
QARS glutaminyl-tRNA synthetase 3.18 
REV1 REV1, polymerase (DNA directed) 3.18 
APBB1IP 
amyloid beta (A4) precursor protein-binding, family B, member 1 interacting 
protein 3.17 
CLOCK clock homolog (mouse) 3.17 
KLRF1 killer cell lectin-like receptor subfamily F, member 1 3.17 
TMEM218 transmembrane protein 218 3.17 






acetylglucosaminyltransferase, isozyme A 3.16 
POLR3B polymerase (RNA) III (DNA directed) polypeptide B 3.16 
SUCLA2 succinate-CoA ligase, ADP-forming, beta subunit 3.16 
XYLB xylulokinase homolog (H. influenzae) 3.16 
C17orf57, 
ITGB3 
chromosome 17 open reading frame 57, integrin, beta 3 (platelet 
glycoprotein IIIa, antigen CD61) 3.15 
NOS2 nitric oxide synthase 2, inducible 3.15 
PIK3C2G phosphoinositide-3-kinase, class 2, gamma polypeptide 3.15 
SLC12A1 
solute carrier family 12 (sodium/potassium/chloride transporters), member 
1 3.15 
USO1 USO1 vesicle docking protein homolog (yeast) 3.15 
MTA3 metastasis associated 1 family, member 3, uncharacterized LOC100130921 3.14 
ODZ1 odz, odd Oz/ten-m homolog 1 (Drosophila) 3.14 
SLFN11 schlafen family member 11 3.14 
TEX11 testis expressed 11 3.14 
IYD iodotyrosine deiodinase 3.13 
RGS8 regulator of G-protein signaling 8 3.13 
SI sucrase-isomaltase (alpha-glucosidase) 3.13 
DOCK5 dedicator of cytokinesis 5 3.12 
NCALD neurocalcin delta 3.12 
TNFRSF19 tumor necrosis factor receptor superfamily, member 19 3.12 
ARID2 AT rich interactive domain 2 (ARID, RFX-like) 3.11 
PDE6C phosphodiesterase 6C, cGMP-specific, cone, alpha prime 3.11 
IGHMBP2 immunoglobulin mu binding protein 2 3.1 
PLEKHG4 
pleckstrin homology domain containing, family G (with RhoGef domain) 
member 4 3.1 
SIPA1L2 signal-induced proliferation-associated 1 like 2 3.1 
AMY2A amylase, alpha 2A (pancreatic) 3.09 
MEF2BNB MEF2BNB-MEF2B readthrough, myocyte enhancer factor 2B 3.09 
PDK2 pyruvate dehydrogenase kinase, isozyme 2 3.09 
ENDOV endonuclease V 3.08 
FAM176A family with sequence similarity 176, member A 3.08 
RIPK2 receptor-interacting serine-threonine kinase 2 3.07 
USH1C Usher syndrome 1C (autosomal recessive, severe) 3.07 
KHDRBS3 KH domain containing, RNA binding, signal transduction associated 3 3.06 
SCUBE2 signal peptide, CUB domain, EGF-like 2 3.06 
UNC45B unc-45 homolog B (C. elegans) 3.06 
AP2A2 adaptor-related protein complex 2, alpha 2 subunit 3.05 
C3orf62, 
MIR4271 chromosome 3 open reading frame 62, microRNA 4271 3.05 
CYP3A43 cytochrome P450, family 3, subfamily A, polypeptide 43 3.05 
SSBP3 single stranded DNA binding protein 3 3.05 
TMTC1 transmembrane and tetratricopeptide repeat containing 1 3.05 
TP53BP2 tumor protein p53 binding protein, 2 3.05 




SYT1 synaptotagmin I 3.04 
CADPS2 Ca++-dependent secretion activator 2 3.03 
DYNC2H1 dynein, cytoplasmic 2, heavy chain 1 3.03 
PLS1 plastin 1 3.03 
SETD9 SET domain containing 9 3.03 
TBCK TBC1 domain containing kinase 3.03 
UTRN utrophin 3.03 
ARHGEF6 Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6 3.02 
ARID2 AT rich interactive domain 2 (ARID, RFX-like) 3.02 
DMD dystrophin 3.02 
FAM76B family with sequence similarity 76, member B 3.02 
LINC00277 long intergenic non-protein coding RNA 277 3.02 
LRRC7 leucine rich repeat containing 7 3.02 
SUCLA2 succinate-CoA ligase, ADP-forming, beta subunit 3.02 
CCDC152 coiled-coil domain containing 152 3.01 
OLAH oleoyl-ACP hydrolase 3.01 
RAET1E retinoic acid early transcript 1E 3.01 
DKFZp686O132
7 uncharacterized LOC401014 3 
KRT79 keratin 79 3 
PAWR PRKC, apoptosis, WT1, regulator 3 
PECR peroxisomal trans-2-enoyl-CoA reductase 3 
SCN5A sodium channel, voltage-gated, type V, alpha subunit 3 
TMEM68 transmembrane protein 68 3 
ABCC12 ATP-binding cassette, sub-family C (CFTR/MRP), member 12 2.99 
AKD1 adenylate kinase domain containing 1 2.99 
ALB albumin 2.99 
LOC728978 uncharacterized LOC728978 2.99 
ODF2L outer dense fiber of sperm tails 2-like 2.99 
TMED8 transmembrane emp24 protein transport domain containing 8 2.99 
ADCY1 adenylate cyclase 1 (brain) 2.98 
CDK7 cyclin-dependent kinase 7 2.98 
MADD MAP-kinase activating death domain 2.98 
PFKFB4 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 2.98 
PLEKHG1 
pleckstrin homology domain containing, family G (with RhoGef domain) 
member 1 2.98 
SLC7A8 
solute carrier family 7 (amino acid transporter light chain, L system), 
member 8 2.98 
CABIN1 calcineurin binding protein 1 2.97 
FAM46A family with sequence similarity 46, member A 2.97 
KIAA1244 KIAA1244 2.97 
ZCCHC17 zinc finger, CCHC domain containing 17 2.97 
AKD1 adenylate kinase domain containing 1 2.96 
APEX1 APEX nuclease (multifunctional DNA repair enzyme) 1 2.96 




AUTS2 autism susceptibility candidate 2 2.96 
KIAA0100 KIAA0100 2.96 
LRBA LPS-responsive vesicle trafficking, beach and anchor containing 2.96 
ABTB1 ankyrin repeat and BTB (POZ) domain containing 1 2.95 
ARHGAP42 Rho GTPase activating protein 42 2.95 
C14orf133 chromosome 14 open reading frame 133 2.95 
DMXL2 Dmx-like 2 2.95 
KTN1 kinectin 1 (kinesin receptor) 2.95 
PPIL2 peptidylprolyl isomerase (cyclophilin)-like 2 2.95 
RGS4 regulator of G-protein signaling 4 2.95 
RNF150 ring finger protein 150 2.95 
UBE4B ubiquitination factor E4B 2.95 
WDR93 WD repeat domain 93 2.95 
BMP4 bone morphogenetic protein 4 2.94 
IZUMO2 IZUMO family member 2 2.94 
MYOM2 myomesin (M-protein) 2, 165kDa 2.94 
C6orf170 chromosome 6 open reading frame 170 2.93 
KANSL1L KAT8 regulatory NSL complex subunit 1-like 2.93 
WDR41 WD repeat domain 41 2.93 
ZNF284 zinc finger protein 284 2.93 
F11 coagulation factor XI 2.92 
FREM1 FRAS1 related extracellular matrix 1 2.91 
LRRC37B leucine rich repeat containing 37B 2.91 
MACC1 metastasis associated in colon cancer 1 2.91 
SLC4A4 solute carrier family 4, sodium bicarbonate cotransporter, member 4 2.91 
WDR48 WD repeat domain 48 2.91 
ERO1LB ERO1-like beta (S. cerevisiae) 2.9 
FAS Fas (TNF receptor superfamily, member 6) 2.9 
SPINK4 serine peptidase inhibitor, Kazal type 4 2.9 
XRN2 5'-3' exoribonuclease 2 2.9 
DOCK2 dedicator of cytokinesis 2 2.89 
FRMD5 FERM domain containing 5 2.89 
IL2RB interleukin 2 receptor, beta 2.89 
LIMCH1 LIM and calponin homology domains 1 2.89 
LRIG2 leucine-rich repeats and immunoglobulin-like domains 2 2.89 
MCM10 minichromosome maintenance complex component 10 2.89 
PPP2R5C protein phosphatase 2, regulatory subunit B', gamma 2.89 
STK32B serine/threonine kinase 32B 2.89 
ZCWPW1 zinc finger, CW type with PWWP domain 1 2.89 
ATP11C ATPase, class VI, type 11C 2.88 
CCDC66 coiled-coil domain containing 66 2.88 
CTPS2 CTP synthase 2 2.88 




SGK1 serum/glucocorticoid regulated kinase 1 2.88 
TMEM150C transmembrane protein 150C 2.88 
TMEM212 transmembrane protein 212 2.88 
VPS39 vacuolar protein sorting 39 homolog (S. cerevisiae) 2.88 
ATP11A ATPase, class VI, type 11A 2.87 
CPNE8 copine VIII 2.87 
DUSP15, 
C20orf57 dual specificity phosphatase 15, chromosome 20 open reading frame 57 2.87 
JMJD1C jumonji domain containing 1C 2.87 
MACF1 microtubule-actin crosslinking factor 1 2.87 
NEK10 NIMA (never in mitosis gene a)- related kinase 10 2.87 
NKTR natural killer-tumor recognition sequence 2.87 
TBC1D25 TBC1 domain family, member 25 2.87 
USP9Y ubiquitin specific peptidase 9, Y-linked 2.87 
ZNF568 zinc finger protein 568 2.86 
ANK2 ankyrin 2, neuronal 2.85 
ASPRV1 
aspartic peptidase, retroviral-like 1, PCBP1 antisense RNA 1 (non-protein 
coding) 2.85 
MANSC1 MANSC domain containing 1 2.85 
OFCC1 orofacial cleft 1 candidate 1 2.85 
PIEZO2 piezo-type mechanosensitive ion channel component 2 2.85 
ZNF277 zinc finger protein 277 2.85 
ARID1A AT rich interactive domain 1A (SWI-like) 2.84 
ERC2 ELKS/RAB6-interacting/CAST family member 2 2.84 
PGD phosphogluconate dehydrogenase 2.84 
RAB36 RAB36, member RAS oncogene family 2.84 
ZFYVE26 zinc finger, FYVE domain containing 26 2.84 
CADPS Ca++-dependent secretion activator 2.83 
LARGE like-glycosyltransferase 2.83 
SUPT16H suppressor of Ty 16 homolog (S. cerevisiae) 2.83 
TNFSF10 tumor necrosis factor (ligand) superfamily, member 10 2.83 
CTBP2 C-terminal binding protein 2 2.82 
F13B coagulation factor XIII, B polypeptide 2.82 
GCNT3 glucosaminyl (N-acetyl) transferase 3, mucin type 2.82 
TEX14 testis expressed 14 2.82 
AGTR1 angiotensin II receptor, type 1 2.81 
C9orf85 chromosome 9 open reading frame 85 2.81 
HECW2 HECT, C2 and WW domain containing E3 ubiquitin protein ligase 2 2.81 
JHDM1D 
jumonji C domain containing histone demethylase 1 homolog D (S. 
cerevisiae) 2.81 
RGS6 regulator of G-protein signaling 6 2.81 
SPTLC3 serine palmitoyltransferase, long chain base subunit 3 2.81 
DOK5 docking protein 5 2.8 
SLC16A14 solute carrier family 16, member 14 (monocarboxylic acid transporter 14) 2.8 




FCHSD2 FCH and double SH3 domains 2 2.79 
THRA, NR1D1 
thyroid hormone receptor, alpha, nuclear receptor subfamily 1, group D, 
member 1 2.79 
TNIP1 TNFAIP3 interacting protein 1 2.79 
DZANK1 double zinc ribbon and ankyrin repeat domains 1 2.78 
ERGIC1 endoplasmic reticulum-golgi intermediate compartment (ERGIC) 1 2.78 
LYST lysosomal trafficking regulator 2.78 
MCM8 minichromosome maintenance complex component 8 2.78 
ASB15 ankyrin repeat and SOCS box containing 15 2.77 
FRAS1 Fraser syndrome 1 2.77 
FSD2 fibronectin type III and SPRY domain containing 2 2.77 
MYO18A, TIAF1 myosin XVIIIA, TGFB1-induced anti-apoptotic factor 1 2.77 
WDR33, 
SFT2D3 WD repeat domain 33, SFT2 domain containing 3 2.77 
ZNF211 zinc finger protein 211 2.77 
MYH15 myosin, heavy chain 15 2.76 
ZNF518A zinc finger protein 518A 2.76 
ACACB acetyl-CoA carboxylase beta 2.75 
ALB albumin 2.75 
C14orf45 chromosome 14 open reading frame 45 2.75 
C5orf4 chromosome 5 open reading frame 4 2.75 
CALCOCO2 calcium binding and coiled-coil domain 2 2.75 
HAUS3, POLN HAUS augmin-like complex, subunit 3, polymerase (DNA directed) nu 2.75 
MCOLN3 mucolipin 3 2.75 
OCA2 oculocutaneous albinism II 2.75 
PPIG peptidylprolyl isomerase G (cyclophilin G) 2.75 
UBE3C ubiquitin protein ligase E3C 2.75 
UIMC1 ubiquitin interaction motif containing 1 2.75 
DFNB59 deafness, autosomal recessive 59 2.74 
GIGYF2 GRB10 interacting GYF protein 2 2.74 
MTMR7 myotubularin related protein 7 2.74 
MYO5C myosin VC 2.74 
MYOM3 myomesin family, member 3 2.74 
DAPK1 death-associated protein kinase 1 2.73 
NOVA1-AS1 NOVA1 antisense RNA 1 (non-protein coding) 2.73 
RPGRIP1L RPGRIP1-like 2.73 
SART3 squamous cell carcinoma antigen recognized by T cells 3 2.73 
SYP synaptophysin 2.73 
ZC4H2 zinc finger, C4H2 domain containing 2.73 
ARHGAP42 Rho GTPase activating protein 42 2.72 
CLIP4 CAP-GLY domain containing linker protein family, member 4 2.72 
CREM cAMP responsive element modulator 2.72 
GLIPR2 GLI pathogenesis-related 2 2.72 




KRT32 keratin 32 2.72 
NEB nebulin 2.72 
PSD3 pleckstrin and Sec7 domain containing 3 2.72 
RAD54L2 RAD54-like 2 (S. cerevisiae) 2.72 
STK11IP serine/threonine kinase 11 interacting protein 2.72 
TDP2 tyrosyl-DNA phosphodiesterase 2 2.72 
ATP1A1 ATPase, Na+/K+ transporting, alpha 1 polypeptide 2.71 
C12orf26 chromosome 12 open reading frame 26 2.71 
C2orf65 chromosome 2 open reading frame 65 2.71 
DUS4L dihydrouridine synthase 4-like (S. cerevisiae) 2.71 
PALLD palladin, cytoskeletal associated protein 2.71 
ZNF124 zinc finger protein 124 2.71 
DGKG diacylglycerol kinase, gamma 90kDa 2.7 
MRVI1 murine retrovirus integration site 1 homolog 2.7 
RPL34-AS1 RPL34 antisense RNA 1 (non-protein coding) 2.7 
UCP3 uncoupling protein 3 (mitochondrial, proton carrier) 2.7 
VPS13D vacuolar protein sorting 13 homolog D (S. cerevisiae) 2.7 
CNOT2 CCR4-NOT transcription complex, subunit 2 2.69 
COL2A1 collagen, type II, alpha 1 2.69 
COL4A3BP collagen, type IV, alpha 3 (Goodpasture antigen) binding protein 2.69 
MTND2P2B MT-ND2 pseudogene 28, NADH-ubiquinone oxidoreductase chain 2-like 2.69 
PARP2 poly (ADP-ribose) polymerase 2 2.69 
PRR4, PRH1 
proline rich 4 (lacrimal), PRH1-PRR4 readthrough, proline-rich protein 
HaeIII subfamily 1 2.69 
RAD51B RAD51 homolog B (S. cerevisiae) 2.69 
RUNDC3B RUN domain containing 3B 2.69 
TTC37 tetratricopeptide repeat domain 37 2.69 
DEDD death effector domain containing 2.68 
NMD3 NMD3 homolog (S. cerevisiae) 2.68 
ATRX alpha thalassemia/mental retardation syndrome X-linked 2.67 
CCT6P1 chaperonin containing TCP1, subunit 6 (zeta) pseudogene 1 2.67 
CEP192 centrosomal protein 192kDa 2.67 
NAV3 neuron navigator 3 2.67 
SERPINB9 serpin peptidase inhibitor, clade B (ovalbumin), member 9 2.67 
SLC24A1 solute carrier family 24 (sodium/potassium/calcium exchanger), member 1 2.67 
SLC43A2 solute carrier family 43, member 2 2.67 
DOCK10 dedicator of cytokinesis 10 2.66 
KHDRBS3 KH domain containing, RNA binding, signal transduction associated 3 2.66 
LAMA2 laminin, alpha 2 2.66 
LOC647859 occludin pseudogene 2.66 
PARP1 poly (ADP-ribose) polymerase 1 2.66 
REPS2 RALBP1 associated Eps domain containing 2 2.66 
WDR48 WD repeat domain 48 2.66 




BCO2 beta-carotene oxygenase 2 2.65 
CEP85L centrosomal protein 85kDa-like 2.65 
ERGIC2 ERGIC and golgi 2 2.65 
FLJ40852 uncharacterized LOC285962 2.65 
KIAA1033 KIAA1033 2.65 
NAV3 neuron navigator 3 2.65 
PION pigeon homolog (Drosophila) 2.65 
SPTA1 spectrin, alpha, erythrocytic 1 (elliptocytosis 2) 2.65 
ATP6V0A2 ATPase, H+ transporting, lysosomal V0 subunit a2 2.64 
MAPKAPK5 mitogen-activated protein kinase-activated protein kinase 5 2.64 
ZNF148 zinc finger protein 148 2.64 
C5orf42 chromosome 5 open reading frame 42 2.63 
C9orf174 chromosome 9 open reading frame 174, pseudogene 2.63 
CHD8 chromodomain helicase DNA binding protein 8 2.63 
FMN1 formin 1, formin-1-like 2.63 
LZTFL1 leucine zipper transcription factor-like 1 2.63 
NUP54 nucleoporin 54kDa 2.63 
PHACTR4 phosphatase and actin regulator 4 2.63 
TBC1D8B TBC1 domain family, member 8B (with GRAM domain) 2.63 
EPHB3 EPH receptor B3 2.62 
NAP1L1 nucleosome assembly protein 1-like 1 2.62 
PSD3 pleckstrin and Sec7 domain containing 3 2.62 
RAP1B RAP1B, member of RAS oncogene family 2.62 
TRPM3 transient receptor potential cation channel, subfamily M, member 3 2.62 
VASH2 vasohibin 2 2.62 
ZNF552 zinc finger protein 552 2.62 
ADK adenosine kinase 2.61 
AKD1 adenylate kinase domain containing 1 2.61 
CACNA2D4 calcium channel, voltage-dependent, alpha 2/delta subunit 4 2.61 
COL15A1 collagen, type XV, alpha 1 2.61 
EVC Ellis van Creveld syndrome 2.61 
KIAA1841 KIAA1841 2.61 
LRRK2 leucine-rich repeat kinase 2 2.61 
MDH1B malate dehydrogenase 1B, NAD (soluble) 2.61 
MYCBP2 MYC binding protein 2, E3 ubiquitin protein ligase 2.61 
NXF2B, NXF2 nuclear RNA export factor 2B, nuclear RNA export factor 2 2.61 
NXF2B, NXF2 nuclear RNA export factor 2B, nuclear RNA export factor 2 2.61 
PPP4R1L protein phosphatase 4, regulatory subunit 1-like 2.61 
RFX8 regulatory factor X, 8 2.61 
USP8 ubiquitin specific peptidase 8 2.61 
AKAP9 A kinase (PRKA) anchor protein (yotiao) 9 2.6 
CAMK2G calcium/calmodulin-dependent protein kinase II gamma 2.6 




FAM91A2 family with sequence similarity 91, member A2 2.6 
KCNAB2 potassium voltage-gated channel, shaker-related subfamily, beta member 2 2.6 
NHSL1 NHS-like 1 2.6 
PLEKHH2 
pleckstrin homology domain containing, family H (with MyTH4 domain) 
member 2 2.6 
PPIL3 peptidylprolyl isomerase (cyclophilin)-like 3 2.6 
SPEG SPEG complex locus 2.6 
TNNC2 troponin C type 2 (fast) 2.6 
XRRA1 X-ray radiation resistance associated 1 2.6 
ZBTB20 zinc finger and BTB domain containing 20 2.6 
ZNF333 zinc finger protein 333 2.6 
C11orf45 chromosome 11 open reading frame 45 2.59 
GCM1 glial cells missing homolog 1 (Drosophila) 2.59 
INADL InaD-like (Drosophila) 2.59 
ODZ4 odz, odd Oz/ten-m homolog 4 (Drosophila) 2.59 
TPH2 tryptophan hydroxylase 2 2.59 
TRPM3 transient receptor potential cation channel, subfamily M, member 3 2.59 
FAM206A family with sequence similarity 206, member A 2.58 
HECTD1 HECT domain containing E3 ubiquitin protein ligase 1 2.58 
JARID2 jumonji, AT rich interactive domain 2 2.58 
MPP3 membrane protein, palmitoylated 3 (MAGUK p55 subfamily member 3) 2.58 
PLAC8 placenta-specific 8 2.58 
TBL2 transducin (beta)-like 2 2.58 
TRPV2 transient receptor potential cation channel, subfamily V, member 2 2.58 
CNOT10 CCR4-NOT transcription complex, subunit 10 2.57 
DUSP16 dual specificity phosphatase 16 2.57 
EFR3A EFR3 homolog A (S. cerevisiae) 2.57 
MYOM2 myomesin (M-protein) 2, 165kDa 2.57 
NR2C1 nuclear receptor subfamily 2, group C, member 1 2.57 
RBM23 RNA binding motif protein 23 2.57 
SH3BGR SH3 domain binding glutamic acid-rich protein 2.57 
ZSCAN16 zinc finger and SCAN domain containing 16 2.57 
BPIFA2 BPI fold containing family A, member 2 2.56 
C12orf76 chromosome 12 open reading frame 76 2.56 
FAM194A family with sequence similarity 194, member A 2.56 
LARP1B La ribonucleoprotein domain family, member 1B 2.56 
MLLT4 
myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, 
Drosophila); translocated to, 4 2.56 
PDE8B phosphodiesterase 8B 2.56 
SETD5 SET domain containing 5 2.56 
SYT1 synaptotagmin I 2.56 
CCDC92 coiled-coil domain containing 92 2.55 
FAM105B family with sequence similarity 105, member B 2.55 




HELZ helicase with zinc finger 2.55 
MYH10 myosin, heavy chain 10, non-muscle 2.55 
NYNRIN NYN domain and retroviral integrase containing 2.55 
TMBIM6 transmembrane BAX inhibitor motif containing 6 2.55 
ZNF260 zinc finger protein 260 2.55 
ZNF519 zinc finger protein 519 2.55 
ZNF615 zinc finger protein 615 2.55 
ATP13A4 ATPase type 13A4 2.54 
C17orf76-AS1 
C17orf76 antisense RNA 1 (non-protein coding), small nucleolar RNA, C/D 
box 65 2.54 
CCDC88C coiled-coil domain containing 88C 2.54 
DOCK4 dedicator of cytokinesis 4 2.54 
KIAA0586 KIAA0586 2.54 
L3MBTL3 l(3)mbt-like 3 (Drosophila) 2.54 
LIN52 lin-52 homolog (C. elegans) 2.54 
MTHFD2L methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2-like 2.54 
PHLPP1 PH domain and leucine rich repeat protein phosphatase 1 2.54 
PRR4, PRH1 
proline rich 4 (lacrimal), PRH1-PRR4 readthrough, proline-rich protein 
HaeIII subfamily 1 2.54 
ADGB androglobin 2.53 
CHN1 chimerin (chimaerin) 1 2.53 
EYS eyes shut homolog (Drosophila) 2.53 
IQCH IQ motif containing H 2.53 
MSR1 macrophage scavenger receptor 1 2.53 
PLAG1 pleiomorphic adenoma gene 1 2.53 
SPOCK3 sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 3 2.53 
VOPP1 vesicular, overexpressed in cancer, prosurvival protein 1 2.53 
ZC3H13 zinc finger CCCH-type containing 13 2.53 
ZC3H8 zinc finger CCCH-type containing 8 2.53 
APPL1 
adaptor protein, phosphotyrosine interaction, PH domain and leucine zipper 
containing 1 2.52 
ARG2 arginase, type II 2.52 
ARHGAP25 Rho GTPase activating protein 25 2.52 
DENND4A DENN/MADD domain containing 4A 2.52 
FAM183A family with sequence similarity 183, member A 2.52 
FAM70A family with sequence similarity 70, member A 2.52 
FUCA1 fucosidase, alpha-L- 1, tissue 2.52 
GUCY2C guanylate cyclase 2C (heat stable enterotoxin receptor) 2.52 
IKZF5 IKAROS family zinc finger 5 (Pegasus) 2.52 
ITM2A integral membrane protein 2A 2.52 
KDM4C lysine (K)-specific demethylase 4C 2.52 
KIF22 kinesin family member 22 2.52 
PTPN13 
protein tyrosine phosphatase, non-receptor type 13 (APO-1/CD95 (Fas)-
associated phosphatase) 2.52 
TBL1XR1 transducin (beta)-like 1 X-linked receptor 1 2.52 




C3orf33 chromosome 3 open reading frame 33 2.51 
CCNG1 cyclin G1 2.51 
CDC42BPG CDC42 binding protein kinase gamma (DMPK-like) 2.51 
NUDT22 nudix (nucleoside diphosphate linked moiety X)-type motif 22 2.51 
SH3GL3 SH3-domain GRB2-like 3 2.51 
SPRR1B small proline-rich protein 1B 2.51 
STRN3 striatin, calmodulin binding protein 3 2.51 
TCF4 transcription factor 4 2.51 
BLNK B-cell linker 2.5 
COG4 component of oligomeric golgi complex 4 2.5 
CORO7-PAM16 
CORO7-PAM16 readthrough, coronin 7, presequence translocase-associated 
motor 16 homolog 2.5 
KIF5C kinesin family member 5C 2.5 
MUC12 mucin 12, cell surface associated 2.5 
MUSK muscle, skeletal, receptor tyrosine kinase 2.5 
NCK1 NCK adaptor protein 1 2.5 
NLRC5 NLR family, CARD domain containing 5 2.5 
PLAGL1 pleiomorphic adenoma gene-like 1 2.5 
PM20D1 peptidase M20 domain containing 1 2.5 
PON3, PON1 paraoxonase 3, paraoxonase 1 2.5 
PRMT5 protein arginine methyltransferase 5 2.5 
PSEN2 presenilin 2 (Alzheimer disease 4) 2.5 
RABEP1 rabaptin, RAB GTPase binding effector protein 1 2.5 
SLC44A5 solute carrier family 44, member 5 2.5 
USH2A Usher syndrome 2A (autosomal recessive, mild) 2.5 
CNOT7 CCR4-NOT transcription complex, subunit 7 2.49 
CPNE6 copine VI (neuronal) 2.49 
FAM153A, 
FAM153B family with sequence similarity 153, members A-B 2.49 
IQCA1 IQ motif containing with AAA domain 1 2.49 
PDE8A phosphodiesterase 8A 2.49 
PFKM phosphofructokinase, muscle 2.49 
RERG RAS-like, estrogen-regulated, growth inhibitor 2.49 
SLC9A5 
solute carrier family 9, subfamily A (NHE5, cation proton antiporter 5), 
member 5 2.49 
TLR3 toll-like receptor 3 2.49 
TMEM199, 
MIR4723 transmembrane protein 199, microRNA 4723 2.49 
VEZT vezatin, adherens junctions transmembrane protein 2.49 
WTAP Wilms tumor 1 associated protein 2.49 
ABCA8 ATP-binding cassette, sub-family A (ABC1), member 8 2.48 
AFF1 AF4/FMR2 family, member 1 2.48 
C5orf47 chromosome 5 open reading frame 47 2.48 
DCP1B DCP1 decapping enzyme homolog B (S. cerevisiae) 2.48 
DMRT3 doublesex and mab-3 related transcription factor 3 2.48 




GALC galactosylceramidase 2.48 
KDM5D lysine (K)-specific demethylase 5D 2.48 
MRPS11 mitochondrial ribosomal protein S11 2.48 
NOSTRIN nitric oxide synthase trafficker 2.48 
PCYT1A, 
TCTEX1D2 phosphate cytidylyltransferase 1, choline, alpha, Tctex1 domain containing 2 2.48 
PRDM14 PR domain containing 14 2.48 
RYK receptor-like tyrosine kinase 2.48 
SERPINB5 serpin peptidase inhibitor, clade B (ovalbumin), member 5 2.48 
SUPT3H suppressor of Ty 3 homolog (S. cerevisiae) 2.48 
TP73 tumor protein p73 2.48 
ZNF675 zinc finger protein 675 2.48 
BRWD1 bromodomain and WD repeat domain containing 1 2.47 
CACNA1I calcium channel, voltage-dependent, T type, alpha 1I subunit 2.47 
COL13A1 collagen, type XIII, alpha 1 2.47 
DIP2A DIP2 disco-interacting protein 2 homolog A (Drosophila) 2.47 
FEZ2 fasciculation and elongation protein zeta 2 (zygin II) 2.47 
FMO5 flavin containing monooxygenase 5 2.47 
PPP1R12A protein phosphatase 1, regulatory subunit 12A 2.47 
SAA2, SAA4 serum amyloid A2, serum amyloid A4, constitutive, SAA2-SAA4 readthrough 2.47 
STK33 serine/threonine kinase 33 2.47 
VPS39 vacuolar protein sorting 39 homolog (S. cerevisiae) 2.47 
ZNHIT6 zinc finger, HIT-type containing 6 2.47 
AFF1 AF4/FMR2 family, member 1 2.46 
DNM3 dynamin 3 2.46 
GRTP1 growth hormone regulated TBC protein 1 2.46 
HERC3 HECT and RLD domain containing E3 ubiquitin protein ligase 3 2.46 
IFT43 intraflagellar transport 43 homolog (Chlamydomonas) 2.46 
ITGA1, PELO integrin, alpha 1, pelota homolog (Drosophila) 2.46 
ITPA inosine triphosphatase (nucleoside triphosphate pyrophosphatase) 2.46 
KIAA1109 KIAA1109 2.46 
LAMA3 laminin, alpha 3 2.46 
LOC100506674 uncharacterized LOC100506674 2.46 
SMC6 structural maintenance of chromosomes 6 2.46 
SPEF2 sperm flagellar 2 2.46 
TTC21A tetratricopeptide repeat domain 21A 2.46 
ZDHHC23 zinc finger, DHHC-type containing 23 2.46 
ZNF487P zinc finger protein 487, pseudogene 2.46 
AHCYL1 adenosylhomocysteinase-like 1 2.45 
CDKN2AIP CDKN2A interacting protein 2.45 
HERC3 HECT and RLD domain containing E3 ubiquitin protein ligase 3 2.45 
IL4R interleukin 4 receptor 2.45 
LINC00461, 




RARB retinoic acid receptor, beta 2.45 
ROS1, GOPC 
c-ros oncogene 1 , receptor tyrosine kinase, golgi-associated PDZ and coiled-
coil motif containing 2.45 
RXFP2 relaxin/insulin-like family peptide receptor 2 2.45 
SLC25A36 solute carrier family 25 (pyrimidine nucleotide carrier ), member 36 2.45 
SND1 staphylococcal nuclease and tudor domain containing 1 2.45 
STAG1 stromal antigen 1 2.45 
TMEM130 transmembrane protein 130 2.45 
TXLNB taxilin beta 2.45 
ZBTB33 zinc finger and BTB domain containing 33 2.45 
AGPAT4 
1-acylglycerol-3-phosphate O-acyltransferase 4 (lysophosphatidic acid 
acyltransferase, delta) 2.44 
ALG10B, ALG10 asparagine-linked glycosylation 10, alpha-1,2-glucosyltransferase homolog 2.44 
ASPRV1 
aspartic peptidase, retroviral-like 1, PCBP1 antisense RNA 1 (non-protein 
coding) 2.44 
ATP13A5 ATPase type 13A5 2.44 
C10orf90 chromosome 10 open reading frame 90 2.44 
EML6 echinoderm microtubule associated protein like 6 2.44 
GPR180 G protein-coupled receptor 180 2.44 
IKZF5 IKAROS family zinc finger 5 (Pegasus) 2.44 
LANCL1 LanC lantibiotic synthetase component C-like 1 (bacterial) 2.44 
LHCGR luteinizing hormone/choriogonadotropin receptor 2.44 
MED15 mediator complex subunit 15 2.44 
MKL1 megakaryoblastic leukemia (translocation) 1 2.44 
MRO maestro 2.44 
PDK3 pyruvate dehydrogenase kinase, isozyme 3 2.44 
RBM23 RNA binding motif protein 23 2.44 
SEC24B SEC24 family, member B (S. cerevisiae) 2.44 
SSH3 slingshot homolog 3 (Drosophila) 2.44 
ST6GAL1 ST6 beta-galactosamide alpha-2,6-sialyltranferase 1 2.44 
TEC tec protein tyrosine kinase 2.44 
TULP2 tubby like protein 2 2.44 
ABHD12B, 
MIR4454 abhydrolase domain containing 12B, microRNA 4454 2.43 
AHI1 Abelson helper integration site 1 2.43 
CACNA1F calcium channel, voltage-dependent, L type, alpha 1F subunit 2.43 
CARS cysteinyl-tRNA synthetase 2.43 
KIF1B kinesin family member 1B 2.43 
KIRREL kin of IRRE like (Drosophila) 2.43 
MTMR8, ASB12 myotubularin related protein 8, ankyrin repeat and SOCS box containing 12 2.43 
RAB38 RAB38, member RAS oncogene family 2.43 
RCOR3 REST corepressor 3 2.43 
RFX7 regulatory factor X, 7 2.43 
TRIM36 tripartite motif containing 36 2.43 
UBE3D ubiquitin protein ligase E3D 2.43 




EIF2C3 eukaryotic translation initiation factor 2C, 3 2.42 
FANCB Fanconi anemia, complementation group B 2.42 
PTPN6 protein tyrosine phosphatase, non-receptor type 6 2.42 
PTPRE protein tyrosine phosphatase, receptor type, E 2.42 
SGK494 uncharacterized serine/threonine-protein kinase SgK494 2.42 
ST7L suppression of tumorigenicity 7 like 2.42 
TTC6 tetratricopeptide repeat domain 6, tetratricopeptide repeat protein 6-like 2.42 
ZBTB41 zinc finger and BTB domain containing 41 2.42 
AQPEP laeverin 2.41 
ARHGAP26 Rho GTPase activating protein 26 2.41 
GRB14 growth factor receptor-bound protein 14 2.41 
LIPM lipase, family member M 2.41 
NAA16 N(alpha)-acetyltransferase 16, NatA auxiliary subunit 2.41 
ATP11B ATPase, class VI, type 11B 2.4 
CCDC150 coiled-coil domain containing 150 2.4 
GTF2B general transcription factor IIB 2.4 
HERC5 HECT and RLD domain containing E3 ubiquitin protein ligase 5 2.4 
NBEAL1 neurobeachin-like 1, 60S ribosomal protein L12-like 2.4 
NIPAL1 NIPA-like domain containing 1 2.4 
NNT nicotinamide nucleotide transhydrogenase 2.4 
PAK3 p21 protein (Cdc42/Rac)-activated kinase 3 2.4 
RFX3 regulatory factor X, 3 (influences HLA class II expression) 2.4 
RGL1 ral guanine nucleotide dissociation stimulator-like 1 2.4 
TRIM29 tripartite motif containing 29 2.4 
CLEC16A C-type lectin domain family 16, member A 2.39 
DYRK3 dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 3 2.39 
FBXO36 F-box protein 36 2.39 
HORMAD2 HORMA domain containing 2 2.39 
HTR3D 5-hydroxytryptamine (serotonin) receptor 3D, ionotropic 2.39 
LOC100132891 uncharacterized LOC100132891 2.39 
SH3BP5 SH3-domain binding protein 5 (BTK-associated) 2.39 
USP34 ubiquitin specific peptidase 34 2.39 
AHCYL2 adenosylhomocysteinase-like 2 2.38 
EPHA3 EPH receptor A3 2.38 
FER1L5 fer-1-like 5 (C. elegans) 2.38 
FXYD6, FXYD6 
FXYD domain containing ion transport regulator 2 & 6, FXYD6-FXYD2 
readthrough 2.38 
HHIP hedgehog interacting protein 2.38 
IFIT3 interferon-induced protein with tetratricopeptide repeats 3 2.38 
SORBS2 sorbin and SH3 domain containing 2 2.38 
SPAG17 sperm associated antigen 17 2.38 
TLR6 toll-like receptor 6 2.38 
USP54 ubiquitin specific peptidase 54 2.38 





7/P ankyrin repeat domain 20 family, members A1-A7 2.37 
FLJ39653 uncharacterized FLJ39653 2.37 
FMN2 formin 2 2.37 
HARS2 histidyl-tRNA synthetase 2, mitochondrial (putative) 2.37 
HSPA4L heat shock 70kDa protein 4-like 2.37 
IL15 interleukin 15 2.37 
MED23 mediator complex subunit 23 2.37 
NFE2L2 nuclear factor (erythroid-derived 2)-like 2 2.37 
PHLPP1 PH domain and leucine rich repeat protein phosphatase 1 2.37 
PNPLA7 patatin-like phospholipase domain containing 7 2.37 
SLC43A2 solute carrier family 43, member 2 2.37 
SPAG17 sperm associated antigen 17 2.37 
TAPT1 transmembrane anterior posterior transformation 1 2.37 
TSHR thyroid stimulating hormone receptor 2.37 
UTY ubiquitously transcribed tetratricopeptide repeat gene, Y-linked 2.37 
ZNF780B zinc finger protein 780B 2.37 
ITGAV integrin, alpha V 2.36 
PPP1R7 protein phosphatase 1, regulatory subunit 7 2.36 
RELN reelin 2.36 
UGGT2 UDP-glucose glycoprotein glucosyltransferase 2 2.36 
WAC WW domain containing adaptor with coiled-coil 2.36 
ZCCHC2 zinc finger, CCHC domain containing 2 2.36 
ADAL adenosine deaminase-like 2.35 
AFAP1L2 actin filament associated protein 1-like 2 2.35 
CD101 CD101 molecule 2.35 
CDHR3 cadherin-related family member 3 2.35 
CREG1 cellular repressor of E1A-stimulated genes 1 2.35 
CRYZ crystallin, zeta (quinone reductase) 2.35 
IQCB1 IQ motif containing B1 2.35 
KRT10 keratin 10 2.35 
LTBR lymphotoxin beta receptor (TNFR superfamily, member 3) 2.35 
MS4A3 
membrane-spanning 4-domains, subfamily A, member 3 (hematopoietic cell-
specific) 2.35 
PDE6C phosphodiesterase 6C, cGMP-specific, cone, alpha prime 2.35 
PDS5B PDS5, regulator of cohesion maintenance, homolog B (S. cerevisiae) 2.35 
SLC25A26 solute carrier family 25 (S-adenosylmethionine carrier), member 26 2.35 
STAG2 stromal antigen 2 2.35 
STXBP5 syntaxin binding protein 5 (tomosyn) 2.35 
TRAPPC9 trafficking protein particle complex 9 2.35 
ZMYM3 zinc finger, MYM-type 3 2.35 
C5 complement component 5 2.34 
CARD9 caspase recruitment domain family, member 9 2.34 




DDX26B DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 26B 2.34 
EDARADD EDAR-associated death domain 2.34 
FAM65B family with sequence similarity 65, member B 2.34 
FLJ42351 uncharacterized LOC400999 2.34 
GMPS guanine monphosphate synthetase 2.34 
IL13RA2 interleukin 13 receptor, alpha 2 2.34 
LMLN leishmanolysin-like (metallopeptidase M8 family) 2.34 
MECOM MDS1 and EVI1 complex locus 2.34 
MICAL2 
microtubule associated monoxygenase, calponin and LIM domain containing 
2 2.34 
MTX2 metaxin 2 2.34 
PRDM15 PR domain containing 15 2.34 
PTPN12 protein tyrosine phosphatase, non-receptor type 12 2.34 
RAPGEF4 Rap guanine nucleotide exchange factor (GEF) 4 2.34 
RNF175 ring finger protein 175 2.34 
TAB3 TGF-beta activated kinase 1/MAP3K7 binding protein 3 2.34 
TRMT1 tRNA methyltransferase 1 homolog (S. cerevisiae) 2.34 
ZNF638 zinc finger protein 638 2.34 
CDKL5 cyclin-dependent kinase-like 5 2.33 
CLDND1 a domain containing 1 2.33 
EIF2C3 eukaryotic translation initiation factor 2C, 3 2.33 
GPR112 G protein-coupled receptor 112 2.33 
MRPS27 mitochondrial ribosomal protein S27 2.33 
MTMR4 myotubularin related protein 4 2.33 
PTPN14 protein tyrosine phosphatase, non-receptor type 14 2.33 
PTPRQ protein tyrosine phosphatase, receptor type, Q 2.33 
SASH1 SAM and SH3 domain containing 1 2.33 
SSX2IP synovial sarcoma, X breakpoint 2 interacting protein 2.33 
STK31 serine/threonine kinase 31 2.33 
TINAG tubulointerstitial nephritis antigen 2.33 
TTLL7 tubulin tyrosine ligase-like family, member 7 2.33 
ZNF577 zinc finger protein 577 2.33 
ABCA10 ATP-binding cassette, sub-family A (ABC1), member 10 2.32 
ARSK arylsulfatase family, member K 2.32 
EPB41L5 erythrocyte membrane protein band 4.1 like 5 2.32 
EVI5 ecotropic viral integration site 5 2.32 
FAM135A family with sequence similarity 135, member A 2.32 
HDAC4 histone deacetylase 4 2.32 
PCYT1B phosphate cytidylyltransferase 1, choline, beta 2.32 
UNC5B unc-5 homolog B (C. elegans) 2.32 
WFDC8 WAP four-disulfide core domain 8 2.32 
ATP10A ATPase, class V, type 10A 2.31 
DEPDC4 DEP domain containing 4 2.31 




FGD6 FYVE, RhoGEF and PH domain containing 6 2.31 
GALNT14 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 14 (GalNAc-T14) 2.31 
GRIA2 glutamate receptor, ionotropic, AMPA 2 2.31 
IL1RL2 interleukin 1 receptor-like 2 2.31 
LTBP3 latent transforming growth factor beta binding protein 3 2.31 
MX1 
myxovirus (influenza virus) resistance 1, interferon-inducible protein p78 
(mouse) 2.31 
MYD88 myeloid differentiation primary response gene (88) 2.31 
OSBPL6 oxysterol binding protein-like 6 2.31 
OTX2-AS1 OTX2 antisense RNA 1 (non-protein coding) 2.31 
PHKG1 phosphorylase kinase, gamma 1 (muscle) 2.31 
PVR poliovirus receptor 2.31 
RASGRP4 RAS guanyl releasing protein 4 2.31 
SMCHD1 structural maintenance of chromosomes flexible hinge domain containing 1 2.31 
TEX35 testis expressed 35 2.31 
THADA thyroid adenoma associated 2.31 
TNIP3 TNFAIP3 interacting protein 3 2.31 
UBE2E1 ubiquitin-conjugating enzyme E2E 1 2.31 
WDR11 WD repeat domain 11 2.31 
ACVR1C activin A receptor, type IC 2.3 
BOLL bol, boule-like (Drosophila) 2.3 
CAMK2G calcium/calmodulin-dependent protein kinase II gamma 2.3 
CEACAM19 carcinoembryonic antigen-related cell adhesion molecule 19 2.3 
DGCR14, TSSK2 DiGeorge syndrome critical region gene 14, testis-specific serine kinase 2 2.3 
EPC1 enhancer of polycomb homolog 1 (Drosophila) 2.3 
GRB10 growth factor receptor-bound protein 10 2.3 
KIAA1210 KIAA1210 2.3 
LHFP lipoma HMGIC fusion partner 2.3 
LRRC37B leucine rich repeat containing 37B 2.3 
MREG melanoregulin 2.3 
RAB3A RAB3A, member RAS oncogene family 2.3 
RSPH3 radial spoke 3 homolog (Chlamydomonas) 2.3 
SCIN scinderin 2.3 
SLCO1C1 solute carrier organic anion transporter family, member 1C1 2.3 
STX2 syntaxin 2 2.3 
TTN titin 2.3 
ABCB11 ATP-binding cassette, sub-family B (MDR/TAP), member 11 2.29 
ACAA2 acetyl-CoA acyltransferase 2 2.29 
ALG9 
asparagine-linked glycosylation 9, alpha-1,2-mannosyltransferase homolog 
(S. cerevisiae) 2.29 
ARHGAP32 Rho GTPase activating protein 32 2.29 
C21orf49 chromosome 21 open reading frame 49 2.29 
DLG3 discs, large homolog 3 (Drosophila) 2.29 
GNAT2 
guanine nucleotide binding protein (G protein), alpha transducing activity 




LOC284930 uncharacterized LOC284930 2.29 
SKIV2L2 superkiller viralicidic activity 2-like 2 (S. cerevisiae) 2.29 
STC1 stanniocalcin 1 2.29 
TEKT4P2, 
MAFIP 
tektin 4 pseudogene 2, tektin 4 pseudogene, MAFF interacting protein 
(pseudogene) 2.29 
ZNF599 zinc finger protein 599 2.29 
ANKS1B ankyrin repeat and sterile alpha motif domain containing 1B 2.28 
ATAD2B ATPase family, AAA domain containing 2B 2.28 
CTNNBL1 catenin, beta like 1 2.28 
DHRS1 dehydrogenase/reductase (SDR family) member 1 2.28 
FUBP3 far upstream element (FUSE) binding protein 3 2.28 
POT1 protection of telomeres 1 homolog (S. pombe) 2.28 
SEC31A SEC31 homolog A (S. cerevisiae) 2.28 
SH3TC1 SH3 domain and tetratricopeptide repeats 1 2.28 
VSTM2A V-set and transmembrane domain containing 2A 2.28 
ADD3 adducin 3 (gamma) 2.27 
ASIC2 acid-sensing (proton-gated) ion channel 2 2.27 
C12orf39 chromosome 12 open reading frame 39 2.27 
C15orf41 chromosome 15 open reading frame 41 2.27 
C4orf21 chromosome 4 open reading frame 21 2.27 
CLIP4 CAP-GLY domain containing linker protein family, member 4 2.27 
DNAJB5 DnaJ (Hsp40) homolog, subfamily B, member 5 2.27 
FCER1A Fc fragment of IgE, high affinity I, receptor for; alpha polypeptide 2.27 
MCTP1 multiple C2 domains, transmembrane 1 2.27 
MTUS1 microtubule associated tumor suppressor 1 2.27 
MYH10 myosin, heavy chain 10, non-muscle 2.27 
SLC4A7 solute carrier family 4, sodium bicarbonate cotransporter, member 7 2.27 
SMARCE1 
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, 
subfamily e, member 1 2.27 
STIM2 stromal interaction molecule 2 2.27 
ULBP3 UL16 binding protein 3 2.27 
VPS11 vacuolar protein sorting 11 homolog (S. cerevisiae) 2.27 
ZBTB41 zinc finger and BTB domain containing 41 2.27 
ZNF143 zinc finger protein 143 2.27 
CEP170, 
CEP170P1 centrosomal protein 170kDa, centrosomal protein 170kDa pseudogene 1 2.26 
GZMB 
granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine esterase 
1) 2.26 
KDM6B lysine (K)-specific demethylase 6B 2.26 
L2HGDH L-2-hydroxyglutarate dehydrogenase 2.26 
MAGI3 membrane associated guanylate kinase, WW and PDZ domain containing 3 2.26 
MLLT4 
myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, 
Drosophila); translocated to, 4 2.26 
PSMD11 proteasome (prosome, macropain) 26S subunit, non-ATPase, 11 2.26 
RUNX1T1 runt-related transcription factor 1; translocated to, 1 (cyclin D-related) 2.26 
SAMM50, 
PNPLA3 
sorting and assembly machinery component 50 homolog, patatin-like 




SETD5 SET domain containing 5 2.26 
SLFN11 schlafen family member 11 2.26 
SRRM1 serine/arginine repetitive matrix 1 2.26 
SVEP1 sushi, von Willebrand factor type A, EGF and pentraxin domain containing 1 2.26 
ZMYM6 zinc finger, MYM-type 6 2.26 
ACOX2 acyl-CoA oxidase 2, branched chain 2.25 
ARHGAP31 Rho GTPase activating protein 31 2.25 
BAIAP2 BAI1-associated protein 2 2.25 
CNOT4 CCR4-NOT transcription complex, subunit 4 2.25 
CPT1C carnitine palmitoyltransferase 1C 2.25 
FOXRED1 FAD-dependent oxidoreductase domain containing 1 2.25 
FUBP1 far upstream element (FUSE) binding protein 1 2.25 
GFM1 G elongation factor, mitochondrial 1 2.25 
HIBCH 3-hydroxyisobutyryl-CoA hydrolase 2.25 
HSPBAP1 HSPB (heat shock 27kDa) associated protein 1 2.25 
IGSF9B immunoglobulin superfamily, member 9B 2.25 
LOC152586 glycosyltransferase 54 domain-containing protein 2.25 
MLF1IP MLF1 interacting protein 2.25 
PACS1 phosphofurin acidic cluster sorting protein 1 2.25 
PCBD2 
pterin-4 alpha-carbinolamine dehydratase/dimerization nuclear factor 1 
alpha (TCF1) 2 2.25 
PRIC285 peroxisomal proliferator-activated receptor A interacting complex 285 2.25 
RFX7 regulatory factor X, 7 2.25 
RHOBTB2 Rho-related BTB domain containing 2 2.25 
STAT2 signal transducer and activator of transcription 2, 113kDa 2.25 
AP1G1 adaptor-related protein complex 1, gamma 1 subunit 2.24 
ASB6 ankyrin repeat and SOCS box containing 6 2.24 
C10orf88 chromosome 10 open reading frame 88 2.24 
CACNB1 calcium channel, voltage-dependent, beta 1 subunit 2.24 
CAPN3 calpain 3, (p94) 2.24 
COL19A1 collagen, type XIX, alpha 1 2.24 
DGKD diacylglycerol kinase, delta 130kDa 2.24 
FAM178B family with sequence similarity 178, member B 2.24 
HEATR7B2 HEAT repeat family member 7B2 2.24 
KANSL1L KAT8 regulatory NSL complex subunit 1-like 2.24 
MYOF myoferlin 2.24 
NPC2, MIR4709 Niemann-Pick disease, type C2, microRNA 4709 2.24 
PPME1 protein phosphatase methylesterase 1 2.24 
UAP1L1 UDP-N-acteylglucosamine pyrophosphorylase 1-like 1 2.24 
ADAMTS2 ADAM metallopeptidase with thrombospondin type 1 motif, 2 2.23 
C2orf56 chromosome 2 open reading frame 56 2.23 
CLIC6 chloride intracellular channel 6 2.23 





excision repair cross-complementing rodent repair deficiency, 
complementation group 6-like 2 2.23 
FAM133B family with sequence similarity 133, member B 2.23 
FMNL2 formin-like 2 2.23 
GNPDA2 glucosamine-6-phosphate deaminase 2 2.23 
GSTT2B, GSTT2 
glutathione S-transferase theta 2B (gene/pseudogene), glutathione S-
transferase theta 2 2.23 
HDAC8 histone deacetylase 8 2.23 
HMBOX1 homeobox containing 1 2.23 
IBTK inhibitor of Bruton agammaglobulinemia tyrosine kinase 2.23 
KAL1 Kallmann syndrome 1 sequence 2.23 
LARP4 La ribonucleoprotein domain family, member 4 2.23 
POLR3G polymerase (RNA) III (DNA directed) polypeptide G (32kD) 2.23 
RTTN rotatin 2.23 
ST8SIA6 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 6 2.23 
TMEM150C transmembrane protein 150C 2.23 
ZBTB38 zinc finger and BTB domain containing 38 2.23 
ZCCHC8 zinc finger, CCHC domain containing 8 2.23 
ZNF512 zinc finger protein 512 2.23 
ABCC2 ATP-binding cassette, sub-family C (CFTR/MRP), member 2 2.22 
ANKRD12 ankyrin repeat domain 12 2.22 
BAZ2B bromodomain adjacent to zinc finger domain, 2B 2.22 
CAMK2B calcium/calmodulin-dependent protein kinase II beta 2.22 
CD1B CD1b molecule 2.22 
CLDND1 claudin domain containing 1 2.22 
DOCK11 dedicator of cytokinesis 11 2.22 
EP400 E1A binding protein p400 2.22 
FGFR1 fibroblast growth factor receptor 1 2.22 
FRMD3 FERM domain containing 3 2.22 
IL1RAP interleukin 1 receptor accessory protein 2.22 
LOC100506942 uncharacterized LOC100506942 2.22 
LPP LIM domain containing preferred translocation partner in lipoma 2.22 
LRRK1 leucine-rich repeat kinase 1 2.22 
LTBP1 latent transforming growth factor beta binding protein 1 2.22 
MGA MAX gene associated 2.22 
NCOA6 nuclear receptor coactivator 6 2.22 
NID2 nidogen 2 (osteonidogen) 2.22 
NOC3L nucleolar complex associated 3 homolog (S. cerevisiae) 2.22 
NUP155 nucleoporin 155kDa 2.22 
PTPN14 protein tyrosine phosphatase, non-receptor type 14 2.22 
RPH3AL rabphilin 3A-like (without C2 domains) 2.22 
SEL1L3 sel-1 suppressor of lin-12-like 3 (C. elegans) 2.22 
SMG7 smg-7 homolog, nonsense mediated mRNA decay factor (C. elegans) 2.22 




TPP2 tripeptidyl peptidase II 2.22 
ACSF2 acyl-CoA synthetase family member 2 2.21 
ASTE1 asteroid homolog 1 (Drosophila) 2.21 
ASTE1 asteroid homolog 1 (Drosophila) 2.21 
ATP9B ATPase, class II, type 9B 2.21 
C10orf76 chromosome 10 open reading frame 76 2.21 
CCDC150 coiled-coil domain containing 150 2.21 
CDC14A CDC14 cell division cycle 14 homolog A (S. cerevisiae) 2.21 
CYFIP2 cytoplasmic FMR1 interacting protein 2 2.21 
D21S2088E D21S2088E 2.21 
EBAG9 estrogen receptor binding site associated, antigen, 9 2.21 
ESR1 estrogen receptor 1 2.21 
FAM189A1 family with sequence similarity 189, member A1 2.21 
GALNT1 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 1 (GalNAc-T1) 2.21 
GALNT14 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 14 (GalNAc-T14) 2.21 
GKAP1 G kinase anchoring protein 1 2.21 
GLOD4 glyoxalase domain containing 4 2.21 
KATNAL1 katanin p60 subunit A-like 1 2.21 
KDR kinase insert domain receptor (a type III receptor tyrosine kinase) 2.21 
KIAA0528 KIAA0528 2.21 
KIAA1109 KIAA1109 2.21 
MAEA macrophage erythroblast attacher 2.21 
MYO5A myosin VA (heavy chain 12, myoxin) 2.21 
PCDHGA/B/C1-
12 protocadherin gamma subfamily A-C/1-12 2.21 
PTPN3 protein tyrosine phosphatase, non-receptor type 3 2.21 
SQLE squalene epoxidase 2.21 
TSNAX-DISC1 
TSNAX-DISC1 readthrough, disrupted in schizophrenia 1, translin-associated 
factor X 2.21 
TTLL7 tubulin tyrosine ligase-like family, member 7 2.21 
ABCC9 ATP-binding cassette, sub-family C (CFTR/MRP), member 9 2.2 
ANK3 ankyrin 3, node of Ranvier (ankyrin G) 2.2 
CAPRIN1 cell cycle associated protein 1 2.2 
DENND4C DENN/MADD domain containing 4C 2.2 
DGCR5 DiGeorge syndrome critical region gene 5 (non-protein coding) 2.2 
DNAJC6 DnaJ (Hsp40) homolog, subfamily C, member 6 2.2 
ERGIC2 ERGIC and golgi 2 2.2 
FAM228B family with sequence similarity 228, member B 2.2 
GMPS guanine monphosphate synthetase 2.2 
LRRK2 leucine-rich repeat kinase 2 2.2 
MLH3 mutL homolog 3 (E. coli) 2.2 
NAALAD2 N-acetylated alpha-linked acidic dipeptidase 2 2.2 
PLD5 phospholipase D family, member 5 2.2 




RBM26-AS1 RBM26 antisense RNA 1 (non-protein coding) 2.2 
RBM4B RNA binding motif protein 4B 2.2 
SCARA3 scavenger receptor class A, member 3 2.2 
SYNM synemin, intermediate filament protein 2.2 
TMEM25 transmembrane protein 25 2.2 
TRPS1 trichorhinophalangeal syndrome I 2.2 
AKAP13 A kinase (PRKA) anchor protein 13 2.19 
ANKRD26P3 ankyrin repeat domain 26 pseudogene 3 2.19 
C11orf24 chromosome 11 open reading frame 24 2.19 
C1QTNF5, 
MFRP 
C1q and tumor necrosis factor related protein 5, membrane frizzled-related 
protein 2.19 
CEP192 centrosomal protein 192kDa 2.19 
CEP290 centrosomal protein 290kDa 2.19 
CXorf57 chromosome X open reading frame 57 2.19 
FAM228B family with sequence similarity 228, member B 2.19 
GABRA3 gamma-aminobutyric acid (GABA) A receptor, alpha 3 2.19 
HNRNPU heterogeneous nuclear ribonucleoprotein U (scaffold attachment factor A) 2.19 
KIAA0317 KIAA0317 2.19 
LDHA lactate dehydrogenase A 2.19 
LRRC48 leucine rich repeat containing 48 2.19 
LRRIQ1 leucine-rich repeats and IQ motif containing 1 2.19 
PPFIA2 
protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), 
interacting protein (liprin), alpha 2 2.19 
RRH retinal pigment epithelium-derived rhodopsin homolog 2.19 
TUBGCP2 tubulin, gamma complex associated protein 2 2.19 
UBAP2 ubiquitin associated protein 2 2.19 
XPR1 xenotropic and polytropic retrovirus receptor 1 2.19 
ABCC9 ATP-binding cassette, sub-family C (CFTR/MRP), member 9 2.18 
APBB1IP 
amyloid beta (A4) precursor protein-binding, family B, member 1 interacting 
protein 2.18 
CEP41 centrosomal protein 41kDa 2.18 
CUL4B cullin 4B 2.18 
DENND1B DENN/MADD domain containing 1B 2.18 
DNAJC1 DnaJ (Hsp40) homolog, subfamily C, member 1 2.18 
ESYT2 extended synaptotagmin-like protein 2 2.18 
GANC, CAPN3 glucosidase, alpha; neutral C, calpain 3, (p94) 2.18 
HTRA4 HtrA serine peptidase 4 2.18 
KIAA1324L KIAA1324-like 2.18 
KIF27 kinesin family member 27 2.18 
MAN1B1 mannosidase, alpha, class 1B, member 1 2.18 
NDUFA12 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 12 2.18 
NF1 neurofibromin 1 2.18 
NF1 neurofibromin 1 2.18 
NUCB1 nucleobindin 1 2.18 




SLC25A20 solute carrier family 25 (carnitine/acylcarnitine translocase), member 20 2.18 
SNX25 sorting nexin 25 2.18 
SPTLC3 serine palmitoyltransferase, long chain base subunit 3 2.18 
TFDP1 transcription factor Dp-1 2.18 
TXNDC16 thioredoxin domain containing 16 2.18 
WASL Wiskott-Aldrich syndrome-like 2.18 
ABCB7 ATP-binding cassette, sub-family B (MDR/TAP), member 7 2.17 
BRWD1 bromodomain and WD repeat domain containing 1 2.17 
C17orf81 chromosome 17 open reading frame 81 2.17 
CASP7 caspase 7, apoptosis-related cysteine peptidase 2.17 
CLCA4 chloride channel accessory 4 2.17 
CLEC3A C-type lectin domain family 3, member A 2.17 
DHX36 DEAH (Asp-Glu-Ala-His) box polypeptide 36 2.17 
FAM102B family with sequence similarity 102, member B 2.17 
IL1RAP interleukin 1 receptor accessory protein 2.17 
LAT linker for activation of T cells 2.17 
LRRC27 leucine rich repeat containing 27 2.17 
MAP3K15 mitogen-activated protein kinase kinase kinase 15 2.17 
MSL3 male-specific lethal 3 homolog (Drosophila) 2.17 
NCOA6 nuclear receptor coactivator 6 2.17 
PRKAR2B protein kinase, cAMP-dependent, regulatory, type II, beta 2.17 
PTK2B PTK2B protein tyrosine kinase 2 beta 2.17 
RBM23 RNA binding motif protein 23 2.17 
SLC28A3 solute carrier family 28 (sodium-coupled nucleoside transporter), member 3 2.17 
SNORD113-4 small nucleolar RNA, C/D box 113-4 2.17 
SRSF4 serine/arginine-rich splicing factor 4 2.17 
STX16-NPEPL1 
STX16-NPEPL1 readthrough (non-protein coding), syntaxin 16, 
aminopeptidase-like 1 2.17 
SULF1 sulfatase 1 2.17 
TAF1D, 
MIR1304 
TATA box binding protein (TBP)-associated factor, RNA polymerase I,  
microRNA 1304 2.17 
TCEANC2 
transcription elongation factor A (SII) N-terminal and central domain 
containing 2 2.17 
UPK1B uroplakin 1B 2.17 
ANKRD46 
ankyrin repeat domain 46, glyceraldehyde 3 phosphate dehydrogenase 
pseudogene 62 2.16 
BIRC3 baculoviral IAP repeat containing 3 2.16 
C2CD3 C2 calcium-dependent domain containing 3 2.16 
CCDC9 coiled-coil domain containing 9 2.16 
CD2AP CD2-associated protein 2.16 
CDKL3 cyclin-dependent kinase-like 3 2.16 
CLDN10 claudin 10 2.16 
COG7 component of oligomeric golgi complex 7 2.16 
DGKE diacylglycerol kinase, epsilon 64kDa 2.16 
EEF2K eukaryotic elongation factor-2 kinase 2.16 




GTF2I general transcription factor IIi 2.16 
LEF1 lymphoid enhancer-binding factor 1 2.16 
LMOD3 leiomodin 3 (fetal) 2.16 
LOC644135 uncharacterized LOC644135 2.16 
MLL 
myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, 
Drosophila) 2.16 
NEDD4 
neural precursor cell expressed, developmentally down-regulated 4, E3 
ubiquitin protein ligase 2.16 
NFX1 nuclear transcription factor, X-box binding 1 2.16 
PLEKHH2 
pleckstrin homology domain containing, family H (with MyTH4 domain) 
member 2 2.16 
RC3H1 ring finger and CCCH-type domains 1 2.16 
ROBO1 roundabout, axon guidance receptor, homolog 1 (Drosophila) 2.16 
SERPINB4,3 serpin peptidase inhibitor, clade B (ovalbumin), member 3 & 4 2.16 
SFSWAP splicing factor, suppressor of white-apricot homolog (Drosophila) 2.16 
SYCP2 synaptonemal complex protein 2 2.16 
TMBIM6 transmembrane BAX inhibitor motif containing 6 2.16 
ZNF566 zinc finger protein 566 2.16 
ALB albumin 2.15 
ANO3 anoctamin 3 2.15 
CCDC51 coiled-coil domain containing 51 2.15 
CCNK cyclin K 2.15 
CDK5RAP2 CDK5 regulatory subunit associated protein 2 2.15 
CHMP7 charged multivesicular body protein 7 2.15 
EPC2 enhancer of polycomb homolog 2 (Drosophila) 2.15 
FAM54A family with sequence similarity 54, member A 2.15 
FANK1 fibronectin type III and ankyrin repeat domains 1 2.15 
HMBOX1 homeobox containing 1 2.15 
INO80D INO80 complex subunit D 2.15 
MON1A MON1 homolog A (yeast) 2.15 
NEB nebulin 2.15 
PACSIN2 protein kinase C and casein kinase substrate in neurons 2 2.15 
PCP4 Purkinje cell protein 4 2.15 
PPP1R3E protein phosphatase 1, regulatory subunit 3E 2.15 
PRKAA2 protein kinase, AMP-activated, alpha 2 catalytic subunit 2.15 
SASH1 SAM and SH3 domain containing 1 2.15 
SASH1 SAM and SH3 domain containing 1 2.15 
SNX2 sorting nexin 2 2.15 
USP49 ubiquitin specific peptidase 49 2.15 
ZBTB16 zinc finger and BTB domain containing 16 2.15 
ZNF487P zinc finger protein 487, pseudogene 2.15 
ARHGAP20 Rho GTPase activating protein 20 2.14 
ARHGEF11 Rho guanine nucleotide exchange factor (GEF) 11 2.14 
ARMC8 armadillo repeat containing 8 2.14 




DNAJC3 DnaJ (Hsp40) homolog, subfamily C, member 3 2.14 
EXTL2 exostoses (multiple)-like 2 2.14 
GCOM1 GRINL1A complex locus 1 & 2, myocardial zonula adherens protein 2.14 
GDAP1 ganglioside induced differentiation associated protein 1 2.14 
HBE1 hemoglobin, epsilon 1 2.14 
IMPAD1 inositol monophosphatase domain containing 1 2.14 
HLA-DQB1 HLA class II histocompatibility antigen, DQ beta 1 2.14 
LUZP2 leucine zipper protein 2 2.14 
LYPLA1 lysophospholipase I 2.14 
NAE1 NEDD8 activating enzyme E1 subunit 1 2.14 
NAV3 neuron navigator 3 2.14 
PAPOLG poly(A) polymerase gamma 2.14 
PTBP1 polypyrimidine tract binding protein 1 2.14 
RGL2 ral guanine nucleotide dissociation stimulator-like 2 2.14 
RGL2 ral guanine nucleotide dissociation stimulator-like 2 2.14 
RGL2 ral guanine nucleotide dissociation stimulator-like 2 2.14 
RGL2 ral guanine nucleotide dissociation stimulator-like 2 2.14 
RGL2 ral guanine nucleotide dissociation stimulator-like 2 2.14 
SLC47A1 solute carrier family 47, member 1 2.14 
SUSD1 sushi domain containing 1 2.14 
TANC2 tetratricopeptide repeat, ankyrin repeat and coiled-coil containing 2 2.14 
TSHZ2 teashirt zinc finger homeobox 2 2.14 
UBR3 ubiquitin protein ligase E3 component n-recognin 3 (putative) 2.14 
VWA3A von Willebrand factor A domain containing 3A 2.14 
YWHAQ tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein 2.14 
ANKS6 ankyrin repeat and sterile alpha motif domain containing 6 2.13 
ARHGAP5 Rho GTPase activating protein 5 2.13 
C11orf74 chromosome 11 open reading frame 74 2.13 
C9orf153 chromosome 9 open reading frame 153 2.13 
CSTF1 cleavage stimulation factor, 3' pre-RNA, subunit 1, 50kDa 2.13 
ECT2 epithelial cell transforming sequence 2 oncogene 2.13 
GUCY2F guanylate cyclase 2F, retinal 2.13 
KIAA1244 KIAA1244 2.13 
KIAA1377 KIAA1377 2.13 
KIF5C kinesin family member 5C 2.13 
KPNA5 karyopherin alpha 5 (importin alpha 6) 2.13 
PIKFYVE phosphoinositide kinase, FYVE finger containing 2.13 
SENP2 SUMO1/sentrin/SMT3 specific peptidase 2 2.13 
WWC1 WW and C2 domain containing 1 2.13 
ZBTB40 zinc finger and BTB domain containing 40 2.13 
ANKRD13B ankyrin repeat domain 13B 2.12 
BACE2 beta-site APP-cleaving enzyme 2 2.12 




CABLES2 Cdk5 and Abl enzyme substrate 2 2.12 
CITED2 
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal 
domain, 2 2.12 
CMTM8 CKLF-like MARVEL transmembrane domain containing 8 2.12 
DDX23 DEAD (Asp-Glu-Ala-Asp) box polypeptide 23 2.12 
ELOVL6 ELOVL fatty acid elongase 6 2.12 
FAM193B family with sequence similarity 193, member B 2.12 
FNDC5 fibronectin type III domain containing 5 2.12 
GALC galactosylceramidase 2.12 
GEMIN5 gem (nuclear organelle) associated protein 5 2.12 
GFAP glial fibrillary acidic protein 2.12 
GUCY2F guanylate cyclase 2F, retinal 2.12 
HDAC8 histone deacetylase 8 2.12 
LOC729970 hCG2028352-like 2.12 
MCM8 minichromosome maintenance complex component 8 2.12 
MESDC2 mesoderm development candidate 2 2.12 
NALCN sodium leak channel, non-selective 2.12 
NFRKB nuclear factor related to kappaB binding protein 2.12 
PLXNA1 plexin A1 2.12 
REPS1 RALBP1 associated Eps domain containing 1 2.12 
RPAP3 RNA polymerase II associated protein 3 2.12 
RPUSD3 RNA pseudouridylate synthase domain containing 3 2.12 
SCN10A sodium channel, voltage-gated, type X, alpha subunit 2.12 
SNX4 sorting nexin 4 2.12 
SSBP2 single-stranded DNA binding protein 2 2.12 
STIM1, 
MIR4687 stromal interaction molecule 1, microRNA 4687 2.12 
TPCN1 two pore segment channel 1 2.12 
Mar-02 membrane-associated ring finger (C3HC4) 2, E3 ubiquitin protein ligase 2.11 
BTBD7 BTB (POZ) domain containing 7 2.11 
C12orf76 chromosome 12 open reading frame 76 2.11 
CNOT1 CCR4-NOT transcription complex, subunit 1 2.11 
DDX23 DEAD (Asp-Glu-Ala-Asp) box polypeptide 23 2.11 
FLJ30838 uncharacterized LOC400955 2.11 
GFPT2 glutamine-fructose-6-phosphate transaminase 2 2.11 
HBP1 HMG-box transcription factor 1 2.11 
LAIR1 leukocyte-associated immunoglobulin-like receptor 1 2.11 
LRPAP1 low density lipoprotein receptor-related protein associated protein 1 2.11 
LRRK2 leucine-rich repeat kinase 2 2.11 
NEFL neurofilament, light polypeptide 2.11 
NTRK3 neurotrophic tyrosine kinase, receptor, type 3 2.11 
PTCH1 patched 1 2.11 
RWDD2B RWD domain containing 2B 2.11 
RWDD3, 
TMEM56 
RWD domain containing 3, TMEM56-RWDD3 readthrough, transmembrane 





MIR3615 solute carrier family 9, subfamily A, member 3 regulator 1, microRNA 3615 2.11 
STRADB STE20-related kinase adaptor beta 2.11 
UGCG UDP-glucose ceramide glucosyltransferase 2.11 
UTRN utrophin 2.11 
ZNF143 zinc finger protein 143 2.11 
ACSBG1 acyl-CoA synthetase bubblegum family member 1 2.1 
ATIC 
5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP 
cyclohydrolase 2.1 
ATP6V1A ATPase, H+ transporting, lysosomal 70kDa, V1 subunit A 2.1 
DOPEY1 dopey family member 1 2.1 
DZIP1L DAZ interacting protein 1-like 2.1 
ETV2 ets variant 2 2.1 
FAM83A family with sequence similarity 83, member A 2.1 
HERC5 HECT and RLD domain containing E3 ubiquitin protein ligase 5 2.1 
IFT140 intraflagellar transport 140 homolog (Chlamydomonas) 2.1 
METTL7A methyltransferase like 7A 2.1 
MICALL1 MICAL-like 1 2.1 
MIR548AK microRNA 548ak 2.1 
MVD mevalonate (diphospho) decarboxylase 2.1 
NBN nibrin 2.1 
NCAPD3 non-SMC condensin II complex, subunit D3 2.1 
NF1 neurofibromin 1 2.1 
PEX5L peroxisomal biogenesis factor 5-like 2.1 
PLK4 polo-like kinase 4 2.1 
PNPLA6 patatin-like phospholipase domain containing 6 2.1 
PSEN2 presenilin 2 (Alzheimer disease 4) 2.1 
RAPGEF6 Rap guanine nucleotide exchange factor (GEF) 6 2.1 
SCG5 secretogranin V (7B2 protein) 2.1 
SCUBE3 signal peptide, CUB domain, EGF-like 3 2.1 
SLC9A6 
solute carrier family 9, subfamily A (NHE6, cation proton antiporter 6), 
member 6 2.1 
SYCP2 synaptonemal complex protein 2 2.1 
ZFAND1 zinc finger, AN1-type domain 1 2.1 
ZNF250 zinc finger protein 250 2.1 
ZNF527 zinc finger protein 527 2.1 
ACIN1 apoptotic chromatin condensation inducer 1 2.09 
ADCY4 adenylate cyclase 4 2.09 
AOX1 aldehyde oxidase 1 2.09 
APOL2 apolipoprotein L, 2 2.09 
C6orf70 chromosome 6 open reading frame 70 2.09 
CCDC91 coiled-coil domain containing 91 2.09 
CMAS cytidine monophosphate N-acetylneuraminic acid synthetase 2.09 
DKFZp686O132





dihydrolipoamide S-succinyltransferase (E2 component of 2-oxo-glutarate 
complex) 2.09 
EPB41L4A erythrocyte membrane protein band 4.1 like 4A 2.09 
GORASP2 golgi reassembly stacking protein 2, 55kDa 2.09 
HSPG2 heparan sulfate proteoglycan 2 2.09 
JHDM1D 
jumonji C domain containing histone demethylase 1 homolog D (S. 
cerevisiae) 2.09 
JPH1 junctophilin 1 2.09 
KIF15 kinesin family member 15 2.09 
LOC283050 uncharacterized LOC283050 2.09 
MAGEA3 melanoma antigen family A, 3 2.09 
MCOLN2 mucolipin 2 2.09 
MGEA5 meningioma expressed antigen 5 (hyaluronidase) 2.09 
PDILT protein disulfide isomerase-like, testis expressed 2.09 
PTCH1 patched 1 2.09 
RBBP9 retinoblastoma binding protein 9 2.09 
RGS18 regulator of G-protein signaling 18 2.09 
SH3GLB2 SH3-domain GRB2-like endophilin B2 2.09 
ST14 suppression of tumorigenicity 14 (colon carcinoma) 2.09 
STAM2 signal transducing adaptor molecule (SH3 domain and ITAM motif) 2 2.09 
UTS2D urotensin 2 domain containing 2.09 
ZFP106 zinc finger protein 106 homolog (mouse) 2.09 
ZNF451 zinc finger protein 451 2.09 
AGL amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase 2.08 
ASUN asunder, spermatogenesis regulator homolog (Drosphila) 2.08 
CCDC66 coiled-coil domain containing 66 2.08 
CYP2C18, 
CYP2C19 cytochrome P450, family 2, subfamily C, polypeptide 18 & 19 2.08 
DGKB diacylglycerol kinase, beta 90kDa 2.08 
DGKH diacylglycerol kinase, eta 2.08 
DLG5 discs, large homolog 5 (Drosophila) 2.08 
DMXL2 Dmx-like 2 2.08 
DPP10 dipeptidyl-peptidase 10 (non-functional) 2.08 
ETV6 ets variant 6 2.08 
EXD2 exonuclease 3'-5' domain containing 2 2.08 
FAM65A family with sequence similarity 65, member A 2.08 
HMGA2 high mobility group AT-hook 2 2.08 
KCNAB2 potassium voltage-gated channel, shaker-related subfamily, beta member 2 2.08 
KCNU1 potassium channel, subfamily U, member 1 2.08 
KRT25 keratin 25 2.08 
MAP4K5 mitogen-activated protein kinase kinase kinase kinase 5 2.08 
NIPBL Nipped-B homolog (Drosophila) 2.08 
PDE4DIP phosphodiesterase 4D interacting protein, myomegalin-like 2.08 
PDZRN3 PDZ domain containing ring finger 3 2.08 




SLC25A22 solute carrier family 25 (mitochondrial carrier: glutamate), member 22 2.08 
SLCO1C1 solute carrier organic anion transporter family, member 1C1 2.08 
SLIT2 slit homolog 2 (Drosophila) 2.08 
SMTN smoothelin 2.08 
SNX2 sorting nexin 2 2.08 
SRPK1 SRSF protein kinase 1 2.08 
TSPAN12 tetraspanin 12 2.08 
TTC8 tetratricopeptide repeat domain 8 2.08 
VAV3 vav 3 guanine nucleotide exchange factor 2.08 
ALDOA aldolase A, fructose-bisphosphate 2.07 
BMS1P4 BMS1 pseudogene 4 2.07 
BPTF 
bromodomain PHD finger transcription factor, Rho GTPase activating protein 
27 pseudogene 2.07 
CBFA2T2 core-binding factor, runt domain, alpha subunit 2; translocated to, 2 2.07 
CHAF1B chromatin assembly factor 1, subunit B (p60) 2.07 
CISD1 CDGSH iron sulfur domain 1 2.07 
CLPB ClpB caseinolytic peptidase B homolog (E. coli) 2.07 
CLVS2 clavesin 2 2.07 
DBR1 debranching enzyme homolog 1 (S. cerevisiae) 2.07 
DDX58 DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 2.07 
EIF2B2 eukaryotic translation initiation factor 2B, subunit 2 beta, 39kDa 2.07 
FAM48A family with sequence similarity 48, member A 2.07 
GPCPD1 glycerophosphocholine phosphodiesterase GDE1 homolog (S. cerevisiae) 2.07 
HIPK3 homeodomain interacting protein kinase 3 2.07 
ITCH itchy E3 ubiquitin protein ligase 2.07 
KDM6A lysine (K)-specific demethylase 6A 2.07 
LRRC41 leucine rich repeat containing 41 2.07 
LTA lymphotoxin alpha (TNF superfamily, member 1) 2.07 
LTA lymphotoxin alpha (TNF superfamily, member 1) 2.07 
LTA lymphotoxin alpha (TNF superfamily, member 1) 2.07 
LTA lymphotoxin alpha (TNF superfamily, member 1) 2.07 
LTA lymphotoxin alpha (TNF superfamily, member 1) 2.07 
LTA lymphotoxin alpha (TNF superfamily, member 1) 2.07 
LTA lymphotoxin alpha (TNF superfamily, member 1) 2.07 
MAP3K6 mitogen-activated protein kinase kinase kinase 6 2.07 
PAPSS2 3'-phosphoadenosine 5'-phosphosulfate synthase 2 2.07 
PCMTD1 
protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 
1 2.07 
PDZD8 PDZ domain containing 8 2.07 
PLA2G6 phospholipase A2, group VI (cytosolic, calcium-independent) 2.07 
PNPO pyridoxamine 5'-phosphate oxidase 2.07 
PSME4 proteasome (prosome, macropain) activator subunit 4 2.07 
RB1CC1 RB1-inducible coiled-coil 1 2.07 




SCML1 sex comb on midleg-like 1 (Drosophila) 2.07 
SLC9A9 
solute carrier family 9, subfamily A (NHE9, cation proton antiporter 9), 
member 9 2.07 
SUPT6H suppressor of Ty 6 homolog (S. cerevisiae) 2.07 
SYT1 synaptotagmin I 2.07 
THRA, NR1D1 
thyroid hormone receptor, alpha, nuclear receptor subfamily 1, group D, 
member 1 2.07 
UNC79 unc-79 homolog (C. elegans) 2.07 
ZNF227 zinc finger protein 227 2.07 
ZNF765 zinc finger protein 765 2.07 
ACSM3 acyl-CoA synthetase medium-chain family member 3 2.06 
AMN1 antagonist of mitotic exit network 1 homolog (S. cerevisiae) 2.06 
ANKRD49 ankyrin repeat domain 49 2.06 
ARHGEF26 Rho guanine nucleotide exchange factor (GEF) 26 2.06 
CDC14A CDC14 cell division cycle 14 homolog A (S. cerevisiae) 2.06 
CNKSR1 connector enhancer of kinase suppressor of Ras 1 2.06 
DHTKD1 dehydrogenase E1 and transketolase domain containing 1 2.06 
FAM149B1 family with sequence similarity 149, member B1 2.06 
GON4L gon-4-like (C. elegans) 2.06 
HLA-F major histocompatibility complex, class I, F 2.06 
IMMP2L IMP2 inner mitochondrial membrane peptidase-like (S. cerevisiae) 2.06 
KLHL18 kelch-like 18 (Drosophila) 2.06 
LOC283682 uncharacterized LOC283682 2.06 
LRIG3 leucine-rich repeats and immunoglobulin-like domains 3 2.06 
NFATC3 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 3 2.06 
NLRP4 NLR family, pyrin domain containing 4 2.06 
PDE9A phosphodiesterase 9A 2.06 
PHF15 PHD finger protein 15 2.06 
PPIA 
peptidylprolyl isomerase A (cyclophilin A), peptidyl-prolyl cis-trans 
isomerase A-like 2.06 
PSMD11 proteasome (prosome, macropain) 26S subunit, non-ATPase, 11 2.06 
RELB v-rel reticuloendotheliosis viral oncogene homolog B 2.06 
TRRAP transformation/transcription domain-associated protein 2.06 
VRK3 vaccinia related kinase 3 2.06 
ZDHHC23 zinc finger, DHHC-type containing 23 2.06 
ZFAT zinc finger and AT hook domain containing 2.06 
AGER, PBX2 
advanced glycosylation end product-specific receptor, pre-B-cell leukemia 
homeobox 2 2.05 
BBX bobby sox homolog (Drosophila) 2.05 
BTBD9 BTB (POZ) domain containing 9 2.05 
C20orf112 chromosome 20 open reading frame 112 2.05 
CAPN11 calpain 11 2.05 
CCP110 centriolar coiled coil protein 110kDa 2.05 
CHCHD7 coiled-coil-helix-coiled-coil-helix domain containing 7 2.05 
CSTF3 cleavage stimulation factor, 3' pre-RNA, subunit 3, 77kDa 2.05 




DYRK4 dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 4 2.05 
DYX1C1-CCPG1 DYX1C1-CCPG1 readthrough (non-protein coding), cell cycle progression 1 2.05 
ECI2 enoyl-CoA delta isomerase 2 2.05 
EFCAB8 EF-hand calcium binding domain 8 2.05 
FKBP15 FK506 binding protein 15, 133kDa 2.05 
GMPS guanine monphosphate synthetase 2.05 
IDH3G isocitrate dehydrogenase 3 (NAD+) gamma 2.05 
IFT122 intraflagellar transport 122 homolog (Chlamydomonas) 2.05 
LARP6 La ribonucleoprotein domain family, member 6 2.05 
MAN2A2 mannosidase, alpha, class 2A, member 2 2.05 
MAN2C1 mannosidase, alpha, class 2C, member 1 2.05 
MANBA mannosidase, beta A, lysosomal 2.05 
MAPKBP1 mitogen-activated protein kinase binding protein 1 2.05 
MYO3A myosin IIIA 2.05 
NCOA3 nuclear receptor coactivator 3 2.05 
NKTR natural killer-tumor recognition sequence 2.05 
NOP9 NOP9 nucleolar protein homolog (yeast) 2.05 
OXNAD1 oxidoreductase NAD-binding domain containing 1 2.05 
PDCD10 programmed cell death 10 2.05 
PDGFRB platelet-derived growth factor receptor, beta polypeptide 2.05 
PLCG2 phospholipase C, gamma 2 (phosphatidylinositol-specific) 2.05 
PPP1R13B protein phosphatase 1, regulatory subunit 13B 2.05 
RAB28 RAB28, member RAS oncogene family 2.05 
RORA RAR-related orphan receptor A 2.05 
SP110 SP110 nuclear body protein 2.05 
SRRT serrate RNA effector molecule homolog (Arabidopsis) 2.05 
TRIM36 tripartite motif containing 36 2.05 
TRPM3 transient receptor potential cation channel, subfamily M, member 3 2.05 
TSGA13, COPG2 testis specific, 13, coatomer protein complex, subunit gamma 2 2.05 
ZNF568 zinc finger protein 568 2.05 
ADPRHL1 ADP-ribosylhydrolase like 1 2.04 
C1RL-AS1 C1RL antisense RNA 1 (non-protein coding) 2.04 
CDNF cerebral dopamine neurotrophic factor 2.04 
CLN5 ceroid-lipofuscinosis, neuronal 5 2.04 
CRISPLD2 cysteine-rich secretory protein LCCL domain containing 2 2.04 
DCAF5 DDB1 and CUL4 associated factor 5 2.04 
DDR2 discoidin domain receptor tyrosine kinase 2 2.04 
DHX35 DEAH (Asp-Glu-Ala-His) box polypeptide 35 2.04 
DPYSL3 dihydropyrimidinase-like 3 2.04 
EIF2C3 eukaryotic translation initiation factor 2C, 3 2.04 
FAM175A family with sequence similarity 175, member A 2.04 
FBXL13 F-box and leucine-rich repeat protein 13 2.04 




HUWE1 HECT, UBA and WWE domain containing 1, E3 ubiquitin protein ligase 2.04 
KDM5D lysine (K)-specific demethylase 5D 2.04 
KIAA0100 KIAA0100 2.04 
KIFAP3 kinesin-associated protein 3 2.04 
KTN1 kinectin 1 (kinesin receptor) 2.04 
LAMA1 laminin, alpha 1 2.04 
LGMN legumain 2.04 
LNX1 ligand of numb-protein X 1, E3 ubiquitin protein ligase 2.04 
MLL3 myeloid/lymphoid or mixed-lineage leukemia 3 2.04 
MPP4 membrane protein, palmitoylated 4 (MAGUK p55 subfamily member 4) 2.04 
MS4A12 membrane-spanning 4-domains, subfamily A, member 12 2.04 
NBN nibrin 2.04 
NID1 nidogen 1 2.04 
NUP205 nucleoporin 205kDa 2.04 
PCLO piccolo (presynaptic cytomatrix protein) 2.04 
PPP1R12B protein phosphatase 1, regulatory subunit 12B 2.04 
RBM48 RNA binding motif protein 48 2.04 
RP1 retinitis pigmentosa 1 (autosomal dominant) 2.04 
SDHAF2 succinate dehydrogenase complex assembly factor 2 2.04 
SENP1 SUMO1/sentrin specific peptidase 1 2.04 
SERINC5 serine incorporator 5 2.04 
SLC25A19 
solute carrier family 25 (mitochondrial thiamine pyrophosphate carrier), 
member 19 2.04 
TACO1 translational activator of mitochondrially encoded cytochrome c oxidase I 2.04 
VPS41 vacuolar protein sorting 41 homolog (S. cerevisiae) 2.04 
WNK3 WNK lysine deficient protein kinase 3 2.04 
ZFAND4 zinc finger, AN1-type domain 4 2.04 
ZNF569 zinc finger protein 569 2.04 
ZNF609 zinc finger protein 609 2.04 
ADCY5 adenylate cyclase 5 2.03 
AKAP13 A kinase (PRKA) anchor protein 13 2.03 
ATAD5 ATPase family, AAA domain containing 5 2.03 
C14orf166B chromosome 14 open reading frame 166B 2.03 
C7orf10 chromosome 7 open reading frame 10 2.03 
CDADC1 cytidine and dCMP deaminase domain containing 1 2.03 
FAM194B family with sequence similarity 194, member B 2.03 
FAM49A family with sequence similarity 49, member A 2.03 
FMNL2 formin-like 2 2.03 
FRA10AC1 fragile site, folic acid type, rare, fra(10)(q23.3) or fra(10)(q24.2) candidate 1 2.03 
KCNT2 potassium channel, subfamily T, member 2 2.03 
KIAA1045 KIAA1045 2.03 
KIF9 kinesin family member 9 2.03 
LINC00266-1 long intergenic non-protein coding RNA 266-1 2.03 




PCGF5 polycomb group ring finger 5 2.03 
PCSK6 proprotein convertase subtilisin/kexin type 6 2.03 
PIEZO2 piezo-type mechanosensitive ion channel component 2 2.03 
POLQ polymerase (DNA directed), theta 2.03 
PPP1R9B protein phosphatase 1, regulatory subunit 9B 2.03 
PVR poliovirus receptor 2.03 
RAB11FIP2 RAB11 family interacting protein 2 (class I) 2.03 
RASGEF1A RasGEF domain family, member 1A 2.03 
SLC12A1 
solute carrier family 12 (sodium/potassium/chloride transporters), member 
1 2.03 
SLC43A2 solute carrier family 43, member 2 2.03 
STRBP spermatid perinuclear RNA binding protein 2.03 
SUCLA2 succinate-CoA ligase, ADP-forming, beta subunit 2.03 
TEF thyrotrophic embryonic factor 2.03 
TG thyroglobulin 2.03 
TRIM6-TRIM34 
TRIM6-TRIM34 readthrough, tripartite motif containing 34, tripartite motif 
containing 6 2.03 
TULP3 tubby like protein 3 2.03 
ZER1 zer-1 homolog (C. elegans) 2.03 
ABCA4 ATP-binding cassette, sub-family A (ABC1), member 4 2.02 
ALX1 ALX homeobox 1 2.02 
ATP8A2 ATPase, aminophospholipid transporter, class I, type 8A, member 2 2.02 
C12orf52 chromosome 12 open reading frame 52 2.02 
CCNT2 cyclin T2 2.02 
CENPO centromere protein O 2.02 
DENND5B DENN/MADD domain containing 5B 2.02 
DOCK2 dedicator of cytokinesis 2 2.02 
FAM115A, B family with sequence similarity 115, member A & B, protein FAM115A-like 2.02 
FOXRED1 FAD-dependent oxidoreductase domain containing 1 2.02 
KHK ketohexokinase (fructokinase) 2.02 
KIAA1009 KIAA1009 2.02 
MAP3K2 mitogen-activated protein kinase kinase kinase 2 2.02 
MGAT4B 
mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-
acetylglucosaminyltransferase, isozyme B 2.02 
NEB nebulin 2.02 
NEK11 NIMA (never in mitosis gene a)- related kinase 11 2.02 
RAD9B RAD9 homolog B (S. pombe) 2.02 
RBL2 retinoblastoma-like 2 (p130) 2.02 
RHBDF2 rhomboid 5 homolog 2 (Drosophila) 2.02 
SIAE sialic acid acetylesterase 2.02 
SLC12A8 solute carrier family 12 (potassium/chloride transporters), member 8 2.02 
SLC37A1 solute carrier family 37 (glycerol-3-phosphate transporter), member 1 2.02 
ST3GAL6 ST3 beta-galactoside alpha-2,3-sialyltransferase 6 2.02 
TMCO5B transmembrane and coiled-coil domains 5B, pseudogene 2.02 





testis-specific transcript, Y-linked 14 (non-protein coding), non-protein 
coding RNA 185 2.02 
USO1 USO1 vesicle docking protein homolog (yeast) 2.02 
ZNF625-20 ZNF625-ZNF20 readthrough, zinc finger protein 20, zinc finger protein 625 2.02 
ALS2CR11 amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 11 2.01 
BICD1 bicaudal D homolog 1 (Drosophila) 2.01 
C6orf58 chromosome 6 open reading frame 58 2.01 
CC2D1B coiled-coil and C2 domain containing 1B 2.01 
CENPK centromere protein K 2.01 
CLGN calmegin 2.01 
DAB2 disabled homolog 2, mitogen-responsive phosphoprotein (Drosophila) 2.01 
DCT 
dopachrome tautomerase (dopachrome delta-isomerase, tyrosine-related 
protein 2) 2.01 
EIF2AK2 eukaryotic translation initiation factor 2-alpha kinase 2 2.01 
ERCC6L2 
excision repair cross-complementing rodent repair deficiency, 
complementation group 6-like 2 2.01 
EXOC6 exocyst complex component 6 2.01 
EXPH5 exophilin 5 2.01 
GINS4 GINS complex subunit 4 (Sld5 homolog) 2.01 
GPCPD1 glycerophosphocholine phosphodiesterase GDE1 homolog (S. cerevisiae) 2.01 
IL18RAP interleukin 18 receptor accessory protein 2.01 
JAK3 Janus kinase 3 2.01 
KDM2B lysine (K)-specific demethylase 2B 2.01 
KIAA0895 KIAA0895 2.01 
LRP4 low density lipoprotein receptor-related protein 4 2.01 
LRRC16A leucine rich repeat containing 16A 2.01 
MAN1A1 mannosidase, alpha, class 1A, member 1 2.01 
MAPKBP1 mitogen-activated protein kinase binding protein 1 2.01 
MEF2A myocyte enhancer factor 2A 2.01 
MFSD11 major facilitator superfamily domain containing 11 2.01 
MGAT4A 
mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-
acetylglucosaminyltransferase, isozyme A 2.01 
MYO1B myosin IB 2.01 
PHF15 PHD finger protein 15 2.01 
PMPCA peptidase (mitochondrial processing) alpha 2.01 
RHOT1 ras homolog family member T1 2.01 
RUNDC3B RUN domain containing 3B 2.01 
SHCBP1 SHC SH2-domain binding protein 1 2.01 
SLC16A14 solute carrier family 16, member 14 (monocarboxylic acid transporter 14) 2.01 
SLC24A6 solute carrier family 24 (sodium/lithium/calcium exchanger), member 6 2.01 
SLC26A4 solute carrier family 26, member 4 2.01 
SLC30A6 solute carrier family 30 (zinc transporter), member 6 2.01 
STK24 serine/threonine kinase 24 2.01 
TBL1X transducin (beta)-like 1X-linked 2.01 
TEX9 testis expressed 9 2.01 




UCHL1 ubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase) 2.01 
UNC119 unc-119 homolog (C. elegans) 2.01 
USP34 ubiquitin specific peptidase 34 2.01 
WASF2 WAS protein family, member 2 2.01 
WDR7 WD repeat domain 7 2.01 
B4GALT3 UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 3 -2.01 
CD3D CD3d molecule, delta (CD3-TCR complex) -2.01 
EOMES eomesodermin -2.01 
EXD1 exonuclease 3'-5' domain containing 1 -2.01 
FXR1 fragile X mental retardation, autosomal homolog 1 -2.01 
GLT1D1 glycosyltransferase 1 domain containing 1 -2.01 
KIF15 kinesin family member 15 -2.01 
KLRF1 killer cell lectin-like receptor subfamily F, member 1 -2.01 
NELL1 NEL-like 1 (chicken) -2.01 
NFKBIA 
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, 
alpha -2.01 
PLA2G6 phospholipase A2, group VI (cytosolic, calcium-independent) -2.01 
SFMBT2 Scm-like with four mbt domains 2 -2.01 
SH2D2A SH2 domain containing 2A -2.01 
THSD7B thrombospondin, type I, domain containing 7B -2.01 
TMEM74B transmembrane protein 74B -2.01 
TMOD2 tropomodulin 2 (neuronal) -2.01 
TSPAN2 tetraspanin 2 -2.01 
TUBB3 tubulin, beta 3 class III -2.01 
WDFY4 WDFY family member 4 -2.01 
ADCY5 adenylate cyclase 5 -2.02 
ADIPOQ adiponectin, C1Q and collagen domain containing -2.02 
ATP8B4 ATPase, class I, type 8B, member 4 -2.02 
C1orf141 chromosome 1 open reading frame 141 -2.02 
C9orf57 chromosome 9 open reading frame 57 -2.02 
CA5A carbonic anhydrase VA, mitochondrial -2.02 
FAM107A family with sequence similarity 107, member A -2.02 
KLHL32 kelch-like 32 (Drosophila) -2.02 
LOC285423 uncharacterized LOC285423 -2.02 
LOC388276 hCG2045437 -2.02 
MRPS18C 
mitochondrial ribosomal protein S18C, 28S ribosomal protein S18c, 
mitochondrial-like -2.02 
NIT1 nitrilase 1 -2.02 
RHCE Rh blood group, CcEe antigens -2.02 
RNF183 ring finger protein 183 -2.02 
SATB2 SATB homeobox 2 -2.02 
SF3B1 splicing factor 3b, subunit 1, 155kDa -2.02 
SLC22A31 solute carrier family 22, member 31 -2.02 




TCN2 transcobalamin II -2.02 
AP1M2 adaptor-related protein complex 1, mu 2 subunit -2.03 
ASB14 ankyrin repeat and SOCS box containing 14 -2.03 
C20orf152 chromosome 20 open reading frame 152 -2.03 
CCDC144NL coiled-coil domain containing 144 family, N-terminal like -2.03 
CNTN6 contactin 6 -2.03 
FAM206A family with sequence similarity 206, member A -2.03 
ISLR2 immunoglobulin superfamily containing leucine-rich repeat 2 -2.03 
LOC100505875 uncharacterized LOC100505875 -2.03 
LOC100653273 uncharacterized LOC100653273 -2.03 
LOC400541 uncharacterized LOC400541 -2.03 
MFAP5 microfibrillar associated protein 5 -2.03 
MYT1 myelin transcription factor 1 -2.03 
NPR3 
natriuretic peptide receptor C/guanylate cyclase C (atrionatriuretic peptide 
receptor C) -2.03 
PTPRT protein tyrosine phosphatase, receptor type, T -2.03 
RNASE1 ribonuclease, RNase A family, 1 (pancreatic) -2.03 
RYR3 ryanodine receptor 3 -2.03 
SKIV2L2 superkiller viralicidic activity 2-like 2 (S. cerevisiae) -2.03 
SLIT2 slit homolog 2 (Drosophila) -2.03 
TMEM155 transmembrane protein 155 -2.03 
ACSBG2 acyl-CoA synthetase bubblegum family member 2 -2.04 
AKR1B1 aldo-keto reductase family 1, member B1 (aldose reductase) -2.04 
CCDC129 coiled-coil domain containing 129 -2.04 
CDH16 cadherin 16, KSP-cadherin -2.04 
DPEP1 dipeptidase 1 (renal) -2.04 
FPGS folylpolyglutamate synthase -2.04 
HSD11B1 hydroxysteroid (11-beta) dehydrogenase 1 -2.04 
NHP2L1 NHP2 non-histone chromosome protein 2-like 1 (S. cerevisiae) -2.04 
PARP15 poly (ADP-ribose) polymerase family, member 15 -2.04 
PURG purine-rich element binding protein G -2.04 
RGS5 regulator of G-protein signaling 5 -2.04 
SCNN1B sodium channel, non-voltage-gated 1, beta subunit -2.04 
SLC8A2 solute carrier family 8 (sodium/calcium exchanger), member 2 -2.04 
SYCE1 synaptonemal complex central element protein 1 -2.04 
TMCO5A transmembrane and coiled-coil domains 5A -2.04 
AP5Z1, 
MIR4656 adaptor-related protein complex 5, zeta 1 subunit, microRNA 4656 -2.05 
ARMCX2 armadillo repeat containing, X-linked 2 -2.05 
HOXA7 homeobox A7 -2.05 
HOXC4,5, 6 homeobox C4, homeobox C5, homeobox C6 -2.05 
LOC100506030 uncharacterized LOC100506030 -2.05 
SCNN1A sodium channel, non-voltage-gated 1 alpha subunit -2.05 




TG thyroglobulin -2.05 
TG thyroglobulin -2.05 
WDR63 WD repeat domain 63 -2.05 
ANKRD44 ankyrin repeat domain 44 -2.06 
CDT1 chromatin licensing and DNA replication factor 1 -2.06 
COA1 cytochrome C oxidase assembly factor 1 homolog (S. cerevisiae) -2.06 
HK2 hexokinase 2 -2.06 
KIRREL2 kin of IRRE like 2 (Drosophila) -2.06 
LRBA LPS-responsive vesicle trafficking, beach and anchor containing -2.06 
NADSYN1 NAD synthetase 1 -2.06 
PKMYT1 protein kinase, membrane associated tyrosine/threonine 1 -2.06 
PPP4R4 protein phosphatase 4, regulatory subunit 4 -2.06 
ANKRD24 ankyrin repeat domain 24 -2.07 
ARFGAP2 ADP-ribosylation factor GTPase activating protein 2 -2.07 
C14orf164 chromosome 14 open reading frame 164 -2.07 
CFB complement factor B -2.07 
CLSTN2 calsyntenin 2 -2.07 
DCHS2 dachsous 2 (Drosophila) -2.07 
DNAH5 dynein, axonemal, heavy chain 5 -2.07 
IFT80 intraflagellar transport 80 homolog (Chlamydomonas) -2.07 
KLHL28 kelch-like 28 (Drosophila) -2.07 
LOC100130348 uncharacterized LOC100130348, uncharacterized LOC399904 -2.07 
NDUFB2 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 2, 8kDa -2.07 
SH3KBP1 SH3-domain kinase binding protein 1 -2.07 
SLC22A12 solute carrier family 22 (organic anion/urate transporter), member 12 -2.07 
TKTL1 transketolase-like 1 -2.07 
CPA1 carboxypeptidase A1 (pancreatic) -2.08 
EGR1 early growth response 1 -2.08 
ENO1 enolase 1, (alpha) -2.08 
ENPP3 ectonucleotide pyrophosphatase/phosphodiesterase 3 -2.08 
FLJ13197 uncharacterized FLJ13197 -2.08 
MAFF v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian) -2.08 
MRPS18C 
mitochondrial ribosomal protein S18C, 28S ribosomal protein S18c, 
mitochondrial-like -2.08 
PKHD1L1 polycystic kidney and hepatic disease 1 (autosomal recessive)-like 1 -2.08 
PTPRN2 protein tyrosine phosphatase, receptor type, N polypeptide 2 -2.08 
SCN4A sodium channel, voltage-gated, type IV, alpha subunit -2.08 
SEC62 SEC62 homolog (S. cerevisiae) -2.08 
TPK1 thiamin pyrophosphokinase 1 -2.08 
UBE2G2, 
SUMO3 
ubiquitin-conjugating enzyme E2G 2, SMT3 suppressor of mif two 3 homolog 
3 -2.08 
UNG uracil-DNA glycosylase -2.08 
ZMYM4-AS1 ZMYM4 antisense RNA 1 (non-protein coding) -2.08 




ADORA1 adenosine A1 receptor -2.09 
BEST3 bestrophin 3 -2.09 
C1orf198 chromosome 1 open reading frame 198 -2.09 
C4A, C4B 




complement component 4A (Rodgers blood group), complement component 
4B -2.09 
C4B, C4A complement component 4B (Chido blood group), complement component 4A -2.09 
C4B, C4A complement component 4B (Chido blood group) -2.09 
C4B, C4A complement component 4B (Chido blood group) -2.09 
C4B, C4A complement component 4B (Chido blood group) -2.09 
C4B, C4A complement component 4B (Chido blood group) -2.09 
CD163 CD163 molecule -2.09 
CDC14B CDC14 cell division cycle 14 homolog B (S. cerevisiae) -2.09 
CYP11A1 cytochrome P450, family 11, subfamily A, polypeptide 1 -2.09 
DSCAM Down syndrome cell adhesion molecule -2.09 
GTF3C4 general transcription factor IIIC, polypeptide 4, 90kDa -2.09 
HEATR8-TTC4 
HEATR8-TTC4 readthrough, HEAT repeat containing 8, tetratricopeptide 
repeat domain 4 -2.09 
LZTR1 leucine-zipper-like transcription regulator 1 -2.09 
NDUFB2 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 2, 8kDa -2.09 
RBPJ recombination signal binding protein for immunoglobulin kappa J region -2.09 
RNF32 ring finger protein 32 -2.09 
SSPN sarcospan -2.09 
TESC tescalcin -2.09 
TNK2 tyrosine kinase, non-receptor, 2 -2.09 
ABCD4 ATP-binding cassette, sub-family D (ALD), member 4 -2.1 
ANHX anomalous homeobox -2.1 
CAMK4 calcium/calmodulin-dependent protein kinase IV -2.1 
CFLAR-AS1 CFLAR antisense RNA 1 (non-protein coding) -2.1 
DPF3 D4, zinc and double PHD fingers, family 3 -2.1 
ENGASE endo-beta-N-acetylglucosaminidase -2.1 
PLAT plasminogen activator, tissue -2.1 
PRKCZ protein kinase C, zeta -2.1 
SLC12A9 solute carrier family 12 (potassium/chloride transporters), member 9 -2.1 
SLFNL1 schlafen-like 1 -2.1 
TTC29 tetratricopeptide repeat domain 29 -2.1 
ACSL6 acyl-CoA synthetase long-chain family member 6 -2.11 
C20orf112 chromosome 20 open reading frame 112 -2.11 
COL1A1 collagen, type I, alpha 1 -2.11 
DNAH11 dynein, axonemal, heavy chain 11 -2.11 
FAM131A family with sequence similarity 131, member A -2.11 
FANCC Fanconi anemia, complementation group C -2.11 
HIAT1 hippocampus abundant transcript 1 -2.11 




KRT15 keratin 15 -2.11 
LOC100507308 uncharacterized LOC100507308 -2.11 
LOC400940 uncharacterized LOC400940 -2.11 
PIP5KL1 phosphatidylinositol-4-phosphate 5-kinase-like 1 -2.11 
SKIV2L superkiller viralicidic activity 2-like (S. cerevisiae) -2.11 
SKIV2L superkiller viralicidic activity 2-like (S. cerevisiae) -2.11 
SKIV2L superkiller viralicidic activity 2-like (S. cerevisiae) -2.11 
SKIV2L superkiller viralicidic activity 2-like (S. cerevisiae) -2.11 
SKIV2L superkiller viralicidic activity 2-like (S. cerevisiae) -2.11 
SKIV2L superkiller viralicidic activity 2-like (S. cerevisiae) -2.11 
SLC7A13 solute carrier family 7 (anionic amino acid transporter), member 13 -2.11 
VAV3 vav 3 guanine nucleotide exchange factor -2.11 
ZP1 zona pellucida glycoprotein 1 (sperm receptor) -2.11 
B4GALNT1 beta-1,4-N-acetyl-galactosaminyl transferase 1 -2.12 
CHRD chordin -2.12 
COL14A1 collagen, type XIV, alpha 1 -2.12 
DCP1B DCP1 decapping enzyme homolog B (S. cerevisiae) -2.12 
DGKK diacylglycerol kinase, kappa -2.12 
DMD dystrophin -2.12 
DNAH10 dynein, axonemal, heavy chain 10 -2.12 
HEATR2 HEAT repeat containing 2 -2.12 
MECOM MDS1 and EVI1 complex locus -2.12 
PLEKHM1 
pleckstrin homology domain containing, family M (with RUN domain) 
member 1 -2.12 
PREX2 phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 2 -2.12 
RDH12 retinol dehydrogenase 12 (all-trans/9-cis/11-cis) -2.12 
ADCY6, 
MIR4701 adenylate cyclase 6, microRNA 4701 -2.13 
BEST2 bestrophin 2 -2.13 
C10orf112 chromosome 10 open reading frame 112 -2.13 
CAPZA1 capping protein (actin filament) muscle Z-line, alpha 1 -2.13 
ENPP2 ectonucleotide pyrophosphatase/phosphodiesterase 2 -2.13 
GPR89A, 
GPR89B G protein-coupled receptor 89A, G protein-coupled receptor 89B -2.13 
HLA-DPB1 major histocompatibility complex, class II, DP beta 1 -2.13 
HLA-DPB1 major histocompatibility complex, class II, DP beta 1 -2.13 
HLA-DPB1 major histocompatibility complex, class II, DP beta 1 -2.13 
HLA-DPB1 major histocompatibility complex, class II, DP beta 1 -2.13 
HLA-DPB1 major histocompatibility complex, class II, DP beta 1 -2.13 
HLA-DPB1 major histocompatibility complex, class II, DP beta 1 -2.13 
HLA-DPB1 major histocompatibility complex, class II, DP beta 1 -2.13 
HN1 hematological and neurological expressed 1 -2.13 
ITK IL2-inducible T-cell kinase -2.13 
KLC2 kinesin light chain 2 -2.13 




NRAP nebulin-related anchoring protein -2.13 
PI4KB phosphatidylinositol 4-kinase, catalytic, beta -2.13 
SERINC4 serine incorporator 4 -2.13 
TMPRSS2 transmembrane protease, serine 2 -2.13 
ZNF692 zinc finger protein 692 -2.13 
ALPL alkaline phosphatase, liver/bone/kidney -2.14 
B3GNT5 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 5 -2.14 
CCL14-CCL15 CCL14-CCL15 readthrough, chemokine (C-C motif) ligand 14 & 15 -2.14 
MGST3 microsomal glutathione S-transferase 3 -2.14 
MYCBPAP MYCBP associated protein -2.14 
NFRKB nuclear factor related to kappaB binding protein -2.14 
OVGP1 oviductal glycoprotein 1, 120kDa -2.14 
PCDH12 protocadherin 12 -2.14 
RASGRP3 RAS guanyl releasing protein 3 (calcium and DAG-regulated) -2.14 
ZP1 zona pellucida glycoprotein 1 (sperm receptor) -2.14 
C20orf152 chromosome 20 open reading frame 152 -2.15 
CCDC164 coiled-coil domain containing 164 -2.15 
COL24A1 collagen, type XXIV, alpha 1 -2.15 
CYFIP2 cytoplasmic FMR1 interacting protein 2 -2.15 
DOCK2 dedicator of cytokinesis 2 -2.15 
FGR Gardner-Rasheed feline sarcoma viral (v-fgr) oncogene homolog -2.15 
FMO1 flavin containing monooxygenase 1 -2.15 
HSD17B1 hydroxysteroid (17-beta) dehydrogenase 1 -2.15 
OR13A1 olfactory receptor, family 13, subfamily A, member 1 -2.15 
PLXND1 plexin D1 -2.15 
RUSC1-AS1 RUSC1 antisense RNA 1 (non-protein coding) -2.15 
TATDN1 TatD DNase domain containing 1 -2.15 
TRPM8 transient receptor potential cation channel, subfamily M, member 8 -2.15 
WDFY4 WDFY family member 4 -2.15 
BAZ2A bromodomain adjacent to zinc finger domain, 2A -2.16 
COL16A1 collagen, type XVI, alpha 1 -2.16 
DNAH3 dynein, axonemal, heavy chain 3 -2.16 
IDH1 isocitrate dehydrogenase 1 (NADP+), soluble -2.16 
LOC732275 uncharacterized LOC732275 -2.16 
NDRG2 NDRG family member 2 -2.16 
NME1-NME2 NME1-NME2 readthrough, NME/NM23 nucleoside diphosphate kinase 1 & 2 -2.16 
PDCD6IP programmed cell death 6 interacting protein -2.16 
RYR3 ryanodine receptor 3 -2.16 
TTN-AS1 TTN antisense RNA 1 (non-protein coding) -2.16 
ARHGAP4 Rho GTPase activating protein 4 -2.17 
ATAD1 ATPase family, AAA domain containing 1 -2.17 
COL4A6 collagen, type IV, alpha 6 -2.17 




DDB1 damage-specific DNA binding protein 1, 127kDa -2.17 
MEPE matrix extracellular phosphoglycoprotein -2.17 
PADI1 peptidyl arginine deiminase, type I -2.17 
PDE3A phosphodiesterase 3A, cGMP-inhibited -2.17 
PMEL premelanosome protein -2.17 
SLC22A24 solute carrier family 22, member 24 -2.17 
SNORD32B small nucleolar RNA, C/D box 32B -2.17 
USP13 ubiquitin specific peptidase 13 (isopeptidase T-3) -2.17 
C12orf51 chromosome 12 open reading frame 51 -2.18 
CCDC39 coiled-coil domain containing 39 -2.18 
CSMD3 CUB and Sushi multiple domains 3 -2.18 
FGF21 fibroblast growth factor 21 -2.18 
FLJ20444 uncharacterized protein FLJ20444 -2.18 
FN3K fructosamine 3 kinase -2.18 
NMD3 NMD3 homolog (S. cerevisiae) -2.18 
PDE6C phosphodiesterase 6C, cGMP-specific, cone, alpha prime -2.18 
POTEB 
POTE ankyrin domain family, member B, POTE ankyrin domain family 
member B-like -2.18 
POTEB 
POTE ankyrin domain family, member B, POTE ankyrin domain family 
member B-like -2.18 
RIN3 Ras and Rab interactor 3 -2.18 
ZNF575 zinc finger protein 575 -2.18 
ABHD6 abhydrolase domain containing 6 -2.19 
ART4 ADP-ribosyltransferase 4 (Dombrock blood group) -2.19 
CA5BP1 carbonic anhydrase VB pseudogene 1 -2.19 
CXCL12 chemokine (C-X-C motif) ligand 12 -2.19 
CYB5R2 cytochrome b5 reductase 2 -2.19 
DNAJB5 DnaJ (Hsp40) homolog, subfamily B, member 5 -2.19 
DNAJC9-AS1 
DNAJC9 antisense RNA 1 (non-protein coding), chromosome 10 open reading 
frame 103 -2.19 
IPO7 importin 7 -2.19 
KIAA0101 KIAA0101 -2.19 
PLA2G6 phospholipase A2, group VI (cytosolic, calcium-independent) -2.19 
RNF166 ring finger protein 166 -2.19 
SBF2 SET binding factor 2 -2.19 
SCN3A sodium channel, voltage-gated, type III, alpha subunit -2.19 
SLC24A5 solute carrier family 24, member 5 -2.19 
TFAP2D transcription factor AP-2 delta (activating enhancer binding protein 2 delta) -2.19 
WHSC1 Wolf-Hirschhorn syndrome candidate 1 -2.19 
BCL6B B-cell CLL/lymphoma 6, member B -2.2 
BMP5 bone morphogenetic protein 5 -2.2 
CACNA1E calcium channel, voltage-dependent, R type, alpha 1E subunit -2.2 
CACNA1I calcium channel, voltage-dependent, T type, alpha 1I subunit -2.2 
MIR943, WHSC2 microRNA 943, Wolf-Hirschhorn syndrome candidate 2 -2.2 




NR2C2 nuclear receptor subfamily 2, group C, member 2 -2.2 
NSMAF neutral sphingomyelinase (N-SMase) activation associated factor -2.2 
SYNJ2 synaptojanin 2 -2.2 
TEX26-AS1 TEX26 antisense RNA 1 (non-protein coding) -2.2 
TRIM39-RPP21 TRIM39-RPP21 readthrough, tripartite motif containing 39 -2.2 
TRIM39-RPP21 TRIM39-RPP21 readthrough, tripartite motif containing 39 -2.2 
TRIM39-RPP21 TRIM39-RPP21 readthrough, tripartite motif containing 39 -2.2 
TRIM39-RPP21 TRIM39-RPP21 readthrough, tripartite motif containing 39 -2.2 
AGAP2 ArfGAP with GTPase domain, ankyrin repeat and PH domain 2 -2.21 
ARID4A AT rich interactive domain 4A (RBP1-like) -2.21 
CCDC153 coiled-coil domain containing 153 -2.21 
CFTR 
cystic fibrosis transmembrane conductance regulator (ATP-binding cassette 
sub-family C, member 7) -2.21 
IQCJ, SCHIP1 
IQ motif containing J, schwannomin interacting protein 1, IQCJ-SCHIP1 
readthrough -2.21 
LOC348817 uncharacterized LOC348817, CCDC13 antisense RNA 1 (non-protein coding) -2.21 
PDE10A phosphodiesterase 10A -2.21 
RALYL RALY RNA binding protein-like -2.21 
TATDN1 TatD DNase domain containing 1 -2.21 
TFEB transcription factor EB -2.21 
TMEM14B transmembrane protein 14B -2.21 
ABCA9 ATP-binding cassette, sub-family A (ABC1), member 9 -2.22 
CSNK2B casein kinase 2, beta polypeptide -2.22 
FAM65B family with sequence similarity 65, member B -2.22 
PNCK pregnancy up-regulated non-ubiquitously expressed CaM kinase -2.22 
PSAP prosaposin -2.22 
SNORD32B small nucleolar RNA, C/D box 32B -2.22 
SNORD32B small nucleolar RNA, C/D box 32B -2.22 
SNORD32B small nucleolar RNA, C/D box 32B -2.22 
SNORD32B small nucleolar RNA, C/D box 32B -2.22 
SNORD32B small nucleolar RNA, C/D box 32B -2.22 
SNORD32B small nucleolar RNA, C/D box 32B -2.22 
SSBP1, 
MIR5096 single-stranded DNA binding protein 1, mitochondrial, microRNA 5096 -2.22 
TBC1D5 TBC1 domain family, member 5 -2.22 
AHNAK2 AHNAK nucleoprotein 2 -2.23 
ARHGEF3 Rho guanine nucleotide exchange factor (GEF) 3 -2.23 
C1orf51 chromosome 1 open reading frame 51 -2.23 
CAB39L calcium binding protein 39-like -2.23 
CBR3-AS1 CBR3 antisense RNA 1 (non-protein coding) -2.23 
ENOSF1 enolase superfamily member 1 -2.23 
FUT8 fucosyltransferase 8 (alpha (1,6) fucosyltransferase) -2.23 
GRID1 glutamate receptor, ionotropic, delta 1 -2.23 
NUAK1 NUAK family, SNF1-like kinase, 1 -2.23 




RBFOX1 RNA binding protein, fox-1 homolog (C. elegans) 1 -2.23 
SLC27A1 solute carrier family 27 (fatty acid transporter), member 1 -2.23 
TAB1 TGF-beta activated kinase 1/MAP3K7 binding protein 1 -2.23 
TMC5 transmembrane channel-like 5 -2.23 
ADCYAP1 adenylate cyclase activating polypeptide 1 (pituitary) -2.24 
C3 complement component 3 -2.24 
CFP complement factor properdin -2.24 
FBXO18 F-box protein, helicase, 18 -2.24 
GAB1 GRB2-associated binding protein 1 -2.24 
LILRA6 
leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), 
member 6 -2.24 
LINC00499 long intergenic non-protein coding RNA 499 -2.24 
ODZ4 odz, odd Oz/ten-m homolog 4 (Drosophila) -2.24 
PDE4DIP phosphodiesterase 4D interacting protein, myomegalin-like -2.24 
PPEF1 protein phosphatase, EF-hand calcium binding domain 1 -2.24 
RHOU, DUSP5P ras homolog family member U, dual specificity phosphatase 5 pseudogene -2.24 
STAC3 SH3 and cysteine rich domain 3 -2.24 
SUSD4 sushi domain containing 4 -2.24 
TTBK1 tau tubulin kinase 1 -2.24 
BZRAP1 benzodiazapine receptor (peripheral) associated protein 1 -2.25 
CAPRIN1 cell cycle associated protein 1 -2.25 
CCR8 chemokine (C-C motif) receptor 8 -2.25 
PCOLCE-AS1 PCOLCE antisense RNA 1 (non-protein coding) -2.25 
TYRP1 tyrosinase-related protein 1 -2.25 
AATK apoptosis-associated tyrosine kinase -2.26 
C10orf112 chromosome 10 open reading frame 112 -2.26 
DMBT1 deleted in malignant brain tumors 1 -2.26 
FER1L6 fer-1-like 6 (C. elegans) -2.26 
GABRA2 gamma-aminobutyric acid (GABA) A receptor, alpha 2 -2.26 
HERC5 HECT and RLD domain containing E3 ubiquitin protein ligase 5 -2.26 
NAAA N-acylethanolamine acid amidase -2.26 
PPP1R16A protein phosphatase 1, regulatory subunit 16A -2.26 
SPTBN4 spectrin, beta, non-erythrocytic 4 -2.26 
SSPN sarcospan -2.26 
ZBTB8OS zinc finger and BTB domain containing 8 opposite strand -2.26 
ATP6V1G2 ATP6V1G2-DDX39B readthrough (non-protein coding) -2.27 
C4orf17 chromosome 4 open reading frame 17 -2.27 
CATSPERB catsper channel auxiliary subunit beta -2.27 
DEK DEK oncogene -2.27 
GAL3ST4 galactose-3-O-sulfotransferase 4 -2.27 
HMGCLL1 3-hydroxymethyl-3-methylglutaryl-CoA lyase-like 1 -2.27 
SNORD84 
small nucleolar RNA, C/D box 84, DEAD (Asp-Glu-Ala-Asp) box polypeptide 
39B -2.27 




ZNF799 zinc finger protein 799 -2.27 
ABCB11 ATP-binding cassette, sub-family B (MDR/TAP), member 11 -2.28 
CD36 CD36 molecule (thrombospondin receptor) -2.28 
EYS eyes shut homolog (Drosophila) -2.28 
IL17D interleukin 17D -2.28 
REC8 REC8 homolog (yeast) -2.28 
SH3D21 SH3 domain containing 21, uncharacterized -2.28 
TTC37 tetratricopeptide repeat domain 37 -2.28 
ZDHHC17 zinc finger, DHHC-type containing 17 -2.28 
ZNF497 zinc finger protein 497 -2.28 
FEZ1 fasciculation and elongation protein zeta 1 (zygin I) -2.29 
FRY furry homolog (Drosophila) -2.29 
POR P450 (cytochrome) oxidoreductase -2.29 
PYHIN1 pyrin and HIN domain family, member 1 -2.29 
SLC12A9 solute carrier family 12 (potassium/chloride transporters), member 9 -2.29 
TACC2 transforming, acidic coiled-coil containing protein 2 -2.29 
ACE2 angiotensin I converting enzyme (peptidyl-dipeptidase A) 2 -2.3 
ARC activity-regulated cytoskeleton-associated protein -2.3 
CCDC155 coiled-coil domain containing 155 -2.3 
GATA4 GATA binding protein 4 -2.3 
IL24 interleukin 24 -2.3 
LOC340515 uncharacterized LOC340515 -2.3 
LPA lipoprotein, Lp(a) -2.3 
MLXIPL MLX interacting protein-like -2.3 
RUNDC3B RUN domain containing 3B -2.3 
SCN1A sodium channel, voltage-gated, type I, alpha subunit -2.3 
SYT9 synaptotagmin IX -2.3 
TLE3 transducin-like enhancer of split 3 (E(sp1) homolog, Drosophila) -2.3 
Mar-10 membrane-associated ring finger (C3HC4) 10, E3 ubiquitin protein ligase -2.31 
ESRP1 epithelial splicing regulatory protein 1 -2.31 
GAGE1-13/A-H G antigen 1-12/A-I -2.31 
ITGB1BP1 integrin beta 1 binding protein 1 -2.31 
JAKMIP1 janus kinase and microtubule interacting protein 1 -2.31 
KAZN kazrin, periplakin interacting protein -2.31 
LOC387895 uncharacterized LOC387895 -2.31 
MASP2 mannan-binding lectin serine peptidase 2 -2.31 
PAX8 paired box 8 -2.31 
RNF216 ring finger protein 216 -2.31 
SHC4 SHC (Src homology 2 domain containing) family, member 4 -2.31 
USP50 ubiquitin specific peptidase 50 -2.31 
ZACN zinc activated ligand-gated ion channel -2.31 
ANKHD1-
EIF4EBP3 
ankyrin repeat and KH domain containing 1, eukaryotic translation initiation 
factor 4E binding protein 3 -2.32 




EMC1 ER membrane protein complex subunit 1 -2.32 
ESR2 estrogen receptor 2 (ER beta) -2.32 
IL23R interleukin 23 receptor -2.32 
LILRA4 
leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), 
member 4 -2.32 
MYO15B myosin XVB pseudogene -2.32 
NXPE2 neurexophilin and PC-esterase domain family, member 2 -2.32 
PGA3 pepsinogen 3, group I (pepsinogen A) -2.32 
PTPRO protein tyrosine phosphatase, receptor type, O -2.32 
TAF6 
TAF6 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 
80kDa -2.32 
ACPL2 acid phosphatase-like 2 -2.33 
ATP13A4 ATPase type 13A4 -2.33 
BIVM-ERCC5 BIVM-ERCC5 readthrough, complementation group 5 -2.33 
C12orf35 chromosome 12 open reading frame 35 -2.33 
CCDC78 coiled-coil domain containing 78 -2.33 
CRTAC1 cartilage acidic protein 1 -2.33 
DNAH12 dynein, axonemal, heavy chain 12 -2.33 
DNAH9 dynein, axonemal, heavy chain 9 -2.33 
FAM98B family with sequence similarity 98, member B -2.33 
FBN2 fibrillin 2 -2.33 
GUCY2GP guanylate cyclase 2G homolog (mouse), pseudogene -2.33 
USP3 ubiquitin specific peptidase 3 -2.33 
ZNF470 zinc finger protein 470 -2.33 
AMOT angiomotin -2.34 
CYP4F12 cytochrome P450, family 4, subfamily F, polypeptide 12 -2.34 
HAL histidine ammonia-lyase -2.34 
MARK2 MAP/microtubule affinity-regulating kinase 2 -2.34 
PLCB1 phospholipase C, beta 1 (phosphoinositide-specific) -2.34 
PXDN peroxidasin homolog (Drosophila) -2.34 
RPS4Y2 ribosomal protein S4, Y-linked 2 -2.34 
AFF3 AF4/FMR2 family, member 3 -2.35 
DNAH11 dynein, axonemal, heavy chain 11 -2.35 
EML5 echinoderm microtubule associated protein like 5 -2.35 
GART 
phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide 
synthetase -2.35 
PADI4 peptidyl arginine deiminase, type IV -2.35 
RPS6KL1 ribosomal protein S6 kinase-like 1 -2.35 
TIAM1 T-cell lymphoma invasion and metastasis 1 -2.35 
ACADM acyl-CoA dehydrogenase, C-4 to C-12 straight chain -2.36 
ENPEP glutamyl aminopeptidase (aminopeptidase A) -2.36 
GRINA 
glutamate receptor, ionotropic, N-methyl D-aspartate-associated protein 1 
(glutamate binding) -2.36 
HMCN1 hemicentin 1 -2.36 
PPFIA1 
protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), 




SYCP2L synaptonemal complex protein 2-like, transmembrane protein 14B -2.36 
A2ML1 alpha-2-macroglobulin-like 1 -2.37 
COBL cordon-bleu homolog (mouse) -2.37 
IL13RA2 interleukin 13 receptor, alpha 2 -2.37 
RP1 retinitis pigmentosa 1 (autosomal dominant) -2.37 
STX5 syntaxin 5 -2.37 
DDHD2 DDHD domain containing 2 -2.38 
KIF1A kinesin family member 1A -2.38 
LOC100131825 uncharacterized LOC100131825 -2.38 
MOK MOK protein kinase -2.38 
PDGFC platelet derived growth factor C -2.38 
SOD2 superoxide dismutase 2, mitochondrial -2.38 
TRPA1 transient receptor potential cation channel, subfamily A, member 1 -2.38 
TTC40 tetratricopeptide repeat domain 40 -2.38 
AKR1B15 aldo-keto reductase family 1, member B15 -2.39 
ANKRD55 ankyrin repeat domain 55 -2.39 
BPIFB1 BPI fold containing family B, member 1 -2.39 
COL25A1 collagen, type XXV, alpha 1 -2.39 
DNAH11 dynein, axonemal, heavy chain 11 -2.39 
GAL3ST1 galactose-3-O-sulfotransferase 1 -2.39 
KRTAP5-10 keratin associated protein 5-10 -2.39 
TMPRSS3 transmembrane protease, serine 3 -2.39 
TRPC6 transient receptor potential cation channel, subfamily C, member 6 -2.39 
UNC80 unc-80 homolog (C. elegans) -2.39 
CLEC2B C-type lectin domain family 2, member B -2.4 
DLG4 discs, large homolog 4 (Drosophila) -2.4 
ECE2 endothelin converting enzyme 2 -2.4 
ELP4 elongation protein 4 homolog (S. cerevisiae) -2.4 
GAS8 5-hydroxyisourate hydrolase pseudogene, growth arrest-specific 8 -2.4 
PDE1B phosphodiesterase 1B, calmodulin-dependent -2.4 
PROL1 proline rich, lacrimal 1 -2.4 
BPIFB6 BPI fold containing family B, member 6 -2.41 
CMYA5 cardiomyopathy associated 5 -2.41 
DUOX1 dual oxidase 1 -2.41 
FAM13C family with sequence similarity 13, member C -2.41 
FLJ46010 FLJ46010 protein -2.41 
IL16 interleukin 16 -2.41 
PKHD1L1 polycystic kidney and hepatic disease 1 (autosomal recessive)-like 1 -2.41 
RELN reelin -2.41 
RENBP renin binding protein -2.41 
RIPK3 receptor-interacting serine-threonine kinase 3 -2.41 
RTDR1 rhabdoid tumor deletion region gene 1 -2.41 




SSPO SCO-spondin homolog (Bos taurus) -2.41 
TSLP thymic stromal lymphopoietin -2.41 
VAV3 vav 3 guanine nucleotide exchange factor -2.41 
ZNF839 zinc finger protein 839 -2.41 
DMTF1 cyclin D binding myb-like transcription factor 1 -2.42 
ESR1 estrogen receptor 1 -2.42 
IQGAP1 IQ motif containing GTPase activating protein 1 -2.42 
KCNU1 potassium channel, subfamily U, member 1 -2.42 
PIH1D2 PIH1 domain containing 2 -2.42 
RNF175 ring finger protein 175 -2.42 
SPHK2 sphingosine kinase 2 -2.42 
VPS26B vacuolar protein sorting 26 homolog B (S. pombe) -2.42 
WDR72 WD repeat domain 72 -2.42 
ZNF3 zinc finger protein 3 -2.42 
CES3 carboxylesterase 3 -2.43 
FBXO9 F-box protein 9 -2.43 
RAD1 RAD1 homolog (S. pombe) -2.43 
SPATA9 spermatogenesis associated 9 -2.43 
ABCC6 ATP-binding cassette, sub-family C (CFTR/MRP), member 6 -2.44 
BCL2L14 BCL2-like 14 (apoptosis facilitator) -2.44 
CCDC30 coiled-coil domain containing 30 -2.44 
CCDC93 coiled-coil domain containing 93 -2.44 
GTF2H3 general transcription factor IIH, polypeptide 3, 34kDa -2.44 
LILRA3 leukocyte immunoglobulin-like receptor, subfamily A, member 3 -2.44 
MMD2 monocyte to macrophage differentiation-associated 2 -2.44 
MYH14 myosin, heavy chain 14, non-muscle -2.44 
NRG3 neuregulin 3 -2.44 
PDE4DIP phosphodiesterase 4D interacting protein, myomegalin-like -2.44 
PMFBP1 polyamine modulated factor 1 binding protein 1 -2.44 
SLC7A11-AS1 SLC7A11 antisense RNA 1 (non-protein coding) -2.44 
TANC1 tetratricopeptide repeat, ankyrin repeat and coiled-coil containing 1 -2.44 
TRAF3IP3 TRAF3 interacting protein 3 -2.44 
DHX16 DEAH (Asp-Glu-Ala-His) box polypeptide 16 -2.45 
DHX16 DEAH (Asp-Glu-Ala-His) box polypeptide 16 -2.45 
DHX16 DEAH (Asp-Glu-Ala-His) box polypeptide 16 -2.45 
DHX16 DEAH (Asp-Glu-Ala-His) box polypeptide 16 -2.45 
DHX16 DEAH (Asp-Glu-Ala-His) box polypeptide 16 -2.45 
DLG2 discs, large homolog 2 (Drosophila) -2.45 
DSG4 desmoglein 4 -2.45 
FRMPD4 FERM and PDZ domain containing 4 -2.45 
GCLC glutamate-cysteine ligase, catalytic subunit -2.45 
SDR16C5 short chain dehydrogenase/reductase family 16C, member 5 -2.45 




UNC80 unc-80 homolog (C. elegans) -2.45 
CCDC171 coiled-coil domain containing 171 -2.46 
LOC284998 uncharacterized LOC284998 -2.46 
NPHP4 nephronophthisis 4 -2.46 
PITPNM1 phosphatidylinositol transfer protein, membrane-associated 1 -2.46 
C12orf10 chromosome 12 open reading frame 10 -2.47 
COX7B cytochrome c oxidase subunit VIIb -2.47 
FAM227B family with sequence similarity 227, member B -2.47 
FAM71D family with sequence similarity 71, member D -2.47 
MX2 myxovirus (influenza virus) resistance 2 (mouse) -2.47 
OSGEPL1 O-sialoglycoprotein endopeptidase-like 1 -2.47 
PRDM15 PR domain containing 15 -2.47 
TEX29 testis expressed 29 -2.47 
AMOT angiomotin -2.48 
C22orf43 chromosome 22 open reading frame 43 -2.48 
KAT7 K(lysine) acetyltransferase 7 -2.48 
LYPLA1 lysophospholipase I -2.48 
MYH13 myosin, heavy chain 13, skeletal muscle -2.48 
NFKBIL1 
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor-
like 1 -2.48 
NFKBIL1 
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor-
like 1 -2.48 
PLA2G4E phospholipase A2, group IVE -2.48 
PSMG4 proteasome (prosome, macropain) assembly chaperone 4 -2.48 
RIMS2 regulating synaptic membrane exocytosis 2 -2.48 
THOC2 THO complex 2 -2.48 
C12orf56 chromosome 12 open reading frame 56 -2.49 
E2F5 E2F transcription factor 5, p130-binding -2.49 
MMAB methylmalonic aciduria (cobalamin deficiency) cblB type -2.49 
DAOA D-amino acid oxidase activator -2.5 
FAM149A family with sequence similarity 149, member A -2.5 
HERC2 
HECT and RLD domain containing E3 ubiquitin protein ligase 2, putative 
HERC2-like protein 3-like -2.5 
LRIG1 leucine-rich repeats and immunoglobulin-like domains 1 -2.5 
EYS eyes shut homolog (Drosophila) -2.51 
LAMP3 lysosomal-associated membrane protein 3 -2.51 
PLA2G4A phospholipase A2, group IVA (cytosolic, calcium-dependent) -2.51 
SLC26A8 solute carrier family 26, member 8 -2.51 
TDRD1 tudor domain containing 1 -2.51 
ARSE arylsulfatase E (chondrodysplasia punctata 1) -2.52 
HLF hepatic leukemia factor -2.52 
RBCK1 RanBP-type and C3HC4-type zinc finger containing 1 -2.52 
CASD1 CAS1 domain containing 1 -2.53 
DLGAP4 discs, large (Drosophila) homolog-associated protein 4 -2.53 




SMPDL3B sphingomyelin phosphodiesterase, acid-like 3B -2.53 
WDR7 WD repeat domain 7 -2.53 
GUCY1A3 guanylate cyclase 1, soluble, alpha 3 -2.54 
PPARGC1A peroxisome proliferator-activated receptor gamma, coactivator 1 alpha -2.54 
SDK1 sidekick cell adhesion molecule 1 -2.54 
TRAT1 T cell receptor associated transmembrane adaptor 1 -2.54 
BMP7 bone morphogenetic protein 7 -2.55 
C19orf45 chromosome 19 open reading frame 45 -2.55 
IL7R interleukin 7 receptor -2.55 
UNC80 unc-80 homolog (C. elegans) -2.55 
DIABLO diablo, IAP-binding mitochondrial protein -2.56 
DKFZp686O132
7 uncharacterized LOC401014 -2.56 
FBLN1 fibulin 1 -2.56 
BAIAP2L2 BAI1-associated protein 2-like 2 -2.57 
COMTD1 catechol-O-methyltransferase domain containing 1 -2.57 
JAKMIP3 Janus kinase and microtubule interacting protein 3 -2.57 
LRP1B low density lipoprotein receptor-related protein 1B -2.57 
GRM4 glutamate receptor, metabotropic 4 -2.58 
MYO5B myosin VB -2.58 
ZRANB3 zinc finger, RAN-binding domain containing 3 -2.58 
CACNA1D calcium channel, voltage-dependent, L type, alpha 1D subunit -2.59 
CSMD3 CUB and Sushi multiple domains 3 -2.59 
GLYATL1 glycine-N-acyltransferase-like 1 -2.59 
IGKV1-5 immunoglobulin kappa variable 1-5 -2.59 
LOC100287562 uncharacterized LOC100287562 -2.59 
MCOLN3 mucolipin 3 -2.59 
NECAB1 N-terminal EF-hand calcium binding protein 1 -2.59 
OTOGL otogelin-like -2.59 
PDE11A phosphodiesterase 11A -2.59 
THAP9 THAP domain containing 9 -2.59 
ARAP2 ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 2 -2.6 
CDK2 cyclin-dependent kinase 2 -2.6 
CHEK2 checkpoint kinase 2 -2.6 
ITGA4 integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor) -2.6 
PDGFRA, 
FIP1L1 
platelet-derived growth factor receptor, alpha polypeptide, FIP1 like 1 (S. 
cerevisiae) -2.6 
SEL1L2 sel-1 suppressor of lin-12-like 2 (C. elegans) -2.6 
TDP1 tyrosyl-DNA phosphodiesterase 1 -2.6 
UOX urate oxidase, pseudogene -2.6 
C17orf57, 
ITGB3 
chromosome 17 open reading frame 57, integrin, beta 3 (platelet 
glycoprotein IIIa, antigen CD61) -2.61 
COX4I2 cytochrome c oxidase subunit IV isoform 2 (lung) -2.61 
DDX18 DEAD (Asp-Glu-Ala-Asp) box polypeptide 18 -2.61 




HTN3 histatin 3 -2.61 
MCTP1 multiple C2 domains, transmembrane 1 -2.61 
MKNK1 MAP kinase interacting serine/threonine kinase 1 -2.61 
MYCBPAP MYCBP associated protein -2.61 
SMARCB1 
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, 
subfamily b, member 1 -2.61 
LRP1B low density lipoprotein receptor-related protein 1B -2.62 
MYD88 myeloid differentiation primary response gene (88) -2.62 
PIK3C2G phosphoinositide-3-kinase, class 2, gamma polypeptide -2.62 
POLR2F polymerase (RNA) II (DNA directed) polypeptide F -2.62 
POLR2F polymerase (RNA) II (DNA directed) polypeptide F -2.62 
RIMS1 regulating synaptic membrane exocytosis 1 -2.62 
FRAS1 Fraser syndrome 1 -2.63 
GDPD2 glycerophosphodiester phosphodiesterase domain containing 2 -2.63 
KALRN kalirin, RhoGEF kinase -2.63 
MIR4273 microRNA 4273 -2.63 
SPAG1 sperm associated antigen 1 -2.63 
TRPA1 transient receptor potential cation channel, subfamily A, member 1 -2.63 
C11orf10 chromosome 11 open reading frame 10 -2.64 
KIAA1875 KIAA1875 -2.64 
TRIM66 tripartite motif containing 66 -2.64 
ADCY2 adenylate cyclase 2 (brain) -2.65 
ATP8B5P ATPase, class I, type 8B, member 5, pseudogene -2.65 
FGD3 FYVE, RhoGEF and PH domain containing 3 -2.65 
LINC00571 long intergenic non-protein coding RNA 571 -2.65 
PKLR pyruvate kinase, liver and RBC -2.65 
SLAIN2 SLAIN motif family, member 2 -2.65 
TDRD9 tudor domain containing 9 -2.65 
TRIM29 tripartite motif containing 29 -2.65 
VRK2 vaccinia related kinase 2 -2.65 
C10orf129 chromosome 10 open reading frame 129 -2.66 
COL6A6 collagen, type VI, alpha 6 -2.66 
MTFP1 mitochondrial fission process 1 -2.66 
MYO1G myosin IG -2.66 
SORBS1 sorbin and SH3 domain containing 1 -2.66 
TRIM29 tripartite motif containing 29 -2.66 
ZFYVE28 zinc finger, FYVE domain containing 28 -2.66 
CHI3L2 chitinase 3-like 2 -2.67 
NBLA00301 Nbla00301 -2.67 
NRBP1 nuclear receptor binding protein 1 -2.67 
RIMBP2 RIMS binding protein 2 -2.67 
SNORD97 small nucleolar RNA, C/D box 97 -2.67 
SPG11 spastic paraplegia 11 (autosomal recessive) -2.67 




DNHD1, FXC1 dynein heavy chain domain 1, fracture callus 1 homolog (rat) -2.68 
KIAA1967 KIAA1967 -2.68 
MIR4462 microRNA 4462 -2.68 
OSTalpha organic solute transporter alpha -2.68 
ABCC4 ATP-binding cassette, sub-family C (CFTR/MRP), member 4 -2.69 
CERS2 ceramide synthase 2 -2.69 
FLJ46906 uncharacterized LOC441172 -2.69 
SPATA20 spermatogenesis associated 20 -2.69 
EPB41L3 erythrocyte membrane protein band 4.1-like 3 -2.7 
HTR3D 5-hydroxytryptamine (serotonin) receptor 3D, ionotropic -2.7 
PDZD2 PDZ domain containing 2 -2.7 
PSMB9 
proteasome (prosome, macropain) subunit, beta type, 9 (large 
multifunctional peptidase 2) -2.7 
PSMB9 
proteasome (prosome, macropain) subunit, beta type, 9 (large 
multifunctional peptidase 2) -2.7 
PSMB9 
proteasome (prosome, macropain) subunit, beta type, 9 (large 
multifunctional peptidase 2) -2.7 
PSMB9 
proteasome (prosome, macropain) subunit, beta type, 9 (large 
multifunctional peptidase 2) -2.7 
SPPL2A signal peptide peptidase like 2A -2.7 
TRO trophinin -2.7 
C3P1 complement component 3 precursor pseudogene -2.71 
POTEB 
POTE ankyrin domain family, member B, POTE ankyrin domain family 
member B-like -2.71 
POTEB 
POTE ankyrin domain family, member B, POTE ankyrin domain family 
member B-like -2.71 
SLC35C2 solute carrier family 35, member C2 -2.71 
FBXO32 F-box protein 32 -2.72 
TMCO6 transmembrane and coiled-coil domains 6 -2.72 
WDR52-AS1 WDR52 antisense RNA 1 (non-protein coding) -2.72 
ZMAT1 zinc finger, matrin-type 1 -2.72 
MAST4 microtubule associated serine/threonine kinase family member 4 -2.73 
SEC14L2 SEC14-like 2 (S. cerevisiae) -2.73 
SNCAIP synuclein, alpha interacting protein -2.73 
ABCB6, ATG9A 
ATP-binding cassette, sub-family B (MDR/TAP), member 6, autophagy 
related 9A -2.74 
MFSD6 major facilitator superfamily domain containing 6 -2.74 
MYH7B myosin, heavy chain 7B, cardiac muscle, beta -2.74 
PPARGC1B peroxisome proliferator-activated receptor gamma, coactivator 1 beta -2.74 
TEX11 testis expressed 11 -2.74 
TPM3 tropomyosin 3 -2.74 
WAC WW domain containing adaptor with coiled-coil -2.74 
CLPTM1L CLPTM1-like -2.75 
FAM208A family with sequence similarity 208, member A -2.75 
GPR160 G protein-coupled receptor 160 -2.75 
HEATR8-TTC4 
HEATR8-TTC4 readthrough, HEAT repeat containing 8, tetratricopeptide 
repeat domain 4 -2.75 




ZC3H14 zinc finger CCCH-type containing 14 -2.76 
ANKZF1 ankyrin repeat and zinc finger domain containing 1 -2.77 
CADPS Ca++-dependent secretion activator -2.77 
HECTD2 HECT domain containing E3 ubiquitin protein ligase 2 -2.77 
FAM65C family with sequence similarity 65, member C -2.78 
GPT glutamic-pyruvate transaminase (alanine aminotransferase) -2.78 
HIBCH 3-hydroxyisobutyryl-CoA hydrolase -2.78 
NAV3 neuron navigator 3 -2.78 
RANBP17 RAN binding protein 17 -2.78 
CDH16 cadherin 16, KSP-cadherin -2.79 
COPB1, PSMA1 
coatomer protein complex, subunit beta 1, proteasome (prosome, 
macropain) subunit, alpha type, 1 -2.79 
ACAT1 acetyl-CoA acetyltransferase 1 -2.8 
CCDC108 coiled-coil domain containing 108 -2.8 
CYP3A4 cytochrome P450, family 3, subfamily A, polypeptide 4 -2.8 
MUC6 mucin 6, oligomeric mucus/gel-forming -2.8 
TMPPE, GLB1 
transmembrane protein with metallophosphoesterase domain, galactosidase, 
beta 1 -2.8 
C20orf112 chromosome 20 open reading frame 112 -2.81 
CASP8 caspase 8, apoptosis-related cysteine peptidase -2.81 
RAPGEF5 Rap guanine nucleotide exchange factor (GEF) 5 -2.81 
C12orf63 




cadherin, EGF LAG seven-pass G-type receptor 3 (flamingo homolog, 
Drosophila), microRNA 4793 -2.82 
FHAD1 forkhead-associated (FHA) phosphopeptide binding domain 1 -2.82 
IQCH IQ motif containing H -2.82 
LOC100508781 protein FAM115A-like -2.82 
ANXA4 annexin A4 -2.83 
DHRS12 dehydrogenase/reductase (SDR family) member 12 -2.83 
FPGS folylpolyglutamate synthase -2.83 
GPR18 G protein-coupled receptor 18 -2.83 
PEX5 peroxisomal biogenesis factor 5 -2.83 
PIP5K1B phosphatidylinositol-4-phosphate 5-kinase, type I, beta -2.83 
VWA3B von Willebrand factor A domain containing 3B -2.83 
CD96 CD96 molecule -2.84 
CPAMD8 C3 and PZP-like, alpha-2-macroglobulin domain containing 8 -2.84 
SLC22A10 solute carrier family 22, member 10 -2.84 
VARS2 valyl-tRNA synthetase 2, mitochondrial (putative) -2.84 
VARS2 valyl-tRNA synthetase 2, mitochondrial (putative) -2.84 
VARS2 valyl-tRNA synthetase 2, mitochondrial (putative) -2.84 
VARS2 valyl-tRNA synthetase 2, mitochondrial (putative) -2.84 
VARS2 valyl-tRNA synthetase 2, mitochondrial (putative) -2.84 
ZNF503-AS1 ZNF503 antisense RNA 1 (non-protein coding) -2.84 
DDX47 DEAD (Asp-Glu-Ala-Asp) box polypeptide 47 -2.86 




CLDN12 claudin 12 -2.87 
GNRHR2 gonadotropin-releasing hormone (type 2) receptor 2 -2.87 
MEGF6 multiple EGF-like-domains 6 -2.87 
SPATA7 spermatogenesis associated 7 -2.87 
USP20 ubiquitin specific peptidase 20 -2.88 
AVIL advillin -2.89 
CCDC33 coiled-coil domain containing 33 -2.89 
CCND3 cyclin D3 -2.89 
SFPQ splicing factor proline/glutamine-rich -2.89 
VEPH1 ventricular zone expressed PH domain homolog 1 (zebrafish) -2.89 
ZNF660 zinc finger protein 660, zinc finger protein 197 -2.89 
POU2F2 POU class 2 homeobox 2 -2.9 
CSMD1 CUB and Sushi multiple domains 1 -2.91 
INPP5D inositol polyphosphate-5-phosphatase, 145kDa -2.91 
LOC100507431 uncharacterized LOC100507431 -2.91 
PPP1R7 protein phosphatase 1, regulatory subunit 7 -2.91 
LOC100124692 maltase-glucoamylase (alpha-glucosidase) pseudogene -2.92 
SGK1 serum/glucocorticoid regulated kinase 1 -2.92 
NFE2L2 nuclear factor (erythroid-derived 2)-like 2 -2.93 
MYOM3 myomesin family, member 3 -2.93 
ACPP acid phosphatase, prostate -2.94 
BBS1 Bardet-Biedl syndrome 1 -2.94 
FGF13 fibroblast growth factor 13 -2.94 
GRIK1 glutamate receptor, ionotropic, kainate 1 -2.94 
KAZALD1 Kazal-type serine peptidase inhibitor domain 1 -2.94 
MYEOV myeloma overexpressed (in a subset of t(11;14) positive multiple myelomas) -2.94 
RYR3 ryanodine receptor 3 -2.94 
SERPINF2 
serpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment epithelium 
derived factor) -2.94 
TRAK2 trafficking protein, kinesin binding 2 -2.94 
WNK2 WNK lysine deficient protein kinase 2 -2.94 
CCDC146 coiled-coil domain containing 146 -2.95 
CCDC171 coiled-coil domain containing 171 -2.95 
RYR2 ryanodine receptor 2 (cardiac) -2.95 
SPAG17 sperm associated antigen 17 -2.95 
TMEM134 transmembrane protein 134 -2.96 
FAM118A family with sequence similarity 118, member A -2.97 
INADL InaD-like (Drosophila) -2.97 
RC3H1 ring finger and CCCH-type domains 1 -2.97 
MAPK10 mitogen-activated protein kinase 10 -2.98 
OVGP1 oviductal glycoprotein 1, 120kDa -2.98 
RNF17 ring finger protein 17 -2.98 





polyamine oxidase (exo-N4-amino), mitochondrial GTPase 1 homolog (S. 
cerevisiae) -2.99 
RYR3 ryanodine receptor 3 -2.99 
ATP8A2 ATPase, aminophospholipid transporter, class I, type 8A, member 2 -3 
LEF1 lymphoid enhancer-binding factor 1 -3 
LINC00313 long intergenic non-protein coding RNA 313 -3.02 
MDC1 mediator of DNA-damage checkpoint 1 -3.02 
MDC1 mediator of DNA-damage checkpoint 1 -3.02 
MDC1 mediator of DNA-damage checkpoint 1 -3.02 
MDC1 mediator of DNA-damage checkpoint 1 -3.02 
MDC1 mediator of DNA-damage checkpoint 1 -3.02 
MDC1 
mediator of DNA-damage checkpoint 1, MDC1 antisense RNA 1 (non-protein 
coding) -3.02 
MDC1-AS1 MDC1 antisense RNA 1 (non-protein coding) -3.02 
MTMR7 myotubularin related protein 7 -3.02 
MUC19 mucin 19, oligomeric -3.02 
TDRD1 tudor domain containing 1 -3.02 
COL4A3 collagen, type IV, alpha 3 (Goodpasture antigen) -3.03 
HEPH hephaestin -3.03 
SCN3A sodium channel, voltage-gated, type III, alpha subunit -3.03 
ABTB1 ankyrin repeat and BTB (POZ) domain containing 1 -3.04 
PTPRK protein tyrosine phosphatase, receptor type, K -3.04 
USP20 ubiquitin specific peptidase 20 -3.04 
ATXN7L1 ataxin 7-like 1 -3.06 
KALRN kalirin, RhoGEF kinase -3.06 
ZNF827 zinc finger protein 827 -3.06 
GRIA2 glutamate receptor, ionotropic, AMPA 2 -3.08 
MFSD4 major facilitator superfamily domain containing 4 -3.08 
SACM1L SAC1 suppressor of actin mutations 1-like (yeast) -3.08 
GARNL3 GTPase activating Rap/RanGAP domain-like 3 -3.09 
PIGQ phosphatidylinositol glycan anchor biosynthesis, class Q -3.09 
SLC26A7 solute carrier family 26, member 7 -3.09 
COL3A1 collagen, type III, alpha 1, microRNA 3606 -3.1 
LOC100506950 uncharacterized LOC100506950 -3.1 
ACSS3 acyl-CoA synthetase short-chain family member 3 -3.11 
GTPBP10 GTP-binding protein 10 (putative), claudin 12 -3.11 
MUC2 mucin 2, oligomeric mucus/gel-forming -3.11 
TXNDC12 thioredoxin domain containing 12 (endoplasmic reticulum) -3.11 
C1QTNF5 
C1q and tumor necrosis factor related protein 5, membrane frizzled-related 
protein -3.12 
MAP7D2 MAP7 domain containing 2 -3.12 
VWA7 von Willebrand factor A domain containing 7 -3.12 
VWA7 von Willebrand factor A domain containing 7 -3.12 
VWA7 von Willebrand factor A domain containing 7 -3.12 




VWA7 von Willebrand factor A domain containing 7 -3.12 
Mar-01 membrane-associated ring finger (C3HC4) 1, E3 ubiquitin protein ligase -3.13 
ANAPC1 anaphase promoting complex subunit 1 -3.13 
CFP complement factor properdin -3.13 
GNB1L guanine nucleotide binding protein (G protein), beta polypeptide 1-like -3.13 
USH2A Usher syndrome 2A (autosomal recessive, mild) -3.13 
OTUD3 OTU domain containing 3 -3.14 
PLSCR4 phospholipid scramblase 4 -3.14 
SEPP1 selenoprotein P, plasma, 1 -3.14 
TRPA1 transient receptor potential cation channel, subfamily A, member 1 -3.14 
TBC1D5 TBC1 domain family, member 5 -3.15 
ASIC4 acid-sensing (proton-gated) ion channel family member 4 -3.16 
C2orf88 chromosome 2 open reading frame 88 -3.16 
EFCAB6 EF-hand calcium binding domain 6 -3.16 
NPC1L1 NPC1 (Niemann-Pick disease, type C1, gene)-like 1 -3.16 
VAV3 vav 3 guanine nucleotide exchange factor -3.16 
C3orf24 chromosome 3 open reading frame 24 -3.17 
KRTAP15-1 keratin associated protein 15-1 -3.17 
ERBB3 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian) -3.18 
LONRF1 LON peptidase N-terminal domain and ring finger 1 -3.18 
PTPRO protein tyrosine phosphatase, receptor type, O -3.18 
LMO7 LIM domain 7 -3.19 
ROS1, GOPC c-ros oncogene 1 , receptor tyrosine kinase -3.19 
DNAH11 dynein, axonemal, heavy chain 11 -3.2 
PTPRD protein tyrosine phosphatase, receptor type, D -3.2 
WRAP73 WD repeat containing, antisense to TP73 -3.2 
EXOC1 exocyst complex component 1 -3.21 
ADAM32 ADAM metallopeptidase domain 32 -3.24 
CPVL carboxypeptidase, vitellogenic-like -3.24 
GCGR glucagon receptor -3.24 
TDRD12 tudor domain containing 12 -3.24 
ACSM1 acyl-CoA synthetase medium-chain family member 1 -3.25 
CATSPERB catsper channel auxiliary subunit beta -3.25 
GPR112 G protein-coupled receptor 112 -3.26 
COQ6 coenzyme Q6 homolog, monooxygenase (S. cerevisiae) -3.27 
PCDH15 protocadherin-related 15 -3.27 
RAD18 RAD18 homolog (S. cerevisiae) -3.27 
GLDN gliomedin -3.28 
TMX4 thioredoxin-related transmembrane protein 4 -3.28 
GNGT1 
guanine nucleotide binding protein (G protein), gamma transducing activity 
polypeptide 1 -3.29 
INADL InaD-like (Drosophila) -3.29 
JAKMIP3 Janus kinase and microtubule interacting protein 3 -3.29 




ZBTB22 zinc finger and BTB domain containing 22 -3.3 
ZBTB22 zinc finger and BTB domain containing 22 -3.3 
ZBTB22 zinc finger and BTB domain containing 22 -3.3 
ZBTB22 zinc finger and BTB domain containing 22 -3.3 
ZBTB22 zinc finger and BTB domain containing 22 -3.3 
CDC123 cell division cycle 123 homolog (S. cerevisiae) -3.31 
MYH8 myosin, heavy chain 8, skeletal muscle, perinatal -3.31 
EYS eyes shut homolog (Drosophila) -3.33 
SMTN smoothelin -3.33 
MECOM MDS1 and EVI1 complex locus -3.34 
SPEG SPEG complex locus -3.34 
TNXB tenascin XB -3.34 
TNXB tenascin XB -3.34 
TNXB tenascin XB -3.34 
TNXB tenascin XB -3.34 
TNXB, TNXA tenascin XB, tenascin XA (pseudogene) -3.34 
TNXB, TNXA tenascin XB, tenascin XA (pseudogene) -3.34 
SERPINE3 
serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor 
type 1), member 3 -3.35 
TRBV5-1 T cell receptor beta variable 5-1 -3.35 
TTF2 transcription termination factor, RNA polymerase II -3.35 
CASQ1 calsequestrin 1 (fast-twitch, skeletal muscle) -3.36 
EPB41L3 erythrocyte membrane protein band 4.1-like 3 -3.37 
GAS6-AS1 GAS6 antisense RNA 1 (non-protein coding) -3.37 
SIDT2 SID1 transmembrane family, member 2 -3.37 
CCDC84 coiled-coil domain containing 84 -3.38 
CREB3L3 cAMP responsive element binding protein 3-like 3 -3.39 
KCNAB1 potassium voltage-gated channel, shaker-related subfamily, beta member 1 -3.39 
FER1L5 fer-1-like 5 (C. elegans) -3.4 
KIAA1456 KIAA1456 -3.4 
FANK1 fibronectin type III and ankyrin repeat domains 1 -3.43 
RPH3A rabphilin 3A homolog (mouse) -3.43 
DNAH10 dynein, axonemal, heavy chain 10 -3.45 
ZBED3-AS1 ZBED3 antisense RNA 1 (non-protein coding) -3.45 
APLP2 amyloid beta (A4) precursor-like protein 2 -3.46 
ETV6 ets variant 6 -3.47 
GGCT gamma-glutamylcyclotransferase -3.47 
ABCA4 ATP-binding cassette, sub-family A (ABC1), member 4 -3.48 
PPP2R5B protein phosphatase 2, regulatory subunit B', beta -3.51 
VPS33A vacuolar protein sorting 33 homolog A (S. cerevisiae) -3.51 
ZNF704 zinc finger protein 704 -3.51 
COG2 component of oligomeric golgi complex 2 -3.52 
FRY furry homolog (Drosophila) -3.52 




DNAH11 dynein, axonemal, heavy chain 11 -3.53 
CATSPERD catsper channel auxiliary subunit delta -3.55 
CPA1 carboxypeptidase A1 (pancreatic) -3.55 
LAMA2 laminin, alpha 2 -3.55 
MFAP5 microfibrillar associated protein 5 -3.55 
C4orf45 chromosome 4 open reading frame 45 -3.56 
LOC100132815 importin 5 pseudogene -3.56 
PLRG1 pleiotropic regulator 1 -3.56 
FOXN3 forkhead box N3 -3.57 
PPFIBP1 PTPRF interacting protein, binding protein 1 (liprin beta 1) -3.57 
CALCOCO2 calcium binding and coiled-coil domain 2 -3.58 
FGD2 FYVE, RhoGEF and PH domain containing 2 -3.58 
KLHL24 kelch-like 24 (Drosophila) -3.58 
SORCS3 sortilin-related VPS10 domain containing receptor 3 -3.58 
DDX4 DEAD (Asp-Glu-Ala-Asp) box polypeptide 4 -3.59 
NELL1 NEL-like 1 (chicken) -3.59 
C4orf37 chromosome 4 open reading frame 37 -3.6 
FHAD1 forkhead-associated (FHA) phosphopeptide binding domain 1 -3.61 
CUBN cubilin (intrinsic factor-cobalamin receptor) -3.62 
PSEN1 presenilin 1 -3.62 
BRSK2 BR serine/threonine kinase 2 -3.63 
C14orf38 chromosome 14 open reading frame 38 -3.63 
SCML4 sex comb on midleg-like 4 (Drosophila) -3.63 
STAMBPL1 STAM binding protein-like 1 -3.63 
ACAN aggrecan -3.64 
SP140 SP140 nuclear body protein -3.64 
SMCR7L Smith-Magenis syndrome chromosome region, candidate 7-like -3.66 
PSME4 proteasome (prosome, macropain) activator subunit 4 -3.69 
UTP20 UTP20, small subunit (SSU) processome component, homolog (yeast) -3.69 
C3orf24 chromosome 3 open reading frame 24 -3.7 
SLC4A5 solute carrier family 4, sodium bicarbonate cotransporter, member 5 -3.7 
DCTN2 dynactin 2 (p50) -3.72 
SLIRP SRA stem-loop interacting RNA binding protein -3.73 
UNC5C unc-5 homolog C (C. elegans) -3.73 
ABCB5 ATP-binding cassette, sub-family B (MDR/TAP), member 5 -3.75 
C9orf43 chromosome 9 open reading frame 43 -3.75 
PVRL4 poliovirus receptor-related 4 -3.75 
ALDH1L1 aldehyde dehydrogenase 1 family, member L1 -3.76 
STK11IP serine/threonine kinase 11 interacting protein -3.77 
CYP4V2 cytochrome P450, family 4, subfamily V, polypeptide 2 -3.79 
IKZF1 IKAROS family zinc finger 1 (Ikaros) -3.82 
LYPD6B LY6/PLAUR domain containing 6B -3.82 





RAB3 GTPase activating protein subunit 2 (non-catalytic), aurora kinase A 
pseudogene 1 -3.85 
DAOA D-amino acid oxidase activator -3.86 
TAF1 
TAF1 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 
250kDa -3.89 
RPUSD4 RNA pseudouridylate synthase domain containing 4 -3.9 
RNH1 ribonuclease/angiogenin inhibitor 1 -3.92 
SPTB spectrin, beta, erythrocytic -3.92 
ARMCX4 armadillo repeat containing, X-linked 4 -3.93 
DOCK2 dedicator of cytokinesis 2 -3.94 
DNAH1 dynein, axonemal, heavy chain 1 -3.95 
GTF2H1 general transcription factor IIH, polypeptide 1, 62kDa -3.95 
ACAT1 acetyl-CoA acetyltransferase 1 -3.98 
KDM3B lysine (K)-specific demethylase 3B -3.98 
UNC80 unc-80 homolog (C. elegans) -4.02 
CTSB cathepsin B -4.03 
KIAA1731 KIAA1731 -4.03 
GRAMD1C GRAM domain containing 1C -4.07 
CEP192 centrosomal protein 192kDa -4.08 
C3orf32 chromosome 3 open reading frame 32 -4.09 
PDE4B phosphodiesterase 4B, cAMP-specific -4.09 
SLC44A5 solute carrier family 44, member 5 -4.09 
METAP1D methionyl aminopeptidase type 1D (mitochondrial) -4.1 
PPARGC1A peroxisome proliferator-activated receptor gamma, coactivator 1 alpha -4.12 
ATP1A4 ATPase, Na+/K+ transporting, alpha 4 polypeptide -4.14 
BNIPL BCL2/adenovirus E1B 19kD interacting protein like -4.17 
EAF2 ELL associated factor 2 -4.17 
KLHL7 kelch-like 7 (Drosophila) -4.17 
ATP2A3 ATPase, Ca++ transporting, ubiquitous -4.18 
NUP205 nucleoporin 205kDa -4.18 
CHRNA9 cholinergic receptor, nicotinic, alpha 9 (neuronal) -4.19 
PTPRC protein tyrosine phosphatase, receptor type, C -4.19 
MS4A4A membrane-spanning 4-domains, subfamily A, member 4A -4.2 
PTGER3 prostaglandin E receptor 3 (subtype EP3) -4.23 
USH1C Usher syndrome 1C (autosomal recessive, severe) -4.23 
NALCN sodium leak channel, non-selective -4.25 
SYNE1 spectrin repeat containing, nuclear envelope 1 -4.27 
STK31 serine/threonine kinase 31 -4.28 
HIF3A hypoxia inducible factor 3, alpha subunit -4.29 
USP53 ubiquitin specific peptidase 53 -4.31 
GLUD1 glutamate dehydrogenase 1 -4.33 
TANK TRAF family member-associated NFKB activator -4.33 
DDX10 DEAD (Asp-Glu-Ala-Asp) box polypeptide 10 -4.37 




SRPK2 SRSF protein kinase 2 -4.4 
CACNA1S calcium channel, voltage-dependent, L type, alpha 1S subunit -4.42 
IL17RE interleukin 17 receptor E -4.43 
PPFIBP2 PTPRF interacting protein, binding protein 2 (liprin beta 2) -4.43 
LY9 lymphocyte antigen 9 -4.44 
ADAM29 ADAM metallopeptidase domain 29 -4.45 
GNL3 
guanine nucleotide binding protein-like 3 (nucleolar), small nucleolar RNA, 
C/D box 19B -4.45 
GCOM1-2 GRINL1A complex locus 1-2 -4.5 
MASP1 
mannan-binding lectin serine peptidase 1 (C4/C2 activating component of 
Ra-reactive factor) -4.51 
FHAD1 forkhead-associated (FHA) phosphopeptide binding domain 1 -4.52 
STAC3 SH3 and cysteine rich domain 3 -4.53 
TF transferrin -4.55 
DDX10 DEAD (Asp-Glu-Ala-Asp) box polypeptide 10 -4.6 
ANTXRL anthrax toxin receptor-like -4.61 
KRT24 keratin 24 -4.61 
CACNA1I calcium channel, voltage-dependent, T type, alpha 1I subunit -4.62 
ECT2L epithelial cell transforming sequence 2 oncogene-like -4.64 
MIPOL1 mirror-image polydactyly 1 -4.64 
IL1RAPL1 interleukin 1 receptor accessory protein-like 1 -4.7 
KANSL1L KAT8 regulatory NSL complex subunit 1-like -4.75 
SYCP2 synaptonemal complex protein 2 -4.75 
MSR1 macrophage scavenger receptor 1 -4.84 
ANAPC11 anaphase promoting complex subunit 11 -4.89 
ABCF1 ATP-binding cassette, sub-family F (GCN20), member 1 -4.97 
ABCF1 ATP-binding cassette, sub-family F (GCN20), member 1 -4.97 
ABCF1 ATP-binding cassette, sub-family F (GCN20), member 1 -4.97 
ABCF1 ATP-binding cassette, sub-family F (GCN20), member 1 -4.97 
ABCF1 ATP-binding cassette, sub-family F (GCN20), member 1 -4.97 
ABCF1 ATP-binding cassette, sub-family F (GCN20), member 1 -4.97 
ABCF1 ATP-binding cassette, sub-family F (GCN20), member 1 -4.97 
CDHR2 cadherin-related family member 2 -5.01 
RABGAP1L RAB GTPase activating protein 1-like -5.07 
EIF5 eukaryotic translation initiation factor 5 -5.08 
CD8A CD8a molecule -5.09 
EMCN endomucin -5.09 
C17orf70 chromosome 17 open reading frame 70 -5.1 
KCNQ5 potassium voltage-gated channel, KQT-like subfamily, member 5 -5.12 
ZRANB3 zinc finger, RAN-binding domain containing 3 -5.14 
SEMA5A 
sema domain, seven thrombospondin repeats (type 1 and type 1-
like),semaphorin 5A -5.16 
USP40 ubiquitin specific peptidase 40 -5.16 
TMEM108 transmembrane protein 108 -5.17 




DNAH2 dynein, axonemal, heavy chain 2 -5.22 
MIR3661 microRNA 3661 -5.22 
SLC6A1 solute carrier family 6 (neurotransmitter transporter, GABA), member 1 -5.27 
PKHD1L1 polycystic kidney and hepatic disease 1 (autosomal recessive)-like 1 -5.31 
NUP188 nucleoporin 188kDa -5.33 
NXF2B, NXF2 nuclear RNA export factor 2B, nuclear RNA export factor 2 -5.33 
NXF2B, NXF2 nuclear RNA export factor 2B, nuclear RNA export factor 2 -5.33 
SPNS2 spinster homolog 2 (Drosophila) -5.43 
TACC2 transforming, acidic coiled-coil containing protein 2 -5.52 
PIP5K1B phosphatidylinositol-4-phosphate 5-kinase, type I, beta -5.53 
EP400NL EP400 N-terminal like -5.57 
MYO1D myosin ID -5.58 
SGCD sarcoglycan, delta (35kDa dystrophin-associated glycoprotein) -5.65 
CGNL1 cingulin-like 1 -5.71 
HK1 hexokinase 1 -5.9 
TNIP1 TNFAIP3 interacting protein 1 -5.9 
ALPK1 alpha-kinase 1 -6.06 
RHCG Rh family, C glycoprotein -6.08 
RSPH10B radial spoke head 10 homolog B (Chlamydomonas) -6.11 
OPRM1 opioid receptor, mu 1 -6.23 
DNAH3 dynein, axonemal, heavy chain 3 -6.38 
PZP pregnancy-zone protein -6.55 
TIE1 tyrosine kinase with immunoglobulin-like and EGF-like domains 1 -6.62 
SNAP91 synaptosomal-associated protein, 91kDa homolog (mouse) -6.77 
EMC1 ER membrane protein complex subunit 1 -7.06 
CNTN4 contactin 4 -7.47 
DCC deleted in colorectal carcinoma -7.55 
SELENBP1 selenium binding protein 1 -8.25 
LOC285857 uncharacterized LOC285857 -9.33 
CR1 complement component (3b/4b) receptor 1 (Knops blood group) -9.7 
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